RAFAEL ROSELL, MD, PhD

Dr. Rafael Rosell is **Director** of the Cancer Biology and Precision Medicine Program at the Catalan Institute of Oncology, Hospital Germans Trias i Pujol (Badalona, Barcelona, Spain), **Chief Scientific Officer, Chairman and Founder** of Pangaea Biotech SL (Barcelona), **Chief Medical Officer and President** of the Dr Rosell Oncology Institute, Quirón Dexeus University Hospital (Barcelona) and **Founder and President** of the Molecular Oncology Research Foundation (Barcelona). He is **Founder and Director of International Relations and Projects,** Spanish Lung Cancer Group (SLCG) and a member of the **Foundation Council and Steering Committee** of the European Thoracic Oncology Platform (ETOP).

Dr. Rosell's contributions to translational medical oncology, with particular emphasis on the field of non-small-cell lung cancer with EGFR mutations, have earned him international recognition: in 2013 he was recognized by The Lancet as the highest authority in lung cancer in Europe; he received the Raymond Bourgine Award from the International Congress on Anti-Cancer Treatment (ICACT) for contributions to cancer research in 2012; in 2011 he was honored by the European Society of Medical Oncology (ESMO) with the Hamilton Fairley Award for lifetime achievements in science and clinical/laboratory research, and in 2008 the Bonnie J. Addario Lung Cancer Foundation presented him with the "Asclepios" Award to pioneers in research. Dr Rosell has also been named Professor *Honoris Causa* by the University of Cordoba in Argentina, Eminent Clinical Scholar in Residence by the Winship Cancer Institute, Emory Univeristy School of Medicine, Georgia, USA, and awarded the Silver Caravel by the city of Bari, Italy in recognition of his work in lung cancer.

The innovative work of Dr. Rosell's multidisciplinary team has long focused on the design and selection of personalized cancer treatments based on genetic analysis and characterization of each patient's tumor in order to optimize outcomes to treatment. Investigations center on characterization of new genes involved in the development of cancer and resistance to targeted therapies. Among others, the group has performed groundbreaking analyses of EGFR, KRAS and ALK as well as RNA expression analysis of multiple genes such as BRCA1, AEG1 and RAP80, demonstrating significant improvements in response to targeted treatments. In the field of lung cancer in particular they have achieved special recognition for their investigations in neoadjuvant chemotherapy, demonstrating a survival benefit in locally advanced lung cancer, as well as in metastatic patients.

Dr. Rosell has authored over 600 articles published in peer-reviewed medical and scientific journals, and he has given more than 800 presentations at medical and scientific conferences around the world. He is Editor-in-Chief of *Translational Lung Cancer Research,* Associate Editor for *Clinical Lung Cancer* and is on the Editorial Board of several professional journals, including *Annals of Oncology*, *Clinical Cancer*

Research and *Future Oncology*. He is past president of the Asociación Espanola de Investigación sobre el Cancer (ASEICA) and past editor of *Revista de Oncología*, the official publication of five Spanish oncology societies.

Dr. Rosell is a member of the International Association for the Study of Lung Cancer (IASLC) and was Scientific Chair of their 2005 World Conference on Lung Cancer. He is an active member of the Protocol Review Committee of the European Organization for Research and Treatment of Cancer (EORTC), and serves on the Scientific Program Sub-Committee (non-small-cell lung cancer, metastatic) for the annual congress of the European Medical Oncology Society (ESMO). He was Scientific Chair of the 1st & 2nd European Lung Cancer Congress jointly sponsored by IASLC and ESMO. He also participated in the ASCO Scientific Programs Committee from 2002 through 2004.

EDUCATION

1970-1972: Internal Medicine Training, under Prof. Ciril Rozman
Hospital Clínico de Barcelona

1972: Degree in general medicine with numerous distinctions in several categories of medical science. University of Barcelona

Specialist Training:
1974: Educational Council for Foreign Medical Graduates (USA)
1977: Hematology University of Barcelona
1978: Internal Medicine University of Barcelona
1982: Medical Oncology University of Barcelona

MD Thesis: A general analysis of the Tumor Registry of the St. Andreu Hospital - Manresa. The evolution of its role and function from 1977-1985
Universidad Autonoma de Barcelona

1977: Specialist degree in Clinical Oncology and Chemotherapy,
granted by the regional government of Barcelona.

PROFESSIONAL EXPERIENCE

1972: Medical assistant under Prof. Ciril Rozman
Hospital Clínico de Barcelona

1973: Internal Medicine (registration)
Hospital Valle d'Hebron, Barcelona

1973-1976: Medical Resident (Oncology & Hematology)
Red Cross Hospital, Barcelona

1977: Medical Adjunct (Oncology & Hematology)
Red Cross Hospital, Barcelona

1977-1983: Director, Medical Oncology Department
Hospital General Ntra Sra de la Esperanza
Barcelona

1982: Memorial Sloan-Kettering Cancer Center, New York
under Dr. R. Gralla, Department of Medicine (Developmental Chemotherapy)

1988-1989: Associate Professor, Department of Medicine
Autonomous University of Barcelona

1989-1992: Full Professor, Department of Medicine
Autonomous University of Barcelona

1991-2014: President, Founder Spanish Lung Cancer Group
Barcelona

1992-present: Associate Professor, Medical Oncology (Lecturer)
Autonomous University of Barcelona

1983-2014: Director, Medical Oncology Service
University Hospital Germans Trias i Pujol
Badalona, Barcelona

1993-present: Director, Cancer Molecular Biology Laboratory
Hospital Germans Trias i Pujol
Badalona, Barcelona

2003-2014: Scientific Director for Oncology
Catalan Institute of Oncology, Hospital Germans Trias I Pujol
Badalona, Barcelona

2007-present: Chairman, Pangaea Biotech, SL
Director, Medical Oncology Service
Quirón Dexeus University Hospital
Barcelona

2007-2014: Head, Medical Oncology Service
Dr Rosell Oncology Institute

Quirón Dexeus University Hospital
Barcelona

2014-present: Director, Cancer Biology and Precision Medicine Program
Catalan Institute of Oncology
Hospital Germans Trias i Pujol
Badalona

2014-present: Chief Medical Officer, President
Dr Rosell Oncology Institute
Quirón Dexeus University Hospital
Barcelona

2014-present: Founder & President, Fundación Molecular Oncology Research (MORe)
Barcelona

2014-present: Director, International Relations and Projects, Spanish Lung Cancer Group
Barcelona

MEMBERSHIP IN PROFESSIONAL ASSOCIATIONS

- International Association for the Study of Lung Cancer (IASLC); Chair, 2005 World Conference on Lung Cancer
- European Society for Medical Oncology (ESMO); member, Scientific Program Sub-Committee (non-small-cell lung cancer, metastatic) for the ESMO annual congress
- European Organization for Research and Treatment of Cancer (EORTC); member of the EORTC Protocol Review Committee
- American Society of Clinical Oncology (ASCO); member of Scientific Program Committee 2002-2004
- Spanish Lung Cancer Group (President, 1991-2014)
- International Lung Adenocarcinoma Consensus Classification Panel (ILACCP)
- Catalan Society of Oncology; former President (1984-1986)
- Spanish Society of Medical Oncology
- Spanish Society of Cancer Research (ASEICA); former President
- American Association for Cancer Research
- Honorary Member of Argentina Association of Clinical Oncology
- Italian Association of Thoracic Oncology (AIOT)
- Bonnie J Addario Lung Cancer Foundation, member of Medical Advisory Board
- Foundation Council and Steering Committee Member: European Thoracic Oncology Platform (ETOP).
- Founding member, European Cancer Concord (ECC)
- President, Society of Translational Medicine

EDITORIAL BOARD MEMBER OF PROFESSIONAL JOURNALS

- PLOS ONE, Academic Editor
- Clinical Lung Cancer, Associate Editor
- Annals of Oncology
- Future Oncology
- Cancer & Chemotherapy Reviews
- Drugs
- Revisiones en Cáncer
- The Oncologist
- Nowotwory

- American Journal of Cancer
- Revista de Oncología, former Editor-in-Chief
- Oncology Realtime
- Personalized Medicine in Oncology
- World Journal of Respirology, Editor-in-Chief
- Clinical Cancer Research
- Revista Colombiana de Hematología y Oncología
- Translational Lung Cancer Research, Editor-in-Chief
- British Journal of Cancer
- Annals of Translational Medicine, Co-Editor-in-Chief
- Oncotarget

REVIEWER

- New England Journal of Medicine
- Journal of Clinical Oncology
- Annals of Oncology
- Cancer Research
- Clinical Cancer Research
- Journal of Chemotherapy
- Cancer Discovery

AWARDS

- ***Premio ECO*** awarded in recoginition of Greatest Scientific and Clinical Achievements by the Fundación para la Excelencia y la Calidad de la Oncología (ECO), 2014
- ***Ambaixador*** prize in recognition of notable achievements at international level from 'Regió7 i TVM' newspaper, 2014
- ***Josep Trueta Medal and Plaque for Merit in Healthcare*** from the autonomous Government of the Generalitat of Catalonia, 2013
- ***Recognition as an ESMO Host Institute*** for supporting and hosting young oncologists as part of the ESMO Fellowship Program, 2012
- ***Raymond Bourgine Award*** for contributions to cancer research, awarded by the International Congress on Anti-Cancer Treatment, 2012
- ***Hamilton Fairley Award*** for lifetime achievements in science and clinical/laboratory research, awarded by the European Society of Medical Oncology, 2011
- ***Asclepios Award to pioneers in research,*** The Bonnie J. Addario Lung Cancer Foundation. November 2008
- ***Silver Caravel Award,*** presented by the Mayor of Bari in recognition of outstanding research performed in pharmacogenomics. Bari, Italy. November 2006
- ***Professor Honoris Causa,*** awarded by Universidad Nacional de Córdoba, Argentina, November 2006
- ***Certificate of Merit***, awarded in recognition of outstanding scientific achievement during his Presidential Symposium presentation at the 31st European Society for Medical Oncology (ESMO) Congress, Istanbul, Turkey, October 2006
- ***Distinguished Cancer Clinical Scholar in Residence***, awarded by the Winship Cancer Institute of the Emory Univeristy School of Medicine, Atlanta, USA, October 2005
- ***Certificate of Appreciation*** for dedicated service to ASCO by participation in the Scientific Programs Committee May 2002 through June 2004, awarded by the American Society of Clinical Oncology, New Orleans, USA, June 2004
- ***Certificate of Recognition*** for outstanding contributions to the field of lung cancer research, treatment and quality of life, awarded by the Alliance for Lung Cancer Advocacy, Support, and Education (ALCASE), 1997

DIRECTOR OF DOCTORAL THESES

- Rosa Maria Nadal Ríos, Universitat Autónoma de Barcelona 2014 “Caracterización molecular de células tumorales circulantes en sangre periférica de pacientes con cáncer de mama’
- Andrés Felipe Cardona, Universitat Autónoma de Barcelona “Genotipificación del adenocarcinoma de pulmon de célula no pequeña en Colombia”
- Cristina Queralt Herrero, Universitat Autónoma de Barcelona, 2014 “Estudi de les mutacions del gen EGFR en pacients d'estadis avançats de CPCNP”
- Itziar de Aguirre Egaña, Universitat Autónoma de Barcelona, 2014 “LKB1/AMPK/TSC2 signaling pathway alterations in NSCLC”
- Amaya Gascó Hernández. Hospital Universitario Quirón Dexeus, 2013. "Perfil molecular en cáncer escamoso de pulmón”.
- Pamela Céliz, Universitat Autónoma de Barcelona, 2012 “Factores pronósticos y predictivos de respuesta en pacientes con carcinoma de vejiga localmente avanzado tratados con quimioterapia neoadyuvante”
- Christian Diego Rolfo, Università Degli Studi Di Palermo “Relationship between metabolic activity (SUV max) by 18-FDG PET and histology, stage, survival and Epidermal Growth Factor Receptor (EGFR) mutations in patients with non-small-cell lung cancer (NSCLC).”
- Mª Regina Gironés i Sarrió, Universidad Autònoma de Barcelona, 2009 “Caracterització oncològica i geriàtrica dels malalts grans amb càncer de pulmó de la consulta d’oncologia mèdica a l’ambit d’un hospital comarcal.”
- Tania Carolina Fleitas Kanonnikoff, Universidad Autònoma de Barcelona, 2009 “Estudio de celulas endoteliales circulantes, celulas endoteliales progenitoras, microparticulas circulantes y marcadores de angiogénesis en pacientes con carcinoma pulmonar no microcitico”
- Anna Martínez Cardús, Universidad Autónoma de Barcelona, 2008 “Pharmacogenomic study for the identification of genes involved in response and acquisition of resistance to oxaliplatin in colorectal cancer”
- Mª Fernanda Salazar Zaffaroni, Universidad Autónoma de Barcelona, 2008 “Detección de hipermetilación de CHFR en suero y sus implicaciones en la supervivencia de los pacientes de cáncer de pulmón no microcítico avanzado”
- María Sánchez Ronco, Universidad Autónoma de Madrid, 2006 “Investigación trasnacional en el cáncer no microcítico de pulmón. Valor predictivo de los genes BRCA1, 14-3-3σ y catorce polimorfismos”
- Manuel Dómine Gómez, Universidad Autónoma de Madrid, 2004 “Pharmacogenomic evaluation of patients with advanced NSCLC”
- Daniel Escuin Borràs, Universitat Autónoma de Barcelona, 2004 “Novel mechanistic link between microtubule disruption and inhibition of tumor angiogenesis”
- Albert Font Pous, Universitat Autónoma de Barcelona, 1998 “Valor pronóstico de las mutaciones del oncogen KRAS y de las pérdidas de heterocigosidad en el cromosoma 18q en el cáncer de colon y recto”

FUNDING GRANTED

- Three-year grant (2011-2014) for 2.1 million Euros from La Caixa Foundation for "Programa de Genètica en el Càncer de Pulmó, Mutacions del en EGFR"

- Grant from “Redes Tematicas de Investigacion Cooperativa en Salud” (RD12/0036/0040). Project coordinated by Dr Luis Montuenga. Dr Rosell’s group participating in WP5: “Molecular and genetic profiling of metastatic disease for predicting response and resistance to conventional and novel treatments”

- Three-year grant for from 75,000€ from “la Marató de TV3”. Project: “Molecular characterization of Non-Small Cell Lung Cancer (NSCLC) KRAS mutant tumors: clinical implications of new biomarkers.

CAREER HIGHLIGHTS

Journal	Impact factor
Cancer Research	9.329
Clinical Cancer Research	8.722
Cancer Cell	23.523
Lung Cancer	3.958
Clinical Lung Cancer	3.104
Nature	41.456
Nature Genetics	29.352
Nature Reviews Cancer	37.400
Nat Rev Clin Oncol	14.180
NEJM	55.873
Oncogene	8.459
J Thoracic Oncology	5.282
Annals of Oncology	7.040
Jama	35.289
PNAS	9.674
PloS One	3.234
Lancet	45.217
Lancet Oncology	24.690
J Clinical Oncology	18.443
JNCI	12.583

2016

- Rosell R, Karachaliou N. "Large-scale screening for somatic mutations in lung cancer." The Lancet. 2016 Jan 14. [Epub ahead of print]

- Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O. "Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort." *Ann Oncol*. 2016 Feb;27(2):281-6.

- Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S, Pirker R, Douillard JY, Le Chevalier T, Filipits M, Rosell R, Kratzke R, Popper H, Soria JC, Shepherd FA, Seymour L, Tsao MS. "Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer." *J Clin Oncol*. 2016 Feb 1. [Epub ahead of print]

2015

- Rosell R, Karachaliou N. "Lung cancer in 2014: optimizing lung cancer treatment approaches." *Nat Rev Clin Oncol*. 2015 Feb;12(2):75-6. Epub 2014 Dec 23.

- Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Gonzalez Cao M, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. "The Hippo effector YAP promotes resistance to

RAF- and MEK-targeted cancer therapies." *Nat Genet.* 2015 Feb 9. [Epub ahead of print]

- Khoon Lee C, Wu Y-L, Ni Ding P, Lord S, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla R, Chih-Hsin Yang J. "Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis" *J Clin Oncol* 33. Epub ahead of print April 20, 2015

- Tsao MS, Marguet S, Le Teuff G, Lantuejoul S, Shepherd FA, Seymour L, Kratzke R, Graziano SL, Popper HH, Rosell R, Douillard JY, Le-Chevalier T, Pignon JP, Soria JC, Brambilla EM. "Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection." *J Clin Oncol*. 2015 Apr 27. [Epub ahead of print]

- Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J. "AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas." *Cancer Cell.* 2015 Apr 13;27(4):533-46.

- Karachaliou K, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez J.M, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano J.L, Molina-Vila M.A, Rosell R. "Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial" *JAMA Oncology* 2015; 1(2):149-157

- Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Samarzija B, Felip E, Ciuleanu T-E, Hirsh V, Wehler T, Spicer J, Salgia R, Shapiro G, Sheldon E, Teofilovici F, Vukovic V, Fennell D. "A Randomized Phase 2 Study Of Ganetespib, A Heat Shock Protein 90 Inhibitor, In Combination With Docetaxel in Second-Line Therapy Of Advanced Non-Small-Cell Lung Cancer (GALAXY-1)" *Ann Oncol* (2015) Aug;26(8):1741-8

- Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. "RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer." *Nat Med.* 2015 Sep;21(9):1038-47. Epub 2015 Aug 24.

2014

- Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C, Massuti B, Song Y, Vergnenegre A, Lu H, Lopez-Vivanco G, Hu W, Robinet G, Yan J, Insa A, Xu X, Majem M, Chen X, de las Peñas R, Karachaliou N, Sala M.A, Wu Q, Isla D, Zhou Y, Baize N, Zhang F, Garde J, Germonpre P, Rauh S, ALHusaini H, Sanchez-Ronco M, Drozdowskyj A, Sanchez J.J, Camps C, Liu B, Rosell R.

"Two biomarker-directed randomized trials in European and Chinese patients with non-small-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies" *Annals of Oncology* Epub August 27, 2014

- Rosell R as part of NSCLC Meta-analysis Collaborative Group "Preoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis of individual participant data" *Lancet* 2014; 383:1561-71 Epub February 25

- Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R. "The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial". *Clin Cancer Res.* April 1, 2014 20:2001-2010

- Molina-Vila MA, Bertran-Alamillo J, Gasco A, Mayo-de-las-Casas C, Sanchez-Ronco M, Pujantell-Pastor L, Bonanno L, Favaretto A, Cardona A, Vergnenegre A, Majem M, Massuti B, Moran T, Carcereny E,Viteri S, Rosell R. "Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer" *Clin Cancer Res* 2014 Sep 1;20(17):4647-59

- Rosell R, "What new therapeutic targets exist for EGFR-mutant NSCLC?" *Lancet Oncology* Epub Aug 27 2014

- Rosell R, Karachaliou N, Wolf J, Ignatius Ou S-H. "ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy" *Lancet Respir Med* Epub November 19, 2014

2013

- Karachaliou N, Costa C, Gimenez-Capitan A, Molina-Vila M.A, Bertran-Alamillo J, Mayo C, Massuti B, Majem M, Carcereny E, Moran T, Sanchez J.J, Viteri S, Gasco A, Wannesson L, Souglakos J, Jimeno J, Rosell R. "BRCA1, LMO4 and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations" *Journal of Thoracic Oncology* 2013 Mar;8(3):295-300

- Rosell R, Bivona TG, Karachaliou N. "Genetics and biomarkers in personalisation of lung cancer treatment." *Lancet.* 2013 Aug 24;382(9893):720-31

- Rosell R. "Mediating resistance in oncogene-driven cancers." *N Engl J Med.* 2013 Apr 18;368(16):1551-2

- Rosell R, Karachaliou N "Lung cancer: Maintenance therapy and precision medicine in NSCLC." *Nat Rev Clin Oncol.* 2013 Oct;10(10):549-50. Epub 2013 Aug 20

2012

- Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez J. M, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno M. A, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A,

Queralt C, de Aguirre I, Ramirez J. L, Sanchez J. J, Molina M. A, Taron M, Paz-Ares L. "Erlotinib versus chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial" *Lancet Oncology* 2012 Mar;13(3):239-246. Epub 2012 Jan 26.

- Zhang Z, Lee JC, Lin L, Olivas V, Au V, Laframboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. "Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer." *Nat Genet*. 2012 Jul 1;44(8):852-860. doi: 10.1038/ng.2330.

2011

- Rosell R, Molina M. A, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta E, Massuti B, Queralt C, de Aguirre I, Sanchez J. M, Sanchez-Ronco M, Mate J. L, Ariza A, Benlloch S, Sanchez J. J, Bivona T, Sawyers C, Taron M "Pre-treatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations." *Clin Cancer Research* 2011;17:1160-1168

- Bivona T, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller V, Costa C, Hannon G, Sawyers C "FAS and NF-kB signalling modulate dependence of lung cancers on mutant EGFR" *Nature* 2011 24 March Vol471; 523-526

2010

- Rosell. R. (as member of Collaborative Group) "Adjuvant chemotherapy with or without postoperative therapy improves survival in non-small cell lung cancer: Meta-analyses based on individual patient data from 37 randomized controlled trials". *The Lancet* April 10 2010 Vol 375;9722:1267-1277

2009

- Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba J. L, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno M. A, Catot S, Rolfo C, Reguart N, Palermo R, Sanchez J. M, Bastus R, Mayo C, Bertran-Alamillo J, Molina M. A, Sanchez J. J, Taron M. "Screening for epidermal growth factor receptor mutations in lung cancer" *N Engl J Med* Sep 3rd, 2009; 361:958

PROFESSIONAL ACHIEVEMENTS

2016

PUBLICATIONS

Original articles

- Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D,

Milia J, Gautschi O. “Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.” *Ann Oncol*. 2016 Feb;27(2):281-6.

- Ferrara R, Pilotto S, Peretti U, Caccese M, Kinspergher S, Carbognin L, Karachaliou N, Rosell R, Tortora G, Bria E. “Tubulin inhibitors in non-small cell lung cancer: looking back and forward.” *Expert Opin Pharmacother*. 2016 Mar 10:1-17. [Epub ahead of print]

- Bria E, Pilotto S, Simbolo M, Fassan M, de Manzoni G, Carbognin L, Sperduti I, Brunelli M, Cataldo I, Tomezzoli A, Mafficini A, Turri G, Karachaliou N, Rosell R, Tortora G, Scarpa A. “Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis.” *Sci Rep*. 2016 Mar 10;6:22982

- Vergnenegre A, Massuti B, de Marinis F, Carcereny E, Felip E, Do P, Sanchez JM, Arez LP, Chouaid C, Rosell R; GECP; AIOT and GFPC groups. “Economical analysis of first line treatment by erlotinib in an EGFR mutated population with advanced non-small cell lung cancers NSCLC.” *J Thorac Oncol*. 2016 Feb 17.

- Buj R, Mallona I, Díez-Villanueva A, Barrera V, Mauricio D, Puig-Domingo M, Reverter JL, Matias-Guiu X, Azuara D, Ramírez JL, Alonso S, Rosell R, Capellà G, Perucho M, Robledo M, Peinado MA, Jordà M. “Quantification of Unmethylated Alu (QUAlu): a tool to assess global hypomethylation in routine clinical samples.” *Oncotarget.* 2016 Feb 7.[Epub ahead of print]

- Goel S, Viteri S, Morán T, Coronado C, Dios JL, Miguel-Lillo B, Fernández-García EM, Rosell R “Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors.” *Invest New Drugs*. 2016 Feb;34(1):75-83.

- Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S, Pirker R, Douillard JY, Le Chevalier T, Filipits M, Rosell R, Kratzke R, Popper H, Soria JC, Shepherd FA, Seymour L, Tsao MS. “Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.” *J Clin Oncol*. 2016 Feb 1. [Epub ahead of print]

Review articles

- Santarpia M, Daffinà MG, Karachaliou N, González-Cao M, Lazzari C, Altavilla G, Rosell R. “Targeted drugs in small-cell lung cancer.” *Transl Lung Cancer Res*. 2016 Feb;5(1):51-70.

- Codony-Servat J, Verlicchi A, Rosell R. “Cancer stem cells in small cell lung cancer.” *Transl Lung Cancer Res*. 2016 Feb;5(1):16-25.

- Karachaliou N, Pilotto S, Lazzari C, Bria E, de Marinis F, Rosell R. “Cellular and molecular biology of small cell lung cancer: an overview.” Transl Lung Cancer Res. 2016 Feb;5(1):2-15.

- Rosell R, Karachaliou N. “Large-scale screening for somatic mutations in lung cancer.” The Lancet. 2016 Jan 14. [Epub ahead of print]

PARTICIPATION IN SCIENTIFIC MEETINGS

MAJOR INTERNATIONAL MEETINGS

ICACT, Paris

- Rosell R. "Combinatorial targeted therapy in EGFR mutant lung cancer – A burning need to improve survival" 27th International Congress on Anti-Cancer Treatment (ICACT), Paris, France, 3 February 2015 **(Invited lecture)**

OTHER MEETINGS

- Rosell R. "DNA repair and synthetic lethality" 37th Anual EORTC-PAMM Congress, Antwep, Belgium, 10-12 February 2016 **(Invited lecture)**

- Rosell R. "El Futuro de la Investigación en el Cáncer de Pulmón" IV Curso de Capacitación en Cáncer de Pulmón, Grupo Español de Cáncer de Pulmón (GECP), Alcalá de Henares, Spain, 10-12 March 2016. **(Invited lecture)**

2015

PUBLICATIONS

Original articles

- Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sánchez-Reyes R, Amieva-Rivera E, Rodríguez J, Vargas C, Carranza H, Otero J, Karachaliou N, Astudillo H, Rosell R. "The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. *Lung Cancer* 87 (2015) 169–175

- Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa SI, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell R, Kurata T, Ou SH. "The Role of Smoking Status on the Progression-Free Survival of Non-Small-Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Double Chemotherapy: A Meta-Analysis of Prospective Randomized Trials". *The Oncologist.* 2015 Mar;20(3):307-15.

- Bugés C, Carcereny E, Moran T, Cardona AF, Reguart N, Capdevila L, Cros S, Rosell R. "Interstitial Lung Disease Arising From Erlotinib Treatment in a Caucasian Patient". *Clin Lung Cancer*. 2015 Vol. 16, No. 2, e1-3

- de Marinis F, Vergnenegre A, Passaro A, Dubos-Arvis C, Carcereny E, Drozdowskyj A, Zeaiter A, Perez-Moreno P, Rosell R. "Evaluation of erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial" *Future Oncology* 2015 11(3), 421–429

- Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Gonzalez Cao M, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies." *Nat Genet.* 2015 Feb 9. 2015 Mar;47(3):250-6

- Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, Aupérin A, Le Chevalier T, Stephens RJ, Arriagada R, Higgins JP, Johnson DH, Van Meerbeeck J, Parmar MK, Souhami RL, Bergman B, Douillard JY, Dunant A, Endo C, Girling D, Kato H, Keller SM, Kimura H, Knuuttila A, Kodama K, Komaki R, Kris MG, Lad T, Mineo T, Piantadosi S, Rosell R, Scagliotti G, Seymour LK, Shepherd FA, Sylvester R, Tada H, Tanaka F, Torri V, Waller D, Liang Y; Non-Small Cell Lung Cancer Collaborative Group. "Adjuvant chemotherapy for resected early-stage non-small cell lung cancer." *Cochrane Database Syst Rev.* 2015 Mar 2;3:CD011430.

- Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian M, Serke M, Kaminsky B, Randerath W, Gerigk U, Ko YD, Krüger S, Schnell R, Rothe A, Kropf-Sanchen C, Heukamp L, Rosell R, Büttner R, Wolf J. "ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability." *Oncotarget.* 2015 Apr 30;6(12):10577-85.

- Tsao MS, Marguet S, Le Teuff G, Lantuejoul S, Shepherd FA, Seymour L, Kratzke R, Graziano SL, Popper HH, Rosell R, Douillard JY, Le-Chevalier T, Pignon JP, Soria JC, Brambilla EM. "Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection." *J Clin Oncol.* 2015 Apr 27. [Epub ahead of print]

- Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J. "AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas." *Cancer Cell.* 2015 Apr 13;27(4):533-46.

- Li J, Zhang J, Jiang X, Rosell R, He J, Chan H C "The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer*" Int J Oncol. 2015 May;46(5):2107-15*

- Karachaliou K, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez J.M, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano J.L, Molina-Vila M.A, Rosell R. "Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial" *JAMA Oncology* 2015; 1(2):149-157

- Khoon Lee C, Wu Y-L, Ni Ding P, Lord S, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla R, Chih-Hsin Yang J. "Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis" *J Clin Oncol* 2015 Jun 10;33(17):1958-65

- Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Samarzija B, Felip E, Ciuleanu T-E, Hirsh V, Wehler T, Spicer J, Salgia R, Shapiro G, Sheldon E, Teofilovici F, Vukovic V, Fennell D. "A Randomized Phase 2 Study Of Ganetespib, A Heat Shock Protein 90 Inhibitor, In Combination With Docetaxel in Second-Line Therapy Of Advanced Non-Small-Cell Lung Cancer

(GALAXY-1)" *Ann Oncol* (2015) Aug;26(8):1741-8

- Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. "RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer." *Nat Med.* 2015 Sep;21(9):1038-47. Epub 2015 Aug 24.

- Yang Y, Wu N, Shen J, Teixido C, Sun X, Lin Z, Qian X, Zou Z, Guan W, Yu L, Rosell R, Liu B, Wei J. "MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer." *Gastric Cancer*. 2015 Sep 24. [Epub ahead of print]

- Bosch-Barrera J, Holguin F, Baldó X, Rubio M, Porta R, Fuentes R, Teixidó C, Ramirez JL, Ferran N, Sebastián F, Rosell R. "Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression." *Anticancer Res*. 2015 Sep;35(9):4871-5.

- Nilsson RJ, Karachaliou N, Berenguer J, Gimenez-Capitan A, Schellen P, Teixido C, Tannous J, Kuiper JL, Drees E, Grabowska M, van Keulen M, Heideman DA, Thunnissen E, Dingemans AC, Viteri S, Tannous BA, Drozdowskyj A, Rosell R, Smit EF, Wurdinger T. "Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer." *Oncotarget*. 2015 Nov 2. [Epub ahead of print]

- Gonzalez-Cao M1, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, Muñoz-Couselo E, Manzano JL, Cortes J, Berros JP, Drozdowskyj A, Sanmamed M, Gonzalez A, Alvarez C, Viteri S, Karachaliou N, Martin Algarra S, Bertran-Alamillo J, Jordana-Ariza N, Rosell R. "BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors" *Melanoma Res*. 2015 Dec;25(6):486-95.

- Bell EH, Chakraborty AR, Mo X, Liu Z, Shilo K, Kirste S, Stegmaier P, McNulty M, Karachaliou N, Rosell R, Bepler G, Carbone DP, Chakravarti A. "SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer." *Clin Cancer Res.* 2015 Dec 15. [Epub ahead of print]

- Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. "BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer." Scientific Reports. 2015 Dec 7;5:17499.
- Bonanno L, Costa C, Majem M, Sanchez J. J, Rodriguez I, Gimenéz-Capitan A, Molina-Vila M.A, Vergenegre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M, Rosell R. "Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-

small-cell lung cáncer" *Molecular Cancer (*submittted)

- Wu N, Costa C, Zou Z, Capitan A, Yu L, Hu W, Zhu L, Sun X, Sanchez J, Guan W, Liu B, Rosell R, Wei J. "High BIM mRNA levels associated with longer survival to second-line docetaxel in gastric cancer" *Cancer Science (*submitted)

- Margelí M, Quiroga V, Tapia G, Castella E, Sola M, Morgades M, Rosell R, Barnadas A, Cirauqui B. "HIP1 expression predicts outcome in breast cancer patients treated with neoadjuvant chemotherapy" *BMC Cancer* (submitted)

Review articles

- Veliz I, Loo Y, Castillo O, Karachaliou N, Nigro O, Rosell R. "Advances and challenges in the molecular biology and treatment of glioblastoma—Is there any hope for the future?" *Annals of Translational Medicine* Vol 3, No 1 January 2015

- Moran T, Vila L, de los Llanos Gil M, Indacochea A, Hardy-Werbin M, Carcereny E, Remón J, Rosell R. "Second Line Treatment in EGFR/ALK-NSCLC Patients" *J OncoPathology*, Volume 3, Number 1, February 2015, pp. 55-65(11)

- Carcereny E, Moran T, Capdevila L, Cros S, Vila L, de los Llanos Gil M, Remon J, Rosell R. "The epidermal growth factor receptor (EGRF) in lung cancer." *Transl Respir Med.* 2015 Feb 24;3:1. eCollection 2015.

- Karachaliou N, Rosell R. "Evaluation of Biomarkers for HER3-targeted Therapies in Cancer." *EBioMedicine.* 2015 Feb 16;2(3):192-3.

- Karachaliou N, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R. "Real-time liquid biopsies become a reality in cancer treatment." *Ann Transl Med.* 2015 Mar;3(3):36.

- Karachaliou N, Rosell R. "Targeted treatment of mutated *EGFR*-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics" *Lung Cancer Targets and Therapy*, Volume 2014:5 Pages 73—79

- Karachaliou N, Rosell R. "Relationship between gene mutation and lung cancer metastasis" *Cancer & Metastasis Rev* 2015 May 5. [Epub ahead of print]

- Gridelli C, Rossi A, Carbone D, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R. "Non-small-cell lung cancer". *Nat Rev Disease Primers* 2015 Art: 15009 Epub 21 May

- Santarpia M, Altavilla G, Rosell R. "Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer" *Expert Review of Respiratory Medicine* 2015 Jun;9(3):255-68

- Santarpia M, Altavilla G, Pitini V, Rosell R. "Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors." *Future Oncol.* 2015;11(8):1259-74.

- Santarpia M1, Gil N, Rosell R. "Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer." *Expert Rev Clin Pharmacol*. 2015 Jul;8(4):461-77. Epub 2015 Jun 11

- Karachaliou N, Molina-Vila M.A, Rosell R. "The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer." *Expert Review of Respiratory Medicine* Jun 2015, Vol. 9, No. 3, Pages 241-244: 241-244.

- Rosell R, Karachaliou N. "Relationship between gene mutation and lung cancer metastasis." *Cancer Metastasis Rev*. 2015 Jun;34(2):243-8.

- Morales-Espinosa D, García-Román S, Karachaliou N, Rosell R. "Pharmacogenomics in the treatment of lung cancer: an update." *Pharmacogenomics.* 2015 Oct;16(15):1751-60. Epub 2015 Oct 2.

- Teixidó C, González-Cao M, Karachaliou N, Rosell R. "Predictive factors for immunotherapy in melanoma." *Ann Transl Med.* 2015 Sep;3(15):208.

- Bustamante Alvarez JG, González-Cao M, Karachaliou N, Santarpia M, Viteri S, Teixidó C, Rosell R. "Advances in immunotherapy for treatment of lung cancer." *Cancer Biol Med*. 2015 Sep;12(3):209-22.

- Rosell R, Karachaliou N, Chaib I, Pilotto S, Bria E, Fernández-Martínez JL, Ramirez JL. "Deciphering crosstalk circuits in non-small cell lung cancers with an increasing interval length of low dose CT screening." *EBioMedicine*. 2015 Jul 21;2(8):780-1. eCollection 2015.

- Teixidó C, Karachaliou N, González-Cao M, Morales-Espinosa D, Rosell R. "Assays for predicting and monitoring responses to lung cancer immunotherapy." *Cancer Biol Med.* 2015 Jun;12(2):87-95.

- Karachaliou N, Cao MG, Teixidó C, Viteri S, Morales-Espinosa D, Santarpia M, Rosell R. "Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints." *Cancer Biol Med*. 2015 Jun;12(2):79-86.

- Rosell R, Palmero R. "PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors." *Cancer Biol Med*. 2015 Jun;12(2):71-3.

- González-Cao M, Karachaliou N, Viteri S, Morales-Espinosa D, Teixidó C, Sánchez Ruiz J, Molina-Vila MÁ, Santarpia M, Rosell R. "Targeting PD-1/PD-L1 in lung cancer: current perspectives." *Lung Cancer: Targets and Therapy* 2015 Volume 2015:6 Pages 55—70

- Karachaliou N, Pilotto S, Teixidó C, Viteri S, Gonzalez-Cao M, Riso A, Morales-Espinosa D, Molina M.A, Chaib I, Santarpia M, Richardet E, Bria E, Rosell R. "Melanoma: oncogenic drivers and the immune system." *Annals Trans Med* 2015 Vol 3, No 18

- González-Cao M, Rodón J, Karachaliou N, Sánchez J, Santarpia M, Viteri S, Pilotto S, Teixidó C, Riso A, Rosell R. "Other targeted drugs in melanoma." *Ann Transl Med.* 2015 Oct;3(18):266.

- Molina-Vila MA, de-Las-Casas CM, Bertran-Alamillo J, Jordana-Ariza N, González-Cao M, Rosell R. "cfDNA analysis from blood in melanoma." *Ann Transl Med*. 2015 Nov;3(20):309.

- Codony-Servat J, Rosell R. "Cancer stem cells and immunoresistance: clinical implications and solutions." *Transl Lung Cancer Res*. 2015 Dec;4(6):689-703.

- Viteri S, González-Cao M, Barrón F, Riso A, Rosell R. "Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer." *Transl Lung Cancer Res*. 2015 Dec;4(6):756-62.

- Morales-Espinosa D, García-Román S, Teixidó C, Karachaliou N, Rosell R. "Immunotherapy meets targeted therapy: will this team end the war against cancer?" *Transl Lung Cancer Res*. 2015 Dec;4(6):752-5.

- Santarpia M, González-Cao M, Viteri S, Karachaliou N, Altavilla G, Rosell R. "Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role." *Transl Lung Cancer Res*. 2015 Dec;4(6):728-42.

- Pilotto S, Molina-Vila MA, Karachaliou N, Carbognin L, Viteri S, González-Cao M, Bria E, Tortora G, Rosell R. "Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity." *Transl Lung Cancer Res.* 2015 Dec;4(6):721-7.

- Karachaliou N, Pilotto S, Bria E, Rosell R. "Platelets and their role in cancer evolution and immune system." *Transl Lung Cancer Res*. 2015 Dec;4(6):713-20.

- Pilotto S, Carbognin L, Karachaliou N, Garassino M, Cuppone F, Petraglia S, Rosell R, Tortora G, Bria E. "Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer." *Transl Lung Cancer Res*. 2015 Dec;4(6):704-12.

Contributions to books

- Russo A, Rosell R, Rolfo C (Eds.) "Targeted Therapies for Solid Tumors: A Handbook for Moving Toward New Frontiers in Cancer Treatment" Series: Current Clinical Pathology, Humana Press 2015, I, 624 p. ISBN 978-1-4939-2046-4

Editorials

- Morales-Espinosa D, Rosell R. "Second-line treatment in EGFR-unselected patients: is it time to close one arm of this river's DELTA?" *J Thorac Dis*. 2015 Mar;7(3):227-9. doi: 10.3978/j.issn.2072-1439.2015.01.34.

- Rosell R, Karachaliou N. "Lung cancer in 2014: optimizing lung cancer treatment approaches." *Nat Rev Clin Oncol.* 2015 Feb;12(2):75-6. Epub 2014 Dec 23.

ORGANIZATION OF COURSES AND CONFERENCES

- Conference Scientific Co-Chair XI Congress on Lung Cancer, Spanish Lung Cancer Group, Barcelona, Spain 26-27 November 2015

PARTICIPATION IN SCIENTIFIC MEETINGS

MAJOR INTERNATIONAL MEETINGS

BTOG, Dublin

- Camidge D, Gettinger S, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Shaw A, Weiss GJ, Narasimhan NI, Dorer DJ,1 Rivera VM, Clackson T, Haluska FG. "Efficacy and Safety of AP26113 in ALK+ Non–Small Cell Lung Cancer (NSCLC), Including Patients with Brain Metastases" British Thoracic Oncology Group annual congress, Dublin, Ireland, January 29 2015 **(Poster)**

ICACT, Paris

- Rosell R. "Early adaptive resistance in EGFR mutant NSCLCs and dynamic evolution of ALK positive NSCLCs" 26th International Congress on Anti-Cancer Treatment (ICACT), Paris, France, 3 February 2015 **(Invited lecture)**

- Rosell R "EGFR TKI early adaptive resistance. The important role of STAT3 activation" 26th International Congress on Anti-Cancer Treatment (ICACT), Paris, France, 3 February 2015 **(Invited lecture)**

ELCC, Geneva

- Rosell R, Gettinger S, Bazhenova L, Langer C, Salga R, Gold K, Shaw A, Dorer D, Kerstein D, Camidge R. "Phase I/II study of brigatinib (AP26113) in patients with advanced malignancies including ALK+ NSCLC: Analysis of safety and efficiency at selected phase II doses" 5th European Lung Cancer Conference, 15-18 April, Geneva, Switzerland. Abstract 990

ASCO, Chicago

- Massuti B, Cobo M, Rodriguez-Paniagua J.M, Ballesteros A.I, Moran T, Arrabal R, Gonzalez Larriba J.L, Barneto I, Pun Y.W, De Castro J, Ponce Aix S, Baamonde C, Munoz M.A, Lopez-Vivanco G, Rivas J-J, Isla D, Lopez R, Sanchez J.M, Sanchez-Paya J, Rosell R. "Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract:2007-000067-15; NCTgov: 00478699)" ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract 7507 **(Oral)**

- Karachaliou N, Nilsson J, Berenguer J, Gimenez Capitan A, Schellen P, Teixido C, Leonie Kuiper J, Drees E, Grabowska, van Keulen M, Tannous J, Heideman D, Thunnissen E, Dingemans A-M, Viteri Ramirez S, Tannous B, Drozdowskyj A, Smit E, Wurdinger T, Rosell R. "EML4-ALK rearrangement in blood platelets and outcome to crizotinib in non-small-cell lung cancer patients" ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract 8082 **(Poster)**

- Martinez-Bueno A, Baulies , Molina-Vila M.A, Bertran-Alamillo J, Gonzalez Cao M, Gonzalez X, Viteri Ramirez S, Karachaliou N, Teixido C, Sanchez-Ronco M, Tresserra F, Cusido M.T, Fabregas R, Rosell R. "Association of non-disruptive P53 mutations with poor progression-free survival (PFS) in resected breast cancer treated with neoadjuvant chemotherapy" ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract, 1042 **(Poster)**

- Etxaniz O, Carrato C, de Aguirre I, Queralt C, Munoz A, Ramirez J.L, Rosell R, Villà S, Diaz, R Estival A, Teixido P, Indacochea A, Ahlal S, VilÃ Martinez L, Balana C. "IDH 1 /2 status and low grade gliomas (LGG): Correlation with outcome upfront Pignatti criteria and molecular profile in a retrospective analysis of a single-centre cohort from Spain" ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract 2046 **(Poster)**

- Lee C, Davies L, Wu Y-L, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Throngprasert S, Fukuoka M, Gralla R, Gebski V, Mok T, Chih-Hsin Yang J. "The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials" ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract 8072 **(Poster)**

- Scheffler M, Schultheis A, Teixido C, Yves S, Michels F, Morales-Espinosa D, Viteri S, Merkelbach-Bruse S, Fischer R, Fassunke J, Sebastian M, Heidi Serke M, Randerath W, Gerigk U, Ko Y-D, Krüger S, Schnell R, Rothe A, Rosell R, Büttner R, Wolf J. "ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitve impact and genetic variability" ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract 8066 **(Poster)**

- Camidge R, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Tsang Shaw A, Weiss G, Narasimhan N, Dorer N, Rivera V, Clackson T, Conlan M, Kerstein D, Haluska F, Gettinger . "Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC)" ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract 8062 **(Poster)**

- Bepler G, Chen W, Patrick S, Astrow S, Stephens C, Gandara D, Rosell R, Ramirez J.L, Scagliotti G, Busso S, Volante M, Novello S. "Validation of ERCC1 (E1) for response prediction to platinum-gemcitabine" ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract 8036 **(Poster)**

- Moran T, Quiroga V, Carcereny Costa E, Cirauqui B, Margeli M, VilÃ L, de los Llanos GIL Gil Moreno M, Indacochea A, Cuadra Urteaga J.L, Queralt C, de Aguirre I, Ramirez J.L, Castella E, Lopez Y, Mate J.L, Rosell R. "Non-Small Cell Lung Cancer (NSCLC) harboring Epidermal Growth Factor Receptor mutations (EGFR-m) and breast cancer (BC): A retrospective analysis of a single institution" ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract e19112 **(Proceedings)**

- Romeo M, Karachaliou N, Chaib I, Queralt C, de Aguirre I, Carmen Gomez M, Sanchez-Ronco M, Radua J, Ramirez J.L, Rosell R. "RAP80 mRNA expression impact on sporadic high-grade serous ovarian cancer survival ASCO" Annual Congress, Chicago USA, May 29-June 2 2015, Abstract e16571 **(Proceedings)**

- Carcereny Costa E, Estival A, VilÃ Martinez L, de los Llanos Gil Moreno M, Moran T, Gutierrez B, Nancy Perez E, Luis Y, Jove J, Buges C, Quiroga V, Cuadra-Urteaga J.L, Cros S, Hardy-Werbin M, Teruel I, Ahlal S, Pardo N, Indacochea A, Capdevila L, Rosell R. "Prevalence of ROS1 translocation, HER2, and BRAF mutations in a cohort of advanced Non-Small Cell Lung Cancer (NSCLC) patients (p) triple negative (TN)" ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract e22139 **(Proceedings)**

- Garcia Campelo R, Moran T, Cardenal F, Alonso-Jaudenes Curbera G, Carcereny Costa E, Pallares E, Camps C, Insa A, Lopez-Vivanco G, Porta R, Bastus R, Isla D, Reguart N, Bover I, Majem M, Massuti B, Ramirez J.L, Drozdowskyj A, Karachaliou N, Rosell R. "BIM and

SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p)" ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract e19078 **(Proceedings)**

- Viteri Ramirez S, Mayo-de las Casas C, Jordana-Ariza N, Morales-Espinosa D, Molina-Vila M.A, Karachaliou N, Gonzalez Cao M, Simo-Perdigo M, Bertran-Alamillo J, Codony J, Garzon M, Perez-Rosado A, Martinez-Bueno A, Gonzalez X, Ovalle E, Rosell R. "Serial mutational analysis to monitor disease evolution in blood from advanced non small cell lung cancer (NSCLC) patients (p)" ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract e19085 **(Proceedings)**

- Cirauqui B, Quiroga V, Chaib I, Sanchez B, Karachaliou N, Ramirez J.L, Quer A, Munoz A, Drozdowskyj A, Pollan C, Planas I, Verges J, Cuadras P, Massuet A, Lezcano C, VilÃ Martinez L, de los Llanos Gil M, Hardy M, Rosell R, Margeli M. DNA repair- and apoptosis-pathways to regulate response to chemo-radiotherapy (CRT) in patients (p) with locally advanced head and neck cancer (HNC) ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract e17025 **(Proceedings)**

- Morales-Espinosa D, Molina-Vila M.A, Gimenez Capitan A, Garcia-Roman S, Bertran-Alamillo J, Mendez P, Ramirez-Serrano J.L, Codony C, Viteri Ramirez S, Karachaliou N, Rosell R. "Analysis of gene expression in the re-replication pathway and selective blockade with checkpoint inhibitors as a potential therapeutic option in NSCLC" ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract e13516 **(Proceedings)**

- Wu N, Wei J, Yu L, Gimenez Capitan A, Sanchez J.J, Rosell R, Liu B. "Association of high BIM mRNA levels with longer survival in advanced gastric cancer" ASCO Annual Congress, Chicago USA, May 29-June 2 2015, Abstract e15075 **(Proceedings)**

WCLC, Denver

- Rosell R "Targeting STAT3 and cancer stem cells in EGFR-mutant lung cancer patients: StatStem" 16th World Conference on Lung Cancer, Denver, USA, 6-9 September 2015 **(Invited lecture)** Abstract ID: 1902

- Massuti B, Rodriguez-Paniagua J.M, Cobo Dols M, Arrabal R, Ballesteros I, Wah Pun Y, Moran T, Lopez De Castro P, González-Larriba J.L, Hernando Trancho F, De Castro J, Diaz-Agüero P, Barneto I, Baamonde C, Ponce S, Martin De Nicolas J.L, Muñoz M.A, Peñalver J, Isla M.D, Rivas De Andres J.J, Lopez-Vivanco G, Pac J, Sanchez J, Sanchez-Paya J, Rosell R. "Results of a phase III trial of customized adjuvant CT after resection of NSCLC with lymph node metastases. SCAT: a Spanish Lung Cancer Group trial." 16th World Conference on Lung Cancer, Denver, USA, 6-9 September 2015 **(Oral)** Abstract ID: 2983

- Gettinger S, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Shaw A, Weiss G, Dorer D, Rivera V, Conlan M, Kerstein D, Camidge R. "Brigatinib (AP26113) Efficacy and Safety in ALK+ NSCLC: Phase 1/2 Trial Results." 16th World Conference on Lung Cancer, Denver, USA, 6-9 September 2015 **(Oral)** Abstract ID: 2125

- Reguart N, Gimenez-Capitan A, Molina M.A, Galvan P, Pare L, Viteri S, Teixidó C, Rodriguez S, Castellví J, Aldeguer E, Viñolas N, Rosell R, Prat A. "Detecting ALK, ROS1 and RET fusion genes in advanced non-small cell lung cancer (NSCLC) using a novel multiplexed nCounter-based assay." 16th World Conference on Lung Cancer, Denver, USA, 6-9 September 2015 **(Mini Oral)** Abstract ID: 2254

- Ma P, Thiagarajan P, Zhang W, Wu X, Leahy P, Shi I, Feng Y, Veig M, Lindner D, Danielpour D, Yin L, Zhang Z, Rosell R, Bivona T. "Transcriptome-metabolome reprogramming of EGFR-mutant lung cancer cells under precision inhibitors contributes to early adaptive drug-escape via mitochondrial priming requiring BCL-Xl" 16th World Conference on Lung Cancer, Denver, USA, 6-9 September 2015 **(Mini Oral)** Abstract ID: 3085

- Romero Vielva L, Maestre J.A, Viteri S, Gonzalez Cao M, Morales D, Rosell R. "Surgical resection after definitive chemoradiotherapy." 16th World Conference on Lung Cancer, Denver, USA, 6-9 September 2015 **(Poster)** Abstract ID: 782

- Morales-Espinosa D, Molina-Vila M.A, Gimenez-Capitan A, García-Román S, Bertrán-Alamillo J, Méndez-Romero P, Ramírez-Serrano J-L, Viteri S, Karachaliou N, Rosell R. "Analysis of gene expression in the re-replication pathway and selective blockade with checkpoint inhibitors as a therapeutic option in NSCLC" 16th World Conference on Lung Cancer, Denver, USA, 6-9 September 2015 **(Poster)** Abstract ID: 2594

- Scagliotti G, Treat J.A, Rosell R, Xu C, Li B, Chi H, Orlando H, Zhou C. "Pooled analysis of Gemcitabine plus platinum in patients with advanced squamous NSCLC" 16th World Conference on Lung Cancer, Denver, USA, 6-9 September 2015 **(Poster)** Abstract ID: 149

ELCC, VIENNA

- Stahel R, Dafni U, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Massutí B, Cardenal F, Aix P, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Carcereny E, Sanchez Ronco M, Molina M.A, Rosell R. "A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation.The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial." European Lung Cancer Congress (ELCC), Vienna, Austria, 25-29 September 2015 **(Oral)** Abstract ID: 3BA

- Cardona Zorrilla A.F, Arrieta O, Rojas L, Corrales L, Vargas C, Carranza H, Cuello M, Martin C, Rosell R. "Acquired Resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-Mutant lung cancer among Hispanics (CLICaP)." European Lung Cancer Congress (ELCC), Vienna, Austria, 25-29 September 2015 **(Poster)** Abstract ID: 153

- Camidge R, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Shaw A, Weiss G, Dorer D, Rivera V, Conlan M, Kerstein D, Gettinger S. "Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study" European Lung Cancer Congress (ELCC), Vienna, Austria, 25-29 September 2015 **(Poster)** Abstract ID: 3061

- Silvia G, Molina-Vila M.A, Borrell J, Puig de la Bellacasa R, Morales D, Bertrán-Alamillo J, Giménez-Capitán A, Karachaliou N, Rosell R. "PB1 a new DDR2 inhibitor: Potential treatment to SCC patients." European Lung Cancer Congress (ELCC), Vienna, Austria, 25-29 September 2015 **(Poster)** Abstract ID: 3118

- Morales-Espinosa D, Molina-Vila M.A, Giménez-Capitán A, García-Román S, Bertrán-Alamillo J, Méndez-Romero P, Ramírez-Serrano J, Viteri S, Karachaliou N, Rosell R. "Analysis of gene expression in the re-replication pathway and selective blockade with

checkpoint inhibitors as a therapeutic option in NSCLC." European Lung Cancer Congress (ELCC), Vienna, Austria, 25-29 September 2015 **(Poster)** Abstract ID: 3120

SEOM, Madrid

- Massuti B, Sánchez Torres J.M, Cobo Dols M, Moran T, González Larriba J.L, Barneto I, de Castro J, Ponce Aix S, Sánchez-Payá J, Rosell R. " Ensayo clínico Fase III de tratamiento quimioterápico adyuvante seleccionado en función de niveles de expresión BRCA1 en pacientes con cáncer de pulmón no microcítico resecado con afectación ganglionar: Primer análisis de supervivencia EC SCAT Grupo Español Cáncer de Pulmón." XV Congreso Nacional de SEOM, Madrid, Spain, 28-30 October **2015 (Oral)**

- Massuti B, Jantus Lewintre E, González Larriba J.L, Rodriguez-Abreu D, Juan O, Dómine M, Provencio Pulla M, de Castro J, Rosell R, Camps C. "Polimorfismos en factores relacionados con angiogénesis como factores predictivos en pacientes con cáncer de pulmón no escamoso metastático tratados con Carboplatino-Paclitaxel y Bevacizumab: resultados finales estudio ANGIOMET GECP." XV Congreso Nacional de SEOM, Madrid, Spain, 28-30 October **2015 (Oral)**

SLCG, Barcelona

- Rosell R. "BELIEF study" Spanish Lung Cancer Group VI Congress on Lung Cancer, Barcelona, Spain, 26-27 November 2015 **(Plenary lecture)**

OTHER MEETINGS

- Rosell R. "Integrated Research in STAT3 and Cancer Stem Cells, early adaptive resistance to EGFR inhibition". BilbaoPraxis 2015 Cancer, Bilbao, Spain, 6 March 2015 **(Invited lecture)**

- Rosell R. "Bypass tracks in lung cancer resistance: An opportunity for synthetic lethal approaches" VI Curso Avances en el Abordaje Multidisciplinar del Cáncer de Pulmón, Madrid, Spain, 21 April 2015 **(Invited lecture)**

- Rosell R. "Blood biomarkers for precision medicine in oncology" I Sesión Avances en Diagnostico Oncológico, Madrid Spain, 29 April 2015 **(Invited lecture)**

- Rosell R. "Integrated Research in signal trasducer and activator of transcription 3 (STAT3) and Cancer Stem Cells: Early adaptive resistance to EGFR inhibition" 28º Congreso Nacional Nanobiomedicina, Tarragona, Spain 22 May 2015 **(Invited lecture)**

- Molina Vila M.A, Mayo C, de Aguirre I, Queralt C, Jordana N, Karachaliou N, Ramirez J.L, Rosell R. "Liquid biopsy as an alternative" Targeted Therapy for Lung Cancer, Paris France, 6-7 May 2015 **(Invited lecture)**

- Chaib I, Sanchez Ronco B, Codony C, Codony J, Morales D, Teixido C, Puid de la Bellacasa R, Estrada R, Garcia Roman S, Ramirez J.L, Gimenez-Capitan A, Karachaliou N, Pilotto S, Martinez Bueno A, Molina M.A, Lopez-Vivanco G, Cardona A, Sanchez J.M, de Marinis F, Porvencio M, Nadal E, Moran T, Carcereny E, Massuti B, Requart N, Camps C, Jantus E, Vergenegre A, Zhou C, Rosell R. "Faliure of EGFR treatment: mechanisms and current strategies" Targeted Therapy for Lung Cancer, Paris France, 6-7 May 2015 **(Invited lecture)**

- Rosell R. "Ceritinib in the current management of ALK positive NSCLC" CNIO 3rd International Symposium on Novel Anticancer Agents for Practicing Oncologists, Madrid,

Spain, 10 June 2015 **(Invited lecture)**

- Rosell R. "Bench to bedside and back" RTICC 5th Investigators' Meeting, Madrid, Spain, 18 June 2015 **(Invited lecture)**

- Nakagawa K, Shu Kam Mok T, Wu Y-L, Rosell R, Tsuji F, Wang T, Sbar E, "ARCHER 1050: First-line dacomitinib vs gefitinib for advanced NSCLC in patients with EGFR activating mutation(s)" 13th Annual Meeting of JSMO, Sapporro, Japan, July 16 - 18, 2015 **(Poster)**

- Rosell R. "Targeting STAT3 and cancer stem cells in EGFR-mutant lung cancer patients (StatStem Project)", Universitair Ziekenhuis, Brussels, Belgium, 17 September 2015 **(Invited lecture)**

- Rosell R. "Translational research from Spain: What could we do?" I Reunión Investigación Traslacional en Melanoma, Hospital Universitario Quirón-Dexeus, Barcelona, Spain, October 2nd, 2015 **(Invited lecture)**

- Rosell R. "Medicina de precisión y cáncer de pulmón" III Jornadas Cáncer de Pulmón, Hospital Universitario General de Castellon, Castellon, Spain, 16 October 2015 **(Invited lecture)**

- Rosell R. "BELIEF" ETOP Annual Meeting, Zurich, Switzerland, November 13th, 2015 **(Invited lecture)**

- Rosell R. "Biological markers of response to immune checkpoint inhibitors." ESO – RUSSCO Session "Immune Checkpoint blockage in Cancer Therapy", Moscow, Russia, 18th November 2015 **(Invited lecture)**

- Rosell R. "Futuro del tratamiento sistémico en cáncer de pulmón no microcítico" V Jornadas Multidisciplinarias de Actualización en Cáncer de Pulmón, XVI Reunión Anual del Grupo Gallego de Cáncer de Pulmón, Vigo, Spain 20-21 November 2015 **(Invited lecture)**

- Rosell R. "Current findings in translational oncology and precision medicine in lung cancer" Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Barcelona, Spain, 1 December 2015 **(Invited lecture)**

- Rosell R. "Next generation tools for driver-specific diagnostic and prognostic testing in blood" Avances en biopsia líquida para monitorización de tumors, Labco Quality Diagnostics, Barcelona, Spain, 2 December 2015 **(Invited lecture)**

2014

PUBLICATIONS

Original articles:

- Cebrián A, Taron M, Sala N, Ardanaz E, Chirlaque MD, Larrañaga N, Redondo ML, Sánchez MJ, Gómez del Pulgar T, Camps C, Rosell R, González CA, Lacal JC. "Variants in phospholipid metabolism and upstream regulators and non-small cell lung cancer susceptibility". *Clin Transl Oncol.* 2014 Jan;16(1):107-12.

- Sanmartín E1, Sirera R, Usó M, Blasco A, Gallach S, Figueroa S, Martínez N, Hernando C, Honguero A, Martorell M, Guijarro R, Rosell R, Jantus-Lewintre E, Camps C. "A Gene Signature Combining the Tissue Expression of Three Angiogenic Factors is a Prognostic Marker in Early-stage Non-small Cell Lung Cancer". *Ann Surg Oncol.* 2014 Feb;21(2):612-20.

- Pujol JL, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, Vansteenkiste J, O'Byrne KJ, de Blas B, Heighway J, von Heydebreck A, Thatcher N. "Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer". *Lung Cancer.* 2014 Feb;83(2):211-8.

- Yue G, Sun X, Gimenez-Capitan A, Shen J, Yu L, Teixido C, Guan W, Rosell R, Liu B, Wei J. "TAZ Is Highly Expressed in Gastric Signet Ring Cell Carcinoma" *BioMed Research International* Volume 2014, 24 February 2014

- Rosell R as part of NSCLC Meta-analysis Collaborative Group "Preoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis of individual participant data" *Lancet* 2014; 383:1561-71 Epub February 25

- Molina-Vila MA1, Nabau-Moretó N, Tornador C, Sabnis AJ, Rosell R, Estivill X, Bivona TG, Marino-Buslje C. "Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues". *Hum Mutat.* 2014 Mar;35(3):318-28. Epub 2014 Jan 8.

- Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R. "The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial". *Clin Cancer Res.* April 1, 2014 20:2001-2010

- Reguart N, Rosell R, Cardenal F, Cardona A, Isla D, Palmero R, Moran T, Rolfo C, Pallarès M.C, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina M.A, Taron M. "Phase I/II Trial of Vorinostat (SAHA) and Erlotinib for Non-small Cell Lung Cancer (NSCLC) Patients with Epidermal Growth Factor Receptor (EGFR) Mutations after Erlotinib Progression" *Lung Cancer* 84 (2014)161-167

- Wei J, Costa C, Shen J, Yu L, Sanchez J. J, Qian X, Sun X, Zou Z , Gimenez-Capitan A, Yue G, Guan W, Rosell R, Liu B. "Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer" *British Journal of Cancer* May 27;110(11):2662-8 Epub May 8, 2014

- Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, Ortego J, Gallego R, Codony-Servat J, Garcia-Albeniz X, Jares P, Castells A, Lozano J.J, Rosell R, Maurel J. "RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer (mCRC) patients treated with first-line FOLFOX/XELOX chemotherapy" *European Journal Of Cancer* 2014 July Vol. 50, Issue 11, p1973–1981 Epub May 12, 2014

- Karachaliou N, Gimenez-Capitan A, Drozdowskyj A, Viteri S, Moran T, Carcereny E, Massuti B, Vergnenegre A, de Marinis F, Molina M.A, Teixido C, Rosell R. "ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation" *Translational Lung Cancer Research* 2014;3(3):122-130

- Serrano M, Ortega F, Alvarez-Cubero M, Nadal R, Sanchez-Rovira P, Salido M, Rodríguez M, García-Puche J, Delgado-Rodriguez M, Solé F, García M, Perán M, Rosell R, Marchal J, Lorente J. "EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer" *Oncotarget* 2014 *5*(17), 7486-7497

- Bosch-Barrera J, Sais E, Lorencio C, Porta R, Izquierdo A, Menéndez JA, Brunet J, Sirvent JM, Rosell R. "Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma". *Lung Cancer* 2014 Epub Jul 24.

- Park KS, Raffeld M, Moon YW, Xi L, Bianco C, Pham T, Lee LC, Mitsudomi T, Yatabe Y, Okamoto I, Subramaniam D, Mok T, Rosell R, Luo J, Salomon DS, Wang Y, Giaccone G. "CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance." *J Clin Invest.* 2014 Jul 1;124(7):3003-15, Epub, Jun 9.

- Molina-Vila MA, Bertran-Alamillo J, Gasco A, Mayo-de-las-Casas C, Sanchez-Ronco M, Pujantell-Pastor L, Bonanno L, Favaretto A, Cardona A, Vergnenegre A, Majem M, Massuti B, Moran T, Carcereny E,Viteri S, Rosell R. "Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer" *Clinical Cancer Research* 2014, Sep 1;20(17):4647-59, Epub Apr 2.

- Rolfo C, Hong D, Bivona T, Raez L, Bronte G, Buffoni L, Reguart N, Santos E, Germonpre P, Taron M, Passiglia F, Van Meerbeeck J, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R. "Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors" *Cancer Treatment Reviews* 2014 Sep;40(8):990-1004, Epub, June 7

- Blackhall F.H, Peters S, Bubendorf L, Dafni U, Kerr K.M, Hager H, Soltermann A, O'Byrne K.J, Dooms C, Sejda A, Hernández-Losa J, Marchetti A, Savic S, Tan Q, Thunnissen E, Speel EJ, Cheney R, Nonaka D, de Jong J, Martorell M, Letovanec I, Rosell R, Stahel R.A. "Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project" *J Clinical Oncology* Sep 1;32(25):2780-7. Epub 2014 Jul 28.

- Bosch-Barrera J, Sais E, Lorencio C, Porta R, Izquierdo A, Menéndez JA, Brunet J, Sirvent JM, Rosell R. "Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma". *Lung Cancer* 2014 Oct;86(1):102-4.

- Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C, Massuti B, Song Y, Vergnenegre A, Lu H, Lopez-Vivanco G, Hu W, Robinet G, Yan J, Insa A, Xu X, Majem M, Chen X, de las Peñas R, Karachaliou N, Sala M.A, Wu Q, Isla D, Zhou Y, Baize N, Zhang F, Garde J, Germonpre P, Rauh S, ALHusaini H, Sanchez-Ronco M, Drozdowskyj A, Sanchez J.J, Camps C, Liu B, Rosell R. "Two biomarker-directed randomized trials in European and Chinese patients with non-small-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies" *Annals of Oncology* Nov;25(11):2147-55.

- Shen J, Wei J, Guan W, Wang H, Ding Y, Qian X, Yu L, Zou Z, Xie L, Costa C, Bivona T, Rosell R, Liu B. "Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer." *J Transl Med*. 2014 Dec 14;12(1):355.

- Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall

FH, Baas P, Camps C, Rosell R, Stahel RA; ETOP Lungscape Investigators. "Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters." *J Thorac Oncol.* 2014 Nov;9(11):1675-84.

Review articles:

- Bonanno L1, Favaretto A, Rosell R. "Platinum drugs and DNA repair mechanisms in lung cancer". *Anticancer Res.* 2014 Jan;34(1):493-501.

- Rosell R, Massuti B, Karachaliou N. "Preface to the special issue: the 10th Congress of Spanish Lung Cancer Group I" *Translational Lung Cancer Research* Vol 3, No 2 April 2014

- García Campelo R, Massuti B, Mosquera J, Rosell R. "10th Congress on Lung Cancer—updates on clinical trials: GOAL" Special issue: the 10th Congress of Spanish Lung Cancer Group I *Translational Lung Cancer Research* Vol 3, No 2 April 2014

- Teixidó C, Karachaliou N, Peg V, Gimenez-Capitan A, Rosell R. "Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements" Special issue: the 10th Congress of Spanish Lung Cancer Group I *Translational Lung Cancer Research* Vol 3, No 2 April 2014

- Karachaliou N, Rosell R, Molina M.A, Viteri S. "Predicting resistance by selection of signaling pathways" Special issue: the 10th Congress of Spanish Lung Cancer Group I *Translational Lung Cancer Research* Vol 3, No 2 April 2014

- Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch F, Mok T, Morgillo F, Rosell R, Spigel D, Yang JC, Ciardiello F. "Treatment of Advanced Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology." *Clin Lung Cancer.* 2014 May;15(3):173-81 Epub Dec 27 2013

- Karachaliou N, Rosell R, Morales-Espinosa D, Viteri S. "Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond." *Expert Rev Anticancer Ther.* 2014 Jul;14(7):807-15, Epub Mar 10.

- Karachaliou N, Rosell R. "Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond" *Cancer Biology and Medicine* Vol 11, No 3: Sept 2014

- Rosell R, "What new therapeutic targets exist for EGFR-mutant NSCLC?" *Lancet Oncology* 2014 Oct;15(11):1184-5.

- Karachaliou N, Rosell R. "Targeted treatment of mutated *EGFR*-expressing non-small cell lung cancer: focus on erlotinib with companion diagnostics" *Lung Cancer: Targets and Therapy* Nov 13 2014:5 73-79

- Karachaliou N, Rosell R. "Unmet medical needs in NSCLC treatment: how to design pre-emptive combination therapies" *EMJ Oncol*. Nov 17 2014;2:48-53.

- Rosell R, Karachaliou N, Wolf J, Ignatius Ou S-H. "ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy" *Lancet Respir Med* Epub November 19, 2014

- Rosell R, Karachaliou N. "Lung cancer in 2014" *Nature Reviews Clinical Oncology* 2014 Dec 23. [Epub ahead of print]

- Rosell R. “Expression profiles and clinicopathological features in early resected non-small-cell lung cancer” *EBioMedicine*, Volume 1, Issues 2–3, December 2014, Pages 156-166

- Karachaliou N, Rosell R, Codony J, Teixido C, Garcia-Roman S, Morales-Espinosa D, Gonzalez Cao M, Viteri S, Veliz I, Loo Y, Castillo O “A critical question for cancer therapy: what new targets exist? *Translational Lung Cancer Research* Vol 3, No 6 (December 2014)

- Rosell R, Karachaliou N, Wolf J, Ignatius Ou S-H. “ALK and ROS1 NSCLC: two molecular subgroups sensitive to targeted therapy” Lancet Respiratory Medicine (submitted) *Lancet Respir Med*. 2014 Dec;2(12):966-8

Contributions to books:

- Rosell R, Taron M, Moran T, Carcereny E, Romero L, Hernando-Trancho F, Wei J, Massuti B. “Lung: Principles of radiation, chemotherapy and biological therapy for lung cancer.*” European Society of Thoracic Surgeons Textbook of Thoracic Surgery* Edited by Jaroslaw Kuzdzal, published by Medycyna Praktyczna S.J *(in press)*

- Simon G, Rosell R, Gandara D. “Pharmacogenomics in lung cancer: predictive biomarkers for chemotherapy” Chapter 47 in *Thoracic Oncology: The IASLC Multidisciplinary Approach (in press)*

ORGANIZATION OF COURSES AND CONFERENCES

- Director and Chair “VIII Annual Meeting of the French and Spanish Lung Cancer Groups”, Paris, France, May 15-16, 2014

- Conference Scientific Chair Plenary Session & VII Educational Symposium of the Spanish Lung Cancer Group, Madrid, Spain 20 - 21 November 2014

PARTICIPATION IN SCIENTIFIC MEETINGS

MAJOR INTERNATIONAL MEETINGS

ICACT, Paris

- Rosell R. “Genetics and biomarkers for personalization of lung cancer treatment” 25th International Congress on Anti-Cancer Treatment (ICACT), Paris, France, 4-6 February 2014 **(Invited lecture)**

- Rosell R “Mechanisms of resistance to targeted therapy” 25th International Congress on Anti-Cancer Treatment (ICACT), Paris, France, 4-6 February 2014 **(Invited lecture)**

ELCC, Geneva

- Rosell R. “Systemic treatment in EGFR/ALK NSCLC patients: second line and beyond” European Lung Cancer Congress (ELCC), Geneva, Switzerland, 26-29 March 2014 **(Invited lecture)**

AACR, San Diego

- Jimeno J, Acosta G, Molina M. A, Karachaliou N, Villacañas O, Bertran J, Garcia A, Teixido C, Ramon y Cajal S, Taron M, Rosell R, Albericio F. “Astrocytic Elevated Gene 1(AEG-1) as

a Target for Pharmacological Anticancer Intervention" AACR Annual Meeting 2014, April 5-9, 2014, San Diego, U.S.A **(Poster)**

ASCO, Chicago

- Karachaliou N, Drozdowskyj A, Gimenez Capitan A, Cardona Zorrilla A. F, Gervais R, Massuti B, Moran T, Majem M, Felip E, Carcereny Costa E, Garcia Campelo R, Viteri Ramirez S, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Ramirez J. L, Ma P, Rosell R. "Effect of BIM and mTOR expression on clinical outcome to erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) patients (p)". ASCO Annual Meeting, Chicago, U.S.A, 30 May - 3 June 2014 Abstract No: 8072 **(Poster)**

- Massuti B, García Campelo R, Rodriguez Abreu D, Remon J, Majem M, Galvez E, Ortega J. A, Aparisi F, Reguart N, Sala M. A, Isla D, Sanchez Ronco M, Verdu A, Molina-Vila M. A, Mayo-de las Casas C, Pereira E, Cajal R, Gonzalez-Arenas M. C, Carcereny E, Rosell R. "Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL)." ASCO Annual Meeting, Chicago, U.S.A, 30 May - 3 June 2014 Abstract No: TPS8127 **(Poster)**

- Garcia Campelo R, Felip E, Massuti B, Majem M, Carcereny Costa E, Palmero R, Molina-Vila M. A, Martinez P, Marti-Ciriquian J. L, Alonso-Jaudenes Curbera G, Pallares C, Cardenal F, Gonzalez-Arenas M. C, Mayo-de las Casas C, Sanchez-Ronco M, Rosell R. "Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL)". ASCO Annual Meeting, Chicago, U.S.A, 30 May - 3 June 2014Abstract No: 8079 **(Poster)**

- Cuadra-Urteaga J. L, Balana C, Etxaniz O, Chaib I, Ramirez J. L, Mejia E, Ojanguren I, Estival A, Munoz A, Sanz C, Indacochea A, Ahlal S, Vila L, de los Llanos Gil M, Teruel I, Hardy M, Rosell R. "Prognostic value of miR-196, IDO, and AXL in patients (p) with localized gastrointestinal stromal tumors (GIST)." ASCO Annual Meeting, Chicago, U.S.A, 30 May - 3 June 2014 Abstract No:10553 **(Poster)**

- Margeli M, Quiroga V, Castella E, Tapia G, Sola M, Sanchez-Ronco M, Radua J, Buges C, Espasa L, Capdevila L, Luna M. A, Ballester R, Arce J, Mariscal A, Vizcaya S, Vila L, Indacochea A, Barnadas A, Rosell R, Cirauqui B. "HIP1 expression and response to chemotherapy in breast cancer." ASCO Annual Meeting, Chicago, U.S.A, 30 May - 3 June 2014 Abstract No: 1046 **(Poster)**

- Gettinger S, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Tsang Shaw A, Weiss G, Narasimhan N, Dorer D, Rivera V, Clackson T, Haluska F, Camidge R. "Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC)." ASCO Annual Meeting, Chicago, U.S.A, 30 May - 3 June 2014 Abstract No: 8047 **(Poster)**

- Ma P, Thiagarajan P, Leahy P, Bagai R, Shi I, Zhang W, Feng Y, Veigl M, Lindner D, Danielpour D, Yin L, Rosell R, Bivona T. "Adaptive cell plasticity in autocrine TGFβ2 coordinated transcriptome-metabolome reprogramming of *EGFR*-mutant lung cancer in precision therapy escape." ASCO Annual Meeting, Chicago, U.S.A, 30 May - 3 June 2014 Abstract No: e19043 **(Proceedings)**

- Cardona A. F, Karachaliou N, Drozdowskyj A, Gimenez Capitan A, Molina-Vila M. A, Arrieta O, Carranza H, Vargas C. A, Otero J, Rosell R. "BIM expression in EGFR-mutant

non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib in Colombia." ASCO Annual Meeting, Chicago, U.S.A, 30 May - 3 June 2014 Abstract No: e19098 **(Proceedings)**

- Massuti B, Jantus-Lewintre E, Gonzalez Arriba J. L, Rodriguez Abreu D, Juan O, Domine M, Provencio M, Garde J, Garcia Gomez R, Maestu I, Perez Carrion R. M, Artal A, Rolfo C, Terrasa J, Oramas J, De Las Penas R, Sanchez Ronco M, De Castro J, Rosell R, Camps C. "ANGIOMET: Analysis of the correlations between angiogenic markers and outcome in patients (p) with advanced nonsquamous NSCLC (NS-NSCLC) treated with carboplatin, paclitaxel, and bevacizumab (CPB)." ASCO Annual Meeting, Chicago, U.S.A, 30 May - 3 June 2014 Abstract No: e19014 **(Proceedings)**

- Carcereny E, Centeno C, Munoz A, Moran T, Queralt C, Tierno M, Andreo F, Llatjos M, Ramirez J. L, Estival A, Serra P, de Aguirre I, Castella E, Botia M, Mijangos E, Montañes A, de los Llanos Gil M, Vila L, Ruiz Manzano J, Rosell R. "Is cytology sample from endobronquial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA) sufficient for analysis of major known driver mutations in non-small cell lung cancer (NSCLC)?" ASCO Annual Meeting, Chicago, U.S.A, 30 May - 3 June 2014 Abstract No: e22110 **(Proceedings)**

- Foo C, St. John J, Westesson O, Hahner N, Caulin A, Skinner M, Catalano J, Lung K, Parikh U, Wellde A, Barry J, Wellde G, Rosell R, Weissman J, Polkinghorn W, Bivona T, Giannikopoulos P. "Clinical validation of a comprehensive cancer genomics analysis for lung cancer patients." ASCO Annual Meeting, Chicago, U.S.A, 30 May - 3 June 2014Abstract No: e22122 **(Proceedings)**

ESMO, MADRID

- Rosell R, Karachaliou N, Molina M, Codony J, Ramirez J, Chaib I, Garcia-Roman S, Morales-Espinosa D, Estrada R, Bertran J, Codony C, Gimenez-Capitan A, Gonzalez-Cao M, Massuti Sureda B, Vergnenegre A, Moran T, Carcereny E, Teixido C, Villanueva A, Sanchez-Ronco M. "Can we do better with our current therapies for NSCLC? The Spanish Lung Cancer Group approach" 39th ESMO Annual Meeting, Madrid, Spain, 26-30 September, 2014 **(Invited lecture)**

- Seymour L, Le Teuff G, Tsao M, Brambilla E, Shepherd F, Soria J, Kratzke R, Graziano S, Douillard J, Rosell R, Reiman A, Lacas B, Bourredjem A, Le Chevalier T, Pirker R, Filipits M, Hainaut P, Janne P, Pignon J. "Prognostic and predictive biomarkers for ACT (adjuvant chemotherapy) in resected non-small cell lung cancer (R-NSCLC): LACE-Bio" 39th ESMO Annual Meeting, Madrid, Spain, 26 – 30 September, 2014 **(Oral)**

- Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Lee C, Kraemer S, Schnell D, Rosell R. "A phase Ib open label clinical trial of continuous once daily oral afatinib (A) plus sirolimus (S) in patients (pts) with EGFR mutation positive (EGFR M+) NSCLC and/or disease progression following prior erlotinib (E) or gefitinib (G)"
- ESMO Annual Meeting, Madrid, Spain, 26 – 30 September, 2014 **(Poster)**

- Gettinger S, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Shaw A, Weiss G, Narasimhan N, Dorer D, Rivera V, Clackson T, Haluska F, Camidge R. "ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC): Updated efficacy and safety data" 39th ESMO Annual Meeting, Madrid, Spain, 26 – 30 September, 2014 **(Poster)**

- Leon L,Golsorkhi A, Liu S, Drozdowskyj A, Rosell R. "Overall survival analyses of first-line erlotinib versus chemotherapy in the EURTAC study population controlling for the use of post-study therapy" 39th ESMO Annual Meeting, Madrid, Spain, 26 – 30 September, 2014 **(Poster)**

- Peters S, Mok T, Perol M, Ou S, Rosell R, Bara I, Henschel V, Camidge D. "Randomised, multicentre, phase III, open-label study of alectinib vs crizotinib in treatment-naïve anaplastic lymphoma kinase (ALK)-positive advanced NSCLC (ALEX study)" 39th ESMO Annual Meeting, Madrid, Spain, 26 – 30 September, 2014 **(Poster)**

- Karachaliou N, Drozdowskyj A, Gimenez-Capitan A, Morales-Espinosa D, Moran T, Carcereny Costa E, Cobo M, Domine M, Bover I, Camps C, Provencio M, Vergnenegre A Lopez-Vivanco G, Majem M, Viteri S, Massuti Sureda B, Rosell R. "PALB2 mRNA expression as a predictive and prognostic marker in advanced non-small-cell lung cancer (NSCLC) patients (p) treated with cisplatin- docetaxel chemotherapy" 39th ESMO Annual Meeting, Madrid, Spain, 26 – 30 September, 2014 **(Poster)**

- Campos Parra A, Cardona A, Corrales L, Sánchez Reyes R, Rodríguez J, Vargas C, Carranza H, Otero J, Rosell R, Arrieta O. "Common and rare EGFR mutations in non-small cell lung cancer" 39th ESMO Annual Meeting, Madrid, Spain, 26 – 30 September, 2014 **(Poster)**

- Gonzalez-Cao M, Soriano V, Rodriguez D, Puertolas T, Muñoz E, Soria A, Mayo de Las Casas C, Molina M, Perez E, Magem M, Garcia A, Manzano J, Cortes J, Rosell R. "BRAF mutation analysis in cell free tumoral DNA (cfDNA) of melanoma patients: preliminary results from the Spanish Melanoma Group prospective study GEM1304" 39th ESMO Annual Meeting, Madrid, Spain, 26 – 30 September, 2014 **(Poster)**

OTHER MEETINGS

- Rosell R. "What we talk about when we talk about ALK" Xalkori Launch Meeting, Madrid, Spain, January 30th 2014 **(Invited lecture)**

- Rosell R. "Genetics and biomarkers for personalized treatment: Current single EGFR TKI is incomplete therapy for patients with EGFR mutations" Genyo, Granada, Spain, February 10, 2014 **(Invited lecture)**

- Rosell R. "Personalized cancer treatment: identifying 'druggable' intracellular pathways for a specific patient" Leaping Forward Lisbon International Clinical Congress, Lisbon, Portugal, February 18, 2014 **(Invited lecture)**

- Rosell R. "Moving forward to synthetic lethal approaches for improving survival in NSCLC" 4th Congress of the International Society of Oncology and Biomarkers, Barcelona, Spain, March 15 2014 **(Invited lecture)**

- Rosell R. Charla Magistral, 3er Curso de Capacitacación en Cancer de Pulmón, Alcalá de Henares, April 10-12, 2014 **(Invited lecture)**

- Rosell R. "Mechanismos de resistencia en EGFR mutados", V Curso Avances en el Abordaje Multidisciplinar del Cáncer de Pulmón, Madrid, May 6, 2014 **(Invited lecture)**

- Rosell R. "Molecular mechanisms involved in lung cancer", Lung Regeneration and Beyond / 3rd DZL International Conference, Hannover, May 9, 2014 **(Invited lecture)**

- Rosell R. "Biomarkers and customized therapy: Q. Where are we? A. Not in the right place" VIII Annual Meeting of the French and Spanish Lung Cancer Groups", Paris, France, May 15-16, 2014 **(Invited lecture)**

- Rosell R. "GECP-GFCP relationships: past, present, future. Thoughts and summary of 23 years of the SLCG" VIII Annual Meeting of the French and Spanish Lung Cancer Groups", Paris, France, May 15-16, 2014 **(Invited lecture)**

- Rosell R. "Collaborative groups: Ongoing and new trials by the Spanish Lung Cancer Group" SAKK Bi-Annual Meeting, Berne Switzerland, 26 June 2014 **(Invited lecture)**

- Rosell R. "Mechanism of action of EGFR TKIs" Afatinib Expert Meeting, Madrid, Spain, 30 June 2014 **(Invited lecture)**

- Rosell R. "New TKIs targeting EGFR" 8th ESOG Marbella, Spain, 3 July 2014 **(Invited lecture)**

- Rosell R. "Initial indifference to selective inhibition of some EGFR mutant NSCLC and BRAF mutant melanomas (intrinsic resistance)" CNIO, Madrid, Spain 19 September 2014 **(Invited lecture)**

- Rosell R. "Research challenges in melanoma: How real are the expectations for melanoma patients? Some caveats on translational research and opportunities for novel biomarkers and synthetic lethal approaches" II Foro Oncología S. XXI Melanomacare, Hospital Quirón, Malaga, Spain, 3 October 2014 **(Invited lecture)**

- Rosell R. "Molecular subgroups of NSCLC highly sensitive to targeted therapy" II Jornadas Cáncer de Pulmón, Castellón, Spain, 17 October 2014 **(Invited lecture)**

- Rosell R. "The burning need to repurpose drugs in NSCLC and SCLC" Plenary Session and VII Educational Symposium of the Spanish Lung Cancer Group, Madrid, Spain 20-21 November 2014 **(Invited lecture)**

- Rosell R. "Synthetic lethal therapy with EGFR TKIs plus repurposing drugs in EGFR mutant lung cancer customized by BIM mRNA expression" Plenary Session and VII Educational Symposium of the Spanish Lung Cancer Group, Madrid, Spain 20-21 November 2014 **(Invited lecture)**

2013

ORGANIZATION OF COURSES AND CONFERENCES

- Director and Chair "VII Annual Meeting of the French and Spanish Lung Cancer Groups", Barcelona, Spain 15-16 May 2013

- Conference Scientific Chair, Spanish Lung Cancer Group 10th Congress on Lung Cancer, Barcelona, Spain, November 21-22, 2013

- Director, European Thoracic Oncology Platform (ETOP) Annual Meeting, Barcelona, Spain, 22-23 November 2013

PUBLICATIONS

Original articles:

- Karachaliou N, Costa C, Gimenez-Capitan A, Molina-Vila M.A, Bertran-Alamillo J, Mayo C, Massuti B, Majem M, Carcereny E, Moran T, Sanchez J.J, Viteri S, Gasco A, Wannesson L, Souglakos J, Jimeno J, Rosell R. "BRCA1, LMO4 and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations" *Journal of Thoracic Oncology* 2013 Mar;8(3):295-300

- Ball D, Mitchell A, Giroux D, Rami-Porta R; Rosell R. IASLC Staging Committee and Participating Institutions. "Effect of tumor size on prognosis in patients treated with radical

radiotherapy or chemoradiotherapy for non-small cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer". *J Thorac Oncol.* 2013 Mar;8(3):315-21.

- Mayo C, Ortega F. G, Giménez-Capitán A, Molina-Vila M. A, Serrano M. J, Viteri S, Costa C, Gascó A, Bertran-Alamillo J, Karachaliou N, Lorente J. A, Tarón M, Rosell R. "CK-coated magnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors" *Translational Lung Cancer Research (TLCR)* 2013 April; 2(2): 65-71

- Garrido P, Rosell R, Arellano A, Ramos A, Massutí B, Andreu T, Cardenal F, Arnaiz M, Dómine M, Perez Casas A, Morán T, Amador R, Cobo M , Delgado R, Zamora J. "Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: Mature results of the Spanish Lung Cancer Group 0008 study." *Lung Cancer.* 2013 Apr 20. Jul;81(1):84-90

- Bonanno L, Costa C, Majem M, Favaretto A, Rugge M, Rosell R. "The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy." *Ann Oncol.* 2013 Apr;24(4):1130-2. Epub 2013 Feb 20.

- Sanz-Santos J, Cirauqui B, Sanchez E, Andreo F, Serra P, Monso E, Castellà E, Llatjós M, Mesa M, Ruiz-Manzano J, Rosell R. "Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of intrathoracic lymph node metastases from extrathoracic malignancies." *Clin Exp Metastasis.* 2013 Apr;30(4):521-8. Epub 2012 Nov 30.

- Georgoulias V, Douillard JY, Khayat D, Manegold C, Rosell R, Rossi A, Menez-Jamet J, Iché M, Kosmatopoulos K, Gridelli C. "A multicenter randomized phase IIb efficacy study of vx-001, a Peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics". *Clin Lung Cancer.* 2013 Jul;14(4):461-5. Epub 2013 May 4.

- Shepherd FA, Domerg C, Hainaut P, Jänne PA, Pignon JP, Graziano S, Douillard JY, Brambilla E, Le Chevalier T, Seymour L, Bourredjem A, Teuff GL, Pirker R, Filipits M, Rosell R, Kratzke R, Bandarchi B, Ma X, Capelletti M, Soria JC, Tsao MS. "Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy". *J Clin Oncol.* 2013 Jun 10;31(17):2173-81 Epub 2013 Apr 29.

- Rosell R as part of Surrogate Lung Project Collaborative Group "Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data." *Lancet Oncol.* 2013 Jun;14(7):619-26. Epub 2013 May 14.

- Graziano SL, Lacas B, Vollmer R, Kratzke R, Popper H, Filipits M, Seymour L, Shepherd FA, Rosell R, Veillard AS, Taron M, Pignon JP. "Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA." *Lung Cancer.* 2013 Oct;82(1):149-55. Epub 2013 Aug 4.

- Skrzypski M, Dziadziuszko R, Jassem E, Szymanowska-Narloch A, Gulida G, Rzepko R, Biernat W, Taron M, Jelitto-Górska M, Marjański T, Rzyman W, Rosell R, Jassem J. "Main Histologic Types of Non-Small-Cell Lung Cancer Differ in Expression of Prognosis-related Genes." *Clin Lung Cancer.* 2013 Nov;14(6):666-673.e2. Epub 2013 Jul 17.

- Lecumberri R, López Vivanco G, Font A, González Billalabeitia E, Gúrpide A, Gómez Codina J, Isla D, Galán A, Bover I, Domine M, Vicente V, Rosell R, Rocha E. "Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study". Thromb Res. 2013 Dec;132(6):666-70.

- Szymanowska-Narloch A, Jassem E, Skrzypski M, Muley T, Meister M, Dienemann H, Taron M, Rosell R, Rzepko R, Jarząb M, Marjański T, Pawłowski R, Rzyman W, Jassem J. "Molecular profiles of non-small cell lung cancers in cigarette smoking and never-smoking patients."Adv Med Sci. 2013 Dec 1;58(2):196-206.

Review articles:

- Karachaliou N, Wei J, Marques A.D, Rosell R. "Front-line erlotinib in unselected patients with advanced NSCLC and poor performance status – the TOPICAL study" Translational Lung Cancer Research Vol 2, No 1 February 2013

- Santarpia M, De Pas T.M, Altavilla G, Spaggiari L, Rosell R. "Moving towards molecular-guided treatments: Erlotinib and clinical outcomes in non-small-cell lung cancer (NSCLC) patients." *Future Oncology* 2013 Mar;9(3):327-45

- Nadal R, Lorente J.A, Rosell R, Serrano M.J. "Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies" *Expert Rev Mol Diagn*. 2013 Apr;13(3):295-307

- Morán T, Quiroga V, de los Llanos Gil M, Vilà L, Pardo N, Carcereny E, Capdevila L, M Muñoz-Mármol A, Rosell R. "Targeting EML4-ALK driven non-small cell lung cancer (NSCLC)" *Translational Lung Cancer Research (TLCR)* 2013 April; 2(2): 128-141

- Costa C, Giménez-Capitán A, Karachaliou N, Rosell R. "Comprehensive molecular screening: from the RT-PCR to the RNA-seq". *Translational Lung Cancer Research (TLCR)* 2013 April; 2(2): 87-91

- Karachaliou N, Mayo C, Costa C, Magrí I, Gimenez-Capitan A, Molina-Vila MA, Rosell R. "KRAS Mutations in Lung Cancer. *Clin Lung Cancer.*" May;14(3):205-14 [Epub Oct 31 2012]

- Rosell R, Bivona TG, Karachaliou N. "Genetics and biomarkers in personalisation of lung cancer treatment." *Lancet.* 2013 Aug 24;382(9893):720-31.

- Wannesson L, Viteri S, Costa C, Karachaliou N, Molina-Vila MA, Rosell R. "Signaling Pathways Modulating Dependence of Lung Cancer on Mutant Epidermal Growth Factor Receptor and Mechanisms of Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors." *Curr Pharm Des.* 2013 Nov 5. [Epub ahead of print]

- Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, Sanchez-Cespedes M, Assenov Y, Müller F, Bock C, Taron M, Mora J, Muscarella LA, Liloglou T, Davies M, Pollan M, Pajares MJ, Torre W, Montuenga LM, Brambilla E, Field JK, Roz L, Lo Iacono M, Scagliotti GV, Rosell R, Beer DG, Esteller M. "A prognostic DNA methylation signature for stage I non-small-cell lung cancer." *J Clin Oncol.* 2013 Nov 10;31(32):4140-7. Epub 2013 Sep 30.

- Hodoglugil U, Carrillo MW, Hebert JM, Karachaliou N, Rosell R, Altman RB, Klein TE "PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor." *Pharmacogenet Genomics.* 2013 Nov;23(11):636-42.

Contributions to books:

- Rosell R, Bonanno L. "EGFR inhibitors: patient selections and clinical outcome" *Personalized Cancer Management* E-Book Edited by Duc Hong Lee, Future Medicine Ltd August 2013, Pages 160-176, Doi: 10.2217/ebo.12.152 http://www.futuremedicine.com/doi/abs/10.2217/ebo.12.152

- Rosell R, Taron M, Rolfo c. D, Rodriguez-Abreu D, Wei J "Diagnostic, prognostic and therapeutic value of gene signatures in non-small-cell lung cancer" *Diagnostic, prognostic and therapeutic value of gene signatures.* Edited by Antonio Russo, Stefano Iacobelli, Juan Lucio Iovanna, Published by Springer, Humana Press ISBN 978-1-61779-358-5

Editorials:

- Rosell R. "Mediating resistance in oncogene-driven cancers." *N Engl J Med.* 2013 Apr 18;368(16):1551-2.

- Karachaliou N, Rosell R. "Optimal detection of ALK rearranged lung adenocarcinomas" *Journal of Thoracic Oncology* 2013 Mar;8(3):255-6

- Karachaliou N, Rosell R. "Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitors" *Ann Palliat Med* Vol 2, No 3 (July 2013)

- Karachaliou N, Rosell R. "Small-cell lung cancer: where are we now and what can we expect for the future?" *Future Oncol.* 2013 Aug;9(8):1065-8.

- Rosell R, Karachaliou N "Lung cancer: Maintenance therapy and precision medicine in NSCLC." *Nat Rev Clin Oncol.* 2013 Oct;10(10):549-50. Epub 2013 Aug 20.

PARTICIPATION IN SCIENTIFIC MEETINGS

MAJOR INTERNATIONAL MEETINGS

ICACT, Paris

- Rosell R. "Understanding adaptive resistance in EGFR mutant NSCLC: Deconstructing the myth of T790M" 24th International Congress on Anti-Cancer Treatment (ICACT), Paris France, 5-6 February 2013 **(Invited lecture)**

- Rosell R. "Molecular based decision making for personalized cancer management" 24th International Congress on Anti-Cancer Treatment (ICACT), Paris France, 5-6 February 2013 **(Invited lecture)**

AACR, Washington

- Méndez P, Ramirez J.L, Gascó A, Morán T, Carcereny E, Taron M, Mate J.L, Sansano I, Pérez M, Botia M, Tierno M, Groen H, Rosell R. "FGFR1 and SOX2 amplification in squamous cell carcinoma (SCC) of the lung" AACR Annual Meeting, April 6-10, 2013, Washington DC, USA **(Poster)**

EMCTO, Lugano

- Rosell R. "The BELIEF Trial" European Thoracic Oncology Platform Satellite/Society symposium, European Multidisciplinary Conference in Thoracic Oncology (EMCTO), Lugano Switzerland, 9th May 2013 **(Invited lecture)**

- Mok T, Nakagawa K, Rosell R, Wu Y, Trygstad C, Capizzi R, DeBenedetto R, Goldberg, Wang T, Antic V. "ARCHER 1050: Phase 3 randomized study of first-line dacomitinib versus gefitinib for advanced non-small cell lung cancer in patients with activating epidermal growth factor receptor (EGFR) mutation(s)" European Multidisciplinary Conference in Thoracic Oncology (EMCTO), Lugano, Switzerland , 9 - 11 May 2013 **(Poster)**

ASCO, Chicago

- Moran T, Cobo M, Domine M, Sanchez-Ronco M, Bover I, Provencio M, Massuti B, Vergnenegre A, Lopez-Vivanco G, Robinet G, Insa A, Majem M, De Las Penas R, Sala M. A, Isla D, Baize N, Garde J, Chaib I, Camps C, Rosell R. "Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC)." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract LBA8002 **(Oral)**

- Weissman J, Giannikopoulos P, St. John J, Uzilov A, Costa C, Karachaliou N, Sansano I, Jantus-Lewintre E, Stahel R, Vergnenegre A, Gervais R, Perez-Gracia J.L , Lozano M, Wellde A, Bordoni R, Cardona Zorrilla A. F, Polkinghorn W, Wellde G, Rosell R, Bivona T. G. "Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract 11010 **(Oral)**

- Ramalingam S, Goss G, Gojko Andric Z, Bondarenko I, Zaric B, Ceric T, Vladimir Poddubskaya E, Ciuleanu T.E, Spicer J, Felip E, Hirsh V, Manegold C, Rosell R, Khuri F, Vukovic V, Teofilovici F, El-Hariry I, Guo W, Bahcall S, Fennell D. "A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1)." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract CRA8007 **(Oral)**

- Peters S, Weder W, Meldgaard P, O'Byrne K. J, Wrona A, Dooms C, Hernandez-Losa J, Marchetti A, Nicolson M, Tan Q, Smit E, Dingemans A. M, Savic S, Blackhall F, Baas P, Jantus-Lewintre E, Kerr K, Dafni U, Rosell R, Stahel R. "The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract 7514 **(Poster Discussion)**

- Carcereny E, Bertran-Alamillo J, Molina-Vila M. A, Gervais R, Massuti B, Bonanno L, Moran T, Majem M, Felip E, Garcia-Campelo R, Vergnenegre A, Viteri S, Gasco A, Wannesson L, Mayo-de las Casas C, Pujantell-Pastor L, Favaretto A, Karachaliou N, Rosell R. "Nondisruptive mutations of TP53 and overall survival (OS) in advanced non-small-cell lung cancer (NSCLC) patients (p)." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract 11029 **(Poster Discussion)**

- Karachaliou N, Drozdowskyj A, Costa C, Molina-Vila M. A, Gimenez Capitan A, Vergnenegre A, Massuti B, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Heidecke C, Estrada-Tejedor R, Teixido J, Bivona T, Giannikopoulos P, Ono M, Rosell R. "ROR1 mRNA expression in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with the T790M mutation: A potential therapeutic target." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract 11027 **(Poster Discussion)**

- Gasco A, Mendez P, Ramirez J. L, Viteri S, Moran T, Carcereny E, Costa E, Gimenez Capitan A, Sansano I, Perez M, Tierno M, Botia M, Taron M, Groen H, Rosell R. "Fibroblast growth factor receptor 1 (FGFR1) and SRY-related HMG-box (SOX2) amplification in squamous cell carcinoma (SCC) of the lung." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract 11025 **(Poster discussion)**

- Lopez-Vivanco g, Marti t, Kotov i, Chaib I, Ponce-Aix S, García Campelo R, Sanchez J. M, Artal A, Bover I, Taron M, Sanchez-Ronco M, Rolfo C. D, Massuti B, Stahel R, Rosell R. "Components of homologous recombination and translesion synthesis (TLS) in pemetrexed/cisplatin-treated non-small-cell lung cancer (NSCLC) patients (p)." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract 11028 **(Poster Discussion)**

- Bivona T. G, Giannikopoulos P, Costa C, Karachaliou N, Viteri S, Garcia-Campelo R, St. John J, Uzilov A, Wellde A, Polkinghorn W, Majem M, Felip E, Carcereny E, Heidecke C, Massuti B, Wellde G, Weissman J, Rosell R. "Integrated genomic analysis of EGFR-mutant non-small cell lung cancer immediately following erlotinib initiation in patients." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract 11067 **(Poster)**

- Bonanno L, Costa C, Sanchez J. J, Majem M, Gimenez Capitan A, Rodriguez I, Vergnenegre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M, Rosell R. "The predictive role of integrated BRCA1 and HERC2 mRNA expression in advanced non-small cell lung cancer (NSCLC) patients (p) treated with platinum-based first-line chemotherapy." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract 11078 **(Poster)**

- García Campelo R, Felip E, Massuti B, Majem M, Carcereny E, Cardenal F, Molina-Vila M.A, Martinez Marti A, Marti-Ciriquian J. L, Alonso-Jaudenes Curbera G, Pallares C, Palmero R, Gonzalez-Arenas M. C, Mayo-de las Casas C, Sanchez-Ronco M, Rosell R. "Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell lung cancer (NSCLC) (NCT01513174/GECP-GOAL)." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract 2581 **(Poster)**

- Fennell D. A, Goss G. D, Socinski M. A, Nakagawa K, Schiller J, Bonomi P, Hirsh V, Kelly K, Spicer J. F, Rosell R, Zaric B, Ciuleanu T. E, Vukovic V. M, Teofilovici F, El-Hariry I, Guo W, Ramalingam S. "GALAXY-2 trial: A randomized phase III study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced non-small cell lung adenocarcinoma." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract TPS8126 **(Poster)**

- Mok T, Nakagawa K, Rosell R, Long Wu Y, Trygstad C, Capizzi R, Young Lee M, Tsuji F, DeBenedetto R, Goldberg Z, Wang T, Liang J. Q, Letrent S, O'Connell J, Antic V. "Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (EGFR) activating mutation(s)." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract TPS8123 **(Poster)**

- Gonzalez Cao M, Costa C, Molina-Vila M. A, Cusido M. T, Viteri S, Baulies S, Martinez-Bueno A, Fabregas R, Tresserra F, Sansano I, Ara C, Amselen D, Ubeda B, Simo-Perdigo M, Gasco A, Rodriguez I, Rosell R. "Molecular analysis in breast cancer subtypes and correlation

with pathologic complete response (pCR) to neoadjuvant chemotherapy." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract e22119 **(Proceedings)**

- Remon J, Moran T, Alcaraz D, Capdevila L, Porta R, Reguart N, Lianes P, Carcereny E, Bosch-Barrera J, Rosell R. "Treatment strategies after failure to reversible tyrosine kinase inhibitors (rTKI) in EGFR mutant (mut) non-small cell lung cancer (NSCLC) patients (p): A retrospective analysis of 41 Spanish p." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract e19089 **(Proceedings)**

- Capdevila L, Carcereny E, de Aguirre I, Cros S, Queralt C, Moran T, Buges C, Mijangos E, Pardo N, Rosell R. "Tyrosine kinase inhibitors (TKI) treatment of non-small cell lung cancer (NSCLC) patients (p) based on EGFR mutations (m) status in serum only." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract e19088 **(Proceedings)**

- Aparicio G, Villaamil V. M, Taron M, Rosell R, Aparicio L. A. "Predictive markers in metastatic transitional cell carcinoma (mTCC) patients treated with carboplatin plus pemetrexed regimen." ASCO Annual Meeting, Chicago, U.S.A, 31 May - 4 June 2013 Abstract e15558 **(Proceedings)**

ESMO, Amsterdam

- Massuti B, Cobo M, Rodriguez-Paniagua M. J, Ballesteros I. M, Moran T, Arrabal R, González-Larriba J. L, Pereira E, Sánchez-Torres J. M, Rosell R. "Treatment compliance of customized postoperative chemotherapy after NSCLC resection: A toxicity/safety analysis of SCAT (Spanish Customized Adjuvant Therapy) trial - Spanish Lung Cancer Group/GECP" 17th ECCO 38th ESMO 32nd ESTRO European Cancer Congress, Amsterdam, 27 September – 1 October 2013 **(Oral)**

- Gasco A, Costa C, Rodriguez I, Bonanno L, Moran T, Karachaliou N, Gimenez-Capitan A, Rodriguez S, Rosell R, Maurel J. "RAC1b mRNA expression and prognosis in advanced non-small cell lung cancer treated with first-line chemotherapy" 17th ECCO 38th ESMO 32nd ESTRO European Cancer Congress, Amsterdam, 27 September – 1 October 2013 **(Poster)**

- Rosell R, Liu B, Cobo M, Wei J, Domine M, Qian X, Sánchez-Ronco M, Zou Z, Massuti B, Vergnenegre A. " Pooled analysis of the European (EUR) and Chinese (Ch) BRCA1-RAP80 Expression Customization (BREC) randomized trials of customized therapy in advanced non-small-cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC and ChiCTR-TRC-12001860)" 17th ECCO 38th ESMO 32nd ESTRO European Cancer Congress, Amsterdam, 27 September – 1 October 2013 **(Poster)**

- Garcia Campelo R, Felip E, Massuti T, Majem M, Carcereny E, Palmero R, Molina M. A, González-Arenas C, Sanchez- Ronco M, Rosell R. "Phase IB study to evaluate the efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients with epidermal growth factor receptor (EGFR) mutation positive advanced non-small-cell lung cancer (NSCLC) patients (pts). (NCT=1513174/GECP-GOAL)" 17th ECCO 38th ESMO 32nd ESTRO European Cancer Congress, Amsterdam, 27 September – 1 October 2013 **(Poster)**

- Rosell R, Liu B, Cobo M, Wei J, Domine M, Qian X, Sánchez-Ronco M, Zou Z, Massuti B, Vergnenegre A. "Pooled analysis of the European (EUR) and Chinese (Ch) BRCA1-RAP80

Expression Customization (BREC) randomized trials of customized therapy in advanced non-small-cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC and ChiCTR-TRC-12001860)" 17th ECCO 38th ESMO 32nd ESTRO European Cancer Congress, Amsterdam, 27 September – 1 October 2013 **(Poster)**

- Garcia Campelo R, Felip E, Massuti T, Majem M, Carcereny E, Palmero R, Molina M.A, González-Arenas C, Sanchez- Ronco M, Rosell R. "Phase IB study to evaluate the efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients with epidermal growth factor receptor (EGFR) mutation positive advanced non-small-cell lung cancer (NSCLC) patients (pts). (NCT=1513174/GECP-GOAL)" 17th ECCO 38th ESMO 32nd ESTRO European Cancer Congress, Amsterdam, 27 September – 1 October 2013 **(Poster)**

- Gil M, Remon J, Alcaraz D, Capdevila L, Sais E, Reguart N, Morán M, Carcereny E, Porta R, Rosell R. "Treatment strategies after failure to reversible tyrosine kinase inhibitors (rTKI) in EGFR mutant (mut) non-small cell lung cancer (NSCLC) patients (p): A retrospective analysis of 41 Spanish patients" 17th ECCO 38th ESMO 32nd ESTRO European Cancer Congress, Amsterdam, 27 September – 1 October 2013 **(Poster)**

- Vilà L, Pardo N, Cuadra J. L, Capdevila L, Moran T, Carcereny E, Queralt C, De Aguirre I, Taron M, Rosell R. "Tyrosine kinase inhibitors (TKI) treatment of non-small cell lung cancer (NSCLC) patients (p) based on EGFR mutations (m) status in serum only" 17th ECCO 38th ESMO 32nd ESTRO European Cancer Congress, Amsterdam, 27 September – 1 October 2013 **(Poster)**

- Morales-Espinosa D, Costa C, Karachaliou N, Molina-Vila M. A, Gimenez-Capitan A, Bonnano L, Majem M, Massuti B, Sanchez J. J, Rosell R. "MED12, a component of the transcriptional MEDIATOR complex, and STAT3 influence outcome to platinum-based chemotherapy in patients (p) with advanced non-small-cell lung cancer (NSCLC)" 17th ECCO 38th ESMO 32nd ESTRO European Cancer Congress, Amsterdam, 27 September – 1 October 2013 **(Poster)**

IASLC, Sydney

- Rosell R, Moran T, Cobo Dols M, Domine M, Sanchez-Ronco M, Bover I, Provencio M, Massuti B, Vergnenegre A, Lopez-Vivanco G, Robinet G, Insa A, Majem M, De Las Peñas R, Angeles Sala M.A, Isla D, Baize N, Garde J, Chaib I, Camps C. "The Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR) (NCT00617)" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Oral)**

- Ramalingam S, Shapiro G, Hirsh V, Zaric B, Ceric T, Poddubskaya E, Goldman J, Ciuleanu T, Khuri F, Spicer J, Skrylnik O, Felip E, Manegold C, Andric Z, Rosell R, Badovinac S, Pieters T, Modiano M, Vukovic V, Yalcin I, Teofilovici F, El-Hariry I, Guo W, Bahcall S, Goss G, Fennell D "GALAXY-1: Randomized phase II study of docetaxel with or without ganetespib in advanced lung adenocarcinoma: Results in biomarker sub-groups and all adenocarcinoma patients". IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Oral)**

- Spigel D, Kim E, Lynch T, McCleod M, Waterhouse D, Paz-Ares L, Harper P, Hainsworth J, De Marinis F, Kabbinavar F, Rosell R, Socinski M, Vergnenegre A, Garcia-Ribas I, Burris H, Shepherd A. "Randomized Phase III Trial of Gemcitabine (G)/Carboplatin (C) with or without Iniparib (I) in Patients (Pts) with Previously Untreated Stage IV Squamous Lung Cancer" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Oral)**

- Vergnenegre A, Rosell R, Massuti B, Do P, Corre R, Felip E, Palmero R, Garcia-Gomez R, De Marinis F, Santarpia M, Wright E, Chouaid C. "Cost-utility analysis of first-line treatment with erlotinib versus chemotherapy in EGFR-mutant advanced non-small-cell lung cancer (NSCLC): economic analysis of EURTAC trial" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Oral)**

- Brambilla E, Marguet S, Le Teuff G, Lantuejoul S, Shepherd F, Seymour L, Kratzke R, Graziano S, Popper H, Pignon J. P, Rosell R, Douillard J-Y, Le Chevalier T, Soria J-C, Sound Tsao M. "Prognostic and predictive value of a new IASLC/ATS/ERS lung adenocarcinoma classification in a pooled analysis of four adjuvant chemotherapy trials: a LACE-Bio study" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Oral)**

- Carcereny E, Moran T, Estival A, Andreo F, Lletjos M, Mijangos E, Sanz J, Castellà E, Capdevila L, de los Llanos Gil M, Rodriguez L, Hardy-Werbin M, De Aguirre I, Rosell R. "Cytology samples (s) for EGFR, KRAS and ALK testing in Non-Small-Cell Lung Cancer (NSCLC)" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Mini oral)**

- Bivona T, Gianikopoulos P, Costa C, Karachaliou N, St. John J, Wilkerson M, Cauhlin A, Westesson O, Boley N, Hahner N, Parikh U, Lozano M, Viteri S, Perez-Gracia J, Curioni A, Jantus-Lewintre E, Camps C, Vergnenegre A, Gervais R, Wellde A, Barry J, Wellde Jr. G, Cardona A, Stahel R, Polkinghorn W, Rosell R, Weissman J. "Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired resistance to erlotinib". IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Mini oral)**

- Karachaliou N, Costa C, Gimenez-Capitan A, Drozdowskyj A, Gervais R, Vergnenegre A, De Marinis F, Majem M, Felip E, Garcia-Campelo R, Moran T, Viteri S, Gasco A, Massuti B, Rosell R. "The concomitant presence of echinoderm microtubule associated protein like 4 - anaplastic lymphoma kinase (EML4-ALK) EML4-ALK fusion gene in EGFR-mutant non-small-cell lung cancer (NSCLC) patients treated with erlotinib or chemotherapy in the EURTAC trial" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Mini oral)**

- Massuti B, Cobo M, Rodriguez-Paniagua M, Ballesteros I, Moran T, Arrabal R, Gonzalez J. L Larriba, Barneto I, Wah Pun Y, Castro Carpeño J, Iglesias L, Baamonde C, Muñoz M. A, Lopez-Vivanco G, Rivas De Andres J. J, Isla D, Lopez R, De Las Peñas R, Rodriguez D, Lopez De Castro P, Artal A, Esteban Gonzalez E, Hernando Trancho F, Provencio M, Valdivia J, Diaz Agero P, Martin De Nicolas J. L, Pereira E, Sanchez J. M, Rosell R. "First analysis of toxicity and treament compliance in customized postoperative chemotherapy based on BRCA1 levels after NSCLC resection: SCAT (Spanish Customized Adjuvant Therapy) trial. Spanish Lung Cancer Group/GECP" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Mini oral)**

- Bramuglia G, Martin C, Cardona A, Arrieta O, Campos Parra A, Carranza H, Vargas C, Otero J, Powazniak Y, Trigo M, Sena S, Más L, Oblitas G. A, Pastrán Z, Bernal L, Sánchez-Reyes R, Zúñiga-Orlich C, Rosell R. "Update genotyping non-small cell lung cancer (NSCLC) in Latin America: Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Mini oral)**

- Remon J, Moran T, Jové M, Capdevila L, Alcaraz D, Carcereny E, Plana M, Reguart N, Porta R, Rosell R. "Treatment strategies after failure to reversible Tyrosine Kinase Inhibitors (rTKI) in EGFR mutant (mut) Non-Small Cell Lung Cancer (NSCLC) patients (p). A retrospective analysis of 59 Spanish Patients" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Poster)**

- García-Campelo R, Felip E, Massuti B, Majem M, Carcereny E, Palmero R, Molina M. A, Cajal R, Sánchez-Ronco M, Rosell R. "Phase IB study to evaluate the efficacy and tolerability of Olaparib (AZD2281) plus gefitinib in patients (p) with epidermical frowth factor receptor non-small-cell lung cancer (NSCLC) patients (p)". (NCT=1513174/GECP-GOAL) IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Poster)**

- Massuti B, González-Larriba J. L, Jantus-Lewintre E, Rodríguez-Abreu D, Juan O, Sanchez Ronco M, Domine M, Provencio M, Garde J, García Gómez R, Maestu I, Pérez de Carrión R, Artal A, Rolfo C, de Castro J, Terrasa J, Oramas J, de las Peñas R, Ferrara L, Soto M, Martínez N, Serra O, Rosell R, Camps C. "Study of the correlations between SNPs in angiogenic genes and treatment response/ outcome in patients with advanced NSCLC (non-squamous histology) treated in first line with carboplatin, paclitaxel and bevacizumab (CPB). The ANGIOMET study". IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Poster)**

- Rosell R, Molina M.A, Drozdowskyj A, Costa C, Giménez-Capitan A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S. "Impact of EGFR T790M mutations and BIM mRNA expression on progression-free survival (PFS) and overall survival (OS) in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Poster)**

- Massuti B, Lopez-Vivanco G, Marti T, Kotov I, Chaib I, Ponce-Aix S, Garcia-Campelo R, Sanchez J. M, Artal A, Bover I, Taron M, Sanchez-Ronco M, Rolfo C, Stahel R, Rosell R. "Outcome in pemetrexed/cisplatin-treated non-small-cell lung cancer (NSCLC) patients according to mRNA expression levels of BRCA1, TS, AEG1 and REV3" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Poster)**

- Sanchez-Torres J. M, Rodriguez D, Oramas J, Lopez Criado P, Macias J. A, Bosch J, Martinez-Banaclocha N, Diz P, Iglesias L, Rolfo C, Esquerdo G, Juan O, Garde J, Esteller M, Rosell R. "The PHALCIS Trial (PHarmacogenomic ALimta CISplatin): A clinical trial in progress by The Spanish Lung Cancer Group" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Poster)**

- Karachaliou N, Drozdowskyj A, Costa C, Molina M. A, Gimenez-Capitan A, Vergenenegre A, Massuti B, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S,

Heidecke C, Estrada-Tejedor R, Teixido J, Bivona T, Giannikopoulos P, Ono M, Rosell R. "ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer (NSCLC) patients with the EGFR T790M mutation" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Poster)**

- Morales-Espinosa D, Costa C, Karachaliou N, Molina-Vila M. A, Gimenez-Capitan A, Bonanno L, Majem M, Massuti B, Sanchez J. J, Rosell R. "MED12, a component of the transcriptional MEDIATOR complex, and STAT3 influence outcome to platinum-based chemotherapy in patients (p) with advanced non-small-cell lung cancer (NSCLC)" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Poster)**

- Wei J, Qian X, Zou Z, Wang L, Yu L, Sanchez-Ronco M, You C, Song Y, Lu H, Hu W, Yan J, Xu X, Chen X, Li X, Wu Q, Zhou Y, Zhang F, Rosell R, Liu B. "Chinese randomized phase II trial of customized chemotherapy based on BRCA1-RAP80 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) (ChiCTR-TRC-12001860/BREC-CHINA)" IASLC 15th World Conference on Lung Cancer, Sydney Australia October 27-31 2013 **(Poster)**

Spanish Lung Cancer Group 10th Congress on Lung Cancer, Barcelona

- Rosell R. "Moving forward to synthetic lethality approaches for improving survival in NSCLC" Spanish Lung Cancer Group 10th Congress on Lung Cancer, Barcelona, Spain, 21-22nd November 2013 **(Plenary lecture)**

OTHER MEETINGS

- Rosell R. "The landscape of the future of lung cancer treatment" The Future in Lung Cancer: One Step Beyond, Madrid, 21 February 2013 **(Invited lecture)**

- Rosell R. "Building on EGFR Inhibition: Synthetic Lethality Strategies"ESMO Symposium 2013: Signaling Pathways in Cancer, Sitges, Barcelona 1-2 March 2013 **(Invited lecture)**

- Rosell R. "The EGFR story in NSCLC" The 1st International Congress on Controversies in Personalized Oncology: Breast, Colon, Lung, Melanoma (CONPO), Barcelona, 7 - 9 March 2013 **(Invited lecture)**

- Rosell R. "Adaptive Resistance in Lung Cancer" IV Curso Avances en el Abordaje Multidisciplinar del Cáncer de Pulmón, Madrid, 14 March 2013 **(Invited lecture)**

- Rosell R. "Adaptive Resistance to Targeted Therapies in Lung Cancer" 2013 Lung Cancer Conference, Lung Cancer Treatment in the Era of Personalised Medicine, Luxembourg, 14-15 March 2013 **(Invited lecture)**

- Rosell R. "Novel Targets Identified by Molecular Profiling" 6th International Conference on Molecular Targeted Therapy in Lung Cancer, Sorrento, Italy, 17-20 April 2013 **(Invited lecture)**

- Rosell R. "Genetics and Biomarkers in Personalization of Lung Cancer Treatment" Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, 23 April 2013 **(Invited lecture)**

- Rosell R. "Understanding Cancer Biology for Better Treatment and Curability" Fundación La Rosaleda, Santiago de Compostela, 23 April 2013 **(Invited lecture)**

- Rosell R. "EGFR mutation: mechanisms of drug resistance" AIOT 7th International Experts Panel Meeting, Sperlonga, Italy, 3 May 2013 **(Invited lecture)**

- Rosell R. "The BREC Study" VII Annual Meeting of the French and Spanish Lung Cancer Groups, 15-16 May 2013 – Barcelona **(Invited lecture)**

- Rosell R. "Precision Medicine for Cancer Management" IGTP – ICO 3rd Can Ruti Symposium, Badalona, Spain 27 June 2013 **(Invited lecture)**

- Rosell R. "DNA repair and prognostic and predictive information for lung cancer treatment" Essen Thoracic Oncology Conference, Essen, Germany, June 28 - 29 2013 **(Invited lecture)**

- Rosell R. "State of the art" ETOP Residential Workshop, Lugano, Switzerland, 29-31 August 2013 **(Invited lecture)**

- Rosell R. "Genetics and tailored treatment of lung cancer" Annual Congress of the European Respiratory Society, Barcelona, 10 September 2013 **(Invited lecture)**

- Rosell R. "Unmet medical needs in NSCLC treatment" XIV Congreso Nacional de Oncología Médica, Salamanca, Spain, 23 October 2013 **(Invited lecture)**

- Rosell R. "Precision Medicine for Cancer Management" 3rd Munich Biomarker Conference, Munich, Germany, November 26-27, 2013 **(Invited lecture)**

- Rosell R. "The BELIEF Trial" ETOP Annual Meeting, Barcelona, Spain, 22-23 November 2013 **(Invited lecture)**

- Rosell R. "Overview of promising new targets" ETOP Annual Meeting, Barcelona, Spain, 22-23 November 2013 **(Invited lecture)**

- Rosell R. "Precision Medicine for Cancer Management" 3rd Munich Biomarker Conference, 26-27 November 2013 **(Invited lecture)**

- Rosell R. "The future of molecular biomarkers in lung cancer" Lung Cancer Molecular Biology Master Class, Aix Marseille University, France, December 4-6, 2013 **(Invited lecture)**

- Rosell R. "Can we do better with our current therapies for NSCLC? The European Approach" Practical and Emerging Agents in Lung Cancer, Dallas U.S.A, December 14 2013 **(Invited lecture)**

- Rosell R. "Erlotinib in Metastatic NSCLC: What have we learned since 2004?" Practical and Emerging Agents in Lung Cancer, Dallas U.S.A, December 14 2013**(Invited lecture)**

- Rosell R. "Genetic Basis of Cancer: New views in cancer progression. International Cáncer Genome Consortium". XXXII Leccion Memorial Fernandez-Cruz, Madrid December 19 2013 **(Invited lecture)**

2012

ORGANIZATION OF COURSES AND CONFERENCES

- Director and Co-Chair "Metastatic Melanoma: Oncogenic lesions and dysregulation of canonical signaling pathways – clinical intervention" Educational Symposium, Instituto Oncológico Dr Rosell, USP Dexeus, Barcelona 26 April 2012

- Director Joint meting of the Cologne and Spanish lung cancer groups, Dexeus University Institute, Barcelona, Spain 14 September 2012

- Conference Scientific Chair Plenary Session & VI Educational Symposium of the Spanish Lung Cancer Group, Alicante, Spain 29 – 30 November 2012

PUBLICATIONS

Original articles:

- Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd FA, Pignon JP, Sève P; LACE-Bio Group. "Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials." *Ann Oncol.* 2012 Jan;23(1):86-93.

- Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez J. M, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno M. A, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez J. L, Sanchez J. J, Molina M. A, Taron M, Paz-Ares L. "Erlotinib versus chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial" *Lancet Oncology* 2012 Mar;13(3):239-246. Epub 2012 Jan 26.

- Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G, Pao W. "Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma." *Eur Respir J.* 2012 Feb;39(2):366-72.

- Gironés R, Torregrosa D, Gómez-Codina J, Maestu I, Tenias JM, Rosell R. "Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians." *Clin Transl Oncol*. 2012 Mar;14(3):183-9.

- Massuti B, Cobo M, Camps C, Dómine M, Provencio M, Alberola V, Viñolas N, Rosell R, Tarón M, Gutiérrez-Calderón V, Lardelli P, Alfaro V, Nieto A, Isla D. "Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum." *Lung Cancer.* 2012 Jun;76(3):354-61. Epub 2011 Dec 23.

- Ramalingam S, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O'Connell J, Boyer M. "Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer." *J Clin Oncol*. 30;27: 3337-3344, 2012 Epub Jul 2

- Zhang Z, Lee JC, Lin L, Olivas V, Au V, Laframboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. "Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer." *Nat Genet*. 2012 Jul 1;44(8):852-860. doi: 10.1038/ng.2330.

- Tabara K, Kanda R, Sonoda K, Kubo T, Murakami Y, Kawahara A, Azuma K, Abe H, Kage M, Yoshinaga A, Tahira T, Hayashi K, Arao T, Nishio K, Rosell R, Kuwano M, Ono M. "Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells." *PLoS One*. 2012;7(7):e41017. Epub 2012 Jul 17.

- Dueñas M, Santos M, Aranda JF, Bielza C, Martínez-Cruz AB, Lorz C, Taron M, Ciruelos EM, Rodríguez-Peralto JL, Martín M, Larrañaga P, Dahabreh J, Stathopoulos GP, Rosell R, Paramio JM, García-Escudero R. "Mouse p53-Deficient Cancer Models as Platforms for Obtaining Genomic Predictors of Human Cancer Clinical Outcomes." *PLoS One.* 2012;7(8):e42494. Epub 2012 Aug 7.

- Provencio M, Camps C, Cobo M, De Las Peñas R, Massuti B, Blanco R, Alberola V, Jimenez U, Delgado JR, Cardenal F, Tarón M, Ramírez JL, Sanchez A, Rosell R. "Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer." *Cancer Chemother Pharmacol.* 2012 Dec;70(6):883-90. Epub 2012 Sep 29.

Review articles:

- Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC. "ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development." *Eur J Cancer*. 2012 May;48(7):961-73. Epub 2012 Mar 6.

- Mayo C, Bertran-Alamillo J, Molina-Vila MÁ, Giménez-Capitán A, Costa C, Rosell R. "Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications." *Pharmacogenomics.* 2012 May;13(7):789-802.

- Rosell R, Cardona A. F, García-Campelo R, Majem M, Carcereny E, Viteri S, Gascó A, Buges C, Santarpia M, Massuti B, Costa C, Molina M. A. "A friendly approach to personalized treatment in lung adenocarcinoma" *Revista Colombiana de Hematología y Oncología* Abril 2012, Vol 1;1

- Reck M, Rosell R, Tiemann M. "Therapeutic standards and perspectives for stage IV non-small cell lung cancer." *Onkologie* 2012;35 Suppl 3:10-3. Epub May 15 2012

Contributions to books:

- Rosell R. *Molecular-Based decision making for personalized cancer management*. E-Book written and edited by Rafael Rosell & Duc Hong Lee. ISBN: 978-1-78084-155-7 (print) ISBN: 978-1-78084-154-0 (epub) ISBN: 978-1-78084-153-3 (pdf) © 2012 Medicine Ltd

- Rosell R, Moran T and Taron M. "Drugs, genomic response signatures and customized cancer therapy." *Chemical Genomics* (pp.301-319) Edited by Haian Fu. New York, Cambridge University Press 2012, First edition (ISBN 978-0-521-88948-3)

- Rosell R, Taron M, Rolfo C. D, Rodriguez-Abreu D, Wei J. "Diagnostic, Prognostic, and Therapeutic Value of Gene Signatures in Non-Small Cell Lung Cancer" chapter in *Current Clinical Pathology*, 2012, 81-94, DOI: 10.1007/978-1-61779-358-5_6

- Rosell R, Bonanno L, Taron M. "Selection of NSCLC patients to treat with EGFR inhibitors in the era of personalized medicine" E-Chapter published by Future Medicine UK 2012 pages 18-32

- Bonanno L, Rosell R. "Customized chemotherapy" *Perspectives in Thoracic Oncology* , textbook edited by Oliver Gautshi, Solange Peters, UNI-MED Germany 2012 *(in press)*

Editorials:

- R Rosell. "Aims and Scope of the World Journal of Respirology" *World Journal of Respirology* ISSN 2218-6255 (online) 2012

- Rosell R, Wei J. "Single Nucleotide Polymorphisms (SNPs) in Non-Small Cell Lung Cancer (NSCLC) Patients." *The Oncologist.* 2012 17:1484-1485

- Rosell R, Wannesson L. "A genetic snapshot of small cell lung cancer."*Cancer Discov.* 2012 Sep;2(9):769-71.

- Rosell R, Molina MA, Serrano MJ. "EGFR mutations in circulating tumour DNA." *Lancet Oncology* 2012 Oct;13(10):971-3.

PARTICIPATION IN SCIENTIFIC MEETINGS

MAJOR INTERNATIONAL MEETINGS

BTOG Dublin

- Rosell R. "Growth factors and DNA repair" 10th Annual British Thoracic Oncology Group Conference, Dublin, Ireland Wednesday 25th January 2012 **(Invited lecture)**

ICACT Paris

- Rosell R. "The predictive role of signalling networks involved in advanced lung cancer: translational and clinical perspectives" 23nd International Congress on Anti-Cancer Treatment (ICACT), Paris, France ,January 31 – February 2 2012 **(Invited lecture, Presidential session)**

- Rosell R. "Cancer Translational Research" 23nd International Congress on Anti-Cancer Treatment (ICACT), Paris, France ,January 31 – February 2 2012 **(Invited lecture)**

- Rosell R. "Lung Cancer Customized Treatment" 23nd International Congress on Anti-Cancer Treatment (ICACT), Paris, France ,January 31 – February 2 2012 **(Invited lecture)**

AACR Chicago

- Costa C, Giménez-Capitán A, Benlloch S, Tarón M, Jimeno J, Viteri S, Gascó A, Camps C, Carcereny E, Massuti B, Rosell R. "Correlation between BRCA1 and LMO4 mRNA

expression levels in erlotinib- treated NSCLC patients with EGFR mutations" AACR Annual Meeting, Chicago U.S.A, March 31 – April 2012 **(Poster)**

- Molina M, Bertran-Alamillo J, Mayo C, Costa C, Giménez-Capitán A, Massuti B, Camps C, Carcereny E, Viteri S, Benlloch S, Rosell R. "Mutations in p53 are associated with shorter time to progression (TTP) and overall survival (OS) in erlotinib-treated, EGFR-mutated patients" AACR Annual Meeting, Chicago U.S.A, March 31 – April 2012 **(Poster)**

ASCO, Chicago

- Rafael Rosell, Miguel Angel Molina-Vila, Miquel Taron, Jordi Bertran-Alamillo, Clara Mayo, Alain Vergnenegre, Filippo De Marinis, Bartomeu Massuti, Javier De Castro, Radj Gervais, Enric Carcereny, Cristina Buges, Teresa Moran, Mariacarmela Santarpia, Enriqueta Felip, Margarita Majem, Joaquim Bosch, Felipe Cardenal, Ana Drozdowskyj, Trever Grant Bivona. "EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Poster Discussion)**

- Jose Miguel Sanchez, Manuel Cobo, Rafael Arrabal, Bartomeu Massuti, Jose Manuel Rodriguez Paniagua, Teresa Moran, Julio Astudillo, Ulpiano Jimenez, Yat Wa Pun, David Aguiar Bujanda, Jorge Freixenet, Jose-Luis Gonzalez-Larriba, Florentino Hernando-Trancho, Jose Gómez-Codina, Juan-Carlos Penalver, Natividad Martinez Banaclocha, Guillermo Lopez-Vivanco, Joaquin Pac, Miquel Taron, Rafael Rosell "Pilot SCAT trial: Spanish customized adjuvant chemotherapy (CT) based on BRCA1 mRNA expression levels (l) in resected stage II-IIIA non-small cell lung cancer (NSCLC) patients (p)." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Poster Discussion)**

- Gregory J. Riely, Julie R. Brahmer, David Planchard, Lucio Crinò, Robert Charles Doebele, Luis Alberto Mas Lopez, Scott N. Gettinger, Christian Schumann, Xiaoyun Li, Barbara McCormick Atkins, Scot Ebbinghaus, Rafael Rosell "A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Poster Discussion)**

- Cristina Buges, Alex Martinez Marti, Rafael Rosell, Alain Vergnenegre, Filippo De Marinis, Bartomeu Massuti, Javier De Castro, Radj Gervais, Enric Carcereny Costa, Teresa Moran, Mariacarmela Santarpia, Enriqueta Felip, Margarita Majem, Rut Porta, Ramon Palmero, Ana Drozdowskyj, Cordula Heidecke, Amaya Gasco, Miquel Taron, Luis G. Paz-Ares. "Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Poster)**

- Enric Carcereny Costa, Miquel Taron, Cristina Queralt, Itziar de Aguirre, Laia Capdevila, Sara Cros, Alain Vergnenegre, Filippo De Marinis, Bartomeu Massuti, Noemi Reguart, Mayumi Ono, Cristina Buges, Mariano Provencio, Pilar Garrido López, Santiago Viteri Ramirez, Amaya Gasco, Jose Miguel Sanchez, Manuel Cobo, Ana Drozdowskyj, Rafael Rosell "Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Poster)**

- Jia Wei, Carlota Costa, Baorui Liu, Jose Javier Sanchez, Ana Gimenez Capitan, Lixia Yu, Zhengyun Zou, Xiaoping Qian, Xia Sun, Jie Shen, Clara Mayo, Miguel Angel Molina-Vila, Susana Benlloch, Miquel Taron, Rafael Rosell "Measuring transcripts of components of the BRCA1 DNA repair pathway, components of the hippo-YAP pathway, β-TrCP, HER2, AEG-1, EZH2 and other genes in advanced gastric cancer." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Poster)**

- Bartomeu Massuti, Ramon Lecumberri, Guillermo M Lopez Vivanco, Albert Font, Enrique Gonzalez-Billalabeitia, Juan Luis Marti-Ciriquian, Jose Gómez-Codina, Manuel Domine, Isabel Bover, Dolores Isla, Antonio Galan, Alfonso Gurpide, Vicente Vicente, Rafael Rosell, Mayte Monreal, Eduardo Rocha "ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)—Final results." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Poster)**

- Susana Benlloch, Miquel Taron, Maria Luisa Botero, Jordi Bertran-Alamillo, Clara Mayo, Ana Gimenez Capitan, Itziar de Aguirre, Cristina Queralt, Jose Luis Ramirez, Rafael Rosell, Barbara Klughammer, Mariette Schlegel, David Chen, Walter Bordogna, Ju Ruey-Jiuan Lee, Barbara Kovach, Patrick O'Donnell, Lin Wu, H. Jeffrey Lawrence. "Retrospective EGFR mutation testing of clinical specimens from the EURTAC trial of erlotinib in non-small cell lung cancer (NSCLC) using a novel allele-specific PCR (AS-PCR) assay." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Poster)**

- Glenwood D. Goss, Christian Manegold, Rafael Rosell, Dean Anthony Fennell, Vojislav M. Vukovic, Iman El-Hariry, Florentina Teofilovici, Aaron S. Enke, Suresh S. Ramalingam. "The GALAXY Trial (NCT01348126): A randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with stage IIIB or IV NSCLC." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Poster)**

- Sanjay Goel, Teresa Moran, Cinthya Coronado, Santiago Viteri Ramirez, Imran Chaudhary, Mohammad Haroon Ghalib, Umang Swami, Yijuan Hou, Enric Carcereny, Jose Alcantara, Jorge Luis Iglesias Dios, Bernardo De Miguel, Cristina Buges, Rafael Rosell. "Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Poster)**

- Gerardo F. Arroyo, Diego Kaen, Alejandro Salvatierra, Sandra Viviana Rojo, Ruben Dario Kowalyszyn, Marcos Ortiz, Marcela Carballido, Luis Alberto Kaen, Juan Jose Zarba, Enrique Luis Roca, Carlota Costa, Miguel Angel Molina-Vila, Jordi Bertran-Alamillo, Clara Mayo, Ana Gimenez Capitan, Jose Javier Sanchez, Susana Benlloch, Antoinette Lemoine, Miquel Taron, Rafael Rosell "F-box and WD repeat domain-containing 7 (FBXW7) mRNA and outcome in biliary tract cancer." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Proceedings)**

- Albert Font Pous, Pamela Celiz, Miquel Taron, Iman Chaib, Jose Luis Gago, Pedro Mendez, Jose Javier Sanchez, Olatz Etxaniz, Luis Cechini, Nuria Pardo, Belen Sanchez, Jose Luis Cuadra, Ivana Valverde, Oscar Buisan, Luis Ibarz, Rafael Rosell "BRCA1, RAP80, and AEG-1 mRNA expression in resectable muscle-invasive bladder cancer (MIBC) patients (p) treated with neoadjuvant cisplatin-based chemotherapy." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Proceedings)**

- Jie Shen, Jia Wei, Wen xian Guan, Hao Wang, Yi tao Ding, Xiaoping Qian, Lixia Yu, Zhengyun Zou, Li Xie, Miquel Taron, Rafael Rosell, Baorui Liu. "Relationship between plasma BRCA1 mRNA expression and sensitivity to docetaxel and cisplatin in gastric cancer." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Proceedings)**

- Laura Bonanno, Carlota Costa, Margarita Majem, Jose Javier Sanchez, Ana Gimenez Capitan, Alain Vergnenegre, Bartomeu Massuti, Clara Mayo, Miguel Angel Molina-Vila, Adolfo G. Favaretto, Cinta Pallares, Susana Benlloch, Massimo Rugge, Miquel Taron, Rafael Rosell. "DNA repair components modulating the function of breast cancer susceptibility gene 1 (*BRCA1*) in advanced non-small cell lung cancer (NSCLC) patients (p) treated with platinum-based chemotherapy." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Proceedings)**

- Andres Felipe Cardona Zorrilla, Oscar Arrieta, Guillermo Federico Bramuglia, Alma Delia Campos-Parra, Henry Alberto Becerra Ramirez, Martin MARCELO Claudio, Eduardo Richardet, Silvia J Serrano, Pilar Archila, Rafael Rosell. "Outcomes in Latin American NSCLC patients harboring wild-type or activating mutations of EGFR (CLICaP Registry)." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Proceedings)**

- Santiago Viteri Ramirez, Carlota Costa, Ana Gimenez Capitan, Susana Benlloch, Miquel Taron, Jose Javier Sanchez, Amaya Gasco, Alejandro Martinez-Bueno, Niki Karachaliou, Carlos Camps, Teresa Moran, Enric Carcereny Costa, Bartomeu Massuti, Felipe Cardenal, Rut Porta, Joaquim Bosch, Ramon Palmero, Cristina Buges, Rafael Rosell. "High mRNA expression of LMO4, a BRCA1 downregulator, correlates with better prognosis in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Proceedings)**

- Rosario Garcia-Campelo, Miquel Taron, Susana Benlloch, Jose Javier Sanchez, Carlota Costa, Ana Gimenez Capitan, Jordi Bertran-Alamillo, Clara Mayo, Miguel Angel Molina-Vila, Margarita Majem, Teresa Moran, Bartomeu Massuti, Carlos Camps, Dolores Isla, Manuel Cobo, Sara Cros, Laia Capdevila, Enric Carcereny Costa, Santiago Viteri Ramirez, Rafael Rosell. "MCPH1 (BRIT1) and outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) harboring EGFR mutations." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Proceedings)**

- Amaya Gasco, Miguel Angel Molina-Vila, Jordi Bertran-Alamillo, Clara Mayo, Carlota Costa, Ana Gimenez Capitan, Bartomeu Massuti, Carlos Camps, Enric Carcereny Costa, Santiago Viteri Ramirez, Alejandro Martinez-Bueno, Susana Benlloch, Laia Capdevila, Sara Cros, Rut Porta, Felipe Cardenal, Joaquim Bosch, Jose Javier Sanchez, Miquel Taron, Rafael Rosell. "Association of p53 mutations with progression-free survival (PFS) and overall survival (OS) in EGFR-mutated non-small cell lung cancer (NSCLC) patients (p) treated with erlotinib." ASCO Annual Meeting, Chicago, U.S.A, 1-5 June 2012 **(Proceedings)**

ESMO, Vienna

- Rosell R. "Concomitant actionable mutations and overall survival (OS) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) included in the EURTAC trial: EGFR exon 19 del/L858R w/ or w/out EGFR T790M, TP53, EML4-ALK and BIM mRNA expression" 37th ESMO Congress Vienna, Austria, 28 September – 2 October 2012 **(Oral)**

- Janne P, Shepherd F, Domerg C, Le Teuff G, Kratzke R, Hainaut P, Pignon J-P, Rosell R, Soria J-C, Tsao M "Prognostic and Predictive Values of KRAS in EGFR-based Subgroups and Combined with P53 in Completely Resected Non-Small Cell Lung Cancer (NSCLC): a LACE-Bio Study" 37th ESMO Congress Vienna, Austria, 28 September – 2 October 2012 **(Oral)**

- Rosell R, Ramalingam S, Fennell D, Manegold C, El Hariry I, Vukovic V, Teofilovici F, Reichert V, Goss G. "Molecular profiling as an outcome predictor in the GALAXY TrialTM (NCT01348126): A randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with Stage IIIb/IV NSCLC" 37th ESMO Congress Vienna, Austria, 28 September – 2 October 2012 **(Poster Discussion)**

- Wei J, Liu B, Yu L, Zou Z, Qiang X, Sánchez J.J, Costa C, Gimenez-Capitan A, Karachaliou N, Rosell R. "Overall survival (OS) to first- and second-line chemotherapy associated with mRNA expression of multiple myeloma SET (MMSET) domain, p53-binding protein 1 (53BP1) and breast cancer susceptibility gene 1 (BRCA1) in advanced gastric cancer patients (p)" 37th ESMO Congress Vienna, Austria, 28 September – 2 October 2012 **(Poster)**

- Bonanno L, Costa C, Majem M, Gimenez-Capitan A, Rodriguez I, Sánchez J.J, Massuti B, Favaretto A, Rugge M, Rosell R. "The predictive role of the 53BP1 pathway in advanced non-small-cell lung cancer (NSCLC) patients (p) treated with first-line platinum-based chemotherapy" 37th ESMO Congress Vienna, Austria, 28 September – 2 October 2012 **(Poster)**

- Garcia-Campelo R, Sánchez J.J, Costa C, Queralt C, De Aguirre I, Molina M.A, Majem M, Cros S, Capdevila L, Rosell R. "MCPH1 (BRIT1) and outcome to erlotinib in non-small-cell lung cancer (NSCLC) patients (p) harboring EGFR mutations" 37th ESMO Congress Vienna, Austria, 28 September – 2 October 2012 **(Poster)**

- Reguart n, Nadal E, Molina M.A, Carcereny E, Queralt C, Insa A, De Aguirre I, Taron M, Isla D, Rosell R. "T790M resistant mutation in plasma of acquired resistant EGFR mutated Non Small Cell Lung Cancer (NSCLC) patients - the TARZO Trial (NCT00503971)" 37th ESMO Congress Vienna, Austria, 28 September – 2 October 2012 **(Poster)**

- Karachaliou N, Costa C, Gimenez-Capitan A, Viteri S, Gasco A, Camps C, Carcereny E, Massuti B, Souglakos J, Rosell R. "High mRNA expression of LMO4, a BRCA1 downregulator, correlates with better prognosis in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations" 37th ESMO Congress Vienna, Austria, 28 September – 2 October 2012 **(Poster)**

- Pardo N, Celiz P, Font A, Taron M, Chaib I, Mendez P, Sánchez J.J, Sanchez B, Cuadra J.L, Rosell R. "Outcome to neoadjuvant cisplatin-based chemotherapy in resectable muscle-invasive bladder cancer (MIBC) patients (p) according to expression levels of BRCA1, RAP80, and AEG-1" 37th ESMO Congress Vienna, Austria, 28 September – 2 October 2012 **(Poster)**

- Ramalingam s, Zaric B, Goss G, Manegold C, Rosell R, Vukovic V, El-Hariry I, Teofilovici F, Enke A, Fennell D. "The GALAXY Trial (NCT01348126): A randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone as second line therapy in patients with stage IIIB or IV NSCLC" 37th ESMO Congress Vienna, Austria, 28 September – 2 October 2012 **(Poster)**

- Fennell D, Petricoin E, Shaw J, El Hariry I, Vukovic V, Teofilovici F, Reichert V, Rosell R. "Proteomic and circulating free DNA analysis outcome predictors in the GALAXY TrialTM (NCT01348126): A randomized phase IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with stage IIIb/IV NSCLC" 37th ESMO Congress Vienna, Austria, 28 September – 2 October 2012 **(Poster)**

SLCG Plenary Session & V Educational Symposium

- Rosell R. "Simultaneous assessment of driver alterations for rapid decisions in daily clinical practice" Plenary Session & VI Educational Symposium of the Spanish Lung Cancer Group, Alicante, Spain, 29 - 30 November 2012 **(Plenary lecture)**

OTHER MEETINGS

- Rosell R. "EGFR activating mutations: refining the outcomes" Avances en el abordaje del CPCNP con mutaciones activadoras de EGFR, Roche sponsored symposium, Madrid 26 January 2012 **(Invited lecture)**

- Rosell R. "Variety of EGFR-mutations and clinical impact" Thoracic oncology – optimisation through holistic approaches, quality assurance and molecular biology, Dresden Interdisciplinary Conference, Friday, 17 February 2012 **(Invited lecture)**

- Rosell R. "EGFR mutations as reference targeted lesions in lung adenocarcinoma – comprehensive molecular testing" III Curso Avances en el Abordaje Multidisciplinar de Cáncer de Pulmón, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid 8 Marzo 2012 **(Invited lecture)**

- Peters S, Blackhall F, Taron M, Rosell R, Hiltbrunner A, Maibach R, King R, Stahel R. "Etopdata system: Combining the comprehensive LUNGSCAPE database with a clinical trials platform" 10th International Congress on Targeted Anticancer Therapies, Amsterdam, The Netherlands, 8 - 10 March 2012 **(Poster)**

- Rosell R. "Detection of mutations in serum" 13th European Congress: Perspectives in Lung Cancer, Amsterdam, The Nethelands, 9 - 10 March 2012 **(Invited lecture)**

- Rosell R. "Molecular biomarkers for customizing chemotherapy in lung cancer"4th Congress of Chinese Association of Molecular Targeted Therapy in Oncology, Drum Tower Hospital of Nanjing, China, 21 April 2012 **(Invited lecture)**

- Rosell R. "Oncogenic driver mutations in melanoma and other tumors: new opportunities for combinatory therapies" Metastatic Melanoma: Oncogenic lesions and dysregulation of canonical signaling pathways – clinical intervention, Educational Symposium, Instituto Oncológico Dr Rosell, USP Dexeus, Barcelona 26 April 2012 **(Closing lecture)**

- Rosell R. "Actionable mutations in EGFR-mutant non-small-cell lung cancer patients: EML4-ALK, TP53, T790M in the EURTAC study" II Curso de Capacitación en Cáncer de Pulmón – GECP, Alcalá de Henares, Madrid, 28 Abril 2012 **(Invited lecture)**

- Rosell R. "Estudios con Erlotinib en 1L de CPCNP EGFR mut+" Llegan nuevos tiempos, Lancamiento de Tarceva, Roche symposium, Madrid, 17 May 2012 **(Invited lecture)**

- Stahel R, Peters S, Blackhall F, Bubendorf L, Dafni O, Kerr K, Taron M, Thunnissen E, Weder W, Smit E, Rosell R. "ETOP activity in the field of biomarkers and predictors" 13th Central European Lung Cancer Conference, Prague, Czech Republic 14 – 27 June 2012 **(Oral)**

- R Rosell. "Erlotinib vs chemotherapy vs gefitinib" 3rd International Congress on Thoracic Oncology AIOT, Naples June 28th – 30th 2012 **(Invited lecture)**

- Ramalingam S, Glenwood G, Manegold C, R Rosell, Teofilovici F, El-Hariry I, Vukovic V. "Erlotinib vs chemotherapy vs gefitinib" 3rd International Congress on Thoracic Oncology AIOT, Naples June 28th – 30th 2012 **(Poster)**

- Rosell R. "Concomitant EML4-ALK fusnion gene and other molecular alterations in EGFR-mutant non-small-cell lung cancer patients treated with erlotinib" Lung Cancer: from Molecular Knowledge to Treatment, Pamplona, Spain 3 July 2012 **(Invited lecture)**

- Dueñas M, Santos, M, Aranda J. F, Martinez-Cruz A. B, Lorz C, Taron M, Rosell R, Paramio J.M, García-Escudero R. "Mouse P53-deficient cancer models as platforms to obtain gemonic predictors for human cancer clinical outcome" 22nd Biennial EARC Congress in Barcelona, Spain, 7-10 July 2012 **(Oral)**

- Ramalingam S, Blackhall F, Rosell R, Mok T, Boyer M, Liang J, O'Connell J, Wang T, Taylor I. "Dacomitinib (D) Versus Erlotinib (E) in Patients (pt) with EGFR-mutated (mu) Advanced Non-small Cell Lung Cancer (NSCLC): Analyses from a Randomized, Phase 2 Trial" ASCO IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology 6-8 September 2012 **(Oral, Plenary session)**

- Rosell R. "Concomitant actionable mutations and overall survival (OS) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) included in the EURTAC trial: EGFR exon 19 del/L858R, T790M, TP53, EML4-ALK, and BIM mRNA expression" Joint meeting of the Cologne and Spanish lung cancer groups, Barcelona, Spain, 14 September 2012 **(Oral)**

- Bonanno L, Rosell R. "Platinum drugs and DNA repair mechanisms in lung cancer" 11th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy Stem cells, DNA repair mechanisms, DNA-damaging agents, Verona, Italy October 11-14, 2012 **(Oral)**

- Rosell R. "Concomitant EML4-ALK Fusion Gene and Other Molecular Alterations in EGFR-mutant Non-small-cell Lung Cancer Patients Treated with Erlotinib" 7th ESOG, Marbella, Spain, 17 October 2012 **(Invited lecture)**

- Garrido P, López-Vivanco G, Rosell R, Espinós B, Castro-Gomez A. " Cost-effectiveness analysis of erlotinib versus platinum based chemotherapy as first-line treatment of non-small cell lung cancer EGFR with activating mutations" ISPOR 15th Annual European Congress, Berlin, Germany 3-7 November 2012 **(Oral)**

- Rosell R. "The BELIEF Trial" ETOP Annual Meeting, Dublin, Ireland, 9-10 November 2012 **(Invited lecture)**

- Rosell R. "Limitations of genotype-directed cancer therapy" ESMO – RUSSCO Joint Symposium, Moscow, Russia, 14 November 2012 **(Invited lecture)**

- Rosell R. "Additional actionable mutations in EGFR mutant non-small cell lung cancer" IDIBELL Cancer Conference on Personalized Cancer Medicine, Barcelona, Spain December 3-4, 2012 **(Invited lecture)**

2011

ORGANIZATION OF COURSES AND CONFERENCES

Director and Chair "Annual Pre-ASCO Meeting of the Spanish Lung Cancer Group", Barcelona 18-19 May 2011

Director and Chair "V Annual Meeting of the French and Spanish Lung Cancer Groups" 19-20 May 2011 – Barcelona

Director "The Role of EGFR Mutations and Other Genetic Alterations in Clinical Practice A Three-Day Course for Russian Biologists" USP Dexeus University Institute, Barcelona 20 – 22 October 2011

Conference Scientific Chair, Spanish Lung Cancer Group 9th Congress on Lung Cancer, Barcelona, Spain, November 17-18, 2011

PUBLICATIONS

Original articles:

- Rosell R, Molina M. A, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta E, Massuti B, Queralt C, de Aguirre I, Sanchez J. M, Sanchez-Ronco M, Mate J. L, Ariza A, Benlloch S, Sanchez J. J,

Bivona T, Sawyers C, Taron M "Pre-treatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations." *Clin Cancer Research* 2011;17:1160-1168

- Bivona T, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller V, Costa C, Hannon G, Sawyers C "FAS and NF-kB signalling modulate dependence of lung cancers on mutant EGFR" *Nature* 2011 24 March Vol471; 523-526

- Font A, Taron M, Gago J. L, Costa C, Sanchez J. J, Carrato C, Mora M, Celiz P, Perez L, Rodriguez D, Gimenez-Capitan A, Quiroga V, Benlloch S, Ibarz L, Rosell R. "BRCA1 expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer." *Annals of Oncology* 2011 Jan;22(1):139-44. Epub 2010 Jul 5.

- Wu X, Ye Y, Rosell R, Amos C. A, Stewart D, Hildebrandt M, Roth J, Minna J, Gu J, Lin J, Buch S, Nukui T, Ramirez Serrano J. L, Taron M, Cassidy A, Lu C, Chang J, Lippman S, Hong W. K, Spitz M, Romkes M, Yang P "Genome-wide scan identifies a genetic predictor of survival in non-small cell lung cancer patients treated with platinum-based chemotherapy" *J Nat Cancer Inst* 2011 103;10 817-825

- Viñolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sanchez-Torres J. M, Barón F. J, Cobo M, Maestu I, Moreno I. Mesía C. Izquierdo A, Felip E, López-Brea M, Márquez A, Sánchez-Ronco M, Tarón M, Santarpia M. C, Rosell R. "Single nucleotide polymorphisms in MDR1 gene correlates with outcome in advanced non-small cell lung cancer patients treated with cisplatin plus vinorelvine". *Lung Cancer* 371 (2011) 191–198

- Sirera R, Bremmes R, Cabrera A, Jantus-Lewintre E, Sanmartin E, Blasco A, del Pozo N, Rosell R, Guijarro R, Galbis J, Camps C. "Circulating DNA is a useful prognostic factor in advanced non-small-cell lung cancer (NSCLC) patients." *Journal of Thoracic Oncology* 2011 6;2 286-290

- Porta R, Massutí B, Colomer R, Reguart N, Sánchez J. M, Mayo C, Lianes P, Queralt C, Guillén V, Hornedo J, Catot S, Isla D, Pradas A, Santander C, Diz P, Oramas J, Polo E, Puig T, Tarón M, Colomer R, Rosell R. "Brain metastasis from lung cancer responding to erlotinib: The importance of EGFR mutation" *European Resp. J.* Mar;37(3):624-31. Epub 2010 Jul 1.

- Yin M, Yan J, Voutsina A, Tibaldi C, Chistiani D, Rosell R, Booton R, Wei Q. "No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small-cell lung cancer: a meta-analysis." *Lung Cancer* 72 2011;370–377

- Hirsh V, Paz-Ares L, Boyer M, Rosell R, Middleton G, Eberhart W, Szczesna A, Reiterer P, Saleh M, Arrieta-Rodriguez O, Bajetta E, Webb R, Raats J, Benner R, Fowst C, Meech S, Readett D, Schiller J. "Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer (NSCLC)" *Journal of Clin Oncology* 2011; 29:19, 2667-2674

- Salazar F, Molina M. A, Sanchez-Ronco M, Moran T, Ramirez J. L, Sanchez J. M, Stahel R, Garrido P, Cobo M, Isla D, Bertran-Alamillo J, Massuti B, Cardenal F, Manegold C, Lianes P, Trigo J. M, Sanchez J. J, Taron M, Rosell R. "First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer." *Lung Cancer* 2011 Apr;72(1):84-91. Epub 2010 Aug 11.

- Reiman T, Lai R, Veillard A. S, Paris E, Soria J. C, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd F, Pignon J. P, Sève P, and for the LACE-Bio Group

"Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials" *Annals of Oncology,* Advance Access April 6, 2011 [Epub ahead of print]

- Schöffski P, Taron M, Jimeno J, Grosso F, Sanfilipio R, Casali PG, Cesne AL, Jones RL, Blay JY, Poveda A, Maki RG, Nieto A, Tercero JC, Rosell R. "Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study" *Eur J Cancer*. 2011 May;47(7):1006-12. Epub 2011 March 4.

- Mendez P, Taron M, Moran T, Fernandez M. A, Requena G, Rosell R. "Improved host-cell reactivation assay to quantify DNA repair capacity in cryopreserved peripheral lymphocytes." *DNA Repair* Jun 10;10(6):603-10. Epub 2011 May 5.

- Camps C, Jantus-Lewintre E, Cabrera A, Blasco A, Sanmartín E, Gallach S, Caballero C, Del Pozo N, Rosell R, Guijarro R, Sirera R. "The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients." *Lung Cancer*. 2011 Jun;72(3):365-9. Epub 2010 Nov 12

- Felip E, Gridelli C, Baas P, Rosell R, Stahel R, & Panel members "1st ESMO Consensus Conference in Lung Cancer; Lugano 2010: Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second- line, and third- line therapy". *Annals of Oncology* 2011 Jul;22(7):1507-19 Epub ahead of print May 20.

- Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla JA, Pedraza V, Boyero L, Rosell R, Fárez-Vidal ME. "Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer." *Int J Cancer*. 2011 Jul 15;129(2):355-64

- Iranzo V, Sirera R, Bremnes RM, Blasco A, Jantus-Lewintre E, Tarón M, Berrocal A, Blasco S, Caballero C, Del Pozo N, Rosell R, Camps C. "Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients." Clinical Lung Cancer 2011 Jul;12(4):224-30.

- Quiroga V, Morán T, Capdevila L, Cros S, Rosell R "Mujer no fumadora diagnosticada de adenocarcinoma de pulmón" Formación Médica Continuada en Oncológia 6;16 1-6

- Jantus-Lewintre E, Sirera R, Cabrera A, Blasco A, Caballero C, Iranzo V, Rosell R, Camps C. "Analysis of the prognostic value of soluble epidermal growth factor receptor plasma concentration in advanced non-small cell lung cancer patients" *Clinical Lung* Cancer 2011 Sep;12(5):320-7. Epub 2011 May 11

- Balaña C, Carrato C, Ramirez J. L, Cardona A. F, Berdiel M, Sanchez J. J, Tarón M, Hostalot C, Musulen E, Ariza A, Rosell R. "Tumor and serum MGMT promoter methylation and protein expression in glioblastoma patients" *Clin Trans Oncol* 2011 Sep;13(9):677-85.

- Santarpia M, Magri I, Sanchez-Ronco M, Costa C, Molina-Vila MA, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Benlloch S, Viteri S, Gasco A, Mederos N, Carcereny E, Taron M, Rosell R. "mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients." *J Transl Med.* 2011 Sep 27;9:163.

- Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez JJ, Qian X, Chen H, Gimenez-Capitan A, Meng F, Moran T, Benlloch S, Taron M, Rosell R, Liu B. "mRNA Expression of BRCA1, PIAS1, and PIAS4 and Survival After Second-line Docetaxel in Advanced Gastric

Cancer." *J Natl Cancer Inst*. 2011 Oct 19;103(20):1552-6. Epub 2011 Aug 23.

- Arrieta O, Cardona AF, Federico Bramuglia G, Gallo A, Campos-Parra AD, Serrano S, Castro M, Avilés A, Amorin E, Kirchuk R, Cuello M, Borbolla J, Riemersma O, Becerra H, Rosell R "Genotyping non-small cell lung cancer (NSCLC) in Latin America" *J Thorac Oncol.* 2011 Nov;6(11):1955-9

- Jantus-Lewintre E, Sanmartin E, Sirera R, Blasco Sanchez J. J, Taron M, Rosell R, Camps C. "Combined VEGF and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC." *Lung Cancer* 2011. Nov;74(2):326-31. Epub 2011 Apr 9

- Bover I, Rolfo C, Jantus-Lewintre E, Sirera R, Camps C, Chaib I, Ramirez-Serrano J. L, Benlloch S, Molina M. A, Simonetti s, Costa C, Gimenez-Capitan A, Mendez P, Taron M, Rosell R. "Fifth Educational Symposium of the Spanish Lung Cancer Group: Report on the Molecular Biology Workshop" *Lung Cancer* Dec;74(3):535-43. Epub 2011 May 25

Review articles:

- R Rosell (as member of Collaborative Group) "International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma" *Journal Thoracic Oncology* 2011 6:2 244 – 285

- Rosell R, Taron M, Massuti B, Mederos N, Magri I, Santarpia M, Sanchez J. M. "Predicting response to chemotherapy with early stage lung cancer". *Cancer Journal* 2011 Jan-Feb; 17(1):49-56

- Santarpia M, Altavilla G, Salazar M. F, Magri I, Pettineo G, Benecchi S, Rosell R, "Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive" *Expert Review of Respiratory Medicine* 2011 Jun;5(3):413-24.

- Gironés R, Torregrosa D, Gómez-Codina J, Maestu I, Tenias J, Rosell R. "Prognostic impact of comorbidity in elderly lung cancer patients: Use and comparison of two scores." *Lung Cancer* 2011 Apr;72(1):108-13. Epub 2010 Aug 19.

- Provencio M, Molina M. A, Méndez M, Rosell R. "Screening for epidermal growth factor receptor mutations in lung cancer and tyrosine-kinase inhibitors." *European Journal Clin Med Oncology* 2010 EJCMO 2011; 3:(2). April 2011 Epub ahead of print October 2010

- Bonanno L, Favaretto A, Rugge M, Taron M, Rosell R. "Role of genotyping in non-small-cell lung cancer (NSCLC) treatment: Current status*" Drugs.* 2011 Dec 3;71(17):2231-46

Contributions to books:

- Felip E, Morán T, Massuti B, Rosell R. "Stage IIIB and IV disease NSCLC: recurrent disease" *Lung Cancer, Current Multidisciplinary Oncology* Edited by Kemp Kernstein, Karen Reckamp and Charles Thomas, Demos Medical Publishing, First edition (ISBN 978-1-936287-06-2)

- Rosell R, Taron M and Jablons D. Lung Cancer Metastasis. Cancer metastasis: Biologic Basis and therapeutics. Edited by D. Lyden, T. Welch and B. Pasaila. Cambridge University Press, First edition; 369-381 (ISBN 9780521887212)

PARTICIPATION IN SCIENTIFIC MEETINGS

MAJOR INTERNATIONAL MEETINGS

British Thoracic Oncology Group Meeting, Dublin

- R Rosell "Growth factor signalling and DNA repair" 9th Annual BTOG Conference Dublin, 26 January 2011 **(Invited lecture)**

- R Rosell "State-of-the-Art Lectures" 9th Annual BTOG Conference Dublin, 27 January 2011 **(Chair)**

ICACT, Paris

- Rosell R "Customized treatment in NSCLC" ICACT 2011 – 22nd International Congress on Anti-Cancer Treatment, February 2 2011, Paris **(Invited lecture)**

- Rosell R "The evolving management of EGFR addicted lung cancer" ICACT 2011 – 22nd International Congress on Anti-Cancer Treatment, February 3 2011, Paris **(Invited lecture and Chair)**

EMCTO, Lugano

- Rosell R. "Chemotherapy selection according to chemotherapy markers" European Multidisciplinary Conference in Thoracic Oncology (EMCTO) 24-26 February 2011, Lugano, Switzerland **(Invited lecture)**

- Rosell R. "Presentation and discussion of the Lugano Consensus: Pathology and molecular testing" European Multidisciplinary Conference in Thoracic Oncology (EMCTO) 24-26 February 2011, Lugano, Switzerland **(Invited lecture)**

- Rosell R, Taron M, Benlloch S, Costa C, Santarpia C, Moran T, Carcereny E, Quiroga V, Massuti B, Gimenez-Capitan A "NanoString multiple target profiling identifies AEG-1 as an essential predictor of erlotinib outcome in EGFR-mutant non-small-cell lung cancer (NSCLC)" European Multidisciplinary Conference in Thoracic Oncology (EMCTO) 24-26 February 2011, Lugano, Switzerland **(Poster discussion)**

- Taron M, Stahel R, Rosell R, Blackhall F. "New tools in the molecular diagnostic of lung cancer" European Multidisciplinary Conference in Thoracic Oncology (EMCTO) 24-26 February 2011, Lugano, Switzerland **(Invited lecture)**

AACR, Orlando

- Rosell R, Molina M. A, Sanchez J. J, Taron M, Benlloch S, Moran T, Carcereny E, Cardena F, Massuti B, Magri I "De novo EGFR T790M mutation modifies outcome to second-line erlotinib in non-small cell lung cancer (NSCLC) according to metastatic site and upfront chemotherapy." AACR 102nd Annual Meeting 2011, Orlando, Florida 2-5 April 2011 **(Poster)**

- Taron M. Benlloch S, Rosell R, Sánchez J. J, Costa C, Santarpia M, Viteri S, Gascó A, Massuti B, Gimenez-Capitan A "NanoString multiple target profiling identifies AEG-1 as an essential predictor of erlotinib outcome in EGFR-mutant non-small cell lung cancer (NSCLC)." AACR 102nd Annual Meeting 2011, Orlando, Florida 2-5 April 2011 **(Poster)**

IASLC/ASCO/ESMO, Malta

- Rosell R. "LKB1 mutation in non-small cell lung cancer" 5th IASLC/ASCO/ESMO International Conference on Molecular Targeted Therapy in Lung Cancer, Malta, April 7 – 11 2011

ASCO, Chicago

- Rosell R. "Erlotinib vs chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) activating mutations: Interim results of the European Tarceva® vs Chemotherapy (EURTAC) phase III randomized trial" **(Oral)**

- Carcereny E, Moina M. A, Sanchez J. J, Bertran-Alamillo B, Mayo C, Aldeguer E, Gimenez-Capitan A, Yeste Z, Costa C, Benlloch S, Martinez A, Buges C, Bosch J, Isla D, Domine M, Provencio M, Sanchez J. M, Camps C, Taron M, Rosell R. "Mutations of the catalytic subunit of PI3K (PIK3CA) in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations in". ASCO Annual Meeting, Chicago U.S.A, 4-8 June 2011 **(Poster)**

- M Taron, S Benlloch, R Rosell, J J Sanchez, C Costa, A Gimenez-Capitan, C Mayo, J Bertran-Alamillo, M A Molina, B Massuti, C Camps, M Majem, D Isla, M Santarpia, S Viteri, A Gasco, T Moran, E Carcereny, C Queralt, I de Aguirre "Identification of AEG-1 and BARD1 as predictors of erlotinib outcome in EGFR-mutant non-small cell lung cancer (NSCLC) by NanoString multiple target profiling" ASCO Annual Meeting, Chicago U.S.A, 4-8 June 2011 **(Poster)**

- J Wei, J. L Ramirez, M Taron, J. J Sanchez, S Benlloch, R Rosell, M Botia, M Perez-Cano, P Mendez, M Tierno, C Queralt, I de Aguirre, B Sanchez, A Martinez, C Buges, J Bosch, B Massuti, C Camps, J M Sanchez, T Moran "DAB2 interactive protein (DAB2IP) methylation in serum DNA of non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations" ASCO Annual Meeting, Chicago U.S.A, 4-8 June 2011 **(Poster)**

- Santarpia M. C, Sanchez-Ronco M, Magri I, Molina M. A, Viteri S, Costa C, Gascó A, Gonzalez-Cao M, Mederos N, Salazar F, Bertran-Alamillo J, Gimenez-Capitan A, Altavilla G, Benlloch S, Yeste Z, Aldeguer E, Taron M, Rosell R. "The nuclear factor kb (NFkB) and Notch signalling pathways and BRCA1 mRNA expression in stage IV non-small-cell lung cancer (NSCLC) patients (p)." ASCO Annual Meeting, Chicago U.S.A, 4-8 June 2011 **(Poster)**

- Moran T, Sanchez J. J, Molina M. A, Bertran-Alamillo J, Gimenez-Capitan A, Yeste Z, Costa C, Aldeguer E, Benlloch S, Taron M, Massuit B, Camps C, Porta R, Isla D, Lopez-Vivanco G, Bover I, Garcia-Campelo R, Rolfo C, Salazar F, Carcereny E, Cardenal F, Magri I, Rosell R. "Initial detection of the double epidermal growth factor receptor (EGFR) mutation (L858R or deletion in exon 19 [del 19] plus T790M) in non-small-cell lung cancer (NSCLC) patients (p) with brain metastases (mets) and the influence of first-line chemotherapy on outcome to erlotinib". ASCO Annual Meeting, Chicago U.S.A, 4-8 June 2011 **(Poster)**

- S Viteri, R Rosell, C Costa, M Taron, J J Sanchez, S Benlloch, T Moran, B Massuti, C Camps, M Majem, E Carcereny, F Cardenal, A Gasco, N Mederos, I Magri, C Rolfo, R Garcia-Campelo, A Gimenez-Capitan, I de Aguirre, C Queralt. "Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations." ASCO Annual Meeting, Chicago U.S.A, 4-8 June 2011 **(Poster)**

- B. Massuti, U. Jimenez, J. M. Rodriguez Paniagua, Y. W. Pun, M. Cobo, E. Carcereny, R. Arrabal, J. Astudillo, I. C. Barneto, R. De Las Penas, C. Baamonde, G. Sales, J. L. Gonzalez-Larriba, G. Lopez-Vivanco, F. Hernando-Trancho, J. Pac, A. Artal-Cortes, J. J. Rivas, R. Rosell, J. M. Sanchez "SCAT trial: Phase III spanish customized adjuvant

treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer." ASCO Annual Meeting, Chicago U.S.A, 4-8 June 2011 **(Poster)**

- R. Sirera, E. Jantus-Lewintre, A. Timon, M. Usó, A. Berrocal, S. Borrego, G. Marcaida, E. Sanmartin, R. Rosell, C. Camps "The surfactant protein b(SFTPB) is a surrogate of circulating tumour cells (CTC) with prognostic value in advanced-stage NSCLC. ASCO Annual Meeting, Chicago U.S.A, 4-8 June 2011 **(Poster)**

- A. F. Cardona, P. L. Ramos, R. Duarte, H. Carranza, C. J. Castro, M. Lema, C. A. Vargas, A. Jimenez, H. A. Becerra, R. Rosell "Screening for mutations in Colombian metastatic non-small-cell lung cancer (NSCLC) patients (ONCOLGroup)" ASCO Annual Meeting, Chicago U.S.A, 4-8 June 2011 **(Poster)**

- D. R. Spigel, P. G. Harper, J. D. Hainsworth, F. De Marinis, F. F. Kabbinavar, E. S. Kim, T. J. Lynch, R. Rosell, F. A. Shepherd, M. A. Socinski, A. Vergnenegre "Randomized phase III trial of gemcitabine/carboplatin +/- iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC)." ASCO Annual Meeting, Chicago U.S.A, 4-8 June 2011 **(Poster)**

- Arrieta, A. F. Cardona, A. Gallo, G. F. Bramuglia, A. D. Campos-Parra, S. Serrano, C. Poleri, E. Amorin, R. Kirchuk, M. Cuello, E. Arechaga, R. Rosell "Genotyping non-small cell lung cancer (NSCLC) in latin america (LATAM)." ASCO Annual Meeting, Chicago U.S.A, 4-8 June 2011 **(Proceedings)**

- Magri, M. Santarpia, M. Sanchez-Ronco, S. Viteri, C. Costa, A. Gasco, N. Mederos, M. Gonzalez Cao, F. Salazar, J. Bertran-Alamillo, A. Gimenez Capitan, M. A. Molina, Z. Yeste, E. Aldeguer, T. Moran, G. Altavilla, S. Benlloch, M. Taron, R. Rosell "Differential expression of BRCA1 and genes involved in the nuclear factor kb (NFKB) and notch signalling pathways in non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) patients (p)." ASCO Annual Meeting, Chicago U.S.A, 4-8 June 2011 **(Proceedings)**

WCLC Amsterdam

- R Rosell "K-ras Biology" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Invited lecture)**

- Rosell R, Moran T, Felip E, Sanchez Torres J. M, Borghaei H, Guan S, Brown H, Fitzgerald T, Clark J, Sathyanarayanan S, Ayers M, Hardwick J, Lu B, Yan L, Johnson D. "An open label, randomized Ph II study evaluating dalotuzumab combined with erlotinib in patients with non-small cell lung cancer following failure of prior chemotherapy" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Oral)**

- Gervais R, Rosell R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Majem M, Sanchez Torres J. M, Porta R, Cobo M, Carreras M, Sanchez-Ronco M, Carcereny E, Moran T, Taron M, Di Seri M, Garrido P, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin A, De Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno M. A, Terrasa J, Munoz Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez D, Lopez-Vivanco G, Gebbia V, Lalchandani D, Bombaron P, Bernabe R, Bearz A, Artal A, Paz Ares L. "The EURTAC (European Tarceva® vs Chemotherapy) study: interim results of a phase III randomized trial of erlotinib vs chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR)

activating mutations" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Oral)**

- Wei J, Rolfo C, Moran T, Sanchez J. J, Molina M. A, Bertran-Alamillo J, Jimenez-Capitan A, Benlloch S, Taron M, Massuti B, Camps C, Porta R, Isla D, Lopez-Vivanco G, Bover I, Garcia-Campelo R, Salazar F, Carcereny E, Cardenal F, Magri I, Rosell R. "Initial detection of the double epidermal growth factor receptor (EGFR) mutation (L858R or deletion in exon 19 [del 19] plus T790M) in non-small-cell lung cancer (NSCLC) patients (p) with brain metastases (mets) and the influence of first-line chemotherapy" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Oral)**

- Boyer M, Blackhall F, Barrios C, Frank R, Heo D, Park K, Rosell R, Talbot D, Taylor I, Liang J, Campbell A, O'Connell J, Ramalingam S "Overall Survival (OS) Results of a Randomized Phase 2 Trial of PF299804 versus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Chemotherapy" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Oral)**

- Arrieta O, Cardona A. F, Lopez A. G, Bramuglia G, Campos Parra A, Serrano J, Castro M, Aréchaga E, Amorin E, Kirchuk R, M Cuello, Borbolla J, Rosell R "Genotyping Non-Small Cell Lung Cancer (NSCLC) in Latin American (LATAM) patients" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Oral)**

- Rosell R, Costa C, Taron M, Sanchez J. J, Benlloch S, Moran T, Massuti B, Camps C, M Majem, Carcereny E, Cardenal F, Gasco A, Mederos N, Magri I, Viteri S, Rolfo C, Garcia-Campelo R, Jimenez-Capitan A, De Aguirre I, Queralt C "Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Mini Oral)**

- Jimenez-Capitan A, Mayo C, Bertran-Alamillo J, Molina M. A, Massuti B, Camps C, Majem M, Isla D, Santarpia M, Viteri S, Gasco A, Moran T, Carcereny E, Queralt C, De Aguirre I, Taron M, Benlloch S, Rosell R, Sanchez J. J, Costa C, "Influence of BRCA1 and astrocyte elevated gene-1 as identified by multiplex target profiling of gene expression on outcome in erlotinib-treated non-small-cell lung cancer patients harboring EGFR mutations" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Mini Oral)**

- Riely G, Brahmer J, Planchard D, Crino L, Doebele R, Maz Lopez L, Gettinger S, Schumann C, Guan S, Atkins B, Ebbinghaus S, Rosell R. "A Randomized Discontinuation Phase II Trial of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Mini Oral)**

- Rosell R. "Mutational profiling for diagnostics/stratification: Further discussion of Wilbur Franklin's presentation: *Decision making – from the bench to the bed"* IASLC Lung Cancer Biomarkers Workshop, 14th Conference on Lung Cancer, Amsterdam, Netherlands 1-2 July 2011 **(Invited discussant)**

- Santarpia M, Sanchez-Ronco M, Magri I, Molina M. A, Viteri S, Costa C, Gasco A, Gonzalez-Cao M, Mederos N, Salazar F, Bertran-Alamillo J, Jimenez-Capitan A, Altavilla G, Benlloch S, Yeste Z, Aldeguer E, Taron M, Rosell R. "The nuclear factor κB (NFκB) and Notch signalling pathways and BRCA1 mRNA expression in stage IV non-small-cell lung cancer (NSCLC) patients (p)" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Poster)**

- Molina M. A, Gasco A, Carcereny E, Sanchez J. J, Bertran-Alamillo J, Mayo C, Aldeguer E, Jimenez-Capitan A, Yeste Z, Costa C, Benlloch S, Martinez A, Buges C, Bosch J, Isla D, Domine M, Provencio M, Sanchez Torres J. M, Camps C, Taron M, Rosell R. "Mutations of the catalytic subunit alfa of PI3K (PIK3CA) in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Poster)**

- Capdevila L, Carcereny E, Mijangos E, Moran T, Cros S, Buges C, Martinez A, De Aguirre I, Taron M, Rosell R. "Impact of KRAS mutations (Krasmut) on clinical outcome in stage IV non-small cell lung cancer (NSCLC) patients (pts) and their relationship with other biomarkers." 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Poster)**

- Cardona A. F, Serrano S, Ramos P. L, Duarte R, Carranza H, Castro C, Lema M, Vargas C, Jiménez J, Archila P, Salazar R, Torres D, Bruges R, Guerra J, Urrego M, Becerra H, Bonilla C, Rosell R. "Screening for mutations in Colombian metastatic non-small-cell lung cancer (NSCLC) patients (ONCOLGroup)" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Poster)**

- Peters S, Blackhall F, Boffetta P, Kerr K, Taron M, Bubendorf L, Ciardiello F, Rosell R, Weder W, King R, Stahel R. "Building a comprehensive database for the Lungscape project: A way to bridge genomics and clinical practice in the European Thoracic Oncology Platform (ETOP)." 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Poster)**

- Ramirez J, Taron M, Sanchez J. J, Benlloch S, Rosell R, Botia M, Perez-Cano M, Mendez P, Tierno M, Queralt C, De Aguirre I, Sanchez B, Martinez A, Buges C, Bosch J, Massuti B, Camps C, Sanchez Torres J. M, Moran T. "DAB2 interactive protein (DAB2IP) methylation in serum DNA of non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Poster)**

- Magri I, Santarpia M, Sanchez-Ronco M, Viteri S, Costa C, Gasco A, Mederos N, Gonzalez-Cao N, Salazar F, Bertran-Alamillo J, Richardet E, Jimenez-Capitan A, Molina M. A, Yeste Z, Aldeguer E, Moran T, Altavilla G, Benlloch S, Taron M, Rosell R. "Differential expression of BRCA1, RAP80 and genes involved in the nuclear factor κB (NFκB) and Notch signalling pathways in non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) patients (p)" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Poster)**

- Blackhall F, Peters S, Kerr K, Kulig K, Bubendorf L, Thunnissen E, Dziadziuszko R, O'Byrne K, Baas P, Weder W, Taron M, Rosell R, Stahel R. "ALK gene rearrangement: prevalence and clinical outcomes in patients with non-small cell lung cancer (NSCLC) in Europe – A European Thoracic Oncology Group (ETOP) LUNGSCAPE Study" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Poster)**

- Caballero E, Artigot A, Sanmartin E, Usó M, Gallach S, Sirera R, Rosell R, Camps C, Jantus Lewintre E. "Advanced NSCLC: Prognostic role of the expression of myeloid-derived suppressor cells related markers in peripheral blood samples." 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Poster)**

- Artigot I, Caballero E, Jantus Lewintre E, Borrego S, Marcaida G, Rosell R, Camps C, Sirera R. "Analysis of the expression of regulatory T-lymphocyte associated markers in peripheral blood samples from advanced NSCLC" 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July 2011 **(Poster)**

EMCC, Stockholm

- Rosell R. "Personalized therapy in lung cancer" ECCO-ESMO European Multidisciplinary Cancer Congress, Stockholm, Sweden 23-27 September 2011 **(Invited lecture)**

- Rosell R. "New therapeutic avenues in lung cancer based on disturbances in PI3K and RAS pathways" Hamilton Fairley Award Lecture, ECCO-ESMO European Multidisciplinary Cancer Congress, Stockholm, Sweden 23-27 September 2011 **(Invited lecture)**

- Taron M, Benlloch S, Sanchez J. J, Rosell R, Costa C, Queralt C, Mayo C, de Aguirre I, Moran T, Massuti B "BRCA1 and Astrocyte Elevated Gene-1 (AEG-1) Expression and Outcome of Erlotinib-Treated Non-Small-Cell Lung Cancer (NSCLC) Patients (p) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations " ECCO-ESMO European Multidisciplinary Cancer Congress, Stockholm, Sweden 23-27 September 2011 **(Oral)**

- De Marinis F, Rosell R, Vergnenegre A, Massuti B, Felip E, Gervais R, Cardenal F, Garcia-Gomez R, Taron M, Paz-Ares L. "Erlotinib Vs Chemotherapy (CT) in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) with Epidermal Growth Factor Receptor (EGFR) Activating Mutations: the EURTAC Phase II Randomized Trial Interim Results." ECCO-ESMO European Multidisciplinary Cancer Congress, Stockholm, Sweden 23-27 September 2011 **(Poster discussion)**

- Rolfo C, Moran T, Sanchez J. J, Molina-Vila M. A, Bertran-Alamillo J, Camps C, Benlloch S, Massuti B, Taron M, Rosell R. "Initial Detection of the Double Epidermal Growth Factor Receptor (EGFR) Mutation (L858R or Deletion in Exon 19 [del 19] Plus T790M) in Non-Small-Cell Lung Cancer (NSCLC) Patients (p) with Brain Metastases (mets) and the Influence of First-Line Chemotherapy On Outcome to Erlotinib" ECCO-ESMO European Multidisciplinary Cancer Congress, Stockholm, Sweden 23-27 September 2011 **(Poster discussion)**

- Rosell R. Santarpia M, Sanchez-Ronco M, Costa C, Molina-Vila M. A, Magri I, Viteri S, Gasco A, Mederos N, Taron M "MRNa Levels and Genetic Status of Genes Involved in the Epidermal Growth Factor Receptor (EGFR) and the Nuclear Factor ?B (NF-$_K$B) Pathways in Metastatic Non-Small-Cell Lung Cancer (NSCLC) Patients (p)" ECCO-ESMO European Multidisciplinary Cancer Congress, Stockholm, Sweden 23-27 September 2011 **(Poster)**

- Wei J, Ramirez J. L, Taron M, Sanchez J. J, Capdevila L, Cros S, Moran T, Carcereny E, Camps C, Rosell R. "DAB2 Interactive Protein (DAB2IP) Methylation in Serum DNA of Non-Small-Cell Lung Cancer (NSCLC) Patients (p) with Epidermal Growth Factor Receptor (EGFR) Mutations" ECCO-ESMO European Multidisciplinary Cancer Congress, Stockholm, Sweden 23-27 September 2011 **(Poster)**

- Cardenal F, Reguart N, Moran T, Insa A, Isla L, Magem M, Rolfo C, De Castro J, Queralt C, Rosell R. "Phase I/II trial of vorinostat (V) in combination with erlotinib (E) in advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression: The TARZO trial (NCT00503971) ECCO-ESMO European Multidisciplinary Cancer Congress, Stockholm, Sweden 23-27 September 2011 **(Poster)**

SEOM, Malaga

- Massuti B, Carcereny B. Felip E, Palmero R, Garcia-Gomez R, Majem M, Sanchez Torres J. M, Porta R, Paz-Ares L, Rosell R. "Resultados de EC Fase III en pacientes con Cáncer

Broncopulmonar Avanzado y mutaciones activadoras del gen EGFR comparando Erlotinib (E) frente Quimioterapia (QT) como primera línea de tratamiento. EURTAC (European Tarceva® vs Chemotherapy)" XIII Congreso Nacional SEOM, Málaga 18-21 octubre 2011 **(Oral, plenary session)**

- Carcereny E, Cros S, Palmero R, Molina M. A, Cuadra J. L, Aldeguer E, Yeste Z, Taron M, Viteri S, Rosell R. "Expresión de los Niveles de mRNA de AEG-1 (Astrocyte Elevated Gene 1) y BRCA1 en Pacientes con Carcinoma de Pulmón de Célula No Pequeña (CPCNP) Estadio IV con Mutación del Receptor del Factor de Crecimiento Epidérmico (EGFR) XIII Congreso Nacional SEOM, Málaga 18-21 octubre 2011 **(Oral)**

- Massutí B, Lecumberri R, López Vivanco G, Font A, González Billalabeitia E, Martí J. L, Vicente V, Rosell R. "EC Fase II Randomizado de asociación de Bemiparina a Quimio-radioterapia en Carcinoma Microcítico de Pulmón: Resultados Finales del Estudio A BELXIII Congreso Nacional SEOM, Málaga 18-21 octubre 2011 **(Oral)**

- Ramirez J. L, Méndez P, Taron M, Sanchez J. J, Cardenal F, Queralt C, Benlloch S, Massutí B,M. Provencio M, Rosell R. "Metilación de la proteïna interactiva DAB2 (DAB2IP) en el DNA sérico de pacientes (p) con Cáncer de Pulmón no microcitíco (CPNM) y mutación en gen del Epidermal Growth Factor Receptor (EGFR)" XIII Congreso Nacional SEOM, Málaga 18-21 octubre 2011 **(Poster)**

- Magri I, Santarpia M, Sanchez-Ronco M, Viteri S, Costa C, Mederos N, Moran N, Taron M, Cobo M, Rosell R. "Expresion diferencial de BRCA1, RAP80 y de los genes relacionados con el factor nuclear KB (NFKB) y con la vía de señalización NOTCH en pacientes (p) con Cáncer de Pulmón no microcítico (CPNM) y Cáncer de Pulmón microcítico (CPCP)" XIII Congreso Nacional SEOM, Málaga 18-21 octubre 2011 **(Poster)**

- Moran T, Gascó A, Sanchez-Ronco M, Molina M. A, Gonzalez M, Benlloch S, Cobo M, Bover I, Taron M, Rosell R. "El factor nuclear κB (NFκB), la vía de señalización Notch y la expresión mRNA de BRCA1 en pacientes (p) con Cáncer de Pulmón no microcítico (CPNM) en estadio IV" XIII Congreso Nacional SEOM, Málaga 18-21 octubre 2011 **(Poster)**

- Insa A, Palmero R, Reguart N, Carcereny E, Isla L, Pallares C, Rolfo C, De Castro J, Queralt C, Rosell R. "Estudio fase I/II de Vorinostat (V) en Combination con Erlotinib (E) en Pacientes (pts) con Cáncer de Pulmón No Microcítico (CPNM) Avanzado con Mutaciones del EGFR tras Progresión a Erlotinib: Ensayo Clínico TARZO (NCT00503971)." XIII Congreso Nacional SEOM, Málaga 18-21 octubre 2011 **(Poster)**

Spanish Lung Cancer Group 9th Congress on Lung Cancer, Barcelona

- Rosell R. "Moving forward to saving lives in NSCLC: Can CSCs be detected in rebiopsies?" Spanish Lung Cancer Group 9th Congress on Lung Cancer, Barcelona, Spain, November 17-18, 2011 **(Invited lecture, plenary session)**

- Garcia Escudero R, Dueñas M, Aranda J, Taron M, Bielza C, Larranaga P, Rosell R, Paramio J. "Prediction of lung adenocarcinoma survival outcome using a 36-gene expression signature based on cancer mouse models" Spanish Lung Cancer Group 9th Congress on Lung Cancer, Barcelona, Spain, November 17-18, 2011 **(Oral)**

- Zhou W, Marcus AI, Kline E, Taron M, Gal AA, Sanchez JJ, Tighiouart M, Fu H, Rosell R, Khuri FR. "LKB1 biology and role in lung cancer: A transatlantic collaboration involving the NATCH trial" Spanish Lung Cancer Group 9th Congress on Lung Cancer, Barcelona, Spain, November 17-18, 2011 **(Oral)**

- Rosell R, Taron M, Massuti B, Cardenal F, Carcereny E, Felip E, Vergnenegre A, Cajal R, Sanchez-Ronco M, Garcia-Campelo R. "Customized Clinical Trials: gefitinib plus olaparib" Spanish Lung Cancer Group 9th Congress on Lung Cancer, Barcelona, Spain, November 17-18, 2011 **(Oral)**

- Bonanno L, Majem M, Costa C, Sanchez J. J, Gimenez-Capitan A, Mayo C, Favaretto A, Benlloch S, Rugge M, Taron M, Rosell R. "The refined BRCA1 model in cisplatin-treated patients" Spanish Lung Cancer Group 9th Congress on Lung Cancer, Barcelona, Spain, November 17-18, 2011 **(Oral)**

- Spiekermann J, Hoffmann A. C, Taron M, Eberhardt W, Rosell R. "Translational research in stage III NSCLC" Spanish Lung Cancer Group 9th Congress on Lung Cancer, Barcelona, Spain, November 17-18, 2011 **(Oral)**

- Reguart N, Palmero R, Cardenal F, Isla L, Insa A, Pallarés C, Magem M, Carcereny E, Moran T, Rolfo C, De Castro J, Viteri S, Queralt C, Taron T, Rosell R. " The TARZO trial (NCT00503971)" Spanish Lung Cancer Group 9th Congress on Lung Cancer, Barcelona, Spain, November 17-18, 2011 **(Oral**

OTHER MEETINGS

- Rosell R. "Promising newer markers including EML4-ALK" 10th Nordic Lung Cancer Symposium, Copenhagen, January 14, 2011 **(Invited lecture)**

- R Rosell "The predictive role of signaling networks involved in lung cance" CURELUNG Kick-off Meeting, Barcelona, 20 January 2011 **(Invited lecture)**

- R Rosell "Erlotinib in the management of NSCLC with mutated EGFR: the relevance of the OPTIMAL study" Inspired V, Lisbon, 22 January 2011 **(Invited lecture)**

- R Rosell "¿Hacia dónde debemos orientar la investigación en la neoadyuvancia?" 1er Simposio de Tratamiento de Inducción en Cáncer de Pulmón, Lledia, March 3 2011 **(Keynote lecture)**

- R Rosell. "Translational lung cancer research in current practice: Benefit for patients" II Curso Avances en el Abordaje Multidiscipliary del Cáncer de Pulmón Hospital Universitario Puerta de Hierro Majadahonda, Madrid 17 de Marzo de 2011**(Invited lecture)**

- R Rosell. "Systemic treatment selection based on molecular biomarkers" Systemic Treatment Selection And Target Therapies In NSCLC, Istituto Oncologico Veneto IRCCS, Padua, Italy 13 May 2011 **(Invited lecture)**

- Rosell R. "Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European erlotinib versus chemotherapy (EURTAC) phase III randomized trial" Annual Pre-ASCO Meeting of the Spanish Lung Cancer Group, Barcelona 18-19 May 2011

- Rosell R. "EURTAC update" V Annual Meeting of the French and Spanish Lung Cancer Groups, Barcelona19-20 May 2011

- Rosell R. "Recent advances in non-small cell lung cancer treatment" Molecular Lung Cancer Symposium, Incheon, South Korea 3 September 2011 **(Invited lecture)**

- Rosell R. “Cancer management and the BREC trials” Drum Tower Hospital, Nanjing, China 4 September 2011 **(Invited lecture)**

- Rosell R. “Nuevas Perspectivas tras la 14º Conferencia Mundial de Cáncer de Pulmón” Post-Mundial de Cáncer de Pulmón, Madrid 15 September 2011 **(Invited lecture)**

- Rosell R. "The predictive role of signalling networks in advanced lung cancer: translational and clinical perspectives" ASEICA Annual Congress, Salamanca 22 September 2011 **(Invited lecture)**

- Rosell R. ““Direct or indirect identification of cancer therapeutic targets” 5 Diagnostic Days, Bonn, Germany 7 October 2011 **(Invited lecture)**

- Rosell R. “Clinical applications of molecular analyses in NSCLC patients (I) - EGFR-mutated patients – our experience. Emerging new approaches for EGFR-mutated patients” The Role of EGFR Mutations and Other Genetic Alterations in Clinical Practice: A Three-Day Course for Russian Biologists, USP Dexeus University Institute, Barcelona 20 – 22 October 2011

- Rosell R. “Clinical applications of molecular analyses in NSCLC patients (III) - The role of other mutations” The Role of EGFR Mutations and Other Genetic Alterations in Clinical Practice: A Three-Day Course for Russian Biologists, USP Dexeus University Institute, Barcelona 20 – 22 October 2011

- Rosell R. “Gene expression analysis for treatment customization” The Role of EGFR Mutations and Other Genetic Alterations in Clinical Practice: A Three-Day Course for Russian Biologists, USP Dexeus University Institute, Barcelona 20 – 22 October 2011

- Rosell R. “Moving forward to saving lives in NSCLC: Can CSCs be detected in rebiopsies?” 15anys de l'ICO, Barcelona, November 24 2011

- Rosell R “Adjuvant vs. Neoadjuvant” Consensus Conference on Adjuvant Chemotherapy, Dresden November 26 2011

2010

ORGANIZATION OF COURSES AND CONFERENCES

- Conference Scientific Co-Chair of the 2nd European Lung Cancer Conference ESMO-IASLC (European Society for Medical Oncology and International Association for the Study of Lung Cancer), Geneva, Switzerland, 28 April-1 May 2010

- Director, “The Current State of Lung Cancer Research”, Course for Italian Medical Oncologists, USP Dexeus University Institute, Barcelona, May 14-15, 2010

- Chair of the NSCLC Consensus Committee on Pathology and Molecular Testing, ESMO Lung Cancer Consensus Conference, Lugano, Switzerland, 19-21 May 2010

- Conference Scientific Chair “Plenary Session and V Educational Symposium of the Spanish Lung Cancer Group” Mallorca, Spain, 25-26 November 2010

PUBLICATIONS

Contributions to books:

- Gautschi O, Mack PC, Gandara D, Rosell R. "Pharmacogenics in lung cancer: Predictive biomarkers for chemotherapy." *Lung Cancer: Principles and Practice"*, Fourth Edition 2010 Edited by Harvey Pass, David Carbone, David Johnson, John Mina, Andrew Turrisi, Giorgio Scagliotti. Published by Lippincott Williams and Wilkins ISBN-10: 0781773652; ISBN-13: 978-0781773652

Original articles:

- Garcia-Olivé I, Monsó E, Andreo F, Sanz-Santos J, Taron M, Molina-Vila MA, Llatjós M, Castellà E, Moran T, Bertran-Alamillo J, Mayo-de-Las-Casas C, Queralt C, Rosell R. "Endobronchial ultrasound-guided transbronchial needle aspiration for identifying epidermal growth factor receptor mutations." *Eur Respir J*. Feb 2010 35:2 391-395

- Douillard J-Y, Tribodet H, Aubert D, Shepherd F, Rosell R, Ding K, Veillard A. S, Winton T, Le Chevalier T, Spiro S, Stephens R, Pignon J. P. "Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-Small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation (LACE)." *Journal of Thoracic Oncology* 2010 Feb;5(2):220-8.

- Souquet P. J, Krzakowski M, Ramlau R, Sun X. S, Lopez-Vivanco G, Puozzo C, Pouget J. C, Pinel M. C, Rosell R "Phase I/II and pharmacokinetic study of IV vinflunine in combination with cisplatin for treatment of advanced non-small cell lung cancer in chemonaive patients." *Clin Lung Cancer* March 1 2010 11;2 105-113

- Margeli M, Cirauqui B, Castellá E, Tapia G, Costa C, Barnadas A, Sanchez-Ronco M, Benlloch S, Taron M, Rosell R. "The prognostic value of BRCA1 mRNA expression levels neoadjuvant chemotherapy in breast cancer" *Plos ONE* March 3 2010 5;3 e9499

- Rosell. R. (as member of Collaborative Group) "Adjuvant chemotherapy with or without postoperative therapy improves survival in non-small cell lung cancer: Meta-analyses based on individual patient data from 37 randomized controlled trials". *The Lancet* April 10 2010 Vol 375;9722:1267-1277

- Mazieres J, Cappuzzo F, Fruh M, Sorensen J. B, Blackhall F, Taron M, Gridelli C, O'Byrne K, Rosell R. "Meeting Report: 2nd meeting of the European Thoracic Oncology Platform (ETOP)." *Lung Cancer* April 2010 68, 121-124

- Carcereny E, Ramirez J. L, Sanchez-Ronco M, Isla D, Cobo M, Moran T, de Aguirre I, Okamoto T, Wei J, Provencio M, Lopez-Vivanco G, Camps C, Domine M, Alberola V, Sanchez J. M, Massuti B, Mendez P, Taron M, Rosell R. "Blood-based CHRNA3 single nucleotide polymorphisms and outcome in advanced non-small-cell lung cancer patients" *Lung Cancer* June 2010 68;491-497

- Provencio M, de las Peñas R, Camps C, Artal A, Massuti B, Cobo M, Perez J. F, Sanchez A, Rosell R. "Cisplatin plus vinorelbine as first-line treatement for advanced non-small-cell lung cancer: is a hemogram on day 8 essential?" *Lung Cancer* June 2010 18. 68;415-419

- Felip E, Rosell R, Maestre J. A, Rodriguez-Paniagua J. M, Morán T, Astudillo J, Alonso G, Borro J. M, González-Larriba J. L, Torres A, Camps C, Guijarro R, Isla D, Aguiló R, Alberola V, Padilla J, Sánchez-Palencia A, Sánchez J. J, Hermosilla E, Massuti B. "Preoperative Chemotherapy plus Surgery versus Surgery plus Adjuvant Chemotherapy versus Surgery Alone in Early-Stage Non-Small Cell Lung Cancer" *Journal of Clinical Oncology* July 1 2010 28;19 3138-3145

- Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla JA, Pedraza V, Boyero L, Rosell R, Fárez-Vidal ME. "Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer." *Int J Cancer.* 2010 Sep 28. Epub ahead of print

- Gironés Sarrió R, Torregrosa MD, López P, Gómez-Codina J, Rosell R. "Smoking habits in elderly lung cancer patients: still no changes in epidemiology? A single-center experience." *Clin Transl Oncol*. 2010 Oct;12(10):686-91.

- Pirker R, Herth F, Kerr K, Filipits M, Taron M, Gandara D, Hirsch F, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F, Stahel R. "Consensus for EGFR mutation testing in non-small cell lung cancer (NSCLC): Results from a European workshop." *Journal of Thoracic Oncology* 2010 Oct;5(10):1706-13.

- Rosell R. "Rafael Rosell Discusses EGFR Mutation Testing for Lung Cancer" New Hot Paper Commentary, *Science Watch, Thompson Reuters*, Published online, November 2010, http://www.sciencewatch.com/dr/nhp/2010/10novnhp/10novnhpRose/

- Simonetti S, Molina MA, Queralt C, de Aguirre I, Mayo C, Bertran-Alamillo J, Sanchez JJ, Gonzalez-Larriba JL, Jimenez U, Isla D, Moran T, Viteri S, Camps C, Garcia-Campelo R, Massuti B, Benlloch S, Y Cajal SR, Taron M, Rosell R. "Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small cell lung cancer." *J Transl Med*. 2010 Dec 18;8:135.

Review articles:

- Paz-Ares L, Soulieres D, Melezínek I, Moecks J, Keil L, Mok T, Rosell R, Klughammer B. "Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis". *Journal of Cell and Mol Medicine* Jan 2010 ;14(1-2):51-69

- Reguart N, Cardona A. F, Rosell R. "Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer." *Cancer Management and Research* 2010:2 143-156

- Colomer R, Alba E, Gonzalez-Martin A, Paz-Ares L, Martin M, Llombart A, Rodriguez Lescure A, Salvador J, Albanell J, Isla D, Lomas M, Rodriguez C. A, Trigo J. M, Tabernero J, Rosell R, Arnada E, Cubedo R, Baselga J. "Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)" *Ann of Oncology* Feb 2010 21:196-198

- Rosell R, Moran T, Carcereny E, Quiroga V, Molina M. A, Costa C, Benlloch S, Taron M. "Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain" *Clin Trans Oncology* 2010 Feb;12(2):75-80.

- Rosell R, Viteri S, Molina M. A, Benlloch S, Taron M. "Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced non-small cell lung cancer" *Current Opinion in Oncology* March 2010 22(2):112-120

- Gridelli C, Ardizzoni A, Douillard J. Y, Hanna N, Manegold C, Perrone F, Pirker R, Rosell R, Shepherd F. A, De Petris L, Di Maio M, de Marinis F. "Recent issues in first-line treatment of advanced non-small cell lung cancer: results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology" *Lung Cancer* June 2010 68;319-331

- Rosell R, Moran T, Viteri S, Carcereny E, Gasco A, Quiroga V, Wei J, Camps C, Massuti B. "Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer" *Expert Opinion on Pharmacotherapy* July 11 2010 11(10):1683-93.

- Rosell R, Moran T, Cardenal F, Porta R, Viteri S, Molina M. A, Benlloch S, Taron T. "Predictive biomarkers in the management of EGFR-mutant lung cancer" *Annals of the New York Academy of Sciences* 2010 Oct;1210:45-52

- Rosell R, Vergenegre A, Lui B, Cobo M, Massuti B, Wei J, Molina M. A, Costa C, Queralt C, Taron M. "Biomarkers in lung oncology" *Pulmonary Pharmacology and Therapeutics* Dec;23(6):508-14

- Wei J, Xie L, Taron M, Rosell R, Lui B. "Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies." *Drug News and Perspectives* 2010 23(10):655-61.

PARTICIPATION IN SCIENTIFIC MEETINGS

MAJOR INTERNATIONAL MEETINGS

AACR Conference on Translational Cancer Medicine

- Rosell R. "The genomic landscape in lung cancer" AACR Conference on Translational Cancer Medicine, Amsterdam March 21-24 2010 **(Invited lecture)**

AACR 101st Annual Meeting, Washington

- Harmon C, De Primo S, Socinski M, Scagliotti G, Rosell R, Govindan R, Page R, Hainsworth J, Brahmer J, Blais N, Novello S, Tye L, Kim S, Williams J, Chao R. "Sunitinib in advanced NSCLC: Correlation of circulating biomarkers with clinical outcomes." AACR 101st Annual Meeting, Washington, U.S.A, April 17-21 **(General poster session) abstract:2179**

IASLC/ESMO 2nd European Lung Cancer Conference, Geneva

- Rosell R. "EGFR mutations: Current status" IASLC/ESMO 2nd European Lung Cancer Conference, Geneva, Switzerland 28th April – 1st May 2010 **(Invited lecture)**

- Rosell R. "Tobacco Control" IASLC/ESMO 2nd European Lung Cancer Conference, Geneva, Switzerland 28th April – 1st May 2010 **(Co Chair, Keynote lecture)**

- Rosell R. "Future directions in the treatment of NSCLC" IASLC/ESMO 2nd European Lung Cancer Conference, Geneva, Switzerland 28th April – 1st May 2010 **(Co Chair, Keynote lecture)**

- Rosell R. "Stage IV: Targeted therapy as first-line treatment" IASLC/ESMO 2nd European Lung Cancer Conference, Geneva, Switzerland 28th April – 1st May 2010 **(Co Chair, Controversy session)**

- Rosell R. "Stage III: Combined treatment" IASLC/ESMO 2nd European Lung Cancer Conference, Geneva, Switzerland 28th April – 1st May 2010 **(Co Chair, Controversy session)**

- Pirker R, Herth F, Kerr K, Filllipits M, Grunenwald D, Popper H, Rosell R. "EGFR mutation testing in non-small-cell lung cancer (NSCLC): Clinical recommendations."

IASLC/ESMO 2nd European Lung Cancer Conference, Geneva, Switzerland 28th April – 1st May 2010 **(Oral)**

- Jantus E, Cabrera A, Sirera R, Usó M, Gallach S, Blasco A, Berrocal A, Taron M, Rosell R. "Molecular expression of angiogenic markers in early-stage NSCLC: Evaluation of the prognostic role" IASLC/ESMO 2nd European Lung Cancer Conference, Geneva, Switzerland 28th April – 1st May 2010 **(Oral)**

ESMO 2010 Lung Cancer Consensus Conference, Lugano

- Rosell R. "NSCLC-consensus on Pathology and Molecular Testing." ESMO 2010 Lung Cancer Consensus Conference, Lugano, Switzerland, 21st May 2010 **(Chair)**

- Rosell R. "NSCLC-consensus on Pathology and Molecular Testing." ESMO 2010 Lung Cancer Consensus Conference, Lugano, Switzerland, 22nd May 2010 **(Chair)**

ASCO, Chigaco, IL

- Rosell R. "Will initial and maintenance therapy with oral anti-EGFR inhibition become the new standard for EGFR mutation-positive NSCLC?" Emerging Novel Strategies for Initial and Maintenance Therapies for NSCLC: Critical Questions Addressed by the Experts, ASCO Satellite Symposium, Chicago, U.S.A 5th June 2010 **(Invited lecture, Co Chair)**

- Rosell R. **"**Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies." ASCO Annual Meeting, Chicago, U.S.A 4-8 June 2010 **(Poster discussion) Abstract: 7514 (40769)**

- Taron. M, Queralt C, Mayo C, de Aguirre I, Gasco A, Insa A, Palmero R, Camps C, Sanchez J, Rosell R. "Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR in-frame deletions of exon 19 according to the size of the deletion." ASCO Annual Meeting, Chicago, U.S.A 4-8 June 2010 **(General Poster Session) Abstract No: 7549**
- Szymanowska-Narloch A, Skrzypski M, Taron M, Dienemann H, Rzyman W, Jarzab M, Muley T, Jassem E, Rosell R, Jassem J. "Gene expression profiles in non-small cell lung cancers (NSCLCs) and in corresponding healthy lung tissues in smokers versus nonsmokers." ASCO Annual Meeting, Chicago, U.S.A 4-8 June 2010 (**General Poster Session) Abstract No: 1545**
- Mendez P, Taron M, Moran T, Carcereny E, Quiroga V, Grassi P, Fernandez M. A, Gomez P, Sanchez J, Rosell R. "Feasibility of a prospective host cell reactivation assay (HCRA) in non-small-cell lung cancer (NSCLC) patients (p)" ASCO Annual Meeting, Chicago, U.S.A 4-8 June 2010 **(General Poster Session) Abstract No: 10586**
- Simonetti S, Molina M. A, Mayo C, Bertran-Alamillo J, Moran T, Benlloch S, Ramon y Cajal S, Wistuba I, Taron M, Rosell R. "Immunohistochemistry (IHC) with EGFR mutation-specific monoclonal antibodies (mAbs) for screening EGFR mutations in non-small-cell lung cancer (NSCLC) patients (p)" ASCO Annual Meeting, Chicago, U.S.A 4-8 June 2010 **(General Poster Session) Abstract No: 7570**

- Costa C, Gimenez Capitan A, Mayo C, Simonetti S, Majem M, Isla D, Benlloch S, Taron M, Sanchez J, Rosell R. "Expression of MET, IGF-1R, IL-6/gp130 and AXL in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations" ASCO

Annual Meeting, Chicago, U.S.A 4-8 June 2010 **(General Poster Session) Abstract No: 7555**

- Molina M. A, Simonetti S, Quiroga V, Viteri S, Campelo R. G, Sanchez J, Benlloch S, Aldeguer E, Taron M, Rosell R. "Survivin and CrkL expression in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations." (Proceedings) **Abstract No: e18063**
- Pirker R, Herth F, Kerr K. M, Filipits M, Grunenwald D, Popper H. H, Rosell R, Smit E, Cappuzzo F, Stahel R. "Clinical recommendations for EGFR mutation testing in non-small cell lung cancer (NSCLC): Results from a European workshop." ASCO Annual Meeting, Chicago, U.S.A 4-8 June 2010 **(Proceedings) Abstract No: e18038**
- Moran T, Costa C, Gimenez Capitan A, Carcereny E, Massuti B, Provencio M, Wei J, Benlloch S, Taron M, Rosell R. "mRNA expression of protein phosphatase 2A/C (PP2A/C) in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations." ASCO Annual Meeting, Chicago, U.S.A 4-8 June 2010 (Proceedings) **Abstract No: e18037**
- Wei J, Yu L, Costa C, Zou Z, Chen H, Benlloch S, Sanchez J, Taron M, Rosell R, Liu B. "BRCA1 and RAP80 mRNA levels and median survival (MS) of advanced gastric cancer patients (p) treated with oxaliplatin plus 5-fluorouracil (FOLFOX)." ASCO Annual Meeting, Chicago, U.S.A 4-8 June 2010 **(Proceedings) Abstract No: e14602**
- Font A, Maurel J, Taron M, Alonso V, Chaib I, Galan M, Sanchez J, Celiz P, Giralt J, Rosell R. "BRCA1 mRNA expression and response in locally advanced esophageal cancer patients (p) treated with chemoradiotherapy." ASCO Annual Meeting, Chicago, U.S.A 4-8 June 2010 **(Proceedings) Abstract No: e14573**
- Vinolas N, Isla D, Felip E, Garrido P, Majem M, Terrasa J, Artal A, Garcia-Campelo M, Amador M. L, Rosell R. "Small cell lung cancer in women: The Spanish female-specific database WORLD07." ASCO Annual Meeting, Chicago, U.S.A 4-8 June 2010 **(Proceedings) Abstract No: e12044**

ESMO 35th Congress, Milan

- Rosell R. "The immediate future of customized treatment in lung cancer" ESMO/JSMO Joint Symposium. Biomarkers and Selected Therapeutics in Lung and GI Cancer, 35th ESMO Congress, Milan Italy, 9 October 2010 **(Invited lecture)**

- Rosell R. "Erlotinib – The Adult" Special Symposium: Targeted Therapies in NSCLC: State-of-the-Art and New Developments, 35th ESMO Congress, Milan Italy 10 October 2010 **(Invited lecture)**

- Simonetti S, Molina M. A, Mayo C, De Aguirre I, Queralt C, Moran T, Viteri S, Benlloch S, Taron M, Rosell R. "Immunohistochemistry (IHC) with EGFR mutation-specific monoclonal antibodies for screening EGFR mutations in non-small cell lung cancer patients" ESMO 8-12 October Milan **(Poster Discussion) Abstract: 373PD**

- Brambilla E, Tsao M, Paris E, Lantuejoul S, Shepherd F. A, Filipits M, Rosell R, Soria J. C, Pignon J. P. "Lace-Bio: Results of pooled analysis of prognostic and predictive values of histology and lymphocytic infiltration" ESMO 8-12 October Milan **(Poster) Abstract: #388**

- Thatcher N, Pujol J. P, Lynch T, Rosell R, Butts C. A, Shepherd R. A, Vansteenkiste J, de Blas B, Groos J, Pirker R. "Chemotherapy (CT) plus cetuximab as first-line treatment for advanced non-small-cell lung cancer (NSCLC): Meta-analysis of individual patient data." ESMO 8-12 October Milan **(Poster) Abstract: #436**

- Rosell R, Molina M. A, Costa C, Bertran-Alamillo J, Mayo C, Moran T, Viteri S, Mendez P, Benlloch S, Taron M. "Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations" ESMO 8-12 October Milan **(Poster) Abstract: #3085**

- Wei J, Costa C, Zou Z, Yu L, Chen H, Qian X, Liu B, Benlloch S, Taron M, Rosell R. **"**mRNA expression of BRCA1, RAP80 and SUMO ligases (PIAS1 and PIAS4) and survival in gastric cancer patients receiving second-line docetaxel" ESMO 8-12 October Milan **(Poster) Abstract: #3187**

- Costa C, Gimenez-Capitan A, Mayo C, Simonetti s, Majem M, Queralt C, de Aguirre I, Benlloch S, Taron M, Rosell R. "AXL mRNA overexpression correlates with lung metastases in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations" ESMO 8-12 October Milan **(Poster) Abstract: #7555**

- Mendez P, Taron M, Moran M, Carcereny E, Quiroga V, Capdevila L, Fernandez M. A, Martinez A, Sanchez J. J, Rosell R. "Prospective study of host cell reactivation assay (HCRA) in non-small-cell lung cancer (NSCLC) patients (p)." ESMO 8-12 October Milan **(Poster) Abstract: 379P**

OTHER MEETINGS

British Thoracic Oncology Group Meeting, Dublin

- Rosell R. "DNA repair and cytotoxic drug sensitivity." British Thoracic Oncology Group Meeting, Dublin, January 27th 2010 **(Invited lecture)**

ICACT, Paris

- Rosell R. "Prognostic factors in early NSCLC" ICACT 2010 – 21st International Congress on Anti-Cancer Treatment, February 1-5 2010, Paris **(Invited lecture)**

- Rosell R. "Molecular biomarkers for predicting chemotherapy response in lung cancer" ICACT 2010 – 21st International Congress on Anti-Cancer Treatment, February 1-5 2010, Paris **(Invited lecture)**

GFPC/SLCG Joint Meeting, Paris

- Rosell R. "Clinical Implications of Basic Research: Towards Personalized Treatment" Spanish Lung Cancer Group/French Lung Cancer Group Joint Meeting, Paris 18-19 March 2010 **(Invited lecture)**

- Rosell R. "Non-EGFR-Addicted Advanced NSCLC: Novel Predictive Biomarkers regardless of histology" Spanish Lung Cancer Group/French Lung Cancer Group Joint Meeting, Paris 18-19 March Paris – 18-19 March 2010 **(Invited lecture)**

Spanish Lung Cancer Group Pre-ASCO meeting, San Sebastian

- Rosell R. "Pre-existing EGFR T790M and BRCA1 mRNA Expression in Erlotinib-Treated EGFR-Mutant NSCLC Patients" SLCG Pre-ASCO, San Sebastian 23rd April 2010 **(Invited lecture)**

- Costa C, Gimenez-Capitan A, Mayo C, Simonetti S, Majem M, Isla D, Benlloch S, Taron M, Sanchez J. J, Rosell R. "Expression of MET, IGF-1R, IL-6/gp130 and AXL in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations" SLCG Pre-ASCO, San Sebastian 23rd April 2010 **(Oral)**

Preceptorship Program on Lung Cancer, Boston U.S.A

- Rosell R. "High BRCA1 messenger RNA levels and the EGFR T790M mutation impair the effect of EGFR TKIs in non-small-cell lung cancer patients with EGFR mutations." Executive Preceptorship in Lung Cancer, Massachusetts General Hospital, Boston, U.S.A, 5-8 May 2010 **(Invited lecture)**

- Rosell R. "Review of GECP trials and future research" Executive Preceptorship in Lung Cancer, Massachusetts General Hospital, Boston, U.S.A, 5-8 May 2010 **(Invited lecture)**

- Rosell R "Detection of EGFR mutations with mutation-specific antibodies in NSCLC" Executive Preceptorship in Lung Cancer, Massachusetts General Hospital, Boston, U.S.A, 5-8 May 2010 **(Invited lecture)**

The Current State of Lung Cancer Research, Barcelona

- Rosell R. "Therapy-Predictive Markers based on EGFR Mutations: The Search for a Biomarker Toolkit" The Current State of Lung Cancer Research, USP Dexeus University Institute, Barcelona, May 14-15, 2010 **(Invited lecture)**

- Rosell R. "Principles of Customized Chemotherapy." The Current State of Lung Cancer Research, USP Dexeus University Institute, Barcelona, May 14-15, 2010 **(Invited lecture)**

- Rosell R. "Adjuvant Treatment of NSCLC." The Current State of Lung Cancer Research, USP Dexeus University Institute, Barcelona, May 14-15, 2010 **(Invited lecture)**

- Rosell R. "BRCA1 SUMOylation and Customized Treatment." The Current State of Lung Cancer Research, USP Dexeus University Institute, Barcelona, May 14-15, 2010 **(Invited lecture)**

- Rosell R. "Advances in Oncogene and Non-Oncogene Addiction." The Current State of Lung Cancer Research, USP Dexeus University Institute, Barcelona, May 14-15, 2010 **(Invited lecture)**

2nd AIOT Italian Conference on Thoracic Oncology, Rome

- Moran T, Rosell R. "Is there a role for pharmacogenomic in clinical practice for advanced NSCLC?" 2nd AIOT Italian Conference on Thoracic Oncology, Rome, Italy 24 – 26 June 2010 **(Invited lecture)**

- Simonetti S, Molina M. A, Quiroga V, Viteri S, Garcia-Campelo R, Sanchez J. M, Benlloch S, Sanchez J. J, Taron M, Rosell R. "Survivin and CRKL expression in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations." 2nd AIOT Italian Conference on Thoracic Oncology, Rome, Italy 24 - 26 June 2010 **(General poster session)**

- Simonetti S, Molina M. A, Mayo C, Bertran-Alamillo J, Queralt C, Moran M, Viteri S, Benlloch S, Ramon y Caja S, Taron M, Rosell R. "Immunohistochemistry with EGFR mutation-specific monoclonal antibodies for screening epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer patients." 2nd AIOT Italian Conference on Thoracic Oncology, Rome, Italy 24 – 26 June 2010 **(General poster session)**

- Moran T, Costa C, Gimenez-Capitan A, Carcereny E, Massuti B, Provencio M, Wei J, Benlloch S, Taron M, Rosell R. "mRNA expression of protein phosphatase 2A/C

(PP2A/C) in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations." 2nd AIOT Italian Conference on Thoracic Oncology, Rome, Italy 24 – 26 June 2010 **(General poster session)**

- Taron M, Queralt C, Mayo C, de Aguirre I, Gasco A, Insa A, Palmero R, Camps C, Sanchez J. J, Rosell R. "Outcome to erlotinib in non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) in-frame deletions of Exon 19 according to the size of the deletion." 2nd AIOT Italian Conference on Thoracic Oncology, Rome, Italy 24 – 26 June 2010 **(General poster session)**

Chilean Cooperative Group for Oncologic Research, Santiago de Chile

- Rosell R. "Oncogene and Non-Oncogene Addiction Markers for Customizing Cancer Treatment" Instituto Nacional del Tórax, Santiago de Chile, 28 July 2010 **(Invited lecture)**

- Rosell R. "Genetic modifiers impairing the effect of erlotinib in EGFR-mutant NSCLC patients" GOCCHI meeting, Santiago de Chile, July 28 2010 **(Invited lecture)**

4th Latin American Conference on Lung Cancer (LALCA 2010), Buenos Aires

- Rosell R. "Applied pharmacogenomics to the tailored use of chemotherapy and molecular drugs" LALCA 2010, Buenos Aires, July 29 2010 **(Invited lecture)**

- Rosell R. "Adjuvant and neoadjuvant treatment of resectable lung cancer" LALCA 2010, Buenos Aires, July 30 2010 **(Invited lecture, Plenary session)**

SEOM, Madrid

- Rosell R. "Issues in the use of oral targeted agents: What order first-second or third line? The need for biomarkers beyond the sensitive EGFR mutations" New Avenues in NSCLC Treatment: The paradigm of BIBW2992, a Novel Oral Trageted Agent, Boehringer Ingelheim Satalite Symposium, Madrid, Spain 28 October 2010 **(Invited lecture)**

SLCG Plenary Session & V Educational Symposium, Palma

- Rosell R. "Gene signatures in stage I NSCLC: How can we identify high-risk patients for adjuvant chemotherapy?" Plenary Session & V Educational Symposium of the Spanish Lung Cancer Group, Palma, Mallorca 25 November 2010 **(Invited lecture)**

- Rosell R. "OTUB1, NPM1, HERC2 and BRCA1/RAP80 in DNA double-strand break repair" Plenary Session & V Educational Symposium of the Spanish Lung Cancer Group, Palma, Mallorca 26 November 2010 **(Invited lecture)**

Other meetings

- Rosell. R. "Prognostic and predictive factors in non-small-cell lung cancer" Spanish Lung Cancer Group, 1er Curso de Capacitación en Cáncer de Pulmón, Madrid, Spain, 25-27 February, 2010 **(Invited lecture)**

- Rosell R. "¿Qué hay más allá de la histología? Clinical Implications of Basic Research: Towards Personalized Treatment"Avances en el Abordaje Multidisciplinar del Cáncer de Pulmón, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid 11th March 2010 **(Invited lecture)**

- Rosell R. "Reduction of cancer networks to abstract models for identification of therapy-predictive markers for radiotherapy" EORTC Radiation Oncology Group Meeting, Barcelona 12th March 2010 **(Invited lecture)**

- Rosell R. "Clinical Implications of Basic Research: Towards Personalized Treatment" Foro de Expertos Sobre CPNM con Mutacion de EGFR, una Entidad Distinta: Ultimos Datos y Evidencias, Madrid 15th March 2010 **(Invited lecture)**

- Rosell R. "Predictive Biomarkers in the Management of EGFR-Mutant Lung Cancer" The New York Academy of Sciences, Towards Personalized Cancer Medicine, Barcelona, May 19-21, 2010 **(Invited lecture)**

- Rosell R. "Genetic modifiers impairing the effect of erlotinib in EGFR-mutant NSCLC patients" 30th Anniversary – GFPC, Lyon, France June 17th 2010 **(Invited lecture)**

- Rosell R. "Oncogene and non-oncogene addiction markers for customizing cancer treatment." Latest Advances on Anticancer Drugs in Clinical Development, Marbella, Spain, 22-25 June 2010 **(Invited lecture)**

- Rosell R. "State of the Art: Biological Biomarkers in NSCLC" 2nd International Thoracic Oncology Congress (ITOC), Dresden, Germany September 16 2010 **(Invited lecture)**

- Rosell R. "Paul Ehrlich Lecture: Tailoring Targeted Therapy of Lung cancer – looking for magic bullets" Annual Meeting of the German, Austrian and Swiss Associations for Hematology and Oncology, Berlin, Germany October 5 2010 **(Invited lecture)**

- Rosell R. "Translational research in lung cancer" 4th Portuguese Lung Cancer Congress, Aviero, Portugal October 14 2010 **(Invited lecture)**

- Rosell R. "Personalized Lung Cancer Therapies: the BREC trial" 2e Journee De La Recherche Clinique, Luxembourg, Belgium 27 October 2010 **(Invited lecture)**

- Rosell R. "Molecular Biomarkers in Lung Cancer Therapy" Drum Tower Hospital, University of Nanjing, Nanjing, China 4 November 2010 **(Invited lecture)**

- Rosell R. "Customized trial based on BRCA1 and RAP80 mRNA levels in patients with advanced NSCLC" Drum Tower Hospital, University of Nanjing, Nanjing, China 4 November 2010 **(Invited lecture)**

- Rosell R. "Targeting the EGFR pathway in NSCLC" Asian Expert Forum in NSCLC, Shanghai, China 6 November 2010 **(Invited lecture)**

- Le Cesne A, Taron M, Rosell R, Jimeno J, Grosso J, Sanfilippo R, Casali P. G, Schoffski P, Jones R. L, Blay J. Y, Poveda A, Maki R. G, Nieto A, Aracli M, Tercero J. C. "Biomarkers of DNA repair efficiency in translocation related sarcoma (TRS) patients treated with trabecetedin (T)." CTOS 16th Annual Meeting, Paris, France 11-13 November 2010 **(Poster)**

- Rosell R. "Phase I-Ii, Randomized Study With Gefitinib And Olaparib (Azd2281) In Stage Iv Nsclc Patients With Egfr Mutations (Exon 19 Deletion Or L858r). Subgroup Analysis Planned For The Egfr T790m Mutation And Brca1 Mrna Expression" ETOP Meeting, Zurich, Switzerland 12 November 2010 **(Invited lecture)**

- Rosell R. "Personalizing targeted therapies in lung cancer" CNIO Frontiers Meeting: Cancer pharmacogenetics: Personalizing medicine, Madrid, Spain, 22 November 2010 **(Invited lecture)**

- Rosell R. "Changing treatment in the first-line setting" Days of Exchanges and Autoevaluation in Thoracic Cancer, 15th, Marseille, France 11 December 2010 **(Invited lecture)**

2009

ORGANIZATION OF COURSES AND CONFERENCES

University doctorate courses

- Aplicacions clíniques de la biologia molecular en el càncer de pulmó" Universitat Autònoma de Barcelona, Hospital Germans Trias i Pujol

Other courses

- Conference Scientific Chair, Spanish Lung Cancer Group 8th Congress on Lung Cancer, Barcelona, Spain, November 26-27, 2009
- Director, "Update in Lung Cancer Management", Course for Boehringer-Ingelheim, Barcelona, Spain, November 11-12 2009
- Director, "Update in Lung Cancer Management" Course for Italian medical oncologists. Catalan Institute of Oncology, Badalona, Barcelona, Spain, 19-20 June 2009.
- Director, "Update in Lung Cancer Management" Course for Latin American medical oncologists. Catalan Institute of Oncology, Badalona, Barcelona, Spain, 20-21 March 2009.
- Director, "The Hallmarks of Cancer: From the bench to the bed." Course for Italian medical oncologists. Catalan Institute of Oncology, Badalona, Barcelona, Spain, 19-21 February 2009.

PUBLICATIONS

Original articles:

- Bartolucci R, Wei J, Sánchez JJ, Pérez-Roca L, Chaib I, Puma F, Farabi R, Mendez P, Roila F, Okamoto T, Taron M, Rosell R. "XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression". *Clin Lung Cancer* 2009 Jan;10(1):47-52
- Safont MJ, Artal-Cortes A, Sirera R, Gómez-Codina J, González-Larriba JL, Barneto I, Carrato A, Isla D, Rosell R, Camps C. "Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer. *Lung Cancer*. Vol 63(1) Jan 2009: 83-87
- Rosell R, Perez-Roca L, Sanchez J.J, Cobo M, Moran T, Chaib I, Provencio M, Domine M, Sala M.A, Jimenez U, Diz P, Barneto I, Macias J. A, De las Peñas R, Catot R, Isla D, Sánchez J. M, Ibeas R, López-Vivanco G, Oramas J, Mendez P, Reguart N, Tarón T. "Customized Treatment in Non-Small-Cell Lung Cancer based on EGFR Mutations and BRCA1 mRNA Expression". *PLoS One* May 2009, Vol 4;5, e5133
- P. Garrido Lopez, R. Rosell, B. Massutí, F. Cardenal, V. Alberola Candel, M. Dómine, R. García Gómez, I. Maestu, D. Isla, M. López-Brea. Predictors of long-term survival in lung cancer patients (p) included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel (D) and carboplatin (Cb) plus induction (I) or consolidation (C) chemotherapy (CT) with docetaxel and gemcitabine (G).

Clin Lung Cancer May 2009, 10;(3), 180-186

- Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba J. L, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno M. A, Catot S, Rolfo C, Reguart N, Palermo R, Sanchez J. M, Bastus R, Mayo C, Bertran-Alamillo J, Molina M. A, Sanchez J. J, Taron M. "Screening for epidermal growth factor receptor mutations in lung cancer" *N Engl J Med* Sep 3rd, 2009; 361:958

- Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer JR, Atkins J, Palleres C, Burgess R, Tye L, Selaru P, Wang E, Chao R, Govindan R. "A phase II study of continuous daily sunitinib dosing in patients with previously-treated advanced non-small cell lung cancer" *British Journal of Cancer* 2009, 101, 9: 1543-1548

Review articles:

- Rosell R, Wei J, Taron M. "Circulating MicroRNA signatures of tumor-derived exosomes for early diagnosis of non small cell lung cancer" *Clin Lung Cancer* 2009, Jan;10(1):8-9

- Danesi R, Altavilla G, Giovanetti E, Rosell R. "Pharmacogenomics of gemcitabine in NSCLC and other solid tumors*." Pharmacogenomics* 2009, Jan;10(1):69-80

- Rosell R, Bertran-Alamillo J, Molina M.A, Taron M. "IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors*" Future Oncology* April 2009 Vol. 5;3, 305-308

- Danesi R, Pasqualetti G, Giovanetti E, Crea F, Altavilla G, Del Tacca M, Rosell R. "Pharmacogenetics in NSCLC chemotherapy". Review article, *Advanced Drug Delivery Reviews* May 2009 61;2009:408-417

- Provencio M, Sanchez A. C, Rosell R. "Cancer treatments: Can we find treasures under the sea?" *Clinical Lung Cancer* 2009, Jul; 10(4):295-300

- Rosell R, Viteri S, Moran T, Wei J. "mAbs and EGFR TKI in lung cancer: The front line setting" E-Updates in Lung Cancer: Controvesies and Challenges Vol 3, August 1 2009

- Garcia-Campelo R, Quindos Varela M, Dopico Vázquez D, Alonso-Jáudenes Crubera G, Carral Maseda A, Rosell R. "Non-small cell lung cancer management based on EGFR mutation status" *American Journal of Hematology /Oncology* 2009;8(12)

- Provencio M, Camps C, Alberola V, Massutti B, Viñolas N, Isla D, Dómine M, Millán I, Cobo M, Rosell R. "Lung cancer and treatment in elderly patients: The Achilles Study" 2009 *Lung Cancer* 2009 Oct;66(1):103-6

- Wei J, Lui B, Cardona A. F, Rosell R. "Molecular biomarkers for predicting chemotherapy response in lung cancer" *Expert Opinion on Medical Diagnostics* Nov 2009 Vol. 3;6 621-629.

- Rosell R. "Therapy Response Predictors in Lung Cancer" *Clinical and Translational Oncology* Nov 2009 11, Extra 4: 17-18

- Molina M. A, Bertran-Alamillo J, Mayo C, Rosell R. "Screening for EGFR mutations in lung cancer" *Discovery Medicine* 2009 Dec;8(43):181-4.

PARTICIPATION IN SCIENTIFIC MEETINGS

MAJOR INTERNATIONAL MEETINGS

IASLC/ASCO/ESMO International Conference on Targeted Therapies in Lung Cancer, Saint Paul de Vence

- Rosell R. "EURTAC: Randomized Study of Lung Cancer Patients with EGFR Mutations" 4th IASLC/ASCO/ESMO International Conference on Targeted Therapies in Lung Cancer, *Saint Paul de Vence, France, April 2nd 2009* **(Invited lecture)**

- Rosell R. "SCAT: Spanish Customized Adjuvant Trial" 4th IASLC/ASCO/ESMO International Conference on Targeted Therapies in Lung Cancer, *Saint Paul de Vence, France, April 4th 2009* **(Invited lecture)**

ASCO, Orlando FL

- Rosell R "Using Biomarkers to Maximize Novel Taxane Therapies in Multiple Tumor Types: *Case Study #2"* ASCO Satellite Symposium, *Orlando, U.S.A, 30th May 2009*, (**Invited lecture)**

- Felip E, Massuti B, Alonso G, González-Larriba J.L, Camps C, Isla D, Costas E, Sánchez J.J, Griesinger F, Rosell R. "Surgery (S) alone, or preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early stage non-small cell lung cancer (NSCLC): results of the NATCH multicenter, randomized phase II trial.". *J Clin Oncol* 27: 2009 May 20 suppl, *ASCO Annual Meeting* **, (Oral) abstr 7500**

- Rosell R, Ramirez J.L, Sanchez-Ronco M, Isla D, Moran T, Cobo M, Massuti B, Taron M, Carbone D, De Aguirre I. "Blood-based CHRNA3 single nucleotide polymorphisms (SNPs) and outcome in advanced non-small-cell lung cancer (NSCLC) patients (p).", *J Clin Oncol* 27: 2009 May 20 suppl, *ASCO Annual Meeting* , **(Poster discussion) abstr 8033**

- Massuti B, Moran T, Porta R, Queralt C, Cardenal F, Mayo C, Camps C, Majem M, Taron M, Rosell R. "Multicenter prospective trail of customized erlotinib for advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptors (EGFR) mutations: final results of the Spanish Lung Cancer Group (SLCG) trial." *J Clin Oncol* 27: 2009 (May 20 suppl, *ASCO Annual Meeting* , **(Poster discussion) abstr 8023**

- Vinolas N, Magem M, Garrido P, Artal A, De Castro J, Campelo G, Isla D, Felip E, Amador M, Rosell R. "Lung cancer in women: the Spanish female-specific database WORLD 07" Poster, *J Clin Oncol* 27: 2009 May 20 suppl, *ASCO Annual Meeting* , **(General poster session) abstr 8084**

- Cardona A. F, Moran T, Reguart N, Porta R, Queralt C, Cardenal F, Carrasco E, Rolfo C, Massuti B, Moran T, Rosell R. "Characteristics and outcomes of non-small-cell lung cancer (NSCLC) patients (pts) carrying epidermal growth factor receptor (EGFR) mutations who progress after initial erlotinib (E) response." Poster, *J Clin Oncol* 27: 2009 May 20 suppl, *ASCO Annual Meeting*, **(General poster session) abstr 8064**

- Reguart N, Cardona A.F, Isla D, Cardenal F, Palermo R, Carrasco E, Rolfo C, Massuti B, Moran T, Rosell R. "Phase I trial of vorinostat in combination with erlotinib in advanced non-small-cell lung cancer (NSCLC) patients with EGFR mutations after erlotinib progression.", *J Clin Oncol* 27: 2009 May 20 suppl *ASCO Annual Meeting 2009*, **(Proceedings) abstr e19057**

- Sanmartin E, Jantus Lewintre E, Sirera R, Miñana M, Navarro A, Cabrera A, Blasco A, Pla A, Rosell R, Camps. C. "Soluble vascular endothelial growth factor receptor 2 (VEGFR2):

New biomarker in advanced non-small-cell lung cancer (NSCLC)?", *J Clin Oncol* 27: 2009, May 20 suppl *ASCO Annual Meeting 2009***, (Proceedings) abstr e22108**

IASLC WCLC, San Francisco CA

- Rosell R. "Optimal Therapy for Resectable Lung Cancer. Pharmacogenomic Approaches." IASLC 13th World Conference on Lung Cancer, San Francisco U.S.A, July 31-August 4th 2009. **(Invited lecture) abstract:E6.3**

- Rosell R "BRCA1 gene and sensitivity to lung cancer chemotherapy" IASLC 13th WCLC, San Francisco, U.S.A, July 31-August 4th 2009 **(Invited lecture) abstract:M9.2**

- Taron M, Benlloch S, Chaib I, Mendez P, Rosell R "Mechanisms of drug resistance with cytotoxics" IASLC 13th World Conference on Lung Cancer, San Francisco U.S.A, July 31-August 4th 2009, **(Invited lecture) abstract:M22.1**

- Rosell R. "Predictive or Prognostic Factors in Chemotherapy" IASLC 13th WCLC, *San Francisco, U.S.A, 1st August 2009* **(Chair)**

- Rosell R. "Biomarkers in adjuvant trials and stereotactic body radiation therapy for early stage NSCLC" IASLC 13th WCLC, *San Francisco, U.S.A, 1st August 2009* **(Chair)**

- Rosell R. "Genetic Polymorphisms" IASLC 13th WCLC, *San Francisco, U.S.A, 1st August 2009* **(Discussant)**

- Felip E, Massuti B, Maestre J. A, Alonso G, Paniagua J. M, González-Larriba J. L., Camps C, Isla D, Overbeck T, Costas E, Sánchez J. J, Rosell R. "A phase III randomized trial of surgery (S) alone, or preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early stage non-small cell lung cancer (NSCLC): NATCH follow-up data" IASLC 13th WCLC, San Francisco, U.S.A, July 31-August 4th 2009, **(Oral**, **Plenary Session) abstract:PRS.3**

- Travis W.D, Brambilla E, Noguchi M, Geisinger K, Beer D, Powell C. A, Johnson B, Riely G. J, Rusch V, Asamura H, Garg K, Austin J, Aberle Dbrambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Hirsch F, Huber R. M, Ishikawa Y, Jett J, Johnson D, Kerr K, Kuriyama K, Lee J. S, Miller V, Mitsudomi T, Nicholson A, Petersen I Roggli V, Rosell R "The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification" IASLC 13th World Conference on Lung Cancer, San Francisco U.S.A, July 31-August 4th 2009**, (Oral) abstract:M18.1**

- Thatcher N, Lynch T. J, Butts C, Rosell R, Shepherd F, Pujol J. L, Vansteenkiste J, Emig M, Groos J, Pirker R "Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): A meta-analysis of randomized phase II/III trials" IASLC 13th World Conference on Lung Cancer, San Francisco U.S.A, July 31-August 4th 2009 **(Oral) abstract**:**A3.7**

- Reiman T, Seve P, Veillard A. S, Soria J. C, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd F, Pignon J. P, Lai R. "Validation of the prognostic and predictive value of class III beta tubulin (TUBB3) for adjuvant chemotherapy (ACT) in completely resected non-small cell lung cancer (R-NSCLC): results from four randomized trials." IASLC 13th World Conference on Lung Cancer, San Francisco U.S.A, July 31-August 4th 2009 **(Oral) abstract:A4.2**

- Cardenal F, Moran T, Queralt C, Porta R, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Sanchez J.J, Taron M, Rosell R. "Multicenter prospective study of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor

receptor (EGFR) mutations SLADB" IASLC 13th WCLC, San Francisco, U.S. A, July 31-August 4th 2009 **(Oral) abstract:B2.4**

- Wei J, Okamoto T, Sanchez-Ronco M, Chaib I, Perez-Roca L, Mendez P, Taron M, Liu B, Rosell R. "Bio-ANITA Project: Increased BRCA1 mRNA levels predict favorable outcome in non-small-cell lung cancer (NSCLC) patients receiving adjuvant cisplatin (cis)/vinorelbine (vrb) IASLC 13th WCLC, San Francisco, U.S.A, July 31-August 4th 2009, **(Oral) abstract:A4.3**

- Massutí B, Cobo M, Sánchez J. M, Rodriguez Paniagua J. M, Jiménez U, Aguiar D, Arrabal R, González Larriba J. L, Reguart N, Astudillo J, Taron M, Rosell R. "The pharmacogenomic approach in adjuvant setting of NSCLC. Postoperative chemotherapy customized according BRCA1 levels. Docetaxel single agent arm compared with platinum doublets. SCAT pilot trial results" IASLC 13th WCLC, San Francisco, U.S.A, July 31-August 4th 2009, **(Oral) abstract:A4.4**

- Szymanowska A, Skrzypski M, Rosell R, Taron M, Muley T, Dienemann H, Meister M, Rzyman W, Rzepko R, Jarzab M, Jassem E, Jassem J. "Gene expression profiles in tumor and normal lung tissue in smoking vs. non-smoking non-small cell lung cancer (NSCLC) patients (pts)" IASLC 13th World Conference on Lung Cancer, San Francisco U.S.A, July 31-August 4th 2009 **(Oral) abstract:B3.2**

- Garrido P, Majem M, Viñolas N, Artal A, Isla D, Felip E, de Castro J, Terrasa J, García-Campelo R, Bover I, Amador M. L, Rosell R. "Lung cancer in women: the Spanish female specific database WORLD 07" IASLC 13th WCLC, San Francisco, U.S.A, July 31-August 4th 2009, **(Poster discussion) abstract:PD1.3.6**

- Carcereny E, Moran T, Felip E, Borghaei H, Fitzgerald T, Clark J, Guan S, Hsu K, Beckman R, Yan L, Rosell R, Johnson D. H. "An Open Label, Randomized Phase I/IIA Trial Evaluating MK-0646, an Anti-IGF-1R Monoclonal Antibody (MoAb), in Combination with Erlotinib for Patients with Recurrent Non-Small Cell Lung Cancer (NSCLC)" IASLC 13th WCLC, San Francisco, U.S.A, July 31-August 4th 2009, **(Poster discussion) abstract:PD3.2.3**

- Moran T, Mayo C, Queralt C, Molina M. A, Benlloch S, Quiroga V, Rolfo C, Cuello M, Carcereny E, Cardona A. F, Taron M, Rosell R. "Mutations of EGFR (mEGFR) in tumor tissue and serum DNA from stage IV non-small-cell lung cancer (NSCLC) patients (p) prospectively treated with erlotinib" IASLC 13th WCLC, San Francisco, U.S.A, July 31-August 4th 2009, **(Poster discussion) abstract:PD7.2.3**

- Isla D, Cobo M, Ramirez J. L, Sanchez-Ronco M, de Aguirre I, Provencio M, Lopez-Vivanco G, Camps C, Domine M, Alberola V, Sanchez J. M, Massuti B, Taron M, Rosell R. "Blood-based CHRNA3 single nucleotide polymorphisms (SNPs) and outcome in advanced non-small-cell lung cancer (NSCLC) patients" IASLC 13th WCLC, San Francisco, U.S.A, July 31-August 4th 2009, **(Poster discussion) abstract:PD9.2.1**

- Romero Vielva L, Rosell R, Maestre Alcácer J. A, Sole Montserrat J, Felip E, Deu Martin M, Sanchez Hernandez J. J, Armengol Carrasco M, Rochera Villach M, Montero Fernandez A, Ojanguren Arranz A, Teixidor Sureda J. "Influence of the mediastinal lymphadenectomy in non small cell lung cancer prognosis." IASLC 13th World Conference on Lung Cancer, San Francisco U.S.A, July 31-August 4th 2009 **(Poster discussion) abstract**:**PD11.4.5**

- Graziano S. L, Azougagh S, Vollmer R, Kratzake R, Popper H, Filipits M, Tsao M, Seymour L, Rosell R, Pignon J. P. "Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small-cell lung cancer

(NSCLC) treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA." IASLC 13th WCLC, San Francisco, U.S.A, July 31-August 4th 2009, **(Poster discussion) e-Poster: PD7.3.2**

- Rosell R, Ramirez J. L, de Aguirre I, Benlloch S, Cuello M, Cardona A. F, Moran T, Carcereny E, Massuti B, Taron M, Gonzalez N, Porta R. "The nicotinic acetylcholine receptor (nAChR) subunit alpha3 (CHRNA3) polymorphism in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations treated with erlotinib", IASLC 13th WCLC, San Francisco, U.S.A, July 31-August 4th 2009, **(Poster discussion) e-Poster:PD9.2.5**

- Reguart N, Isla L, Cardenal F, Cardona A, Palmero R, Rolfo C, Massuti B, Moran T, Samuel Nadal E, Montañés A, Taron M, Queralt C, Rosell R. "Phase I trial of vorinostat in combination with erlotinib for advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression." IASLC 13th WCLC, San Francisco, U.S.A, July 31-August 4th 2009, **(General poster session) abstract:P1.238**

- Jassem E, Szymanowska A, Skrzypski M, Rosell R, Taron M, Muley T, Dienemann H, Meister M, Rzyman W, Rzepko R, Jarzab M, Jassem J. "Expression of sex hormones in tumor and normal lung tissue in smoking vs. non-smoking non-small cell lung cancer (NSCLC) patients (pts)" IASLC 13th World Conference on Lung Cancer, San Francisco U.S.A, July 31-August 4th 2009 **(General poster session) abstract**:**P1.050**

- Millares L, Rodríguez N, Andreo F, Sanz J, Ramírez J. L, López-Lisbona R, Setó L, Tarón M, Rosell R, Monsó. E, Rosell. A. "Aberrant promoter methylation in sputum and bronchial washing in patients at risk for lung cancer" IASLC 13th World Conference on Lung Cancer, San Francisco U.S.A, July 31-August 4th 2009 **(General poster session) abstract**:**P1.077**

- Sanmartin E, Sirera R, Jantus Lewintre E, Miñana M. D, Navarro A, Cabrera Pastor A, Rosell R, Camps C. "Vascular Endothelial Growth Factor Receptor 2: New soluble biomarker in advanced non-small cell lung cancer?" IASLC 13th World Conference on Lung Cancer, San Francisco U.S.A, July 31-August 4th 2009 **(General poster session) abstract**:**P3.177**

ECCO 15 – ESMO 34, Berlin

- Rosell R, "Genetic aberrations as determinants of response to chemotherapy" ECCO 15 – ESMO 34, Berlin, 19-24 September 2009 **(Invited lecture) abstract I-50.**

- Rosell R, Massuti B, Cobo M, Sala M. A, Blanco R, Catot S, de Aguirre S, Queralt C, Mayo C, Taron M. "Mutations of EGFR (mEGFR) in tumor tissue and serum DNA from stage IV non-small-cell lung cancer (NSCLC) patients (p) prospectively treated with erlotinib" ECCO 15 – ESMO 34, Berlin, 19-24 September 2009 **(Oral) abstract O-9000**

- Rosell R. Highlights of Lung Proffered Papers: Lung Cancer. ECCO 15 – ESMO 34, Berlin. September 2009 **(Oral)**

- Belani CP, Ramalingam S, Kalemkerian G, Mok T, Rosell R, Ahn M, Sun L, Gates M, Lubiniecki G. M, Govindan R. "Randomized, double-blind Phase II/III study of first-line paclitaxel plus carboplatin in combination with vorinostat or placebo in patients with advanced non-small-cell lung cancer (NSCLC)" ECCO 15 – ESMO 34, Berlin, 19-24 September 2009 **(Oral) abstract O-9007**

- Massuti B, Sanchez J. M, Alonso G, Maestre J. A, Gonzalez-Larriba J. L, Camps C, Rodriguez-Paniagua J. M, Felip E, Sánchez J. J, Rosell R. "Assessing the value of

preoperative chemotherapy in early-stage non-small cell lung cáncer: Mature data and prognostic factors analysis of a Phase III randomized trial of surgery alone vs preoperative Paclitaxel/Carboplatin (PC) vs postoperative PC. Final NATCH data. An Spanish Lung Cancer Group Trial**"** ECCO 15 – ESMO 34, Berlin, 19-24 September 2009 **(Oral) abstract 21LBA**

- Pujol J. L, Lynch T. J, Rosell R, Butts C. A, Shepherd F. A, Thatcher N, Vansteenkiste J, Manegold C, Groos J, Pirker R "A meta-analysis of four randomized phase II/III trials adding cetuximab to platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC)" ECCO 15 – ESMO 34, Berlin, 19-24 September 2009 **(Oral) abstract O-9009**

- Reguart N, Isla D, Cardona A. F, Palmero R, Cardenal F, Rolfo C, Montañes A, Queralt C, Carcereny E, Rosell R. "Phase I trial of vorinostat in combination with erlotinib for advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression (NCT00503971): The TARZO trial" ECCO 15 – ESMO 34, Berlin, 19-24 September 2009**, (General poster session) P-9150**

- Cardona A. F, Porta R, Masutti B, Moran T, Felip E, Carcereny E, Taron M, Rosell R."The nicotinic acetylcholine receptor (nAChR) subunit alpha3 (CHRNA3) polymorphism in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations treated with erlotinib" ECCO 15 – ESMO 34, Berlin, 19-24 September 2009, (**General poster session) P-9022**

- Jassem J, Szymanowska A, Skrzypski M, Rosell R, Taron M, Muley T, Dienemann H, Meister M, Rzyman W, R. Rzepko R, Jarzab M, Jassem E."Gene expression profiles according to smoking status in early non-small cell lung cancer (NSCLC)" ECCO 15 – ESMO 34, Berlin, 19-24 September 2009 (**General poster session) P-9041**

- Majem M, Domine M, Lianes P, Dorta F. J, Catot S, Guillen C, De las Penas R, Vadell C, Amador M. L, Rosell R. "Lung cancer in women: the Spanish female-specific database WORLD 07" 15 – ESMO 34, Berlin, 19-24 September 2009 **(General poster session) P-9031**

- Sanmartin E, Jantus Lewintre E, Sirera R, Minana M, Navarro A, Cabrera A, Blasco S, Gallach R, Rosell R, Camps C. "Serum levels of vascular endothelial growth factor receptor 2 (VEGFR2): prognostic biomarker in advanced non-small cell lung cancer (NSCLC)?" 15 – ESMO 34, Berlin, 19-24 September 2009 **(General poster session) P-1088**

OTHER MEETINGS

British Thoracic Oncology Group Meeting, Dublin

- Rosell R. "Predictive factors of sensitivity to chemotherapeutic agents" 7th Annual British Thoracic Oncology Group Meeting 2009, *Dublin, Ireland, Wednesday 28th January 2009* **(Invited lecture)**

- Rosell R. "Potential of HDAC inhibition in NSCLC" Satellite symposium, 7th Annual British Thoracic Oncology Group Meeting 2009, *Dublin, Ireland, Wednesday 28th January* **(Invited lecture)**

ICACT, Paris

- Rosell R "Molecular Biomarkers for Predicting Chemotherapy Response in Lung Cancer", 20th International Congress on Anti-Cancer Treatment, *Paris, France, 4th February 2009* **(Invited lecture)**

- Rosell R "QPCR-based gene signatures for predicting survival in stage I NSCLC", 20th International Congress on Anti-Cancer Treatment, *Paris, France, 4th February 2009* **(Invited lecture)**

The Hallmarks of Cancer: From the Bench to the Bed, Barcelona

- Rosell R "Customized Chemotherapy Based on BRCA1" Lung Cancer Course, *Hospital Germans Trias i Pujol, Barcelona, 19th February 2009* **(Invited lecture)**

- Rosell R "Genotyping Lung Cancer: Therapy-Predictive Markers Based on EGFR Mutations" Lung Cancer Course, *Hospital Germans Trias i Pujol Barcelona, 20th February 2009* **(Invited lecture)**

- Rosell R "Adjuvant Treatment of Non-Small-Cell Lung Cancer" Lung Cancer Course, *Hospital Germans Trias i Pujol Barcelona, 20th February 2009* **(Invited lecture)**

- Rosell R "Reduction of cancer networks to abstract models for identification of therapy-predictive markers" Lung Cancer Course, *Hospital Germans Trias i Pujol Barcelona,20th February 2009* **(Invited lecture)**

- Rosell R "Looking for Answers to Targeted Therapy" Lung Cancer Course, *USP Instituto Universitario Dexeus, Barcelona, 21st February 2009* **(Invited lecture)**

Perspectives in Lung Cancer, Brussels

- Rosell R "The Evolving Role of Adjuvant Therapies in NSCLC" 10th European Congress Perspectives in Lung Cancer, *Brussels, Belgium, 6th March 2009* **(Invited lecture)**

- Rosell R "Biomarkers of Efficacy of Antiangiogenic Agents" 10th European Congress Perspectives in Lung Cancer, *Brussels, Belgium, 7th March 2009* **(Invited lecture)**

Update in Lung Cancer Management, Course for Latin American Oncologists

- Rosell R. "Genotyping Lung Cancer: Therapy-Predictive Markers Based on EGFR Mutations" Update in Lung Cancer Management, Course for Latin American Oncologists Barcelona, Spain, *March 20th 2009* **(Invited lecture)**

- Rosell R. "Phase II Second-Line Trials: An Opportunity to Develop Predictive Markers" Update in Lung Cancer Management, Course for Latin American Oncologists Barcelona, Spain, *March 20th 2009* **(Invited lecture)**

- Rosell R. "Principles of Customized Chemotherapy" Update in Lung Cancer Management, Course for Latin American Oncologists Barcelona, Spain, *March 20th 2009* **(Invited lecture)**

- Rosell R. "Reduction of Cancer Networks to Abstract Models for Identification of Therapy-Predictive Markers" Update in Lung Cancer Management, Course for Latin American Oncologists Barcelona, Spain, *March 20th 2009* **(Invited lecture)**

- Rosell R."Adjuvant Treatment of NSCLC" Update in Lung Cancer Management, Course for Latin American Oncologists Barcelona, Spain, *March 20th 2009* **(Invited lecture)**

- Rosell R."Looking for answers to targeted therapies" Update in Lung Cancer Management, Course for Latin American Oncologists Barcelona, Spain, *March 21th 2009* **(Invited lecture)**

CNIO, Madrid

- Rosell. R "Therapy Response Predictors in Lung Cancer" Molecular Markers in Cancer Therapy: Present Use and Future Perspectives, 15th Scientific Symposium, CNIO-Lilly, *Madrid, Spain, 26th March 2009* **(Invited lecture)**

Update in Lung Cancer Management, Course for Italian Oncologists

- Rosell R. "Genotyping lung cancer: Therapy-predictive markers based on EGFR mutations" Update in Lung Cancer Management, Course for Italian Oncologists Barcelona, Spain, *June 19th 2009* **(Invited lecture)**

- Rosell R. "Principles of customized chemotherapy" Update in Lung Cancer Management, Course for Italian Oncologists Barcelona, Spain, *June 19th 2009* **(Invited lecture)**

- Rosell R. "Reduction of cancer networks to abstract models for identification of therapy-predictive markers" Update in Lung Cancer Management, Course for Italian Oncologists Barcelona, Spain, *June 19th 2009* **(Invited lecture)**

- Rosell R. "Adjuvant treatment of NSCLC" Update in Lung Cancer Management, Course for Italian Oncologists Barcelona, Spain, *June 19th 2009* **(Invited lecture)**

- Rosell R. "Looking for answers to targeted therapies" Update in Lung Cancer Management, Course for Italian Oncologists Barcelona, Spain, *June 20th 2009* **(Invited lecture)**

Cursos de Verano, Universidad del País Vasco, San Sebastián

- Rosell R. "Tratamiento individualizado del cancer" Cáncer al día, Cursos de Verano, Universidad del País Vasco, *San Sebastián, 7th July 2009* **(Invited lecture)**

- Rosell R. "Tratamiento del cancer del pulmón" Cáncer al día, Cursos de Verano, Universidad del País Vasco, *San Sebastián, 7th July 2009* **(Invited lecture)**

SEOM, Barcelona

- Rosell R. "Oncogene and non-oncogene addiction, *Customizing Treatment in NSCLC*" Reduction of Cancer Networks to Abstract Models for Identification of Therapy-Predictive Markers, XII Congreso de la Sociedad Española de Oncología Médica (SEOM), *Barcelona, Spain, 22nd October 2009* **(Invited lecture, Presidential Session)**

- Sánchez Torres J. M, Alberola V, Ballesteros P, Insa A, Losa F, Oramas J, Garrido P, Jiménez A, Felip E, Rosell R. "Fase III aleatorizado de cirugía (c) sola, o quimioterapia preoperatoria con paclitaxel/carboplatino (pc) seguida de c, o c seguida de quimioterapia adyuvante con pc en cáncer de pulmón no microcítico (CPNM) (NATCH)" XII Congreso de la Sociedad Española de Oncología Médica (SEOM), Barcelona, Spain, 21-23 octubre 2009, **(Oral, Plenary Session)**

- Carcereny Costa E, Cobo Dols M, Pallarés Curto C, Sánchez Torres J. M, Diz Taín P, Ibeas Rollán R, Jiménez Berlana U, Sala González M. A, Pérez Cano M, Rosell R. "Estudio prospectivo de mutaciones del gen EGFR en pacientes con cáncer de pulmón no microcítico (cpnm) en población española. Descripcion de 350 pacientes(p) y valoración

de la eficacia terapéutica de erlotini" XII Congreso de la Sociedad Española de Oncología Médica (SEOM), Barcelona, Spain, 21-23 octubre 2009, **(Oral)**

- Morán Bueno T, Dómine M, Palmero R, García-Velasco A, Alonso G, Lianes P, Doménech M, Cardona A. F, Boitia M, Rosell R. "Características y evolución clínica de los pacientes (p) con carcinoma de pulmón no microcítico (CPNM) portadores de la mutación del gen EGFR (mutEGFR) en progresión (prog) tras respuesta inicial a erlotinib (E)" XII Congreso de la Sociedad Española de Oncología Médica (SEOM) Barcelona, Spain, 21-23 octubre 2009, **(Oral)**

- Lecumberri Biurrún M. J, Majem M, Viñolas N, Blanco M. J, Serrano S, Braña I, Provencio M, Vadell C, Amador M. L, Rosell R. "Cáncer de pulmón en mujeres: Análisis de la base de datos WORLD'07" XII Congreso de la Sociedad Española de Oncología Médica (SEOM) Barcelona, Spain, 21-23 octubre 2009, **(Oral)**

- Cobo M, Rosell R et al. "Estrategia de selección farmacogenómica en el tratamiento adyuvante del Cáncer de Pulmón no microcítico (CPNM). Estudio piloto de tratamiento quimioterápico (QT) según niveles de expresión de BRCA1. Docetaxel como agente único o combinaciones con cisplatino" XII Congreso de la Sociedad Española de Oncología Médica (SEOM), Barcelona, Spain, 21-23 octubre 2009, **(Oral)**

- Quiroga García V, Pajares I, Martí J. L, Nadal E, Cobo M, González N, Gómez P, Sánchez A, Ramírez J. L, Rosell R. "Polimorfismos (SNP) de los receptores nicotínicos CHRNA3 (nAChRs) y resultado de tratamiento de quimioterapia de primera línea en pacientes (p) con carcinoma pulmonar no microcítico (CPNM)" XII Congreso de la Sociedad Española de Oncología Médica (SEOM), Barcelona, Spain, 21-23 octubre 2009, **(Oral)**

Update in Lung Cancer Management, Course for Boehringer-Ingelheim

- Rosell R. "Advances in oncogene and non-oncogene addiction." Update in Lung Cancer Management, Course for Boehringer-Ingelheim, Barcelona, Spain, *November 11th 2009* **(Invited lecture)**

- Rosell R. "Molecular markers for customizing treatment." Update in Lung Cancer Management, Course for Boehringer-Ingelheim, Barcelona, Spain, *November 11th 2009* **(Invited lecture)**

- Rosell R. "Genotyping lung cancer: Therapy-predictive markers based on EGFR mutations" Update in Lung Cancer Management, Course for Boehringer-Ingelheim, Barcelona, Spain, *November 12th 2009* **(Invited lecture)**

- Rosell R. "Principles of customized chemotherapy" Update in Lung Cancer Management, Course for Boehringer-Ingelheim, Barcelona, Spain, *November 12th 2009* **(Invited lecture)**

Other meetings

- Rosell R. "Prospective studies in the adjuvant and metastatic settings of NSCLC: The Spanish Lung Cancer Group SCAT and BREC trials" *Netherlands Cancer Institute, 15th January 2009* **(Invited lecture)**

- Rosell R. "The EURTAC trial: the relevance of EGFR-specific lung cancer" 11th National Symposium on Lung Cancer, *Amsterdam, The Netherlands, 16th January 2009* **(Invited lecture)**

- Rosell R. "Pharmacogenomics" Latest Therapeutic Advances in the Treatment of NSCLC, *Barcelona, Spain, 17th January 2009* **(Invited lecture)**

- Rosell R. "NSCLC: Pathology, Current Treatments and Future Clinical Needs", MK-000-083-01 Merck Investigators' Meeting, *Barcelona, Spain, 20th January 2009* **(Invited lecture)**

- Rosell R. "Clinical Trials Based on Biomarkers" European Multidiscplinary Conference in Thoracic Oncology (EMCTO) *Lugano, Switzerland, 1st May 2009* **(Invited lecture)**

- Rosell R. "Potential Role of Pharmacogenomics" 5th International Experts Panel Meeting: First Line Treatment of NSCLC, *Sperlonga, Italy, 7 May 2009* **(Invited lecture)**

- Rosell R. "Interrogating the Role of the DNA-Damaging Proteins in Lung Cancer: Biology, Prognosis and Prediction" Emory University-Winship Cancer Institute, *Atlanta, U.S.A, 28th May 2009* **(Invited lecture)**

- Villa S, Mañes A, Hostalot C, Capellades J, Costas E, Carrato C, Rosiñol O, Sanz C, Rosell R, Balañà C. "Short course of radiotherapy and concomitant temozolomide in patients affected with glioblastoma with V-VI prognostic classes. A pilot study", 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology, Yokahama, Japan, May 11th-14th 2009 **(Poster)**

- Rosell R. "Developing Predictive Biomarkers for Selecting Treatment in Intractable Lung Cancers" 1st Jinling Cancer Forum, *Nanjing, China, 27th June 2009* **(Invited lecture)**

- Rosell R. "Mutant EGFR subclasses display different sensitivity to irradiation, cytotoxic drugs and TKIs. Opening Pandora's Box in NSCLC" Conferencia: Nuevas Perspectivas tras la 13ª Conferencia Mundial de Cáncer de Pulmón, Post Mundial de Cancer de Pulmon, *Madrid, Spain 30th September 2009* **(Invited lecture)**

- Rosell R, "Oncogene and non-oncogene addiction for predicting response to radiotherapy: Molecular Markers for Radiotherapy Customization" 15th Congreso SEOR, *Castellon, Spain, October 8th 2009* **(Invited lecture)**

- Rosell R. "L'addicció d'oncògens i addicció no oncogènica en el tractament individualitzat del càncer, en referència particular el càncer de pulmó" Sessions de Recerca Translacional, Institut d'Investigació Sanitària, Hospital Germans Trias i Pujol, *Badalona, Spain, 20 octubre 2009* **(Invited lecture)**

- Rosell R. "Oncogene and non-oncogene addiction: *Customizing Treatment in NSCLC"* 2ª Jornada de Recerca a l'Institut Català de la Salut, *Barcelona, Spain, October 29th 2009* **(Invited lecture)**

- Rosell R. "Moving Forward to Improve Treatment in NSCLC with EGFR Mutations" ETOP Meeting, *Zurich, Switzerland, 14th November 2009* **(Invited lecture)**

- Rosell R. "Developing biomarkers for selecting treatment in intractable lung cancer." 8th Congress on Lung Cancer, Barcelona, 26-27 November 2009 **(Invited lecture, Plenary session)**

PROFESSIONAL ACHIEVEMENTS PRE-2009

PUBLICATIONS 2008

BOOKS

- Rosell R, Taron M, Santarpia C, Salazar F, Ramirez JL, Molina MA. *DNA repair and mitotic checkpoint genes as potential predictors of chemotherapy response in NSCLC.* Cancer Drug Discovery and Development: Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. Edited by: F. Innocenti. Humana Press, as part of Springer Science+Business Media, LLC 2008; 13: 231-247

- Rosell R. *Genotypes that predict toxicity and genotypes that predict efficacy of anti-cancer drugs.* Principles of Molecular Oncology, Humana Press, 2008, Third Edition: 383-390. Edited by M. Bronchud, MA Foote, G Giacconne, O Olopade and P Workman.

ARTICLES & ABSTRACTS

- Socinski MA, Novello S, Brahmer JA, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Palleres C, Tye L, Selaru P, Chao RC, Scagliotti GV. "Multicenter phase II trial of sunitinib in previously treated advanced non-small-cell lung cancer." *J Clin Oncol* 2008; 26:650-656

- Pignon J-P, Tribodet H, Scagliotti GV, Douillard J-Y, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, His P, Ding K, Waller D, Le Chevalier T on behalf of the LACE Collaborative Group. 2Lung adjuvant cisplatin evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients." *J Clin Oncol* J Clin Oncol 2008 Jul 20;26(21):3552-9

- Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, Segal M, Gandara DR, Rosell R, Jablons DM. "A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. *Clin Cancer Res.* 2008 Sep 1;14(17):5565-70.

- Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, Rzyman W, Gulida G, Raz D, Jablons D, Provencio M, Massuti B, Chaib I, Perez-Roca L, Jassem J, Rosell R. "Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung." *Clin Cancer Res.* 2008 Aug 1;14(15):4794-9.

- Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V, Rosell R. 2Ribonucleotide reductase subunits M1 and M2 mRNA expression levels are associated with clinical outcomes of patients with lung adenocarcinomas treated with docetaxel/gemcitabine chemotherapy.". *British J Cancer* 2008; 98: 1710-1715

- Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, Yu L, Rosell R. "ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen." *British J Cancer* 2008; 98:1398-1402

- Rosell R. Lung Cancer Genes. In response to "New treatments hope after lung cancer gene found" *published in The Times Online, 3 April 2008.*

- Santarpia M, Altavilla G, Margeli M, Cirauqui B, Mesiti M, Cavallari V, Ramirez JL, Sanchez-Ronco M, Santarpia L, Taron M, Rosell R. "PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance". *Cancer Invest.* 2008 Dec,26:10:1044-51

- Boukovinas I, Mendez P, Mavroudis D, Koutsopoulos A, Papakotoulas P, Trypaki M, Taron M, Georgoulias V, Rosell R, Souglakos J. "Tumoral BRCA1 mRNA expression levels are associated with clinical response to front-line docetaxel/gemcitabine chemotherapy in patients with lung adenocarcinomas." *PLoS ONE* 2008, Vol 3;11:1-8

- Rosell R, Robinet G, Szczesna A, Ramlau R, Constenia M, Mennecier BC, Pfeifer W, O'Byrne KJ, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson MR, Ellis PA, Pilz K, Reck M. "Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small cell lung cancer." *Ann Oncol* February 2008; 19: 362 - 369.

- Rosell R , Vergnenegre A, Fournel P, Massuti B, Camps C , Isla D , Sanchez JM , Moran T, Sirera R and Taron M. "Pharmacogenetics in lung cancer for the lay doctor." *Targeted Oncology* 2008 , Vol 3 (3): 161-171

- Taron M, Molina MA, Mendez P, Sirera R, Camps C, Felip E, Massuti B, Carrasco E, Benlloch S, Ramon y Cajal S, Mate JL and Rosell R. "The practicalities of pharmacogenomic Analysis- The Spanish Lung Cancer Group Experience." *Le Nouveau Cancérologue* 2008; 1: 1-3

- Rosell R, Manegold C, Moran T, Garrido P, Blanco R, Lianes P, Stahel R, Trigo J, Wei J, Taron M. "Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small cell lung cancer." *Clin Lung Cancer* 2008, Vol 9 (Suppl 2): S76-S82

- Rosell R, and Garcia-Campelo, R." Farmacogenómica como instrumento de individualización del tratamiento del cáncer." *Formación Médica Continuada en Oncología*, Jun 2008 Vol 3, Suppl 1: 71-82

- Gridelli C, Ardizzoni A, Ciardello F, Hanna N, Heymach J, Perrone F, Rosell R, Shephard FA, Thatcher N, Vansteenkiste J, De Petris L, Di Maio M, De Marinis F. "Second-line treatment of advanced non-small-cell lung cancer." *J Thorac Oncol*. 2008 Apr;3(4):430-40.

- Gautschi O, Mack PC, Davies AM, Rosell R, Gandara D. "Pharmacogenomic approaches to individualizing chemotherapy for non-small cell lung cancer: current status and new directions." *Clin Lung Cancer* , Vol 9, (Suppl 3): S129-S138

- Perona R, Massuti B, Rosell R. "Reflections on the IASLC 12th World Conference on Lung Cancer." *Clin Transl Oncol* 2008 Feb;10(2):67-9

- Sirera R, Gil M, Blasco A, Cabrera A, Safont MJ, Iranzo V, Cayuela D, Rosell R, Camps C. Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer. *Lung Cancer* 2008 Jul;61(1):104-8

- Rosell R, de Las Peñas R, Balaña C, Santarpia M, Salazar F, de Aguirre I, Reguart N, Villa S, Wei J, Ramirez JL, Molina MA, Ramon y Cajal S, Jablons D, Taron M. "Translational research in glioblastoma multiforme: molecular criteria for patient selection." *Future Oncol.* 2008 Apr;4(2):219-28. Review.

- Felip E, Rosell R. "Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)." *Ther Clin Risk Manag.* 2008 Jun;4(3):579-85.

- Molina MA, Bertran-Alamillo J, Reguart N, Taron M, Castella E, Llatjós M, Costa C, Mayo C, Pradas A, Queralt C, Botia M, Pérez-Cano M, Carrasco E, Tomas M, Mate JL, Moran T and Rosell R. "A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells." *J Thor Oncol* 2008 , Vol 3;11:1224-1235

- Douillard J-Y, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA. "Impact of post operative radiation therapy (PORT) on survival in completely resected patients with stages I, II or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy in the randomized trial ANITA." *Intl J Radiat Oncol Biol Phys* 2008 Nov 1, 1;72(3):695-701

- Felip E, Font A, Rosell R and Saura C. "Small-cell lung cancer treatment – present status and expectations." *Business Briefing: Eur Pharmacother*

- Font A, Salazar R, Maurel J, Taron M, Ramirez JL, Tabernero J, Gallego R, Casado E, Manzano JL, Carcereny E, Guix M, Fernández-Llamazares J, Rosell R. "Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms." *Cancer Chemother Pharmacol.* 2008; 62:1075-1083

- Rosell R. "Cetuximab may enhance chemotherapy response in NSCLC." *The Oncology Report* Fall 2008 edition

- Rosell R. "Diagnosis and staging", Vermorken JB, Rowett LH (eds. on behalf of the ESMO Educational Committee) Medical Oncology for Non-Oncologists with Focus on Solid Tumors

- Rosell R. "DNA repair genes and platinum compounds in non-small cell lung cancer. Pharmacogenomics", Anticancer Drug Discovery, and Response, Humana Press

- Taron M, Rosell R, Scagliotti G, Font A, Moran T, Mate JL, Sanchez JJ. "Diagnosis and treatment of pleural mesothelioma, current strategies and future concepts." *Lung Cancer* (suppl)

- V. Hirsh, M. Boyer, R. Rosell, R. J. Benner, D. Readett, J. H. Schiller. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* , **abstr 8016**)

- Font, M. Tarón, C. Costa, L. Layos, L. Pérez-Roca, J. Sánchez, I. Chaib, M. Mora, J. Gago, R. Rosell. BRCA1 mRNA expression in patients (p) with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy. *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* , **abstr 5021**)

- M. Provencio, R. de las Peñas, M. Cobo, B. Massuti, A. Artal, J. M. Muñoz-Langa, R. Garcia-Gomez, A. Sanchez-Ruiz, R. Rosell. Cisplatin (CDDP) plus vinorelbine (NVB) as first-line treatment for advanced non-small-cell lung cancer (NSCLC): Retrospective analysis to improve the patient's convenience on day 8 NVB administration. *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* , **abstr 19049**)

- Balañá, C. Carrato, J. Ramírez, M. Berdiel, D. Kaen, J. Sánchez, M. Tarón, C. Hostalot, A. Ariza, R. Rosell. Concordance and clinical value of the MGMT promoter methylation pattern in tissue with paired serum and MGMT protein expression in a series of glioblastoma (GB) patients. *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting,* **abstr 2037***)*

- N. Reguart, J. Bertrán-Alamillo, M. Molina, E. Carrasco, C. Mayo, C. Queralt, M. Tomàs, L. Layos, M. Tarón, R. Rosell. Detection of EGFR mutations in samples with few cancer cells in non-small cell lung cancer (NSCLC) patients (p) and distribution of exon 20 mutations. *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* , **abstr 8073**)

- J. Sánchez, M. Molina, T. Moran, R. A. Stahel, J. Ramírez, F. Salazar, P. Garrido Lopez, J. Bertran-Alamillo, M. Tarón, R. Rosell. Effect of first-line treatment and CHFR and 14-3-3σ methylation status on survival to second-line chemotherapy or EGFR tyrosine kinase inhibitors (TKIs) in stage IV non-small-cell lung cancer (NSCLC). *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* , **abstr 8068**)

- R. Porta, C. Queralt, F. Cardenal, C. Mayo, M. Provencio, C. Camps, D. Isla, J. González-Larriba, M. Tarón, R. Rosell. Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p). *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* , **abstr 8038**)

- J. Jassem, A. Szymanowska, M. Skrzypski, R. Rosell , M. Taron, I. Chaib, W. Rzyman, M. Jarzab, T. Muley, E. Jassem. Gene expression signatures in non-small cell lung cancer (NSCLC) according to cigarette smoking history. *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* , **abstr 22082**)

- Massuti, A. Burgos, A. Yuste, E. Alonso, E. Adrover Cebrián, J. Marti, J. Ponce, M. Cia, J. Ordovas, R. Rosell. Impact in cost of new cytotoxic and biological agents for colorectal and lung cancer: A European model. *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* ,**abstr 17520**)

- R. Bartolucci, M. Botia, P. Mendez, F. Puma, S. Sabatini, S. Catanzani, M. Urbani, P. Saccenti, M. Tarón, R. Rosell. Influence of XPG mRNA levels on the effect of BRCA1 mRNA levels in prognosis of early non-small cell lung cancer (NSCLC). *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* , **abstr 7545**)

- T. Moran, J. González-Larriba, J. Montesinos, J. Delgado, B. Massutí, G. López-Vivanco, J. López-Picazo, A. Peiró, L. G. Paz-Ares, R. Rosell. Pemetrexed (P) alone or in combination with platinum for malignant pleural mesothelioma (MPM): Efficacy and toxicity of the International Expanded Access Program (EAP) in Spanish patients (p). *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* ,**abstr 19038**)

- P. Garrido Lopez, R. Rosell, B. Massutí, F. Cardenal, V. Alberola Candel, M. Dómine, R. García Gómez, I. Maestu, D. Isla, M. López-Brea. Predictors of long-term survival in lung cancer patients (p) included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel (D) and carboplatin (Cb) plus induction (I) or consolidation (C) chemotherapy (CT) with docetaxel and gemcitabine (G). *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* , **abstr 7574**)

- T. Reiman, P. Seve, A. Vataire, A. Dunant, R. Rosell, S. Graziano, L. Seymour, R. Pirker, R. Lai, for the LACE-Bio Group. Prognostic value of class III b-tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin-based chemotherapy (CT): A validation study on three randomized trials. *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* , **abstr 7506**)

- M. Cobo, B. Massuti, T. Morán, I. Chaib, L. Pérez-Roca, U. Jiménez, D. Aguiar Bujanda, J. González-Larriba, J. Gómez, R. Rosell. Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels. *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* ,**abstr 7533**)

- R. Rosell, M. Provencio, M. Dómine, A. Pradas, F. Salazar, N. Reguart, M. Sala, P. Diz, I. Barneto, M. Tarón. Spanish Lung Adenocarcinoma Trial (SLAT) of customized treatment based on EGFR mutations (mut) and BRCA1 mRNA expression: Ancillary analyses of Abraxas and RAP80 expression. *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* ,**abstr 8037**)

- M. Margelí, B. Cirauqui, E. Castellà, G. Tapia, C. Costa, A. Gimenez-Capitan, O. Etxaniz, A. Ariza, M. Tarón, R. Rosell. Use of BRCA1 mRNA expression levels to predict survival in breast cancer patients (p) treated with neoadjuvant chemotherapy. *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* ,**abstr 11510**)

- M. Skrzypski, E. Jassem, S. Benlloch, M. Pérez, W. Rzyman, G. Gulida, J. Sánchez, M. Tarón, J. Jassem, R. Rosell. Validation of 5- and 3-gene expression signatures for predicting outcome in non-small cell lung cancer (NSCLC) patients (p). *J Clin Oncol* 26: 2008 (May 20 suppl, *ASCO Annual Meeting* ,**abstr 7532**)

- R. Rosell. Personalized cancer therapies for non-EGFR receptor dependent tumors. ESMO_JSMO Joint Symposium: Adenocarcinoma of the lung. *33rd ESMO Congress, Stockholm, Sweden, 12-16 September 2008*. Ann Oncol, Vol 19 (Supplement 8): viii43, 2008 (671N).

- R. Rosell, R. Bastus, A. Olaverri, I. Anton, R. Blanco, M. Domine, J. Terrasa,A. Poveda, J. Oramas, D. Isla . Customized chemotherapy based on BRCA1 mRNA expression and EGFR mutations in lung adenocarcinoma. *33rd ESMO Congress, Stockholm, Sweden, 12-16 September 2008.* Ann Oncol, Vol 19 (Supplement 8): viii93, 2008 (238P).

- T. Moran, B. Massuti, U. Jimenez, D. Aguiar, A. Carrato, G. López-Vivanco, I. Maestu, C. Camps, J. Oramas, R. Rosell. Customizing adjuvant chemotherapy based on BRCA1 mRNA levels in resected stage II-IIIA NSCLC patients. *33rd ESMO Congress, Stockholm, Sweden, 12-16 September 2008.* Ann Oncol, Vol 19 (Supplement 8): viii92, 2008 (237P).

- N. Reguart, F. Cardenal, R. Porta, M. Provencio, J.L. González-Larriba, C. Pallarés, B. Massuti, A. Insa, G. López-Vivanco, R. Rosell. What are the differences between bronchioalveolar carcinoma (BAC) and adenocarcinoma patients with EGFR mutations when treated with erlotinib? *33rd ESMO Congress, Stockholm, Sweden, 12-16 September 2008.* Ann Oncol, Vol 19 (Supplement 8): viii99, 2008 (260P).

- R. Sirera, S. Catot, J.L. González-Larriba, I. Bover, G. Alonso, J. Valdivia, R. Ibeas, P. Lianes, P. Martínez del Prado, R. Rosell . Customizing erlotinib in metastatic NSCLC patients harboring EGFR mutations. *33rd ESMO Congress, Stockholm, Sweden, 12-16 September 2008.* .Ann Oncol, Vol 19 (Supplement 8): viii90, 2008 (230PD).

- Reguart. N, Cardona. A. F, Carrasco. E, Gomez. P, Taron. M, Rosell. R. "BRCA 1: A new genomic marker for Non-Small-Cell Lung Cancer". *Clinical Lung Cancer* 2008;9: 331-339

- Morán. T, Garrido. P, Rosell. R. "Long-term Survival Associated With Complete Resection Following Neoadjuvant Chemotherapy in Stage IIIA (N2) and IIIB (T4 N0-1) Non-Small Cell Lung Cancer: A Case Study of the SLCG 99/01 Study". *American Journal of Hematology and Oncology, March 2008,* Vol 7: 101-107

- Levy. B, Galletti. G, Saqi. A, Gal. A, Sanchez. J.J, Rosell R, Giannakakou. P. "Tubulin acetylation expression predicts response to taxane-based chemotherapy in NSCLC." *AACR Annual Meeting*, Apr 12th-16th 2008 **abst** 4957.

- Molina. M.A, Bertran-Alamillo. J, Reguart. N, Castella. E, Llatjos. M, Carrasco. E, Tomas. M, Taron. M, Rosell. R. "Detection of EGFR mutations in samples with few cancer cells can predict response to erlotinib in non-small-cell lung cancer (NSCLC) patients (p) and reveals frequent heterogeneous distribution of exon 20 mutation*" AACR Annual Meeting,* Apr 12th – 16th 2008 **abstr** 3633.

- Perona. R, Massuti. B, Rosell. R. "Reflections on the IASLC 12th World Conference on Lung Cancer" *Clinical and Translational Oncology, February 2008*; 10: 67-69

- Isla. D, Rosell. R. "Futuro del tratamiento del cáncer de pulmon" Capitulo libro: Highlights from ASCO 2008. Cáncer de pulmón. Permanyer Publications 2008.

- Rosell. R, Taron. M, Queralt. C, Wei. J. EGFR Mutations in Circulating Cancer Cells. Personalized Medicine 2008, Vol 5;(6), 567-568

PUBLICATIONS 2007

- Rosell R, Santarpia M, Moran T, Salazar MF, Kaen DL, Ramirez JL. Age-related genetic abnormalities: the Achilles' heel for customizing therapy in elderly lung cancer patients. *Personalized Medicine* 2007;4(1):59-72

- Rosell R. Cancer and alterations in the endocytic pathway. *Future Oncol* 2007 Oct;3(5):487-9

- Garrido P, Gonzalez-Larriba JL, Insa A, Provencio M, Torres A, " D, Sanchez JM, Cardenal F, Domine M, Barcelo JR, Tarrazona V, Varela A, Aguilo R, Astudillo J, Muguruza I, Artal A, Hernandez-Trancho F, Massuti B, Sanchez-Ronco M, Rosell R. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non-small-cell lung cancer patients: The Spanish Lung Cancer Group 9901 Trial". *J Clin Oncol* 2007 Oct 20;25(30):4736-42.

- Rosell R, Taron M, Sanchez JJ, Paz-Ares L. Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. *Future Oncol* 2007;3:277-83

- Rosell R, Felip E, Paz-Ares L. How could pharmacogenomics help improve patient survival? *Lung Cancer* 2007;57(S2):S35-S41

- Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, Mendez P, Chaib I, Perez-Roca L, Szymanowska A, Rzyman W, Puma F, Kobierska-Gulida G, Farabi R, Jassem J. BRCA1: A novel prognostic factor in resected non-small-cell lung cancer. *PLoS One* 2007;11:e1129

- Rosell R, Taron M. Consideraciones genéticas para un tratamiento individualizado del cáncer de pulmón. *JANO* 2007;1655;45-47

- Rosell R, Mendez P, Isla D, Taron M. Platinum resistance related to a functional NER pathway. *J Thorac Oncol* 2007;2:1063-66

- Rosell R, Reguart Aransay N. El cancer de pulmón. *Mujer Más Vital* 2007;7:12-13

- Cobo M, Isla D, Massuti B, Montes A, Sanchz JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer. *J Clin Oncol* 2007;25:2747-54

- Felip E and Rosell R. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy reponse. *Expert Rev. Mol. Diagn*. 2007;7:261-268

- Felip E, Santarpia M, Rosell R. Emerging drugs for non-small cell lung cancer. *Exp Opin Emerg Drugs* 2007;12:449-60

- Camps C, Sirera E, Iranzo V, Taron M, Rosell R. Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. *Clin Lung Cancer* 2007;8:369-75

- Font A, Arellano A, Fernández-Llamazares J, Casas D, Cardenal J, Margeli M, Manzano JL, Abad A, and Rosell R. Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer. *Clin Transl Oncol* 2007;9:177-82

- Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez de Molina V, Cejas P, Skrzypski M, Gallego-Ortega D, de Castro J, Casado E, Garcia-Cabezas MA, Sanchez JJ, Nistal M, Rosell R, Gonzalez-Baron M, Lacal JC. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. *Lancet Oncol* 2007;8:889-7

- Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavijevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. *J Natl Cancer Inst* 2007;99:1-11

- Shepherd MD and Rosell R. Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. *J Thoracic Oncol* 2007;2(Supp):S1-S9

- Marco I, Lopez-Olvera JR, Rosell R, Vidal E, Hurtado A, Juste R, Pumarola M., Lavin S. Severe outbreak of disease in the southern chamois (Rupicapra pyrenaica) associated with border disease vírus infection. *Vet*

Microbiol 2007;25:33-41

- Weiss G, Rosell R, Fossella, Perry M, Stahel R, Barata F, Nguyen B, Paul S, McAndrews P, Hanna N, Kelly K, Bunn PA Jr. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. *Ann Oncol* 2007;18:453-60

- Bellmunt J, Paz-Ares L,Cuello M, Cecere FL, Albiol S, Guillerm V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R, Baselga J on behalf of Spanish Oncology Genitourinary Group (SOGUG). Gene expresión of ERCC1 as a novel prognostic marker in acvanced bladder cancer patients receiving cisplatin-based chemotherapy. *Ann Oncol* 2007;18:522-8

- Taron M, Rosell R, Molina MA. Molecular staging of NSCLC, in "Oncologia Toracica" Francesco Carpagnano, Ragusa Grafica Moderna, 2007:107-14

- Rosell R, Bartolucci R, Puma F, Skrzypski M, Mendez P, Chaib I, Masuti B, Sanchez JM, Wei J, Taron M. The prognostic and predictive role of BRCA1 mRNA expression in selecting patients for customized adjuvant chemothearpy, in "Oncologia Toracica" Francesco Carpagnano, Ragusa Grafica Moderna, 2007:139-46

- Douillard J-Y, Carpagnano F, Rosell R, De Lena M, Riggi M, Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients witn completely resected stage IB-IIIA NSCLC (ANITA), in "Oncologia Toracica" Francesco Carpagnano, Ragusa Grafica Moderna, 2007:147-54

- Rosell R, Jassem E, Skrzypski M, Taron M, Mendez P, Perez L, Szymanowska A, Rzyman W, Guilda G, Jassem J. Poster Discussion: "Increased BRCA1 mRNA: An independent prognostic variable in completely resected chemo-naïve non-small cell lung cancer patients" American Society of Clinical Oncology 43rd Annual Meeting, Chicago IL, USA, June 1-5, 2007. Proc ASCO 2007;25:18S (abstr 7551)

- Brahmer JR, Govindan R, Novello S, Rosell R, Belani CP, Atkins JN, Gillenwater HH, Tye L, Chao R, Socinski MA. Poster discussion: "Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer: results from a phase II study. American Society of Clinical Oncology 43rd Annual Meeting, Chicago IL, USA, June 1-5, 2007. Proc ASCO 2007;25:18S (abstr 7542)

- Bruzzi P, Sormani M, Tiseo M, Boni L, Rosell R, Ardizzoni A. Poster Discussion: Tumor response to chemotherapy as a surrogate endpoint of survival in advanced non-small cell lung cancer: Results of an individual patients data meta-analysis" American Society of Clinical Oncology 43rd Annual Meeting, Chicago IL, USA, June 1-5, 2007. Proc ASCO 2007;25:18S (abstr 7548)

- Felip E, Rosell R, Massuti B, Alonso G, Gonzalez-Larriba JL, Camps C, Isla D, Mas C, Sanchez JJ, Maestre JA. General Poster Session: "The NATCH trial: Observations on the neoadjuvant arm" American Society of Clinical Oncology 43rd Annual Meeting, Chicago IL, USA, June 1-5, 2007. Proc ASCO 2007;25:18S (abstr 7578)

- Camps C, Sirera R, Muñoz-Navarro M, Lopez-VIvanco G, Alonso G, Provencio M, Gonzalez-Larriba J, de las Peñas R, Taron M, Rosell R. General Poster Session: "The quantification of epidermal growth factor receptor in plasma is a prognostic factor in advanced non-small cell lung cancer patients. American Society of Clinical Oncology 43rd Annual Meeting, Chicago IL, USA, June 1-5, 2007. Proc ASCO 2007;25:18S (abstr 7597)

- Reguart N, Porta R, Provencio M, Cardenal F, Cuello M, Ramirez JL, Mayo C, Lilanes P, Taron M, Rosell R. General Poster Session: "14-3-3σ and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations" American Society of Clinical Oncology 43rd Annual Meeting, Chicago IL, USA, June 1-5, 2007. Proc ASCO 2007;25:18S (abstr 7600)

- Etxaniz O, Provencio M, Terrasa J, Carrato A, Lianes P, Bover I, Perez-Caino M, Sanchez J, Taron M, Rosell R. General Poster Session: "Excision repair cross complementing 6 single nucleotide polymorphism and outcome to gemcitabine/cisplatin or docetaxel/cisplatin in stage IV non-small cell lunc cancer patients. American Society of Clinical Oncology 43rd Annual Meeting, Chicago IL, USA, June 1-5, 2007. Proc ASCO 2007;25:18S (abstr 7605)

- Skzypski M, Jassem E, Mendez P, Chaib I, Szymanowska A, Rzyman W, Guilda G, Jassem J, Taron M, Rosell R. General Poster Session: "Expression profile of 29 genes by real-time quantitative PCR in early-stage (I-III) squamous cell carcinoma of the lung. American Society of Clinical Oncology 43rd Annual Meeting, Chicago IL, USA, June 1-5, 2007. Proc ASCO 2007;25:18S (abstr 7612)

- Molina M, Camps C, de las Peñas R, Alonso G, Lopez-Vivanco G, Provencio M, Gonzalez-Larriba J, Salazar F, Sanchez J, Rosell R. General Poster Session: "Elevated levels of thioredoxin in serum correlate with poor outcome ein docetaxel/cisplatin-treated stage IV non-small cell lung cancer patients. American Society of Clinical Oncology 43rd Annual Meeting, Chicago IL, USA, June 1-5, 2007. Proc ASCO 2007;25:18S (abstr 7628)

- Santarpia M, Garrido P, Gonzalez-Larriba J, Azagra P, Cardenal F, Ramirez J, de Aguirre I, Sanchez-Ronco M, Taron M, Rosell R. General Poster Session: "XPD 312 single nucleotide polymorphism in stage IIIA-B non-small cell lung cancer patients <59 years treated with chemotherapy followed by surgery. American Society of Clinical Oncology 43rd Annual Meeting, Chicago IL, USA, June 1-5, 2007. Proc ASCO 2007;25:18S (abstr 7652)

- Isla D, Felip E, Garrido P, Viñolas N, Garcia-Campelo R, Lianes P, Bover I, Terrasa J, Sanchez JJ, Rosell R. General Poster Session: "Sex differences in non-small cell lung cancer patients participating in Spanish Lung Cancer Group trials" American Society of Clinical Oncology 43rd Annual Meeting, Chicago IL, USA, June 1-5, 2007. Proc ASCO 2007;25:18S (abstr 7679)

- Taron M, Cobo M, Isla D, Massuti B, Montes A, Sanchez J, Botia M, Domine M, Sanchez-Ronco M, Rosell R. General Poster Session: "Role or ERCC1, XRCC3, Aurura A and TGFBR1 single-nucleotide polymorphisms and CHFR and 14-3-3σ methylation in a customized cisplatin trial based n ERCC1 mRNA levels in stage IV non-small cell lung cancer patients. American Society of Clinical Oncology 43rd Annual Meeting, Chicago IL, USA, June 1-5, 2007. Proc ASCO 2007;25:18S (abstr 7687)

- Scagliotti GV, Novello S, Brahmer JR, Govindan R, Rosell R, Belani CP, Atkins JN, Tye L, Chao R, Socinski MA. "A phase II study of continuous daily sunitinib dosing in patients with previously-treated advanced non-small cell lung cancer" Poster, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Moran MT, Sanchez JM, Isla D, Cobo M, Paz-Ares L, Catot S, Jimenez U, Diz P, Taron M, Rosell R. "High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer patients with poor performance status" Poster Discussion, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Molina MA, de la Peñas R, Alberola, V, Blasco A, Lopez-Vivanco G, Brea ML, Gonzalez-Larriba JL, Salazar F, Ramirez JL, Rosell R. "Elevated levels of thioredoxin in serum correlate with poor outcome in docetaxel/cisplatin-treated stage IV non-small cell lung cancer patients" Poster, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Reguart N, Porta R, Cantos B, Cardenal F, Cuello M, Lianes P, Majem M, Massuti B, Taron M, Rosell R. "14-3-3 sigma and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations" Poster, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Sirera R, Camps C, Muñoz-Navarro M, Blasco A, Safont MJ, Iranzo V, Baballero C, de las Peñas R, Taron M, Rosell R. "The quantification of the catalytic subunit of telomerase in plasma is a prognostic factor in advanced non-small cell lung cancer patients" Poster, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Sirera R, Camps C, Lopez-Vivanco G, Alonso G, Cantos B, Blasco A, Caballero C, Muñoz-Navarro M, Taron M, Rosell R. "Progostic impact of Epidermal Growth Factor Receptor concentration in plasma in advanced non-small cell lung cancer patients" Poster, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Provencio M, Camps C, Cantos B, Alberola V, Domine M, Isla D, Millan I, Massuti B, Cardenal F, Rosell R. "Non-small cell lung cancer in the elderly" Poster, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Sirera R, Camps C, Gonzalez-Larriba C, Gonzalez-Larriba JL, Lao J, Garcia-Gomez R, Viñolas N, Safont MJ, Gavala J, Taron M, Rosell R. Poster, "Prognostic value of the determination of K-ras mutations plasma in advanced non-small cell lung cancer patients"12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Camps C, Sirera R, Terrasa J, Baron F, Massuti B, Blasco A, Safont MJ, Iranzo V, Taron M, Rosell R. "Vascular endothelial growth factor and basic fibroblast growth factor in blood in advanced non-small cell lung cancer patients: Analysis of their prognostic value" Poster, 12th World Conference on Lung Cancer,

Seoul, Korea, September 2-6, 2007

- Camps C, Sirera R, Blasco A, Caballero C, Safont MJ, Gavila J, Gil M, Cayuela D, Taron M, Rosell R. "Determination of nerve growth factor levels in plasma in patients with advanced non-small cell lung cancer patients. Its correlation with clinical outcome" Poster, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Skrzypski M, Jassem E, Mendez P, Chaib I, Szymanowska A, Rzyman W, Gulida GK, Jassem J, Taron M, Rosell R. "Real time RT-PCR based 3-gene expression signature predicts survival in early-stage squamous cell lung cancer" Poster, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Taron M, Cobo M, Isla D, Massuti B, Mones A, Sanchez JM, Botia M, Domine M, Sanchez Ronco M, Rosell R. "Role of ERCC1, XRCC3, Aurora A and TGFBR1 single nucleotide polymorphisms and CHFR and 14-3-3 sigma methylation in a customized cisplatin trial based on ERCC1 mRNA levels in stage IV non-small-cell lung cancer patients" Poster, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Viñolas N, Isla D, Felip E, Garrido P, Garcia-Campelo R, Lianes P, Bover I, Terrasa J, Vadell C, Rosell R. "Gender differences in non-small cell lung cancer patients: A retrospective study based in Spanish Lung Cancer Group trials" Poster, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Cantos B, de las Peñas R, Blasco A, Cobo M, Massuti B, Jimenez U, Lao J, Palmero R, Taron M, Rosell R. "First-line treatment with vinorelbine plus cisplatin for patients with advanced non-small-cell lung cancer: Molecular correlates" Poster, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Maestu I, Isla D, Pedraza M, Munoz J, ORamas J, Garcia-Gomez R, del Barco S, Cantos B, Taron M, Rosell R. "First-line treatment with vinorelbine plus gemcitabine for elderly patients with advanced non-small-cell lung cancer: Molecular correlates "Poster, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Santarpia C, Gonzalez-Larriba JL, Azagra P, Cantos B, Garrido P, Sanchez JM, de Aguirre I, Sanchez-Ronco M, Taron M, Rosell R. "XPD 312 single nucleotide polymorphism predicts survival in stage IIIA-B non-small-cell lung cancer patients <59 years treated with chemotherapy followed by surgery" Poster, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Jassem E, Chaib I, Skrzypski M, Rosell R, Taron M, Szymanowska A, Rzyman W, Kobierska-Gulida G, Jassem J. "Clinical utility of gene expression levels of ribonucleotide reductase subunit M1, tyrosyl-DNA phosphodiesterase, nuclear factor of activated T cells and BubR1 mRNA expression in completely resected chemonaive non-small-cell lung cancer patients" Poster, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Skrzypski M, Jassem E, Jassem J, Rzyman W, Gulida G, Taron M, Mendez P, Rosell R, Niklinski J. "Real time RT-PCR 3 gene expression signature predicts survival in early-stage squamous cell lung cancer". ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO500

- Govindan R , Brahmer JR, Novello S, Rosell R, Belani CP, Atkins JN, Gillenwater HH, Tye L, Chao RC, Socinski MA. "Phase II study investigating the efficacy and safety of continous daily sunitinib dosing in previously treated advanced non-small cell lung cancer." Poster, ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO6525

- Taron M,Cobo M, Isla L, Massuti B, Montes A, Sánchez JM, Botia M, Domine M, Sanchez-Ronco M, Rosell R. "Role of ERCC1, XRCC3, Aurora A and TGFBR1 gene single nucleotide polymorphisms and CHFR and 14-3-3 σ methylation in a customized cisplatin trial based on ERCC1 mRNA levels in stage IV non-small-cell lung cancer patients." Poster, ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO6528

- Salazar F, Ramírez JL, Reguart N, Porta R, Provencio M, Cardenal F, Cuello M, Lianes P, Taron M, Rosell R. "14-3-3 σ and checkpoint with forkhead and ring finger methylation in serum in erlotinib.treated non-small-cell lung cancer patients with EGFR mutations." Poster, ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO6529

- Clara M, Moran T, Paz-Ares L, Isla D, Cobo M, Massuti B, Insa A, Queralt C, Pradas A, Rosell R. "High correspondence between EGFR mutations in tissue and in circulating DNA from non-small-cell lung cancer patients with poor performance status" Poster, ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO6530

- Santarpia C, Garrido P, González-Larriba JL, Azagra P, Cardenal F, Ramírez JL, De Aguirre I, Sanchez-Ronco M, Tarón M, Rosell R. "XPD 312 single nucleotide polymorphism predicts survival in stage IIIA-B non-small-cell lung cancer patients <59 years treated with chemotherapy followed by surgery." Poster, ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO6531

- Molina MA, Camps C, De Las Peñas R, Alonso G, López-Vivanco G, Provencio M, González-Larriba JL, Salazar F, Sánchez JJ, Rosell R. "Elevated levels of thioredoxin in serum correlate with poor outcome in docetaxel/cisplatin-treated stage IV non-small-cell lung cancer patients." Poster, ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO6534

- Benlloch S, Galbis J, Alenda C, Peiro FM, Marti JL, Baschwitz B, Rodríguez-Paniagua JM, Rosell R, Taron M, Massuti B. "Molecular markers expression in mediastinal nodes from resected stage I non-small cell lung cancer: prognostic impact and potential role as markers of occult micrometastasis." Poster, ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO6543

- Camps C, Sirera R, Bremmes RM, Blasco A, Safont MJ, Caballero C, Cabrera-Pastor A, Gavila J, Taron M, Rosell R. "The quantification of plasmatic free DNA is a prognostic factor in advanced non-small-cell lung cancer patients." Poster, ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO6569

- Provencio M, Blanco R, Alberola V, Delgado JR, Diz P, Almenarez JA, López-Vivanco G, González-Larriba JL, Martin G, Rosell R. "Cisplatin plus vinorelbine as first-line treatment for patients with advanced non-small-cell lung cancer: molecular correlates." Poster, ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO6586

- Maestu I, Isla D, Pedraza M, Muñoz J, Oramas J, García-Gómez R, Del Barco S, Cantos B, Tarón M, Rosell R. "Vinorelbine plus gemcitabine as frst-line treatment for elderly patients with advanced non-small-cell lung cancer: molecular correlates." Poster, ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO6588

- Sirera R, Camps C, López-Vivanco G, García-Campelo R, Provencio M, Gonzalez-Larriba R, De Las Peñas R, Iranzo V, Tarón M, Rosell R. "Analisis of the prognostic value of the quantification of plasmatic epidermal growth factor receptor in advanced non-small-cell lung cancer patients." Poster, ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO6591

- Sirera R, Camps C, García-Gómez R, Viñolas N, Artal A, Guillot M, Blasco A, Safont MJ, Taron M, Rosell R. "Determination of plasma K-ras mutations in codon 12 in advanced non-small-cell lung cancer patients. Analysis of its prognostic role." Poster, ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO6592

- Sirera R, Camps C, Caballero C, Safont MJ, Blasco A, Gavila J, Cabrera-Pastor A, Iranzo V, Taron M, Rosell R. "Nerve growth factor levels in plasma in patients with advanced non-small-cell lung cancer patients. Is it predictive of clinical outcome?" Poster, ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO6593

- Camps C, Sirera R, Alberola V, Safont MJ, Blasco S, Caballero C, Cabrera-Pastor A, Pranzo V, Taron M, Rosell R." Determination of the prognostic value blood levels of vascular endothelial growth factor and basic fibroblast growth factor in advanced non-small-cell lung cancer patients". Poster, ECCO 14 The European Cancer Conference. *EJC Supplements* 2007;5(4):PO6611

- Balaña. C, Capellades. J, Teixidor. P, Roussos. I, Ballester. R, Cuello. M, Arellano. A, Florensa. R, Rosell. R. "Clinical course of high-grade glioma patients with a "biopsy-only" surgical approach: a need for individualised treatment" *Clinicaland Translational Oncology, Vol 9; 797-803, ,December 2007*

PUBLICATIONS 2006

- Rosell R, Taron M, Reguart N, Isla D, Moran T. Epidermal growth factor receptor activation: How exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res 2006;12:7222-31

- Camps C, Sirera R, Bremmes RM, Rodenas V, Blasco A, Safont MJ, Guarde J, Juarez A, Caballero C, Sanchez JJ, Taron M, Rosell R. Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer. *Anticancer Res* 2006;26:4905-9

- Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, González-Larriba JL, Grodzki T, Rodriguez Pereira J, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P,

Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (djuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. *Lancet Oncol* 2006;7:719-27

- Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E, Taron M. Usefulness of predictive tests for cancer treatment. *Bull Cancer* 2006 ;93 :E101-8

- Rosell R, Cobo M, Isla D, Camps C, Massuti B. Pharmacogenomics and gemcitabine. *Ann Oncol* 2006;17 (Supp 5):v13-v16

- Raz DJ, He B, Rosell R, Jablons DM. Current concepts in bronchioloalveolar carcinoma biology. *Clin Cancer Res* 2006;12:3698-704

- Rosell R, Cecere F, Santarpia M, Reguart N, Taron M. Predicting the outcome of chemotherapy for lung cancer. *Curr Opin Pharmacol* 2006;6:323-31

- Raz DJ, He B, Rosell R, Jablons DM. Bronchioloalveolar carcinoma: a review. *Clin Lung Cancer* 2006;7:313-22 Review

- Santarpia M. Altavilla G, Salazar F, Taron M, Rosell R. From the bench to the bed: individualizing treatment in non-small-cell lung cancer. *Clin Transl Oncol* 2006;8:71-6 Review

- Felip E, Rosell R. Clinical experience with erlotinib in non-small-cell lung cancer (NSCLC). *Drugs Today* 2006;42:147-56

- Rosell R, Taron M, Galvez M, Pastor MC, Queralt C, Pradas A, Motia M, Perez M, Reguart N, Moran T, Sanchez JM, Amador ML, Asensio JL, Massuti B, Paz-Ares L on behalf of the Spanish Lung Cancer Group. Determinación de las mutaciones del receptor del factor de crecimiento epidérmico en pacientes con cáncer de pulmón no microcítico tratados únicamente con erlotinib. *FMC: Oncologia* 2006;1:140-9

- Rosell R, Cecere F, Cognetti F, Cuello M, Sanchez JM, Taron M, Reguart, Jablons D. Future directions in the second-line treatment of non-small-cell lung cancer. *Semin Oncol* 2006;33:S45-S51

- Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E, Taron M. Treatment of non-small-cell lung cancer and pharmacogenomics: Where we are and where we are going. *Curr Opin Oncol* 2006;18:135-143

- Felip E, Rosell R. Clinical experience with erlotinib in non-small cell lung cancer. *Drugs Today* 2006;42: 147-56

- De las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, Massuti B, Queralt C, Botia M, Garcia-Gomez R, Isla D, Cobo M, Santarpia M, Cecere F, Mendez P, Sanchez JJ, Rosell R. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. *Ann Oncol* 2006;17:668-75

- Camps C, Massuti B, Jimenez A, Maestu I, Gomez RG, Isla D, Gonzalez JL, Almenar D, Blasco A, Rosell R, Carrato A, Viñolas N, Batista N, Giron CG, Galan A, Lopez M, Blanco R, Provencio M, Diz P, Felip E. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small lung cancer: a Spanish Lung Cancer Group trial. *Ann Oncol* 2006;17:467-72

- Gámez C, Rosell R, Fernández A, Andia E, Arnáiz MD, Cardenal F, Lorenzo C. PET/CT fusion scan in lung cancer: current recommendation and innovations. *J Thorac Oncol* 2006;1:74-77

- Weiss G, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn L, Nguyen B, Paul S, McAndrews P, Bunn P Jr, Kelly K. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. *J Clin Oncol* 2006;24:4405-11

- Rosell R. Circumventing resistance to EGFR-specific cancer therapy. *Adv Lung Cancer* 2006;7:3-7

- Rosell, R. Optimizing chemotherapy in non-small cell lung cancer. *Am J Cancer* 2006;5:211-2

- Felip E and Rosell R: "Lung cancer", in Boyiadzis M, Frame J, Lebowitz P, Fojo T: Hematology-Oncology Therapy, McGraw-Hill Medical, 2006, 262-81 ISBN 0-07-143497-6

- Balaña C, Castellà E, Rosell R. "Clear cell adenocarcinoma presenting as a carcinoma of unknown primary origin", in Fizazi K: Carcinoma of an Unknown Primary Site, Taylor & Francis Group, 2006, 201-7 ISBN 10:0-8247-2799-1 and 13 ISBN 10:0-8247-2799-1 and 13:978-0-8247-2799-4

- Blasco A, Sirera R, Camps C, Giner V, Llobat L, Safont MJ, Berrocal A, Taron M, Sanchez JJ, Rosell R. "Analysis of nerve growth factor blood levels in patients with advanced non-small cell lung cancer patients: its correlation with clinical outcome" American Society of Clinical Oncology 42nd Annual Meeting, Atlanta GE, USA, 2-6 June 2006. Proc ASCO 2006;24:18S (abstr 17025)

- Cecere F, Rosell R, Taron M, Cerbelli A, Milella M, Mendez P, Cuello M, Visca P, Facciolo F, Cognetii F. "mRNA expression of signal transducer and activator of transcription (STAT5) disheveled-3 (Dvl-3) and dicer in early-stage non-small cell lung cancer" American Society of Clinical Oncology 42nd Annual Meeting, Atlanta GE, USA, 2-6 June 2006. Proc ASCO 2006;24:18S (abstr 17038)

- Maestu I, Isla D, Diz P, Muñoz J, Oramas S, Garcia R, Provencio M, Jaen A, Taron M, Rosell R. "Elderly advanced non-small cell lung cancer patients treated with vinorelbine lus gemcitabine: Molecular correlates" American Society of Clinical Oncology 42nd Annual Meeting, Atlanta GE, USA, 2-6 June 2006. Proc ASCO 2006;24:18S (abstr 17043)

- Girones R, Torregrosa D, Maestu I, Diaz-Beveridge R, Gomez-Codina J, Yuste A, Rosell R. "Attitudes toward chemotherapy in elderly patients with advanced non-small lung cancer" 7th Meeting of SIOG Geriatric Oncology: Cancer in the Elderly, The Hague, NL, 2-4 November 2006 (poster)

PUBLICATIONS 2005

- Rosell R, Cobo M, Isla D, Sanchez JM, Taron M, Altavilla G, Santarpia MC, Moran T, Catot S, Etxaniz O. Applications of genomics in NSCLC. *Lung Cancer* 2005;50:S33-S40

- Reguart N, He B, Taron M, You L, Jablons DM, Rosell R. The role of Wnt signaling in cancer and stem cells. *Future Oncol* 2005;1:787-9

- Rosell R, Felip E, Reguart Noemi, Moran T. Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations. *Future Oncol* 2005;1:319-22

- Ramirez JL, Rosell R, Taron M, Gupta J, Alberola V, de las Penas R, Sanchez JM, Moral T, Isla D, Catot S. 14-3-3σ methylation in pre-treatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival. *J Clin Oncol* 2005;23:9105-12

- Garcia-Campelo R, Alonso-Curbera G, Antón Aparicio LM, Rosell R. Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy. *Expert Opin Pharmacother* 2005;6:2015-26

- Camps C, Sirera R, Bremes R, Blasco A, Sancho E, Bayo P, Safont MJ, Sanchez JJ, Taron M, Rosell R. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer*? Lung Cancer* 2005;50:339-46

- Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanches-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran T. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinoma. *Clin Cancer Res* 2005;11:5878-85.

- He B, Barg RN, You L, Xu Z, Reguart N, Mikami I, Batra S, Rosell R, Jablons DM. Wnt signalling in stem cells and non-small-cell lung cancer. *Clin Lung Cancer* 2005;7:54-60

- Rosell R, Ichinose Y, Taron M, Sarries C, Queralt C, Mendez P, Sanchez JM, Nishiyama I, Moran T, Cirauqui B, Mate JL, Besse B, Reguart N, Perez M, Sanchez JJ. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. *Lung Cancer* 2005;50:25-33

- Gridelli C, Aapro M, Aedizzoni A, Balducci L, De Marinis F, Kelly K, Le Chavelier T, Manegold C, Perrone F, Rosell R, Shepherd F, De Petris L, De Maio M, Langer C. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. *J Clin Oncol* 2005;23:3125-37

- Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, Izquierdo A, Diz P, Camps C, Castellanos D, Alberola V, Cardenal F, Gonzalez-Larriba JL, Vieitez JM, Maeztu I, Sanchez JJ, Queralt C, Mayo C, Mendez P, Moran T, Taron M, on behalf of the Spanish Lung Cancer Group. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. *Ann Oncol* 2005;16:1081-86

- Felip E, Taron M, Rosell R, Mendez P, Queralt C, Sanchez Ronco M, Sanchez JJ, Sanchez JM, Maestre J, Majo J. Clinical significance of hypoxia-inducible factor-1α messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery. *Clinical Lung Cancer* 2005;6:299-303

- Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, O'Brien M, Peterson PM, Castellano D, Selvaggi G, Novello S, Blatter J, Kayitalire L, Crino L, Paz-Ares L. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial. *Clin Cancer Res* 2005;11:690-6

- Camps C, Felip E, Sanchez JM, Massuti B, Artal A, Paz-Ares L, Carrato A, Alberola V, Blasco A, Baselga J, Astier L, Voi M, Rosell R. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. *Ann Oncol* 2005;16:597-601

- Font A, Murias A, García Arroyo FR, Martín C, Areal J, Sánchez JJ, Santiago JA, Constenla M, Saladie JM, Rosell R. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. *Ann Oncol* 2005;16:419-24

- Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol J-L, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, Fitzgerald P, Aristides M, Schiller JH. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer. A meta-analysis of survival outcomes. *Lung Cancer* 2005;47:69-80

- Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A, Cress D, Kim YC, Rosell R, McBride C, Robinson L, Sommers E, Haura E. Ribonucleotide reductase M1 gene promoter polymorphisms, activity, and survival inpatients with non-small cell lung cancer. *Lung Cancer* 2005;47:183-192

- Rosell R, Taron M, Altavilla G, Santarpia M. Chemotherapy treatment options for non-small-cell lung cancer. *Business Briefing: European Oncol Rev* 2005;1-6

- Taron M, Sarries C, Ramirez JL, Rosell R: Tumor biology and modern laboratory technology. In Pleura-mesotheliom, Ed. Ch. Manegold, Springer Medezin Verlag Heidelberg, Germany. 2005:7-14

- Rosell R, Cobo M, Isla D, Sanchez JM, Taron M, Altavilla G, Santarpia M, Moran T, Catot S, Etxaniz O. Applications of genomics in NSCLC *Lung Cancer* 2005;50(S2):S33-S40

- Rosell R. Editorial: 11th World Conference on lung cancer of the International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain July 3-6, 2005. *Clin Transl Oncol* 2005;7:321-2

- Sanchez JM, Taron M, Rosell R. "Estadificación biomolecular" in Estadificación del Carcinoma Broncogénico. Text book, ed. Bartolomé Cassallo, Madrid, Spain, 2005

- Choy R, Pass H, Rosell R, Traynor A. "Lung cancer" Oncology: An Evidence-Based Approach". Text book, ed. Springer, Springer Science+Business Media Inc, USA, 2006, 545-621 ISBN: 0-387-24291-0

- Rosell R, Martinez-Balibrea E, Abad A, Cobo M, Isla D, Sanchez JJ, Sanchez-Ronco M, Taron M, Ramirez JM. "Platinum-based cancer chemotherapy" Metal Compounds in Cancer Chemotherapy, 2005: 269-284 ISBN: 81-7736-277-1 Editors: Perez JM, Fuertes MA, Alonso C.

- Rosell R, Cobo M, Isla D, Massuti B, Montes A, Paz-Ares L, Munoz MA, Vinolas N, Vivasnco GL, Felip E. ERCC1 mRNA-based randomized phase III trial of docetaxel doublets with cisplatin or gemcitabine in stage IV non-small-cell lung cancer patients. American Society of Clinical Oncology 41st Annual Meeting, Orlando FL, USA, May 2005. Proc ASCO 2005;23:16S (abstr 7002)
  *** Selected for "Best of ASCO" to be presented at Best of ASCO meetings across the USA and Japan.***

- Cortes-Funes H, Almanza C, Valero P, Garcia Giron C, Velasco A, Colomer R, Camps C, Diz P, Taron M, Rosell R. Epidermal growth factor receptor-activating mutations and response to gefitinib inlung adenocarcinomas. American Society of Clinical Oncology 41st Annual Meeting, Orlando FL, USA, May

2005. Proc ASCO 2005;23:16S (abstr 7076)

- Berrocal A, Sirera R, Camps C, Bremnes RM, Alberola V, Bayo P, Safont MJ, Blasco A, Taron M, Sanchez JJ, Rosell R. The quantification of DNA in the serum is a useful prognostic factor in advanced non-small cell lung cancer patients. American Society of Clinical Oncology 41st Annual Meeting, Orlando FL, USA, May 2005. Proc ASCO 2005;23:16S (abstr 7195)

- Domine M, Isla D, Cobo M, Camps C, Batista N, Almenares J, Barneto I, Ramirez JL, Sanchez JJ, Rosell R. Pharmacogenomic trial of CPT-11-docetaxel in untreated patients with advanced non-small cell lung cancer. A phase II study of the Spanish Lung Cancer Group. Correlation with the single nucleotide polymorphisms of UGT1A1, XPD2 and XRCC1. American Society of Clinical Oncology 41st Annual Meeting, Orlando FL, USA, May 2005. Proc ASCO 2005;23:16S (abstr 7201)

- Alberola V, Camps C, Sirera R, Bremnes RM, Bayo P, Blasco A, Berrocal A, Safont MJ, Taron M, Sanchez JJ, Rosell R. Correlation of blood levels of vascular endothelial growth factor and epidermal growth factor receptor and hemoglobin with response to therapy in advanced non-small cell lung cancer patients. American Society of Clinical Oncology 41st Annual Meeting, Orlando FL, USA, May 2005. Proc ASCO 2005;23:16S (abstr 7228)

- Martín C, Balaña C, Etxaniz O, Morán T, Hostalot C, Catot S, Ballester R, Manzano JL, Rosell R. Evolución clínica de los pacientes con glioma de alto grado tratados con biopsia. *Clin & Transl Oncol* 2005;7:52 (PD-93)

- Etxaniz O, Morán T, Ciraugui B, Martí C, Catot S, Teixidor P, Ballester R, Roussos Y, Rosell R, Balaña C. Gliomatosis cerebro y quimioterapia. Revisión a propósito de dos casos tratados con temozolomida. *Clin & Transl Oncol* 2005;7:156 (L-64)

- Sirera R, Ródenas V, Llobat L, Safont MJ, Blasco A, Tarón M, Bremnes RM, Rosell R, Alberola V, Camps C. Estudio del valor pronóstico del nivel enpacientes con cáncer de pulmón no microcítico avanzado. *Clin & Transl Oncol* 2005;7:76 (PD-160)

- Sirera R, Bremnes RM, Ródenas V, Llobat L, Safont MJ, Blasco A, Alberola V, Tarón M, Rosell R, Camps C. Cuantificación sérica del factor de crecimiento del endotelio vascular y del receptor del factor de crecimiento epidérmico en el cáncer de pulmón no microcítico en estadios avanzados: implicaciones clínicas. *Clin & Transl Oncol* 2005;7:77 (PD-163)

- Salazar MF, Ramirez JL, Tarón M, Sánchez Ronco M, Alberola V, Sánchez JM, Botia M, Méndez PJ, Reguart N, Rosell R. La hipermetilación de 14-3-3 sigma de ADN circulante en suero de pacientes con cáncer de pulmón avanzado de célula no pequeña tratados con gemcitabina-cisplation predice mejor supervivencia global. *Clin & Transl Oncol* 2005;7:79 (PD-167)

- Dómine M, Isla D, Cobo M, Camps C, Batista N, Almenárez J, Medina B, Barreto I, Ramirez JL, Rosell R. Irinotecán-docetaxel (Iritax). Estudio fase II del Grupo Español de Cáncer de Pulmón (GECP) en pacientes con carcinoma no microcítico de pulmón avanzado. Correlación conlospolimorfismos de UGT1A1, XPD2 y XRCC1. *Clin & Transl Oncol* 2005;7:80 (PD-170)

- Cirauqui B, Margeli M, Morán T, Martí C, Etxaniz O, Catot S, Barnadas A, Manzano JL, Rull M, Rosell R. Docetaxel, 5-fluorouracilo y vinorelbina en primera línea de tratamiento de pacientes con cáncer de mama metastático. *Clin & Transl Oncol* 2005;7:146 (L-29)

- Rosell R and Mornex F. Mutidisciplinary treatment of locally advanced lung cancer. Newsletter of the Federation of European Cancer Societies (FECS), 2005;6:2-4

- Camps C, Sirera R, Bremnes R, Llobat L, Safont M, Blasco A, Alberola V, Taron M, Sanchez J, Rosell. Serum levels of vascular endothelial growth factor and epidermal growth factor receptor in advanced non-small cell lung cancer: its correlation with clnical characteristics. 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 *Lung Cancer* 2005;49:S68 (PD-004)

- De Aguirre I, Zhong D, Zhou W, Rosell R, Vertino P. LKB1/AMPK/TSC2 signaling pathway alterations in non-small cell lung cancer. 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 *Lung Cancer* 2005;49:S69 (PD-008)

- Sirera R, Camps C, Bremnes R, Alberola V, Rodenas V, Safont M, Blasco A, Taron M. The analysis of serum DNA concentration by means of hTERT quantification: A useful prognostic factor in advance non-

small cell lung cancer. 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 *Lung Cancer* 2005;49:S74 (PD-026)

- Garrido P, Rosell R, Arellano A, Ramos A, Massuti T, Andreu J, Cardenal F, Arnaiz A, Amador M, Alberola V. Inductin or consolidation chemotherapy with docetaxel and gemcitabine plus concomitant chemoradiotherapy with docetaxel and carboplatin for unresectable stage III non-small cell lung câncer patients. Initial report of the randomized phase II trial SLCG 0008. 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 *Lung Cancer* 2005;49:S78 (PD-042)

- Bunn P, Rosell R, Fossella F, Perry M, Stahel R, Barata F, Nguyen B, Paul S, Hanna N. An exploratory analysis of a phase III study in patients with advanced non-small cell lung cancer: The impact of first-line gemcitabine and platinum therapy on the outcome of second-line therapy with pemetrexed or docetaxel. 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 *Lung Cancer* 2005;49:S86 (PD-068)

- Camps C, Massuti B, Jimenez A, Maestu I, Garcia R, Isla D, Gonzalez-Larriba J, Almenar D, Carrato A, Rosell R. Quality-of-life assessment in two docetaxel dose-schedules as second-line treatment for advanced non small cell lung cancer: Spanish Lung Cancer Group Phase III trial. 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 *Lung Cancer* 2005;49:S86 (PD-069)

- Zinner R, Kortsik C, Dark G, Price A, Manegold C, Rosell R, Paz-Ares L, Herbst R, Crino L, Scagliotti G. Pemetrexed plus carboplatin as 1st treatment for patients with locally advanced or metastatic non-small-cell lung cancer: Results of both a multi-center European and an MD Anderson Cancer Center phase II trials. 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 *Lung Cancer* 2005;49:S91 (PD-083)

- Camps C, Alonso G, de las Peñas R, Provencio M, Terrassa J, Lopez-Vivanco G, Aartal A, Garcia-Gomez R, Pujol E, Rosell R. XPD polymorphism in second-line treatment with gemcitabine or irinotecan in advanced non-small cell lung cancer patients. 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 *Lung Cancer* 2005;49:S118 (P-012)

- Rosell A, Rodriguez N, Lloret J, Arellano E, Fernandez M, de la Torre N, Ramirez J, Gupta J, Taron M, Rosell R. Dysplasia and aberrant DNA methylation profiles in risk and lung cancer patients. 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 *Lung Cancer* 2005;49:S186 (P-272)

- Camps C, Carrato A, Gomez-Aldavan J, Gonzalez-Larriba J, Massuti B, Provencio M, Velasco A, Sirera R, Rosell R. Sequential chemotherapy with gemcitabine and paclitaxel in advanced non-small cell lung cancer: A feasibility phase II st udy by the Spanish Lung Cancer Group. Preliminary study. 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 *Lung Cancer* 2005;49:S240 (P-466)

- Domine M, Isla D, Cobo M, Camps C, Batista N, Almenarez J, Medina B, Barneto I, Ramirez J, Rosell R. CPT-11-docetaxel in untreated patients with advanced non-small cell lung cancer. A phase II study of the Spanish Lung Cancer Group. Correlation with the single nucleotide polymorphisms of UGT1A1, XPD2 and XRCC1. 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 *Lung Cancer* 2005;49:S242 (P-478)

- Kelly K, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn L, Nguyen B, Paul S, McAndrews P, Bunn P. Elderly patients benefit from second-line cytotoxic chemotherapy for advanced non-small cell lung cancer. 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 *Lung Cancer* 2005;49:S250 (P-508)

PUBLICATIONS 2004

- Rosell R, Taron M, Ariza A, Barnadas A, Mate JL, Reguart M, Margeli M, Felip E, Mendez P, Garcia-Campelo R. Molecular predictors of response to chemotherapy in lung cancer. *Semin Oncol* 2004;31(suppl 1):20-27

- Rosell R, Taron M, Sanchez JM, Moran T, Reguart N, Besse B, Isla D, Massuti B, Alberola V, Sanchez JJ. The promise of pharmacogenomics: GEMZAR and ALIMTA. *Oncology* 2004,18(suppl 8):70-76

- Scagliotti GV, Nocello S, Crino L, Rosell R. Pemetrexed in front-line chemothearapy for advanced non-small-cell lung cancer. *Oncology* 2004,18(suppl 8):32-37

- Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale R, Schiller J, von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs J, Averbuch S, Wolf M, Rennie P, Fandi A, Johnson DH. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. *J Clin Oncol* 2004;22:777-784

- Herbst RS, Giaccone G, Schiller J, Natale R, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves J, Wolf M, Krebs A, Averbuch S, Ochs J, Grous J, Fandi A, Johnson DH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. *J Clin Oncol* 2004;22:785-794

- Rosell R. Towards customized trastuzumab in HER-2/*neu*-overexpresseing non-small-cell lung cancers. *J Clin Oncol* 2004;22:1-3 (Editorial)

- Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. *Clin Cancer Res* 2004;10:1318-1325

- Colomer R, Germa JR, Rosell R, Borras JM. Cancer care in rural areas. *Brit J Cancer* 2004;90:1688

- Rico-Villademoros F, Hernando T, Sanz JL, Lopez-Alonso A, Salamanca O, Camps C, Rosell R. The role of the clinical research coordinator – data manager – in oncology clinical trials. *BMC Med Res Methodol* 2004;4:6

- Rosell R, Sanchez JM, Taron M, Moran T, Canela M, Ciuraqui B, Felip E, Massuti B, Camps C. Pemetrexed in previously treated non-small-cell lung cancer. *Oncology* 2004;18(suppl 5):63-71

- Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM. Wnt inhibitory factor-1 (WIF-1) is silenced by promoter hypermethylation in human lung cancer. *Cancer Res* 2004;64:4717-4720

- Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, Queralt C, Sanchez JJ, Maestre J. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. *Clin Cancer Res* 2004;10 (suppl):4215s-4219s

- Reguart N, He B, Xu Z, You L, Lee AY, Mazieres J, Mikami I, Batra S, Rosell R, McCormick F, Jablons DM. Cloning and characterization of the promoter of human Wnt inhibitor factor-1. *Biochem Biophys Res Commun* 2004;323:229-234

- Lynch TJ, Adjei AA, Bunn PA, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. Novel agents in the treatment of lung cancer: Conference summary statement. *Clin Cancer Res* 2004;10(suppl):4199s-4204s

- Alberola V, Sarries C, Rosell R, Taron M, de las Peñas R, Camps C, Massuti B, Insa A, Garcia-Gomez R, Isla D, Artal A, Muñoz MA, Cobo M, Bover I, Gonzalez-Larriba JL, Terrasa J, Almenar D, Barcelo R, Diz P, Sanchez-Ronco M, Sanchez JJ. Effect of the methylenetetrahydrofolate C677T polymorphism n cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer patients. *Clin Lung Cancer* 2004;5:360-365

- Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nuñez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A,Medina B, Aartal A, Lianes P. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. *Annals of Oncology* 2004;15:1194-1203

- Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Sanchez Ronco M, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. *Hum Mol Gen* 2004;13:2443-2449

- Artal-Cortes A, Gomez-Codina J, Gonzalez-Larriba JL, Barneto I, Carrato A, Isla D, Camps C, Garcia-Giron C, Font A, Maestu I, Cambell J, Rosell R on behalf of the Spanish Lung Cancer Group. Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. *Clin Lung Cancer* 2004;6:175-183

- Rosell R, Alberola V, Taron M, Sanchez JM. New approaches to lung cancer treatment. *Current Oncology Reports* 2004;6(S):S16-S17

- Rosell R. Fundamentals of cancer biology for pharmacogenomics. *Current Oncology Reports* 2004;6(S):S20-S22

- Rosell R, Felip E, Garcia-Campelo R, Balaña C. The biology of non-small-cell lung cancer: Identifying new targets for rational therapy. *Lung Cancer* 2004;46.135-48

- Betticher DC, Rosell R. Neoadjuvant treatment of early-stage resectable non-small cell lung cancer. *Lung Cancer* 2004;46(Suppl):S23-S32

- Sarries C, Alberola V, de las Penas R, Cmps C, Massuti B, Garcia-Gomez R, Insa A, Sanchez-Ronco M, Taron M, Rosell R. Combined DNA repair gene single nucleotide polymorphisms (SNPs) in gemcitabine (gem)/cisplatin (cis)-treated non-small-cell lung cancer (NSCLC) patients. American Society of Clinical Oncology 40th Annual Meeting, New Orleans LA USA, June 2004. Discussion. Proc ASCO 2004;23:621 (abstr 7031)

- Felip E, Rosell R, Taron M, Santome L, Mendez P, Sanchez M, Sanchez JJ, Queralt C, Baselga J, Majo J. ERCC1, RRM1 and XPD mRNA expression as a prepdictive marker of outcome in non-small-cell lung cancer (NSCLC) patients after platinum/gemcitabine induction chemotherapy followed by surgery. American Society of Clinical Oncology 40th Annual Meeting, New Orleans LA USA, June 2004. Proc ASCO 2004;23:648 (abstr 7142)

- Taron M, Rosell R, Souglakos J, Mendez P, Felip E, Barnadas A, Sanchez M, QUeralt C, Sanchez JM, Sanchez JJ. BRCA1 and HIF-1α mRNA expression and chemoresistance in non-small-cell lung cancer (NSCLC). American Society of Clinical Oncology 40th Annual Meeting, New Orleans LA USA, June 2004. Proc ASCO 2004;23:650 (abstr 7148)

- Nunez L, Isla D, Rosell R, Taron M, Artal A, Bover I, ALberola V, Camps C, Sanchez JJ, Muñoz MA. TP53 codon 72 single nucleotide polymorphism (SNP) in gemcitabine (gem)/cisplatin (cis)-treated non-small-cell lung cancer (NSCLC) patients. American Society of Clinical Oncology 40th Annual Meeting, New Orleans LA USA, June 2004. Proc ASCO 2004;23:653 (abstr 7161)

- Alberola V, Ramirez JL, de Aguirrre I, Rosell R, de las Penas R, Campcs C, Cobo M, Taron M, Sanchez-Ronco M, Marti JL. Methylene-tetrahydrofolate reductase (MTHFR) single nucleotide polymorphism (SNP) in gemcitbine (gem)/cisplatin (cis)-treated non-small-cell lung cancer (NSCLC) patients. American Society of Clinical Oncology 40th Annual Meeting, New Orleans LA USA, June 2004. Proc ASCO 2004;23:653 (abstr 7163)

- Taron M, Ramirez JL, Balaña C, Rosell R. Serum DNA assays. International Association for the Study of Lung Cancer (IASLC) 9th Central European Lung Cancer Conference, Gdansk, Poland, September 2004. Lung Cancer 2004;45:S3 (abstr)

- Rosell, R. Individualized therapy of non-small-cell lung cancer. International Association for the Study of Lung Cancer (IASLC) 9th Central European Lung Cancer Conference, Gdansk, Poland, September 2004. Lung Cancer 2004;45:S19 (abstr)

- Rosell, R. Improved toxicity profile of pemetrexed vs docetaxel in previously treated non-small cell lung cancer patients translates to cost savings in Spain. ISPOR 7th Annual European Congress, October 24-26, 2004.

- Besse B, Cande C, Spano JP, Martin A, Grenier J, Le Chevalier T, Sabatier L, Rosell R, Kroemer G, Soria JC. Prognostic value of Apaf-1 (apoptotic protease activating factor 1) subcellular localization in early-stage non-small cell lung cancer (NSCLC). 29th Congress of the European Society for Medical Oncology (ESMO), Vienna, Austria, 29 October-2 November, 2004. *Annals of Oncology* 2004;15:iii17 (abstr 62PD)

- Crino L, Queralt C, Felip E, Scagliotti G, Pastorinao U, Font A, Sanchez JM, Moran T, Taron M, Rosell R. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. 29th Congress of the European Society for Medical Oncology (ESMO), Vienna, Austria, 29 October-2 November, 2004. *Annals*

of Oncology 2004;15:iii170 (abstr 643PD)

- Bonnet R, Rosell R, Strausz J, Sanches E, Provencio M, Vernejoux JM, Lena H, Gershanovich L, Boussard B, von Pawel J. Irinotecan plus docetaxel every 3 weeks in chemotherapy naïve patients with inoperable non-small cell lung cancer (NSCLC): results of a phase II study. 29th Congress of the European Society for Medical Oncology (ESMO), Vienna, Austria, 29 October-2 November, 2004. *Annals of Oncology* 2004;15:iii177 (abstr 671P)

- Garcia Campelo R, d. Penas R, Alberola V, Sarries C, Camps C, Garrido P, Sanchez Ronco M, Gonzalez Larriba JL, Taron M, Rosell R. Effect of the methylenetetrahydrofolate reductase (MTHFR) C677T and the methionine synthase (MS) A2756G polymorphisms on cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer (NSCLC) patients: A Spanish Lung Cancer Group study. 29th Congress of the European Society for Medical Oncology (ESMO), Vienna, Austria, 29 October-2 November, 2004. *Annals of Oncology* 2004;15:iii188 (abstr 712P)

- Garcia Campelo R, , Alberola V, Sarries C, d. Penas R, Camps C, Massuti B, Garcia Gomez R, Insa A, Cirauqui B, Taron M, Rosell R. Combined DNA repair gene single nucleotide polymorphisms (SNPs) in gemcitabine/cisplatin- treated non-small-cell lung cancer (NSCLC) patients. 29th Congress of the European Society for Medical Oncology (ESMO), Vienna, Austria, 29 October-2 November, 2004. *Annals of Oncology* 2004;15:iii188 (abstr 713P)

- Rosell A, Lloret JA, Fernandez-Figueras MT, Arellano E, Castella E, Llatjos M, de la Torre N, Rodriguez N, Ramirez J, Taron M, Morera J, Rosell R. Variables associated to bronchial dysplasia. 3rd Annual Association for Cancer Research (AACR) International Conference, Seattle USA, October 16-20, 2004 *Frontiers in Cancer Prevention Research* 2004:73 (abstr A15)

PUBLICATIONS 2003

- Balaña C, Ramirez JL, Taron M, Roussos Y, Ariza A, Ballester R; Sarries C, Mendez P, Sanchez JJ, Rosell R. MGMT methylation in serum and tumor DNA predicts response to BCNU but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003;9:1461-1468

- Rosell R, Scagliotti G, Danenberg KD, Lord R VN, Bepler G, Novello S, Cooc J, Crinò L, Sánchez JJ, Taron M, Boni C, De Marinis F, Tonato M, Marangolo M, Gozzelino F, Di Constanzo F, Rinaldi M, Salonga D, Stephens C. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic nonsmall-cell lung cancer. Oncogene 2003;00:1-6

- Ramirez JL, Sarries C, Lopez de Castro P, Roig B, Queralt C, Escuin D, De Aguirre I, Sanchez JM, Manzano JL, Margeli M, Sanchez JJ, Astudillo J, Taron M, Rosell R. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small cell lung cancer patients. Cancer Letters 2003;193:207-216

- Font A, Sánchez JM, Tarón M, Martinez-Balibrea E, Sánchez JJ, Manzano JL, Margelí M, Richardet M, Barnadas A, Abad A , Rosell R. Weekely regimen of irinotecan / docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Investigational New Drugs 2003;21:435-443.

- Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C, Bover I, Ruiz-Casado R, Azagra P, Jiménez U, González-Larriba J:, Diz P, Cardenal F, Artal A, Carrato A, Morales S, Sánchez JJ, de las peñas R, Felip E, López-Vivanco G. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003;21(17):3207-3213.

- Felip E, Rosell R, Domine M, Santomé, Garrido P, Font A, Carrato A, Terrasa J, Vadell C, Mañe JM, Baselga J. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. Ann Oncol 2003;14:1549-1554.

- Rosell R, Taron M, Alberola V, Massuti B, Felip E. Genetic testing for chemotherapy in non-small-cell lung cancer. Lung Cancer 2003;41S1:S97-S102.

- Rosell R, Crino L, Danenberg K, Scagliotti, Bepler G, Taron M, Alberola V, Provencio M, Camps C, De Marinis F, Sanchez JJ, Peñas R. Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Semin Oncol 2003;30(4) Suppl K:19-25.

- Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B. Nucleotide excision repair pathways involved in cisplatin resistance in non-small cell lung cancer. Cancer Control 2003;10(4):297-305

- Cardenal F, Domine M, Massuti B, Carrato A, Felip E, Garrido P, Juan O, Artal A, Barneto I, Lopez-Vivanco G, Balcells M, Rosell R. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. Lung Cancer 2003;39:201-207

- Camps C, Sarries C, Roig B, Sanchez JJ, Queralt C, Sancho E, Martinez N, Taron M, Rosell R. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin treated advanced non-small cell lung cancer patients. Clin Lung Cancer 2003;4:231-236

- Balaña C, Ramirez JL, Mendez P, Taron M, Rosell R. Circulating tumor DNA and its clinical applications. Nowotwory 2003;53:126-133

- Balaña C, Rosell R, Ballester R, Arellano A, Cirauqui B, Morán T. Nuevos quimioterapicos en neurooncología. Rev Oncol 2003;5:3-14

- Balaña C, Manzano JL, Moreno I, Rosell R. A phase II study of cisplatin, etoposide, and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site. Ann Oncol 2003;14:1425-1429

- Rosell R, Taron M, Camps C, Lopez Vivanco G. Influence of genetic markers on survival in non-small cell lung cancer. Drugs of Today 2003;39:775-786

- Ramirez JL, Taron M, Balaña C, Sarries C, Mendez P, de Aguirre I, Nuñez L, Roig B, Queralt C, Botia M, Rosell R. Serum DNA as a tool for cancer patient management. Rocz Akad Med Bialymst 2003;48:34-4

- Font A, Ramirez JL, Arellano A, Fernandez-Llamazares J, Botia M, Richardet M, Moran T, Abad A, Taron M, Rosell R, for the Spanish Lung Cancer Group. Aberrant promoter methylation profile in serum DNA of docetaxel and radiotherapy treated esophageal cancer patients. American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003;22:355 (abstr 1426)

- Hanna NH, ShepherdvFA, Rosell R, Pereira JR, De Marinis F, Fossella F, Kayitalire L, Paul S, Einhorn LH, Bunn PA. A phase III study of pemetrexed vs docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy. American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003;22:622 (abstr 2503)

- Scagliotti G, Kortsik C, Castellano D, Dark G, Price A, Rosell R, Manegold C, Kayitalire L, Paul S, Blatter J. Phase II randomized study of pemetrexed + carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer. American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003;22:625 (abstr 2513)

- Camps C, Massuti B, Jimenez AM, Maestu I, Almenar D, Garcia R, Gonzalez-Larriba JL, Vinolas N, Garcia C, Rosell R, for the Spanish Lung Cancer Group. Second-line docetaxel administrated every 3 weeks versus weekly in advanced non-small-cell lung cancer (NSCLC): A Spanish Lung Cancer Group (SLCG) phase III trial. American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003;22:625 (abstr 2514)

- Giaccone G, Johnson D, Scagliotti GV, Manegold C, Rosell R, Rennie P, Wolf M, Averbuch S, Grous J, Fandi A. Results of a multivariate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large phase III trials (INTACT 1 and 2). American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003;22:627 (abstr 2522)

- Taron M, Alberola V, Sanchez JJ, Camps C, Massuti B, De Las Penas R, Rosell R, Sarries C, Insa A, Garcia R, for the Spanish Lung Cancer Group. Transcription-coupled repair (TCR) XPD and RRM1 gene polymorphisms predict gemcitabine / cisplatin outcome in non-small-cell lung cancer (NSCLC). American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003;22:641 (abstr 2579)

- Gatzemeier U, Rosell R, Ramlau R, Robinet G, Szczesna A, Quoix E, Font A, Jimenez E, Mueser M, Harstrick A. Cetuximab (C225) in combination with cisplatin/vinorelbine vs. cisplatin /vinorelbine alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC). American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003;22:642 (abstr 2582)

- Cardenal F, Ramirez JL, Astudillo J, Garrido P, Isla D, Terrasa J, Lopez G, Lopez-Brea M, Taron M, Rosell R, for the Spanish Lung Cancer Group. XPD and RRM1 gene polymorphisms predict gemcitabine / cisplatin / docetaxel outcome in stage III non-small-cell lung cancer (NSCLC): A genetic analysis of the Spanish Lung Cancer Group phase II trial 9901. American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003;22:649 (abstr 2612)

- Felip E, De Aguirre I, Maestre JA, Torres A, Rodriguez-Paniagua M, Sanchez JJ, Betticher D, Sederholm C, Griesinger F, Rosell R. Xeroderma pigmentosum complementation group D (XPD) associated with survival in a randomized neoadjuvant/adjuvant paclitaxel/carboplatin trial in early non-small-cell lung cancer (NSCLC). American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003;22:670 (abstr 2694)

- Manzano JL, Botia M, De Aguirre I, Roig B, Massuti B, Queralt C, Sanchez JM, Almenarez J, Taron M, Rosell R, for the Spanish Lung Cancer Group. K-ras mutations in serum DNA of early non-small-cell lung cancer (NSCLC) patients (P): A genetic analysis of an ongoing randomized neoadjuvant /adjuvant paclitaxel / carboplatin trial American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003;22:682 (abstr 2741)

- Blasco A, Camps C, Sancho E, Berrocal A, Martinez N, Martin M, Batista N, Taron M, Sanchez JJ, Rosell R. Genetic lesions in serum DNA of patients with advanced non small cell lung cancer: Relationship with response to platinum based chemotherapy. American Society of Clinical Oncology 39th Annual Meeting, Chicago, IL USA, June 2003. Proc ASCO 2003;22:694 (abstr 2791)

- Sarries C, Alberola V, Mendez P, Nunez L, Queralt C, Sanchez JM, Moran T, Barnadas A, Taron M, Rosell R, for the Spanish Lung Cancer Group. Single nucleotide polymorphisms (SNPs) in DNA repair genes predict survival in gemcitabine / cisplatin-treated non-small-cell lung cancer (NSCLC) patients. American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003;22:859 (abstr 3450)

- Reguart N, Roig B, Vinyolas N, Margeli M, Provencio M, Cardenal F, Baron F, Moreno I, Taron M, Rosell R for the Spanish Lung Cancer Group. XPD polymorphisms in cisplatin / vinorelbine -treated stage IV non-small-cell lung cancer (NSCLC) patients: Genetic analysis of a Spanish Lung Cancer Group phase II trial. American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003;22:877 (abstr 3528)

- Lopez-Martin AA, Constela M, Martin Algarra S, Salinas P, Massuti B, Gascon P, Castellano D, Lopez-Picazo J, Rosell R, Cortes-Funes H. ZD1839 in advanced non-small cell lung cancer (NSCLC) patients progressed to chemotherapy. American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003;22:670 (abstr 2695)

- Felip E and Rosell R. Expert Opinion, World Conference on Lung Cancer, 10-14 August 2003, Vancouver, Canada. Expert Opin Biol Ther 2003;3(8):1-4

- Shepherd FA, Pereira JR, Von Pawel J, Gatzemeier U, Chang Yao Tsao T, Hanna N, Rosell R, Paoletti P, Paul S, Bunn PA, Einhorn L. A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) who were previously treated with chemotherapy. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr PL-5)

- Camps C, Massuti B, Jimenez AM, Batista N, Galan A, Isla D, Blanco R, Carrato A, Garcia C, Rosell R. Two second-line docetaxel dose-schedules in advanced non-small-cell lung cancer (NSCLC): A Spanish Lung Cancer Group (SLCG) phase III trial. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr O-2)

- Taron M, Alberola V, Sarries C, Camps C, Massuti B, de las Peñas R, Mendez P, Insa A, Garcia R, Rosell E. XPD polymorphisms identify a subset of non-small-cell lung cancer (NSCLC) patients with poor survival with gemcitabine/cisplatin. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr O-47)

- Le Chevalier T, Brown A, Natale R, Scagliotti G, Cansteenkiste J, Can Meermeeck JL, Rosell R, Rudd RM, Danson S, Thatcher N, Schiller J., on behalf of the Gemzar NSCLC Meta-analysis Group. Gemcitabine in the treatment of non-small cell lung cancer (NSCLC): A meta-analysis of survival and progression free survival data. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr O-239)

- Scagliotti G, Kortsik C, Manegold C, Dark G, Crino L, O'Brien MER, Rosell R, Kayitalire L, Paul S, Paz-Ares L. Phase II randomized study of pemetrexed plus carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr O-271)

- Domine M, Sanchez JM, Garcia Giron C, Tisaire JL, Moran T, Estevez L, Font A, Casado V, Lobo F, Rosell R. CPT-11 docetaxel (days 1 and 8) in advanced non-small cell lung cancer (NSCLC). A pilot phase II study of the Spanish Lung Cancer Group. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr P-18)

- Massuti B, Camps C, Garrido P, Barceló JR, Viñolas N, Barneto I, Bover I, Chaib C, Martí-Ciriquián JL, Rosell R. A phase II trial of weekly paclitaxel in advanced non-small cell lung cancer non-suitable for platinum-based chemotherapy. Spanish Lung Cancer Group/GECP 00-02. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr P-21)

- Camps C, Blasco A, Sancho E, Berrocal A, Caballero C, Bayo P, Perez-Tur J, Sanchez J, Rosell R. Evaluation of serum circulating tumor DNA in advanced non-small cell lung cancer (NSCLC) and relationship with clinical and biological tumoral characteristics. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr P-109)

- Scagliotti G, Rosell R, Nocello S, Taron M, Mendez P, Queralt C, Caggase D, Selvaggi G. ERCC1 and thymidylate synthase expression in malignant pleural mesothelioma. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr P-148)

- Garrido P, Barceló R, Artal A, Terrasa J, Masuti B, López-Brea M, Camps C, Ruiz A, Rosell R. SLCG 9901: phase II trial with cisplatin, gemcitabine and docetaxel as neoadjuvant treatment in stage IIIA N2 and T4N0-1 non-small cell lung cancer (NSCLC) patients. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr P-203)

- Queralt C, Roig B, Sarries C, Botia M, Nuñez L, Ramírez, Mendez P, Sánchez JM, Taron M, Rosell R. Lack of β-tubulin gene mutations in docetaxel/cisplatin-treated stage IV non-small cell lung cancer (NSCLC) patients at time of tumor progression. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr P-205)

- Muguruza I, Gomez A, Tarrazona V, Madrigal L, Aguilo R, Asstudillo J, Ferrer G, Lago J, Torres JA, Rosell R. Preliminary results (SLCG 9901 phase II trial) of neoadjuvant chemotherapy followed by surgery in selected stage IIIB non-small-cell lung cancer (NSCLC) patients. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr P-210)

- Felip E, Massuti B, de Aguirre I, Alonso G, Maestre J, Torres A, Rodriguez-Paniagua M, Borro JM, Sanchez JJ, Rosell R. Analysis of ceroderma pigmentosum complementation group D (XPD) in the NATCH trial: a neoadjuvant/adjuvant paclitaxel/carboplatin trial in early non-small-cell cancer (NSCLC). International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr P-215)

- Manzano JL, de Aguirre I, Botia M, Ramirez JL, Massuti B, Queralt C, Sanchez JM, Almenarez J, Taron M, Rosell R. K-ras mutations in serum DNA of early non-small-cell lung cancer (NSCLC) patients: a genetic analysis of an ongoing randomized neoadjuvant / adjuvant paclitaxel /carboplatin trial. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr P-217)

- Isla D, Queralt C, Alonso G, Domine M, Barcelo R, Camps C, Lopez-Brea M, Paredes A, Barneto I, Rosell R. Polymorphisms in DNA repair genes and survival in cisplatin/docetaxel-treated stage IV non-small-cell lung cancer (NSCLC) patients: a Spanish Lung Cancer Group phase II trial. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr P-220)

- Viñolas N, Roig B, Reguart N, Provencio M, Cardenal F, Margell M, Baron-Duarte FJ, Alberola V, Cobo M, Rosell R. XPD polymorphisms in cisplatin/vinorelbine-treated stage IV non-small-cell lung cancer (NSCLC) patients: genetic analysis of a Spanish Lung Cancer Group phase II trial. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr P-224)

- Sarries C, Garrido P, Nuñez L, Roig B, Ramirez JL, Isla D, Astudillo J, Sanchez JJ, Taron M, Rosell R. XPD and RRM1 gene polymorphisms predict gemcitabine/cisplatin/docetaxel outcome in stage III non-small-cell lung cancer (NSCLC): a genetic analysis of the Spanish Lung Cancer Group phase II trial 9901. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr P-224)

- Camps C, Blasci Am Sancho E, Berrocal a, Bayo P, Martin M, Taron M, Sanchez J, Perez-Tur J Rosell R. Could K-ras be a prognostic factor in advanced NSCLC? Relationship with response to platinum based chemotherapy. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) S1-S314 (abstr P-284)

PUBLICATIONS 2002

- Rosell R, Monzo M, Alberola V, Taron M, Barnadas A, Sanchez JM, Manzano JL, Sanchez JJ. Determinants of response and resistance to cytotoxics. Semin Oncol 2002 29 (suppl 4): 110-118

- Font A, Sanchez JM, Rosell R, Taron M, Martinez E, Guillot M, Manzano Jl, Margeli E, Barnadas A, Abad A. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors. Lung Cancer 2002;37:213-218

- Giaccone G, Johnson DH, Manegold C, Scagliotti G, Rosell R et al. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Presidential Symposium, 27th ESMO Congress, Nice, France, October 18-22, 2002. Ann Oncol 2002;13(suppl 5):2 (abstr 40)

- Rosell R. What might be the impact of target-directed therapy? 27th ESMO Congress, Nice, France. October 18-22, 2002. Ann Oncol 2002;13 (suppl 5):3 (abstr 8IN)

- Lord RVN, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, Sanchez JJ, Danenberg KD, Danenberg PB, Rosell R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-2291

- Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzioni A, Chemaissani A, Boagets J, Gallant G. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small cell lung cancer: a cooperative multinational trial. Ann Oncol 2002;13:1539-1549

- Rosell R, Taron M, Lord RVN, Scagliotti G, Danenberg K, Gmmerlock P, Gandara D. Moving towards customized chemotherapy in non-small-cell lung cancer. Lung Cancer 2002;37 (Suppl 1):S1-S51

- Rosell R, Lord RVN, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small cell lung cancer. Lung Cancer 2002;38:217-227

- Rosell R, Fosella F, Milas L. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer 2002;38 (Suppl 1):43-49

- Sanchez JM, Balaña C, Font A, Sanchez JJ, Manzano JL, Guillot M, Margeli M, Richardet M, Rosell R. Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Lung Cancer 2002;38:309-315

- Rosell R, Monzo M, O'Brate A, Taron M. Translational oncogenomics:toward rational therapeutic decision-making. Curr Opin Oncol 2002;14: 171-179

- Felip E, Rosell R. Neoadjuvant chemotherapy in non-small cell lung cancer. Curr Med Chem 2002;9:893-898

- Vallejos V, Balaña C, Fraile M, Roussos Y, Capellades J, Cuadras P, Ballester R, Ley A, Arellano A, Rosell R. Use of 201 TI SPECT imaging to assess the response to therapy in patients with high grade gliomas. J Neurooncol 2002;59:81-90

- Ramirez de Molina A, Rodriguez Gonzalez A, Gutierrez R, Martinez-Piñeiro L, Sanchez JJ, Bonilla F, Rosell R, Lacal JC. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002;296:580-583

- Sarries C, Haura EB, Roig B, Taron M, Abad A, Scagliotti G, Rosell R. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics 2002;3:763-780

- Rosell R. Determinants of response and resistance to cytotoxics. First Annual Opinion Leader Roundtable "Targeted Therapies in the Treatment of Lung Cancer". Aspen, Colorado, January 24-28, 2001. Semin Oncol 2002;29(suppl 4):110-118

PUBLICATIONS 2001

- Isla D, Rosell R, Sánchez JJ, et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2001;19:1071-1077

- Rosell R, Taron M, O'Brate A. Predictive molecular markers in non-small cell lung cancer. Curr Opin Oncol 2001;13:101-109

- Rosell R, Felip E, Sanchez JM, et al. Novel approaches in the treatment of non-small-cell lung cancer (NSCLC). Oncology 2001;15 (3 Suppl 6):52-60

- Rosell R, Crinò L. Pemetrexed Combination Therapy in the Treatment of Non-Small Cell Lung Cancer. Semin Oncol 2001;29 (Suppl 5):23-29

- Font A, Abad A, Monzo M, Sanchez JJ, Guillot M, Manzano JL, et al. Prognostic value of k-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 2001;44:549-557

- Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Rosell R, Monzo M, Wu L, et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 2001;61:1309-1313

- Rosell R, Green M, Gumerlock P. Advances in the treatment of non-small cell lung cancer: molecular markers take the stage. Semin Oncol 2001;28 (suppl 2): 28-34.

- Rosell R, Felip E. Predicting response to paclitaxel/carboplatin-based therapy in non-small-cell lung cancer. Semin Oncol 2001;28 (suppl 14): 37-44

- Rosell R, Felip E, Maestre J, Sánchez JM, Sánchez JJ, Manzano JL, Astudillo J, Taron M, Monzo M. The role of chemotherapy in early non-small cell lung cancer management. Lung Cancer 2001;34:S63-S74

- Jassem E, Niklinski J, Rosell R, Niklinska W, Jakobkiewicz J, Monzo M, Chyczewski L, Kobierska G, Skokowski J, Zylicz M, Jassem J. Types and localisation of p53 gene mutations . A report on 332 non-small cell lung cancer patients. Lung Cancer 2001;34: S47-S51

- Rosell R. Managing poor performance non-small cell lung cancer patients. Ann Oncol 2001;12:1659-1661

- Monzo M, Rosell R, Taron M. Drug resistance in non-small cell lung cancer. Lung Cancer 2001;34: S91-S94

- Rosell R, Saijo N. Meeting Report of the Seventh IASLC Lung Cancer Biology Workshop. Molecular Biology and Pharmacogenetic Research in the Treatment of Lung Cancer: Barcelona, Spain,April 30– May 3, 2001 Lung Cancer;34:465-466

- Monzo M, Rosell R, Taron M, O'Brate A, Méndez P. Re-expression of embryonic gene sonic hedgehog (Shh) is correlated with poor survival in resected NSCLC patients. Seventh IASLC Lung Cancer Biology Workshop. Molecular Biology and Pharmacogenetic Research in the Treatment of Lung Cancer: Barcelona, Spain, April 30– May 3, 2001 Lung Cancer 2001;34: S4

- Rosell R, Sarries C, Nuñez L, Roig B, Barnadas A, Pérez C, O'Brate A, Monzo M. Tubulin mutations in non-small cell lung cancer. Seventh IASLC Lung Cancer Biology Workshop. Molecular Biology and

Pharmacogenetic Research in the Treatment of Lung Cancer: Barcelona, Spain, April 30– May 3, 2001. Lung Cancer 2001;34: S5

- Rosell R, Cortes-Funes H. TRAIL/Apo-2L death signaling pathway: implications for chemoresistance. Seventh IASLC Lung Cancer Biology Workshop. Molecular Biology and Pharmacogenetic Research in the Treatment of Lung Cancer: Barcelona, Spain, April 30– May 3, 2001. Lung Cancer 2001;34: S20

- Rosell R, Gandara D. Genetic predictors of chemotherapy response in non-small-cell-lung cancer The 41st annual meeting of the Japanese Respiratory Society. April 4, 2001, Tokyo, Japan. Journal Japanese Respiratory Society 2001;39 (suppl 2):96(Abstract LS 10)

PUBLICATIONS 2000

- Rosell R. Letter to the editor. N Engl J Med 2000; 343:1572

- Rosell R, Felip E. Role of multimodality treatment for lung cancer. Semin Oncol 2000;18:143-151

- Rosel R, Abad A. Tumour site, sex, and survival i colorectal cancer. Lancet 2000;356:857

- Felip E, Rosell R, Alberola V, Gómez-Codina J, Maestre J, Astudillo J, Camps C, González-Larriba JL, Moreno I, Paredes A, Artal A, García-Gómez R, Garrido P, Cardenal F, Barneto I, Sánchez JJ. Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non-small-cell lung cancer: results of a randomized multicenter trial. Clin Lung Cancer 2000;1:287-293

- Felip E, Rosell R. Is the evidence in favour of neoadjuvant chemotherapy in stage IIIA (N2) non-small cell lung cancer solid enough? Monaldi Arch Chest Dis 2000;55:305-310

- Sacristán JA, Kennedy-Martin T, Rosell R, Cardenal F, Antón A, Lomas M, Alberola V, Massutí B, Carrato A, Minshall M. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer. Lung Cancer 2000;28:97-107

- Calvo R, West J, Franklin W, Rosell R, et al. Altered HOX and and WNT7A expression in human lung cancer. Proceedings National Academy Sciences USA 2000;97:12776-12781

- Maurel J, Martinez-Trufero J, Artal A, Martin C, Puertolas T, Zorrilla M, et al. Prognostic impact of bulky mediastinal lymph nodes (N2>2.5 cm) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) treated with platinum-based induction chemotherapy. Lung Cancer 2000;30:107-116

- O'Brate A, Taron M, Gandara D, Rosell R. Sharing new approaches to translational research in non-small-cell lung cancer. Oncologist 2000;5:514-519

PUBLICATIONS 1974-1999

- Cardenal F, López-Cabrerizo MP, Antón A, alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, Montalar J, Vadell C, González-Larriba JL, Nguyen B, Artal A, Rosell R. Randomized phase III study of gemcitabine-cispltain versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999;17:12-18.

- Esteller M, Sánchez-Céspedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.

- Monzó M, Rosell R, Sánchez JJ, Lee JS, O'Brate A, González-Larriba JL, Alberola V, Lorenzo JC, Núñez L, Ro JY, Martin C. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999;17:1786-1793.

- Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, Martin C, Font A, Barnadas A, Abad A. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999;17:2100-2104.

- Rosell R, Calvo R, Sánchez JJ, Maurel J, Guillot M, Monzó M, Núñez L, Barnadas A. Genetic susceptibility associated with rare HRAS1 variable number of tandem repeats alleles in Spanish non-small cell lung cancer patients. Clin Cancer Res 1999;5:1849-1854.

- Rosell R, Monzó M, López-Cabrerizo MP. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer. Oncology 1999;13 (suppl 4) 30-34.

- Rosell R, Bunn PA. Guest Editors. Oncology 1999;13 (suppl 4).

- Rosell R. Docetaxel (taxotere) in the treatment of non-small cell lung cancer; recent results and future developments. Semin Oncol 1999;26 (suppl 11):1-3.

- Rosell R. New approaches in the adjuvant and neoadjuvant therapy of non-smal cell lung cancer, including docetaxel (taxotere) combinations. Semin Oncol 1999;26 (suppl 11):32-37.

- Rosell R. Guest Editor. Semin Oncol 1999;26 (suppl 11).

- Rosell R, Gómez-Codina J, Camps C, Sánchez JJ, Maestre J, Padilla J, Cantó A, Abad A, Roig J. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999;26:7-14.

- Rosell R, Monzó M, Jassem J, Gumerlock P, Jassem E, Martin C, Balaña C, Gandara D, Sánchez JJ. High frequency of p53 mutations in non-small cell lung cancer detected with yeast functional assay. Nowotwory 1999;49 (suppl 1):47-54.

- Rosell R, Martin C, Balaña C. Ifosfamide in non-small-cell lung cancer. Ann Oncol 1999;10 (suppl 5):S25-S28.

- Rosell R. Presentación de la Revista de Oncología. Rev Oncol 1999;1:3-5.

- Calvo R, Rosell R. Homeoboxes, homeodomains and cancer. Rev Oncol 1999;1:167-174.

- Rosell R, Carrato A. From the bench to the bed: the need for translational research. Rev Oncol 1999;1:181-187.

- Escuín D, Rosell R. The anti-apoptosis survivin gene and its role in human cancer: an overview. Clin Lung Cancer 1999;1:138-143.

- Izquierdo MA, Balañá C, Fabregat X, García M, Martinez M, Llorens MA, Gimeno M, Mesia R, Rosell R, Germá JR. Initial phase I trial of a new liposome-encapsulated doxorubicin formulation in patients with refractory solid tumors. Clin Cancer Res1999;5 (suppl):3795s; (abstr 330).

- Monzó M, O'Brate A, Sánchez JM, Guillot M, Sánchez JJ, Aracil C, Rosell R. Clin Cancer Res 1999;5 (suppl):3825s (abstr 474).

- Font A, Rosell R. Oncología Clínica Básica. Cáncer de pulmón. Neoplasias del mediastino: mesotelioma. 1999. Arán Ediciones, S.A.

- Taron M, Plasencia C, Abad A, Guillot M, Martin C, Barnadas A, Rosell R. Preclinical synergy of oxaliplatin (OXA), topoisomerase I-inhibitor (topotecan) and 5-fluorouracil in sensitive and 5-fluorouracil resistant HT29 cell line. Proceedings American Society of Clinical Oncology 1999;18:170a (abstr 651).

- Martin C, Isla D, González-Larriba JL, Felip E, Camps C, Antón A, Carrato A, Azagra P, Alberola V, Massuti B, Sánchez JJ, Monzó M, Rosell R. A phase II study of bi-weekly gemcitabine/paclitaxel in advanced non-small cell lung cancer (NSCLC). Proceedings American Society of Clinical Oncology 1999;18:462a (abstract 1781).

- Balañá C, Barnadas A, Martin C, Monzó M, Rosell R, Font A, Manzano JL, Nuñez L, Guillot M. A phase II study of sequence-dependent docetaxel (D) / Vinorelbine (V) DNA damage-induced apoptosis in patients with non-small cell lung cancer (NSCLC). Proceedings American Society of Clinical Oncology 1999;18:463a (abstract 1786).

- Gómez-Codina J, Artal A, González-Larriba JL, Barneto I, Carrato A, Isla D, Camps C, García-Girón C, Font A, Meana A, Lomas M, Vadell C, Arrivi A, Alonso C, Maestu I, Campbell J, Rosell R. Proceedings American Society of Clinical Oncology 1999;18:469a (abstract 1810).

- Gandara DR, Monzo M, Shi X-B, Holland WS, Rosell R, Gumerlock PH. Mutant p53 alleles with loss of transactivational function: association with poor survival in non-small cell lung carcinoma (NSCLC). Proceedings American Society of Clinical Oncology 1999;18:483a (abstract 1863).

- Rosell R, Monzó M, Felip E, Astudillo J, Sánchez JJ, Rosas I, Martin C, Font A, Barnadas A, Abad A. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. Proceedings American Society of Clinical Oncology 1999;18:1901a (abstr 1901).

- Plasencia C, Taron M, Abad A, Guillot M, Manzano JL, Rosell R. Efectos citotóxicos de la combinación de topotecan y agentes específicos de fase G2/M en un panel de líneas celulares derivadas de tumores humanos. Revista de Oncología 1999;1 (suppl 1):14 (abstract A007).

- Taron M, Plasencia C, Abad A, Guillot M, Martin C, Font A, Rosell R. New association schedules with oxaliplatin, topotecan and 5-FU sensitive and 5-FU-resistent cell lines. Rev Oncol 1999;1 (suppl 1):16 (abstract A006).

- Rosell R. Translational research in lung cancer. Rev Oncol 1999;1 (suppl 1):45 (abstract p).

- Ramírez JL, Sancho E, Núñez L, Sánchez JJ, Balañá C, López P, Martin C, Monzó M, Rosell R. Clinical implications of telomerase activity in non-small cell lung cancer (NSCLC). Rev Oncol 1999;1 (suppl 1):48 (abstract A005).

- Sancho E, Ramírez JL, Rosas I, O'Brate A, Castel A, Cardenal J, Monzó M, Rosell R. The role of telomere addition in the stabilization of radiation induced DNA breaks. Rev Oncol 1999;1 (suppl 1):49 (abstract A068).

- Barnadas A, Rosell R, Vallejos V, Fraile M, Julián JF, Rull M, Fusté F, Abad A, Manzano JL, Guillot M, Martin C, Balañá C, Font A, Mariscal A. Valor predictivo del estudio del ganglio centinela en el cáncer de mama operable. Rev Oncol 1999;1 (suppl 1):76 (abstract 39).

- Felip E, Rosell R, Moreno I, Alberola V, González-Larriba JL, Gómez-Codina J, Sánchez JJ, Paredes A, Camps C, García-Gómez R, Artal A, Garrido P, Cardenal F, Barneto I. Estudio randomizado del Grupo Español de Cáncer de Pulmón de quimioterapia preoperatoria (cisplatino 100 mg/m2 vs 50 mg/m2) en cáncer de pulmón no microcítico estadio IIIAN2. Rev Oncol 1999;1 (suppl 1):88 (abstract 71).

- Gómez-Codina J, Artal A, González-Larriba JL, Campbell J, Barneto I, Carrato A, Isla D, Camps C, García-Girón C, Font A, Meana A, Lomas M, Vadell C, Arrivi A, Alonso C, Maestu I, Rosell R. Tratamiento quimioterápico del carcinoma broncopulmonar microcítico: estudio aleatorizado de cisplatino y etopósido (EP) versus cisplatino y altas dosis de epirubicina (HDEP). Rev Oncol 1999;1 (suppl 1):89 (abstract 73).

- Rosas I, Mendez P, Barnadas A, Felip E, López de Castro P, Manzano JL, Rosell R, Monzó M. Un nuevo gen anti-apoptosis:survivina como marcador de pronóstico en cáncer de pulmón de célula no pequeña (CPCNP). Rev Oncol 1999; 1 (suppl 1):91 (abstr 79).

- Nuñez L, Escuín D; Guillot M, Font A, Abad A, Rosell R, Monzó M. Análisis funcional de alelos mutatntes de p53 en pacientes quirúrgicos con cáncer de pulmón de células no pequeñas (NSCLC). Rev Oncol 1999; 1 (suppl 1): 92 (abstract 82).

- Balañá C, Martin C, Rosell R, Monzó M, Manzano JL, Guillot M. Docetaxel (D) / Vinorelbina (V) en cáncer no microcítico de pulmón (CNMP), estudio fase II de 3 secuencias diferentes de administración y su relación con la apoptosis celular. Rev Oncol 1999;1 (suppl 1):95 (abstract 88).

- Guillot M, Martin C, Manzano JL, Balañá C, Font A, Barnadas A, Abad A, Monzó M, Rosell R. Susceptibilidad genética en cáncer de pulmón asociado a alelos raros HRAS1 VNTR en pacientes españoles con cáncer de pulmón. Rev Oncol 1999;1 (suppl 1):101 (abstract 104).

- Martin C, Balaña C, Font A, Guillot M, Astudillo J, Barnadas A, Abad A, Rosell R. Estudio no randomizado fase II de tratamiento preoperatorio con tres ciclos de docetaxel / cisplatino / gemcitabina en los pacientes afectos de un CPCNP estadio III. Rev Oncol 1999; 1 (suppl 1) :104 (abstract 112).

- Font A, Rigas JR, Memoli VA, Guillot M, Manzano JL, Eastman A, Abad A, Rosell R. Estudio del valor pronóstico de la expresión de bcl-2, bax y bcl-x en pacientes con cáncer de esófago. Rev Oncol 1999;1 (suppl 1): 115 (abstract 138).

- Manzano JL, Barnadas A, Rosell R, Tarrats A, López MP, Muñoz C, Monzó M, Abad A, Balaná C, Martin C, Guillot M, Font A. Implicaciones de las mutaciones del gen p53 en el cáncer epitelial de ovario tratado con quimioterapia. Rev Oncol 1999; 1 (suppl 1):131 (abstract 181).

- Izquierdo MA, Balañá C, Fabregat X, García M, Llorens MA, Gimeno M, Mesia R, del Muro JG, Losa F, Carles J, Rosell R, Germà JR. Ensayo clínico fase I de una nueva doxorubicina liposomial en tumores sólidos avanzados. Rev Oncol 1999; 1 (suppl 1): 133 (abstract 186).

- Font A y Rosell R. Cáncer de pulmón. Neoplasias del mediastino: Mesotelioma. Oncologia Clínica Básica. ARAN Ediciones. 1999

- Rosell R, Sole Sala JM, Boleda M, et al. Catarata por busulfán. Med Clin (Barc) 1974;63:417 421.

- Woessner S, Rosell R, LaFuente et al. Tricoleucemia. A propósito de un caso. Med Clin (Barc) 1974;63:337 342.

- Rosell R. Amiloidosis y discrasias de células plasmáticas. Med Clin (Barc) 1974;64:165 167.

- Rosell R. Referatas en Hematología. Med Clin (Barc) 1974;63:500 504.

- Rosell R. La exploración del enfermo hematológico. Jano 1974;133:21 24.

- Rosell R. Anemias ferropénicas. Jano 1974;135:26 29.

- Rosell R. Preleucemia. Jano 1974;139:19 21.

- Rosell R. Anemia de la insuficiencia renal. Jano 1974;146:33 36.

- Rosell R. Síndrome de Gaisbock: una forma especial de seudopoliglobulia. Jano 1974;147:47 49.

- Rosell R. Las complicaciones hematológicas del cáncer. Jano 1974;151:16 18.

- Rosell R. Enfermedad de Hodgkin I. Jano 1974;152:37 40.

- Rosell R. Enfermedad de Hodgkin II. Jano 1974;153:29 33.

- Rosell R. Enfermedad de Hodgkin III. Jano 1974;154:33 37.

- Rosell R. Enfermedad de Hodgkin IV. Jano 1974;155:23 26.

- Rosell R. Tricoleucosis: una nueva entidad anatomoclínica. Med Clin (Barc) 1975;64:215 217.

- Rosell R, Boleda M, Rodriguez JC et al. Poliquimioterapia de los linfomas no hodgkinianos. Sangre 1975;20:546 548.

- Rosell R. Linfomas no hodgkinianos. Jano 1975;158:34 37.

- Rosell R. Tumor de Burkitt. Jano 1975;175:32 35.

- Rosell R. Hematodermias I. Jano 1975;167:41 43.

- Rosell R. Hematodermias II. Jano 1975;168:24 26.

- Rosell R. Adenopatías solitarias por toxoplasmosis adquirida: una entidad apenas conocida. Jano 1975;183:31-33.

- Sole Sala JM, Rosell R, Sans Sabrafen J. Catarata busulfánica. Arch Soc Esp Oftalmol 1975;35:1065-1067.

- Rosell R. Referatas en Hematología. Med Clin (Barc) 1976;67:228-231.

- Rosell R, Boleda M, Rodriguez JC et al. Poliquimioterapia en los linfomas no hodgkinianos. Med Clin (Barc) 1976;66:388-392.

- Rosell R, Buxo J, Sans Sabrafen J. Poliquimioterapia con dosis masivas de methotrexate en los tumores de cabeza y cuello. Med Clin (Barc) 1976;66:453-457.

- Rosell R. Palidez cutánea y episodios de dolor abdominal. Jano 1976;244:49-51.

- Woessner S, LaFuente R, Rosell R, et al. Systemic mastocytosis: a case report, cytological, cytochemical and ultrastructural considerations. Acta Haemat 1977;58:321-324.

- Rosell R. Secretario de Oncología Clínica: Quimioterapia antineoplásica actual. Medicine 1977;28:2450.

- Sans Sabrafen J, Rosell R. Bases y principios fundamentales de la moderna quimioterapia antineoplásica, estrategia quimioterapeútica oncológica actual. Medicine 1977;28:2497-2510.

- Buxo J, Rosell R. Quimioterapia de las hemopatías malignas. Medicine 1977;28:2548-2560.

- Rosell R. Serie diagnóstico diferencial, presentación de un caso clínico. Medicine 1977;28:2600-2603.

- Rosell R, Pardo P, Modolell A. Associació d'hemopatía maligna i càncer. An Med (Barc)1977;63:71- 718.

- Rosell R. Progressos en l'estratègia quimioteràpica antineoplàsica. An Med (Barc)1977;63:733-735.

- Rosell R., Sans Sabrafen J. Síndromes paraneoplásicos hematológicos. Jano 1978;319:10-14.

- Pardo P, Buxo J, Rosell R et al. Síndrome hipereosinofílico maligno. Presentación de un caso excepcional. Sangre 1978;23:254-256.

- Sans Sabrafen J, Modolell R, Rosell R, et al. Poliquimioterapia de los linfomas malignos no hodgkinianos. Revisión de treinta y siete casos en estadio avanzado. Sangre 1978;23:122-126.

- Pardo P, Sans Sabrafen J, Rosell R, et al. Osteopetrosis de Albers Schonberg. Med Clin (Barc) 1978;71:306-309.

- Rosell R, Isern J, Domenech P, Masdeu I. Ensayo preliminar con carbonato de litio como agente atenuante de la citopenia inducida por los citostáticos. Oncología 1978;80:86-90.

- Rosell R, Valenti JM, Fabregat J, Masdeu I. Ulcera cutánea por adriamicina. Una reacción local severa. Oncología 1978;80:7-10.

- Rosell R. Tractament dels càncers ossis primaris i secundaris. L'internista 1978;5:13-18.

- Camps A, Rosell R, Cerdan M, et al. Síndromes paraneoplásicos. Actas Dermo Sifilográficas 1979;70:401-403.

- Fabregat J, Rosell R, Valenti JM. Levamisol: perspectives actuals com agent adjuvant en la terapèutica oncològica. L'internista 1979;12: 11-17.

- Fabregat J, Valenti JM, Tusquets I, Rosell R. Valor pronóstico de la colesterolemia en las enfermedades neoplásicas. Rev Esp Oncol 1979;26:517-521.

- Rosell R, Fabregat J, Valenti JM et al. Valor pronóstico de las complementemias en la evolución de 192 neoplasias. Oncología 1980;80:3:11-16.

- Tusquets I, Rosell R, Valenti JM et al. Manifestaciones abdominales como expresión metastásica de un cáncer de mama avanzado. Oncología 1980;80:5- 61.

- Rosell R, Isern J, Camprodon R, et al. Experiencia en el uso de la quimioterapia coadyuvante en 36 casos de cáncer de mama. Rev Quir Esp 1981;8:303-307.

- Fabregat J, Rosell R, Valenti JM, et al. Metástasis de la base del cráneo de la neoplasia de mama: a propósito de dos casos. Oncología 1981;80:4:52-55.

- Rosell R. Citostáticos: bases biológicas de su utilización y efectos secundarios. Jano 1982;526:51-55.

- Tusquets I, Rosell R, Fabregat J et al. Actualización del cáncer de próstata. Mir 1982;4:24-27.

- Valenti JM, Rosell R, Palazon J et al. Importancia de las determinaciones seriadas del CEA en el seguimiento de 148 pacientes con cáncer de mama. Oncología 1982;80:5:447-451.

- Fabregat J, Rosell R, Valenti JM, et al. Quimioterapia adyuvante en 70 pacientes con cáncer de mama. Oncología 1982;80:5:13-18.

- Fabregat J, Beltran J, Rosell R, et al. Multicenter phase II trial with 5 day continuous infusion of vindesine in metastatic malignant melanoma. Cancer Treat Rep 1984;68:1199-1200.

- Rosell R. Us dels antiemètics en Oncología. An Med (Barc) 1984;70:60-62.

- Rosell R, Abad Esteve A, Ribas M, Moreno I. Evaluation of a combination antiemetic regimen including iv high dose metoclopramide, dexamethasone and diphenhydramine in cisplatin based chemotherapy regimens. Cancer Treat Rep 1985;69:909-910.

- Monras P, Fernandez C, Rosell R, et al. Utilidad de la evaluación subjetiva en la medición de los efectos secundarios a la quimioterapia. Oncología 1986;9:75-81.

- Moreno I, Rosell R, Fernandez C, Abad Esteve A. Valoración del régimen antiemético con clebopride intravenoso, dexametasona y difenhidramina durante la quimioterapia con cisplatino. Gastroent Hepat 1986;9:74-75.

- Rosell R, Abad Esteve A., Meca F, Monras P, Ribas M. Efecto antiemético de la metoclopramida oral en pacientes ambulatorios que reciben quimioterapia sin cisplatino. Un ensayo randomizado con dosis moderadas de metoclopramida comparando 2.5 mg/Kg con 5.0 mg/Kg en dosis fraccionadas. Oncología 1986;9:11-17.

- Abad Esteve A, Rosell R, Moreno I, et al. Valoración del régimen antiemético con combinación de altas dosis de metoclopramida, dexametasona y difenhidramina en regímenes de quimioterapia con cisplatino. Med Clin (Barc) 1986;87:796-798.

- Rosell R, Badal JM, Codina J, et al. The dose of adjuvant combination chemotherapy and its relationship with the prognosis of breast cancer patients with affected axillary nodes. Folia Oncologica 1986;9:203-214.

- Rosell R. Valoración clínica de fármacos antieméticos en vómitos inducidos por quimioterapia. Rev Farmacol Clin Exp 1986;3 (supl): 15-17.

- Fernandez C, Rosell R, Abad Esteve A, Moreno I, Casals A, Ribas M. Ensayo en fase II de altas dosis de ifosfamida en tumores resistentes. Neoplasia 1987;4:150-153.

- Rosell R, Abad Esteve A, Roig J, Moreno I, Fernandez C, Ribas M. The role of combination cyclophosphamide, doxorubicin and cisplatin (CAP) chemotherapy in advanced non small cell lung cancer. Tumori 1987;73:345-349.

- Abad Esteve A, Llibre JM, Rosell R, Sabria J, Moreno I, Ribas M. Valor de la determinación de los niveles plasmáticos del CEA en el cáncer de pulmón no célula pequeña. Oncología 1987;10:261-264.

- Rosell R, Abad Esteve A, Morera J, et al. A randomized study comparing platinum, doxorubicin and VP 16 with platinum, 4' epidoxorubicin, and VP 16 in patients with non small cell lung cancer. Am J Clin Oncol 1987;10:245-248.

- Rosell R, Abad Esteve A, Ribas M, Moreno I, Fernandez C. Eficacia de las altas dosis de metoclopramida en el control de la emesis aguda inducida por la quimioterapia. Med Clin (Barc) 1987;88:434.

- Pedro Botet ML, Llibre J, Rosell R, Larrousse E. Atherosclerosis, hypertension, and coronary artery disease. Arch Intern Med 1987;147:2217.

- Moreno I, Rosell R, Abad Esteve A, Fernandez C, Inaraja L, Ribas M. Computed tomography and chest radiography in the staging of small cell carcinoma of the lung. Folia Oncologica 1987;10:77-80.

- Rosell R. Estadiaje de los pacientes con cáncer de pulmón. Rev Cancer (Madrid) 1987;1:153-160.

- Barrios J, Berna D, Pujol T, Aliart M, Rosell R. Ensayo randomizado a doble ciego con metoclopramida y clebopride oral en 16 pacientes bajo regimenes de quimioterapia sin cisplatino. Neoplasia 1987;4:215 217.

- Abad Esteve A, Rosell R, Moreno I, Fernandez C, Rosell M, Ribas M. VP 16, vincristina, adriamicina y ciclofosfamida (EVAC) en pacientes con cáncer de pulmón células pequeñas. Med Clin (Barc) 1988;90:569-572.

- Abad Esteve A, Rosell R, Moreno I, Fernandez C, Ribas M. Régimen FAM en cáncer gástrico: un esquema todavía útil. Neoplasia 1988;5:15-17.

- Rosell R. Quimioterapia en el cáncer de pulmón de células escamosas (CPCE). ¿Deus ex machina?. Neoplasia 1988;5:111.

- Rosell R, Moreno I, Abad Esteve A, et al. Eficacia antiemética de altas dosis de clebopride en combinación con dexametasona y difenhidramina para el control de la emesis inducida por cisplatino. Neoplasia 1988;5:166-170.

- Casals-Pascual A, Rosell R, Abad Esteve A, et al. Diagnosis of liver metastases. A Bayesian approach. Cancer J 1988;2:173-176.

- Rosell R. Quimioterapia en enfermos con cáncer de pulmón no célula pequeña (CPNCP), estadios localmente avanzados (III) y diseminados (IV). Tratamiento del oat cell. En Avances en Oncología. E Diaz Rubio (ed), Arán Ediciones, S.A., Madrid, 1988; 137-148.

- Rosell R. A propósito de la Oncología y sus especialidades. Oncología 1988;11:461.

- Fernandez C, Rosell R, Abad Esteve A, et al. Quality of life during chemotherapy in non small cell lung cancer patients. Acta Oncol 1989;28:29-33.

- Rosell R. Historia natural del cáncer de próstata. Med Clin (Barc) 1989;92:140-142.

- Abad Esteve A, Rosell R, Moreno I, et al. Antiemetic efficacy of escalating doses of alizapride against chemotherapy induced emesis. Oncology 1989;46:235-237.

- Rosell R,Abad Esteve A, Moreno I. Métodos de evaluación clínica de antieméticos. Rev Cancer (Madrid) 1989;3:114-119.

- Abad Esteve A, Moreno I, Rosell R. Papel de la metoclopramida en la prevención de las náuseas y vómitos inducidos por la quimioterapia. Rev Cancer (Madrid) 1989;3:125-129.

- Abad Esteve A, Diaz Rubio E, Jimeno JE, Rosell R, Villar A, Gonzalez Larriba JL. Oral idarubicin in measurable gastric cancer. Am J Clin Oncol (CCT) 1989;12:14-16.

- Rosell R, Abad Esteve A, Moreno I. Papel del alizapride en la prevención del vómito agudo inducido por cisplatino. Oncología 1989;12:71.

- Abella E, Encabo B, Rosell R, Carles J, Abad A, Lorenzo JC. Tumor indiferenciado de célula pequeña. Valor diagnóstico de la enolasa neuroespecífica en su clasificación histogenética. Oncología 1989;12:471-475.

- Rosell R, Abad Esteve A, Fabregat X, Tusquets I. ¿La determinación de la hipercomplementemia en las neoplasias sigue siendo un parámetro útil?. Oncología 1989;12:523.

- Rosell R, Abad Esteve A, Moreno I. Valor de las benzamidas sustituidas en el control de la emesis aguda postcisplatino. Med Clin (Barc) 1989;93:756.

- Romeu J, Teixido A, Rosell R, Abad Esteve A, Solans R. Carles J. Carcinoma de origen desconocido. Estudio diagnóstico en 48 casos y su rentabilidad clínica. Med Clin (Barc) 1989;92:201-206.

- Alasture A, Carles J, Rosell R, et al. Reservorios venosos subcutaneos: experiencia y protocolo de actuación. Una nueva vía y una idea práctica para su introducción. Acta Chir Catal 1989;10:77-82.

- Fernandez C, Rosell R et al. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol 1989; 28:29-33.

- Rosell R et al.A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer. Cancer 1990; 65:1692-1699.

- Rosell R et al. Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall-cell lung cancer: a meta-analytic review. J Surg Oncol 1990; 45:124-130.

- Fernandez C, Rosell R, Abad Esteve A, et al. Calidad de vida durante la quimioterapia en pacientes con carcinoma broncogénico no de células pequeñas. Oncología 1990:13:267 272.

- Diaz-Rubio E, Martin M, Rosell R, et al. A randomized double blind cross over trial comparing the antiemetic efficacy of thiethylperazine and methylprednisolone versus thiethylperazine and placebo in patients treated with FAC. Acta Oncol 1990;29:593 595.

- Rosell R. Tumores malignos neuroectodérmicos periféricos, entidades de interés diagnóstico y terapeútico. Oncología 1990;13:74.

- Rosell R. Quimioterapia neoadyuvante en el cáncer de pulmón. Med Clin (Barc) 1990;94:299-301.

- Abad Esteve A, Rosell R, Barnadas A, et al. Modulación bioquímica del fluorouracilo (5 FU). Experiencia con dos combinaciones secuenciales (dosis bajas y dosis altas) de metotrexato (MTX) y ácido folínico (AF) en el cáncer de colon y recto. Neoplasia 1990;7:81-86.

- Rosell R, Abad Esteve A, Olazabal A, Carles J. Evaluación de la respuesta en oncología. Rev Cancer (Madrid) 1990;4:61-72.

- Llibre I, Codina JM, Tor J, Rosell R. Infeccions en pacients amb càncer. An Med (Barc) 1990;76;193-199.

- Rosell R, Abad Esteve A, Moreno I, et al. A randomized study of two vindesine plus cisplatin containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non small cell lung cancer. Cancer 1990;65:1692-1699.

- Rosell R, Abad Esteve A, Carles J, Moreno I. Quality of life in non small cell lung cancer patients. Acta Oncol 1990;29:635-636.

- Rosell R, Moreno I, Maestre J, et al. Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced non small cell lung cancer. J Surg Oncol 1990;45:124-130.

- Rosell R, Milla F, Carles J, Batlle M, Ribelles N, Junca J. Descripción de un nuevo tipo celular, células Pinocho, inducido en el curso del tratamiento de tumores sólidos con interleucina 2. Med Clin (Barc) 1990;95:447-450.

- Diaz Rubio E, Gonzalez Larriba JL, Rosell R, et al. Randomized, double blind cross over study of acute cisplatin induced nausea and vomiting, comparing a new schedule of the combination of metoclopramide and methylprednisolone versus metoclopramide alone. Ann Oncol 1990;1:379-380.

- Carles J, Rosell R, Ribelles N, et al. Sistemas de acceso venoso con reservorio subcutáneo en la población oncológica. Experiencia en 60 pacientes. Oncología 1991;14:196-199.

- Abad A, Rosell R, Barnadas A, Carles J, Ribelles N, Solano V. 5 fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatico biliary tumors. Ann Oncol 1991;2:153.

- Abad Esteve A, Rosell R, Pastor MC, et al. Sequential combination of methotrexate, 5 fluorouracil and high dose folinic acid in advanced colorectal cancer: double synergism? Am J Clin Oncol (CCT) 1991;14:393-396.

- Moreno I, Rosell R, Abad Esteve A, Barnadas A, Carles J, Ribelles N. Randomized trial for the control of acute vomiting in cisplatin treated patients: high dose metoclopramide with dexamethasone and lorazepam as adjuncts versus high dose alizapride plus dexamethasone and lorazepam. Oncology 1991;48:397-402.

- Rosell R. Estudios aleatorios de fármacos antieméticos: necesidad de establecer el criterio de dosis óptima para su correcta comparación de eficacia. Rev Clin Esp 1991;188:117-119.

- Rosell R, Carles J, Ariza A, et al. A phase II study of days 1 and 8 cisplatin and recombinant alpha 2B interferon in advanced non small cell lung cancer. Cancer 1991;67:2448-2453.

- Abad A, Rosell R, Barnadas A. Carboplatino: papel en el tratamiento de los tumores sólidos. Neoplasia 1991;8:213-217.

- Rosell R, et al. A phase II study of days 1 and 8 cisplatin and recombinant alpha-2B interferon in advanced non-small cell lung cancer. Cancer 1991; 67:2448-2453.

- Alvarez A, Rizo A, Serrano B, Lorente L, Rosell R. Utilización de la suramina como antineoplásico. Farmacia Clínica 1991;8:528-532.

- Abad A, Rosell R. Carcinoma gástrico superficial : ¿únicamente un diagnóstico temprano o también una entidad biológica particular? Med Clin (Barc) 1991;97:335-336.

- Brode E, Poveda A, Diaz Rubio E, Rosell R, Benavides A. Pharmacokinetic characterization of mitonafide in man. Meth and Find Exp Clin Pharmacol 1992;14:131-140.

- Rosell R, Carles J, Abad A, et al. Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer. Invest New Drugs 1992;123-128.

- Rosell R, Carles J, Abad A, Ribelles R, Barnadas A, Benavides A, Martin M. Phase I study of mitonafide in 120 hour continuous infusion in non small cell lung cancer. Inves New Drugs 1992;10:171-175.

- Moreno, I Rosell R, Abad A, Barnadas A, Carles J, Ribelles N, Solano V, Font A. Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin treated patients. Eur J Cancer 1992;28A:1344-1347.

- Rosell R et al. Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer. Invest New Drugs 1992; 10:123-128.

- Rosell R, Li S, Skacel Z, Mate JL, Maestre J, Canela M, Tolosa E, Armengol P, Barnadas A, Ariza A. Prognostic impact of mutated K ras gene in surgically resected non small cell lung cancer patients. Oncogene 1993;8:2407-2412.

- Martin M, Rosell R, Guillem V, Diaz Rubio E. LAS 30451: a novel 5 HT3 antagonist. Eur J. Cancer (Suppl) 1993;29A:33-34.

- Carles J, Rosell R, Ariza A, Pellicer I, Sanchez JJ, Fernandez Vasalo G, Abad A, Barnadas A. Neuroendocrine differentiation as a prognostic factor in non small cell lung cancer. Lung Cancer 1993; 10: 209-219.

- Rosell R et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993; 8:2407-2412.

- Carles J, Rosell R et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 1993; 10:209-219.

- Abad Esteve A, Inaraja L, Rosell R et al. Valor de la tomografía computadorizada (TC) en el seguimiento del cáncer gástrico y su beneficio terapéutico. Neoplasia 1993;10:36-39.

- Rosell R et al. A randomized trial of mitomycin/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung cancer. Semin Oncol 1994; 21 (Suppl): 28-33.

- Li S, Rosell R et al. K-ras gene point mutation: a stable tumor marker in non-small cell lung cancer. Lung Cancer 1994;11:19-27.

- Rosell R et al. Prognostic value of K-ras 12 genotypes in patients with advanced non-small cell lung cancer receiving carboplatin with either intravenous or chronic oral dose etoposide. Int J Oncol 1994;5:169-176.

- Rosell R, Gomez Codina J, Camps C, Maestre J, Padilla J, Canto A, Mate JL, Li S, Roig J, Olazabal, A, Canela M, Ariza A, Skacel Z, Morera J, Abad A, Morera J. A randomized trial of preoperative chemotherapy plus surgery versus surgery in non small cell lung cancer. N Engl J Med 1994;330:153-158.

- Rosell R, Maestre J, Font A, Moreno I, Molina F, Milla A, Gomez-Codina J, Camps C. A randomized trial of mitomycin c, ifosfamide and cisplatin (MIC) preoperative chemotherapy plus surgery versus surgery in stage IIIA non small cell lung cancer. Semin Oncol 1994; 21: 28-33.

- Rosell R, Gomez-Codina J, Anton A, et al. Escalating High-Dose Epirubicin Plus Cisplatin in Small Cell Lung Cancer With Granulocyte-Macrophage Colony-Stimulating Factor Use When Appropiate. Semin Oncol 1994; 21 (suppl): 48-53.

- Li S, Rosell R, Urban A, et al. K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma. Lung Cancer 1994;11:19-27.

- Bunn PA, Van Zandwijk N, Pastorino U, ..., Rosell R, et al. European School of Oncology. First Euro-American Forum on Lung Cancer Treatment. Eur J Cancer 1994;5:710-713.

- Green MR, Ginsberg R, Ardizzoni A, ..., Rosell R, et al. Induction therapy for stage III NSCLC. a consensus report. Lung Cancer 1994;11 Suppl:S9-S10.

- Feld R, Borges M, Giner V, ..., Rosell R, et al. Prognostic factors in non-small cell lung cancer. Lung Cancer 1994;11 Suppl:S19-S23.

- Rosell et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-158.

- Rosell R et al. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and k-ras gene status and chemosensitivity. Semin Oncol 1995;22 (Suppl):12-18.

- Rosell R, Gonzalez Larriba JL, Alberola V, et al. Single agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer. Links between p53 and K-ras gene status and chemosensitivity. Semin Oncol 1995;22(Suppl):12-18.

- Abad A, Garcia P, Gravalos C, Tusquets I, Font A, Perez G, Cortés-Funes H, Fabregat X, Barnadas A, Rosell R. Sequential methotrexate, 5-florouracil (5-FU), and high-dose leucovorin versus 5-FU and high-dose leucovorin versus 5-FU alone for advanced colorectal cancer. Cancer 1995;75:1238-1244.

- Rosell R, Molina F, Moreno I, Martinez E, Pifarré A, Font A, Li S, Skacel Z, Gómez-Codina J, Camps C, Monzó M, DeAnta JM. Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer. Lung Cancer 1995;12(Suppl 1):59-70.

- Rosell R, Monzó M, Molina F, Martinez E, Pifarré A, Moreno I, Mate JL, DeAnta JM, Sanchez M, Font A. K-ras genotypes and prognosis in non-small cell lung cancer. Ann Oncol 1995;6(Suppl 3):15-20.

- Alberola V, Rosell R, González-Larriba JL, Molina F, Ayala F, Garcia-Conde J, Benito D, Pérez JM. Single agent taxol, 3-hour infusion, in untreated advanced non-small cell lung cancer. Ann Oncol 1995;6(Suppl 3):49-52.

- Rosell R, Roig J, Martinez-Benazet J, Maestre J. Preface. First Andorran Non-Small Cell Lung Cancer Congress. Ann Oncol 1995;6(Suppl 3):1.

- Ariza A, Mate JL, Isamat M, López D, VonUexküll-Güldeband C, Rosell R, Fernández-Vasalo A, Navas-Palacios JJ. Standard and variant CD44 isoforms are commonly expressed in lung cancer of the non-small cell type but not of the small cell type. J Pathol 1995;177:363-368.

- Rosell R, González-Larriba JL, Alberola V, Molina F, Monzó M, Benito D, Pérez JM, DeAnta JM. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Semin Oncol 1995;22(Suppl 14):12-18.

- Molina F, Rosell R. Biología molecular del cáncer de pulmón (1). Importancia del oncogén K-ras. Medicina y Función Hospitalaria 1995;1:119-124.

- Molina F, Rosell R. Biología molecular del cáncer de pulmón (2). Otros oncogenes. Medicina y Función Hospitalaria 1995;1:220-225.

- Pifarré A, Rosell R, Monzó M. Inestabilidad de secuencias microsatélite en cáncer de pulmón. Rev Cancer (Madrid) 1995;4:132-138.

- González-Larriba JL, Alberola V, Molina F, Ayala F, Benito D, Pérez JM, Rosell R. Treatment of unresectable non-small cell lung cancer. Phase II study of taxol 210 mg/m2 by three-hour infusion. Oncology Rep 1995;2(Suppl):918(AB-242).

- Monzó M, Rosell R, DeAnta JM, González-Larriba JM, Alberola V, Martinez E, Sánchez M, Pifarré A, Ariza A. Association of p53 and K-ras gene mutations with chemosensitivity in patients with non-small cell lung cancer who underwent treatment with taxol. Oncology Rep 1995;2(Suppl):953(AB-056).

- López MP, Abad A, Ojanguren I, Font A, Tarón M, Maurel J, Barnadas A, Rosell R. Prognostic significance of the nm23-H1 protein expression in colorectal cancer. Oncology Rep 1995;2(Suppl):953(AB-049).

- Martinez E, Pifarré A, Rosell R, Monzó M, ÇDeAnta JM, Sánchez M, Ariza A. Molecular staging of non-small cell lung cancer according to k-ras genotype. Oncology Rep 1995;2(Suppl):938(AB-054).

- DeAnta JM, Pifarré A, Martínez E, Rosell R, Monzó M, Sánchez M, Mate JL. K-ras oncogene and p53 tumor suppressor gene alterations in non-small cell lung cancer. Oncology Rep 1995;2(Suppl):938(AB-047).

- Pifarré A, Rosell R, Monzó M, Mate JL, DeAnta JM, Martínez E, Sánchez M. Microsatellite instability in non-small cell lung cancer as a prognostic factor. Oncology Rep 1995;2(Suppl):938(AB-255).

- Rosell R, Font A, Pifarré A, Canela M, Maurel J, Arellano A, Izquierdo J. The role of induction (neoadjuvant) chemotherapy in stage IIIA NSCLC.Chest 1996;109:102S-106S.

- Casado A, Rosell R et al. Phase II study of mitonafide in non-small cell lung cancer. Investl New Drugs 1996; 14:415-417.

- Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (fragmin). Thromb Hemost 1996;75:251-253.

- Carles J, Ariza A, Rosell R, Pellicer I, Fernandez-Vasalo A, Abad A, Samchez JJ, Navas JJ. Prognostic implications of P-glycoprotein, epidermal growth factor receptor and transforming growth factor a: immunohistochemical expression in non-small cell lung cancer. Oncol Rep 1996;3:0-00.

- Jassem E, Rosell R, Monzo M, Jassem J, Skokowski J, Roszkiewicz A, Kobierska G. Occurrence of p53 mutations in non-small cell lung cancer. Nowotwory 1996;46:323-328.

- Rosell R, Monzo M, Pifarre A, Ariza A, Sanchez JJ, Moreno I, Maurel J, López MP, Abad A, DeAnta JM. Molecular staging of non-small cell lung cancer according to K-ras genotypes. Clin Cancer Res 1996;2:1083-1086.

- Rosell R, Font A, Pifarre A, Canela M, Maurel J, Arellano A, Izquierdo J. The role of induction (neoadjuvant) chemotherapy in stage IIIA NSCLC. Chest 1996;109:102S-106S.

- Maurel J, Rosell R, Lorenzo JC. Poor prognosis Ewing's sarcoma and peripheral primitive neuroectodermal tumors (PNET). Cancer Treatt Rev 1996;22:425-436.

- Cuartero-Plaza A, Martinez-Miralles E, Rosell R, Vadell-Nadal C, Farré M, Real FX. Radiolocalization of squamous lung carcinoma with 131I-labeled epidermal growth factor. Clin Cancer Res 1996;2:13-20.

- Carrato A, Rosell R, Camps C, Antón A, García-Gómez R, Aranda E, Massutí B, Díaz-Fernández N, Sánchez J, García-Paredes M. Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer. Lung Cancer 1997;17:261-269.

- Rosell R et al. Preoperative chemotherapy for stage IIIA non-small cell lung cancer. Curr Opin Oncol 1997; 9:149-155.

- Pifarré A, Rosell R et al. Prognostic value of replication errors on chromosomes 2p and 3p in non-small-cell lung cancer. Brit J Cancer 1997; 75:184-189.

- Rosell R et al. Reduced survival in patients with stage I non-small-cell lung cancer associated with DNA-replication errors. Int J Cancer (Pred. Oncol.) 1997; 74:1-5.

- Sánchez-Céspedes M, Rosell R et al. Microsatellite alterations at 5q21, 11p13, and 11p15.5 do not predict survival in non-small cell lung cancer. Clin Cancer Res 1997;3:1229-1235.

- Graus F, Dalmau J, Reñé M, Torà M, Malats N, Verschuuren JJ, Cardenal F, Viñolas N, Garcia del Muro J, Vadell C, Mason WP, Rosell R, Posner JB, Real FX. Anti-Hu antibodies in patients with small cell lung cancer: association with complete response to therapy and improved survival. J. Clin Oncol 1997;15:2866-2872.

- Pifarre A, Rosell R, Monzo M, DeAnta JM, Moreno I, Sanchez JJ, Ariza A, Mate JL, Martinez E, Sanchez M. Prognostic value of replication errors on chromosomes 2p and 3p in non-small cell lung cancer. Brit J Cancer 1997;75:184-189.

- Rosell R, López-Cabrerizo MP, Astudillo J. Preoperative chemotherapy for stage IIIa non-small cell lung cancer. Curr Opin Oncol 1997;9:149-155.

- Sanchez-Cespedes M, López-Cabrerizo M, Moreno I, Ariza A, Monzó M, Rosell R. Importancia de la pérdida de heterozigosidad en el brazo largo del cromosoma 5 (5q21) en cáncer de pulmón no microcítico. Med Clin (Barc) 1997;109:1-5.

- Rosell R, Pifarré A. Aplicaciones clínicas del estudio de las alteraciones genómicas en tumjores sólidos. Med Clin (Barc) 1997;108:000-000.

- Sanchez-Cespedes M, Rosell R, Pifarré A, López-Cabrerizo MP, Barnadas A, Sanchez JJ, Lorenzo JC, Abad A, Monzó M, Navas-Palacios JJ. Microsatellite alterations at 5q21, 11p13 and 11p15.5 do not predict survival in non-small cell lung cancer. Clin Cancer Res 1997;3:1229-1235.

- Barnadas A, Mendiola C, Casado A, Villlar A, Jimeno J, Clerigue M, Rosell R, Diaz-Rubio E, Cortes-Funes H, Garcia de Paredes M. Combination of oral idarubicin and pednimustine in advanced breast cancer: a phase II study. Eur J Cancer 1997;33:312-315.

- Rosell R, Pifarré A, Monzó M, Astudillo J, López-Cabrerizo MP, Calvo R, Moreno I, Sanchez-Cespedes M, Font A, Navas-Palacios JJ. Reduced survival in patients with stage I non-small cell lung cancer associated with DNA-replication errors. Int J Cancer (Predictive Oncology) 1997;74:330-334.

- Rosenfeld MR, Malats N, Schramm L, Graus F, Cardenal F, Viñolas N, Rosell R, Torà M, Real FX, Posner JB, Dalmau J. Serum anti-p53 antibodies and prognosis of patients with small cell lung cancer. J Natl Cancer Inst 1997;89:381-385.

- Rosell R, López-Cabrerizo MP, Maurel J, Calvo R, Martin C, Martinez-Roca M. Detección por tomografía de emisión de positrones de enfermedad residual en cáncer de pulmón. Med Clin (Barc) 1997 (in press).

- Aldea AI, Barnadas A, Tarrat A, Vaquero M, Muñoz C, Krugger M, Monzó M, Rosell R. Análisis de la longitud telomérica en el carcinoma epitelial de ovario. Med Clin (Barc) 1997 (in press).

- Ribelles N, Barnadas A, Lopez D, Vaquero M, Rosell R. Validation of breast cancer prognostic factors. Oncol Rep 1997

- DeAnta JM, Jassem E, Rosell R, Martínez-Roca, Jassem J, Martínez-López E, Monzó M, Sánchez-Hernández JJ, Moreno I, Sánchez-Céspedes M. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene 1997;15:2951-2958.

- Sánchez-Céspedes M, Monzó M, Rosell R, Pifarré A, Calvo R, López-Cabrerizo MP, Astudillo J. Detection of chromosome 3p alterations in serum DNA of non-small cell lung cancer patients. Ann Oncol 1998;9:113-116.

- Rosell R, Felip E, Massuti B, González-Larriba JL, Benito D, López-Cabrerizo MP, Salamanca O, Camps C, Puerto-Pica J. A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer. Semin Oncol 1997;24(Suppl 12):S12-56-S12-60.

- Martinez-Lopez E, Abad A, Font A, Monzó M, Ojanguren I, Pifarré A, Sánchez JJ, Martín C, Rosell R. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998;114:1180-1187.

- Rosell R, López-Cabrerizo, Martín C. Lung cancer: defeatist attitudes versus optimistic reality. Euro Hosp Pharm J 1998;4 (Suppl 1):9-13.

- Calvo R, Pifarré A, Rosell R, et al. H-RAS 1 minisatellite rare alleles: a genetic susceptibility and prognostic factor for non-Hodgkin's lymphoma. J Nat Cancer Inst 1998;90:1095-1098.

- Felip E, Massuti B, Camps C,...Rosell R. Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two phase II trials. Clin Cancer Res 1998;4:2723-2728.

- Rosell R, Tonato M, Sandler A. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer. Semin Oncol 1998;25 (Suppl 9):27-34.

- Rosell R. The integration of newer agents into neoadjuvant therapy. Semin Oncol 1998;25 (Suppl 8):24-27.

- Rosell R. Tentative studies in non-small cell lung cancer in Japan and Spain. Jap J Clin Oncol 1998; 28(8):521-522.

- Antón A, Díaz-Fernández N, González-Larriba JL, Rosell R. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer 1998;22:139-148

INVITED LECTURES AT SCIENTIFIC MEETINGS

2008

- Rosell R. "Customizing erlotinib based on EGFR mutations EURTAC-SLCG (GECP 06/01)" Joint Spanish-French Meeting, Paris, France, 18th January 2008

- Rosell R. "QPCR-based gene signatures for predicting survival in stage I NSCLC" Joint Spanish-French Meeting, Paris, France, 18th January 2008

- Rosell R. "Moving from ASCO 2008 to the SCAT and BREC studies based on BRCA1 mRNA expression" Joint Spanish-French Meeting, Paris, France, 18th January 2008

- Rosell R. "Moving from ASCO 2008 to the SCAT and BREC studies based on BRCA1 mRNA expression" BREC Meeting, Madrid, Spain, 31st January 2008

- Rosell R. "Moving from ASCO 2008 to the SCAT and BREC studies based on BRCA1 mRNA expression" Badalona, Spain, 4th February 2008

- Rosell R. Presidential Session: "Adjuvant treatment of NSCLC" 19th International Congress of AntiCancer Treatment (ICACT), Paris, France, 5-8 February 2008

- Rosell R. "Spanish Lung Adenocarcinoma Trial (SLAT) of customized treatment based on EGFR mutations and BRCA1 mRNA expression: ancillary analysis of Abraxas and RAP80 expression" 19th International Congress of AntiCancer Treatment (ICACT), Paris, France, 5-8 February 2008

- Rosell R. "Aproximación farmacogenómica del cancer del pulmón" 10th Simposium Revisiones en Cancer, Madrid, Spain, 14th February 2008

- Rosell R. "Moving from Empiric Chemotherapy to Treatment Customization in Cancer, Looking for answers…" Personalized Genomics for Cancer Patient Care, Pangaea Biotech Meeting, Barcelona, 15th February 2008

- Rosell R. "Predictors of Response to Chemotherapy: Our Current Knowledge" EACTS Thoracic Oncology Meeting, Milan, Italy, 5th March 2008

- Rosell R. "Personalized Genomics for Lung Cancer Management" 1ª Giornata Forlivese di Pneumo-Oncologia, Rimini, Italy, 7th March 2008

- Rosell R. "NSCLC: Early disease management through personalized genomics" 9th European Congress: Perspectives in Lung Cancer, Turin, Italy, 14th March 2008

- Rosell R. "Moving Towards Genomics for Personalized Lung Cancer Care" Percorso Terapeutico nel Carcinoma Polmonare, Verona, Italy, 15th March 2008

- Rosell R. "Farmacogenética en el cancer del pulmón" Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 28th March 2008

- Rosell R. "Evolución del tratamiento del cáncer de pulmón en la última década" Reunión Nacional de Lanzamiento de Avastin en Cancer de Pulmón No Microcítico, Córdoba, Spain, 3rd-4th April 2008

- Rosell R. "DNA Repair and Angiogenesis in NSCLC". Rompiendo barreras en CPNM, Cordoba, Spain, 4th April 2008

- Rosell R. "Underlying Global Changes in Gene Expression and Prognostic Significance" University of Messina, Taorima, Sicily, Italy, 18th April 2008

- Rosell R. "Moving from empiric chemotherapy to treatment customization in lung cancer" Caratterizzazione biologica e terapia dei tumori solidi. Carcinoma mammario e carcinoma polmonare, Taorima, Sicily, Italy, 19th April 2008

- Rosell R. "Abraxas and RAP80 expression in the Spanish Lung Adenocarcinoma Trial (SLAT) of customized treatment based on EGFR mutations (MUT) and BRCA1 mRNA expression". 1st European Lung Cancer Conference, Geneva, Switzerland, 23rd - 26th April 2008

- Rosell R. "Histone Deacetylase Inhibitors: Rationale and Current Evidence in Lung Cancer and Mesothelioma". New Therapeutic Targets in Thoracic Malignancies, MSD Oncology Scientific Symposium, Geneva, 26th April 2008

- Rosell R. "The Role of the IGF-1R Inhibitor in NSCLC". New Therapeutic Targets in Thoracic Malignancies, MSD Oncology Scientific Symposium, Geneva, 26th April 2008

- Rosell R. "Adjuvant Treatment of NSCLC: Underlying changes in gene expression and
- prognostic significance. QPCR-based gene signatures for predicting survival in stage I NSCLC" XI Reunion Club de Cirujanos Toracicos, Mallorca, Spain, 9th May 2008

- Rosell R. "Are we near to having markers for choosing cytotoxic therapy in NSCLC?" Translating New Developments in Solid Tumors into Clinical Practice. EORTC Solid Tumors Course, Barcelona, Spain, 10th May 2008

- Carrato. C, Balañá. C, Musulen. E, Sanz. C, Berdiel. M, Ramirez. J.L, Sanchez. J.J, Teixidor. P, Rosell. R, Ariza. A "MGMT protein expression and MGMT promoter methylation status in a series of 64 glioblastomas". Poster discussion, 3rd Intercontinental Congress of Pathology, Barcelona, May 17th - 22nd 2008

- Rosell R. "The EURTAC and SLADB. Background and Rationale" EUTRAC Investigators' Meeting, Madrid, Spain, 22nd May 2008

- Rosell R. "Underlying global changes in gene expression and their predictive and prognostic significance in lung cancer" Master Medicina Respiratoria, Hospital Clinic, Barcelona, Spain, 23rd May 2008

- Rosell R. "Underlying global changes in gene expression and their prognostic significance" Emory – Winship Cancer Institute, Atlanta, U.S.A, 29th May 2008

- Rosell R. "Molecular biomarkers of taxane sensitivity and resistance" Personalizing the treatment of solid malignancies with taxane-based therapies. ASCO Annual Meeting, Chicago, U.S.A, 30th May 2008

- Rosell R. "Looking for Answers for Targeted Therapies" 5th European Spring Oncology Conference, Marbella, Spain, 27th June 2008

- Rosell R. "Interchromosomal interactions, gene expression and chemotherapy response". IV Educational Symposium & Plenary Session of the Spanish Lung Cancer Group, Zaragoza, Spain, 27th-29th June 2008

- Rosell R. "Individualizing Therapy: Relevance of Cancer Biology for Appropriate Treatment" Desarrollo Sostenible en Oncología, Zaragoza, Spain, 28th June 2008

- Rosell R. "Replacing Empiric Chemotherapy with BRCA1-Based Customized Chemotherapy" Medical Oncology Workshop, Pangaea Biotech, Dexeus Institute, Barcelona, Spain, 3rd-4th July 2008

- Rosell R. "Looking for Answers for Targeted Therapies" Medical Oncology Workshop, Pangaea Biotech, Dexeus Institute, Barcelona, 3rd-4th July 2008

- Rosell R. "New small molecule inhibitors", 1st International Lung Cancer Conference, Translating Basic Science into Clinical Practice, Liverpool, U.K, 11th July 2008

- Sanz. C, Ramirez. J.L, Ruiz-Xivillé. N, Carrato. C, Granada. I, Millá. F, Ariza. A, Rosell. R, Villá. S, Balañá. C "Realationship and prognostic value of MGMT (06-methyl-DNA-methyltransferase) gene promoter methylation, amplification of EGFR (A-EGFR) and EGFRvIII mutation in a series of Glioblastoma (GB) patients". Poster, 8th EANO Meeting, Barcelona, 12th – 14th September 2008

- R. Rosell. "Profiling new targets in oncology research. An overview". Emerging therapeutic targets in oncology research: Current and future directions. MSD Oncology Satellite Symposium 33rd ESMO Congress, Stockholm, Sweden, 12-16 September 2008.

- Rosell R. "Significant benefits in NSCLC from customizing erlotinib treatment" ESMO PRESS CONFERENCE. 33rd ESMO Conference, Stockholm, Sweden, 12-16th September 2008.

- R. Rosell. "Lung Cancer and Mesothelioma: The role of histone deacetylase and the IGF-1R inhibitors". Emerging therapeutic targets in oncology research: Current and future directions. MSD Oncology Satellite Symposium 33rd ESMO Congress, Stockholm, Sweden, 12-16 September 2008.

- Rosell R. "Customizing Chemotherapy based on BRCA1 Expression in Advanced NSCLC". 7th Kazusa Akademia Respiratory Forum, 6th Chiba International Workshop on Lung Cancer – Frontiers of Lung Cancer, Chiba, Japan, 20th September 2008

- Rosell R. "Customizing Chemotherapy based on BRCA1 Expression in Advanced NSCLC". Drum Tower Hospital, Nanjing, China, 22nd September 2008

- Rosell R. "VEGF-Trap in Advanced NSCLC including Squamous Cell Carcinoma, and Gastric Cancer". Drum Tower Hospital, Nanjing, China, 23rd September 2008

- Rosell R. "Farmacogenética en el cáncer de pulmón" Compostelan Cancer Conference, Santiago de Compostela, Spain, 24th September 2008

- Rosell R. "An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA) for Patients With Recurrent Non-Small Cell Lung Cancer". Ph I Safety Assessment Phase Preliminary Results, MERK, Barcelona, Spain, 25th September 2008

- R. Rosell. "Burning issues in systemic therapy for NSCLC: customized chemotherapy". Symposium 7th Scientific and Educational Conference on Lung Cancer, Gdansk, Poland. Friday, 3rd October 2008

- R. Rosell. "Molecular predictors of anti-EGFR therapy: Gene mutations". Plenary Session, 7th Scientific and Educational Conference on Lung Cancer, Gdansk, Poland. Saturday, 4th October 2008

- Rosell R. "Towards Molecular Models for Personalized Anti-Cancer Intervention" Toulouse, France, 8th October 2008

- Rosell R. "DNA repair machinery" Non-Small-Cell Lung Cancer: An Update, Orbassano, Italy, 21st October 2008

- Rosell R. "Personalized Cancer Therapies for Non-EGFR-Dependent Tumors" Santiago de Compostela, Spain, 29th October 2008

- Rosell R. "EGFR mutations in tissue and in serum DNA from stage IV non-small-cell lung cancer patients prospectively treated with erlotinib". ASCO-NCI-EORTC Annual Meeting on Molecular Markers. Cancer Press Program. October 30- November 1, 2008, Hollywood, Florida

- Rosell R. "Adjuvant Treatment of NSCLC" First International Thoracic Oncology Conference, Riyadh, Saudi Arabia, 13th November 2008

- Rosell R. "Customization of Therapy: A Personalized Approach" First International Thoracic Oncology Conference, Riyadh, Saudia Arabia, 13th November 2008

- Rosell R. "Personalized Therapies for Non-EGFR-Dependent Tumors: Interchromosomal interactions, gene expression and chemotherapy response" IV SLCG Educational Symposium, Zaragoza, Spain, 20th 21st November 2008

2007

- Rosell R. Co-President for the 2nd Messina Conference on Cancer Pharmacogenomics. Opening Lecture: "Molecular understanding of lung cancer: A need for correct treatment" Messina, Italy, January 25-27, 2007

- Rosell R. " How to individualize systemic therapy" Krebskommission Symposium: Non-Small Cell Lung Cancer – Towards an Integrated Approach to Diagnosis and Therapy, Zurich, Switzerland, February 1, 2007

- Rosell R. "Understanding of lung cancer at the molecular level: impact on treatement" 18th International Congress on Anti Cancer Treatment, Paris, France, February 6-9, 2007

- Rosell R. "Spanish Trial in untreated patients" 7th Annual Targeted Therapies for the Treatment of Lung Cancer Conference, Santa Monica CA, USA, February 22-24, 2007

- Rosell R. "Genetic predisposition to lung cancer: Can we identify a high-risk group?" 8th European Perspectives in Lung Cancer, Seville, Spain, March 2-3, 2007

- Rosell R. "Systemic therapy for advanced disease: Selecting chemotherapy" ESMO International Symposium, Geneva, Switzerland, March 30-April 1, 2007

- Queralt C, Mayo C, Pradas A, Molina MA, Reguart N, Ramirez JL, Salazar F, de Aguirre I, Taron M, Rosell R. Abstract oral presentation: "High correspondence between EGFR mutations in tissue and in circulating DNA from non-small-cell lung cancer patients with poor performance status" Annual Meeting 2007, American Association for Cancer Research (AACR), Los Angeles, CA USA, April 14 -18, 2007

- Rosell R. "Single agent docetaxel" International Experts Panel Conference: Second-line Treatment of Advanced NSCLC, Naples, Italy, April 17, 2007

- Rosell R. "Retos de la Investigación: Cáncer de pulmón" El Desafío Oncológico,Valencia, Spain, April 19, 2007

- Rosell R. "A three-gene signatura predicts survival in early-stage squamous cell lung cancer patients" X Reunión del Club de Cirujanos Torácicos, Bilbao, Spain, April 27-29, 200

- Rosell R. "Molecular markers as predictors of tumor response and survival in lung cancer" Eli Lilly Belgium Lecture Tour, Charleroi & Liège, Belgium, May 9-10, 2007

- Moran T, Paz-Ares L, Isla D, Cobo M, Massuti B, Insa A, Queralt C, Pradas A, Taron M, Rosell R. Clinical Science Symposium: "High correspondence between EGFR mutations in tissue and in circulatin DNA from non-small-cell lung cancer patients with poor performance status" American Society of Clinical Oncology 43rd Annual Meeting, Chicago IL, USA, June 1-5, 2007. Proc ASCO 2007;25:18S (abstr 7505)

- Rosell R. "Induction chemotherapy for NSCLC stage 1" Corso Internazionale di Aggiornamento: Cancro del Polmone in Stadio Precoce (Early Lung Cancer), Varese, Italy, June 14-15, 2007

- Rosell R. "ERCC1/RRM1" VIIIth International Lung Cancer Congress, Wailea, Maui, Hawaii, June 27-30, 2007
- Rosell R. "The predictive and prognostic roles of ERCC1expression and Akin DNA repair genes in non-small-cell lung cancer" Oral Presentation, Educational Session, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Felip E, Rosell R, Massuti B, Alonso G, Gonzalez-Larriba JL, Camps C, Isla D, Mas C, Sanchez JJ, Maestre JA. "The NATCH trial: chemotherapy toxicity and response on the neoadjuvant arm" Oral Presentation, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Garrido P, Arellano A, Massutí B, Andreu J, Juan O, Amador R, Cardenal F, Arnaiz D, Ramos A, Rosell, R. "Randomized phase II trial using concomitant chemoradiation plus induction or consolidation chemotherapy for unresectable stage III non-small cell lung cancer patients. Mature results of the SLCG 0008 study" Oral Presentation, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Domine M, Camps C, de las Peñas R, Garcia Campelo R, Viñolas N, Terrasa J, Pérez-Cano M, Sánchez JJ, Tarón M, Rosell R. "Excision repair cross complementing 6 single nucleotide polymorphism and outcome to gemcitabine/ cisplatin or docetaxel/cis in stage IV non-small-cell lung cancer patients" Oral Presentation, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Massuti B, Benlloch S, Galbis J, Alenda C, Mafe JJ, Marci JL, Perio FM, Rosell R, Rodriguez Paniagua JM, Taron M. "Potential role of molecular markers expression to improve mediastinal nodes staging from resected stage I non-small cell lung cancer" Oral Presentation, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007

- Rosell R, Jassem E, Skrzypski M, Taron M, Mendez P, Roca LP, Szymanowska A, Rzyman W, Gulida GK, Jassem J. "Increased BRCA1 mRNA: an independent prognostic variable in completely resected chemonaive non-small-cell lung cancer patients" Oral Presentation, 12th World Conference on Lung Cancer, Seoul,

Korea, September 2-6, 2007

- Rosell R, Molina MA, Moran T, Reguart N, Taron M. "Management of lung cancer based on genetic abnormalities – easy and practical for patients and oncologists". Oral Presentation, ECCO-14 The European Cancer Conference, Barcelona, Spain, September 23-27, 2007

- Rosell R, Jassem E, Skrzypski M, Taron M, Bartolucci R, Mendez P, Perez-Roca L, Rzyman W, Puma F, Jassem J. "A prognostic model based on BRCA1 mRNA expression: a new determinant of outcome in early non-small-cell lung cancer" Invited Speaker, Educational Session, ECCO-14 The European Cancer Conference, Barcelona, Spain, September 23-27, 2007

- Rosell R, Molina MA, Moran T, Reguart N, Taron M. "Management of lung cancer based on genetic abnormalities – easy and practical for patients and oncologists." Invited Speaker, Educational Session, ECCO-14 The European Cancer Conference, Barcelona, Spain, September 23-27, 2007

- Rosell R, Jassem E, Skrzypski M, Taron M, Bartolucci R, Mendez P, Perez-Roca L, Rzyman W, Puma F, Jassem J. "A prognostic model based on BRCA1 mRNA expression: a new determinant of outcome in early non-small-cell lung cancer." Oral Presentation, ECCO-14 The European Cancer Conference, Barcelona, Spain, September 23-27, 2007

- M Taron, JL Ramírez, F. Salazar, M. Berdiel, R. Rosell. "Tumour and serum predictive markers of response to bevazizumab." Invited Speaker, Educational Session, ECCO-14 The European Cancer Conference, Barcelona, Spain, September 23-27, 2007

- Jimeno J, Schoffski P, Casal P, Grosso F, Judson I, Scurr M, Blay JY, Maki R, LeCesne A, Rosell R. "Personalized therapy with trabedectin (Yondelis) in advanced pre-treated sarcomas". Poster, ECCO 14 The European Cancer Conference, Barcelona, Spain, September 23-27, 2007.

- Garrido P, Massuti B, Jiménez A, Samper P, Mesia C, Rodríguez N, Lianes P, Arellano A, Ramos A, Rosell R. "Randomized phase II Trial using concomitant chemoradiation plus induction or consolidation chemotherapy for unresectable stage III non-small cell lung cancer patients. Mature results of the SLCG 0008 study." Oral Presentation, ECCO-14 The European Cancer Conference, Barcelona, Spain, September 23-27, 2007.

- Rosell R. "Cáncer de pulmón: Tratamiento de la enfermedad avanzada basado en el perfil genómico" XI Congreso Nacional, Sociedad Española de Oncología Médica (SEOM), Madrid, Spain, October 3-5, 2007

- Rosell R. Co-Chair, Summit 07, Bonnie J. Addario Lung Cancer Foundation, San Francisco, CA USA, November 9-10, 2007

2006

- Rosell R. "Pharmacogenomics in NSCLC: Is it time for customized therapy?" V Congreso Andino, Centroamericano y del Caribe de Oncología Clínica, Cuzco, Peru, February 4, 2006

- Rosell R. "Aproximación farmacogenómica del cáncer de pulmón" VII Simposio de Revisiones en Cáncer, Madrid, Spain, February 9, 2006

- Rosell R. "Aplicación de la genómica en el diseño del tratamiento del cáncer" 1ª Reunión Internacional sobre Investigación Trasnacional y Medicina Individualizada, Madrid, Spain, February 9, 2006

- Rosell R. "Pharmacogenomics in clinical practice" Lilly Oncology Regional Medical Conference, Rome, Italy, February 17-19, 2006

- Rosell R. "Perspectives in the treatment of lung cancer patients: customized chemotherapy and pharmacogenomics" Lettura magistrale, La chemioterapia del carcinoma del polmone non a piccolo cellule "early-stage": strategie a confronto, Istituto Nazionale Tumori Regina Elena, Roma, Italy, March 2-3, 2006

- Rosell R. "Selección personalizada: el modo iodóneo de tratamiento del cáncer de pulmón" Experiencias actuales y aplicaciones prácticas en farmacogenética y farmacogenómica, Recoletos Conferencia y Formación, Madrid, Spain, March 9, 2006

- Rosell R. "Perspectiva desde la investigación clínica" II Reunión Nacional de Investigación Clínica y Traslacional en Oncología Médica, SEOM-Grupos Cooperativos, Madrid, Spain, March 16-17, 2006

- Rosell R. "Tailored chemotherapy in lung cancer: Lessons from the pre-Genotypic International Lung Trial (GILT), 4th Annual Atlanta Lung Cancer Symposium, Atlanta Georgia USA, March 24-25, 2006

- Rosell R. "Molecular tailoring nel trattamento chemioterapico del NSCLC" XII Conferenca Nazionale Associazione Italiana de Oncologia Medica (AIOM), Rome, Italy, March 29-31, 2006

- Rosell R. "Estudio TARGET: Análisis de mutaciones en 1ª linea de tratamiento" Del Laboratorio a la Clínica: Nuevo Enfoque en el Tratamiento del Cáncer de Pulmón, Madrid, Spain, April 21, 2006

- Rosell R. "Biology of NSCLC Workshop" Interactive Lung Cancer Conference, Lisbon, Portugal, May 6-7, 2006

- Rosell R. "Role of molecular markers in individualised therapy of unresectable NSCLC" The XL Middle East Medical Assembly (MEMA), Beirut, Lebanon, 11 May, 2006

- Rosell R. "Usefulness of predictive tests for cancer treatment" Centenary of the French Cancer Society, Bordeaux, France, 18-19 May, 2006

- Rosell R, Taron M, Reguart N, Lopez-Rios F, Paz-Ares L, Ramirez JL, Massuti B, Cuello M, Jablons D. Oral Presentation: "Pharmacogenomics comes of age in selecting patients for lung cancer treatment" American Society of Clinical Oncology 42nd Annual Meeting, Atlanta GE, USA, 2-6 June 2006

- Tiseo M, Boni L, Rosell R, Fossella FV, Schiller JH, Paesmans M, Radosavijevic D, Paccagnella A, Mazzanti P, Bisset D. Oral Presentation: "CISCA (cisplatin vs. carboplatin) meta-analysis: an individual patients data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small celll lung cancer" American Society of Clinical Oncology 42nd Annual Meeting, Atlanta GE, USA, 2-6 June 2006. Proc ASCO 2006;24:18S (abstr 7011)

- Paz-Ares L, Sanchez JM, Garcia-Velasco A, Massuti B, Lopez-Vivanco G, Provencio M, Montes A, Isla D, Amador ML, Rosell R; Spanish Lung Cancer Group. Oral Presentation: "A prospective phase II trial of erlotinib in advanced non-small cell lung cancer patients with mutations in the tyrosine kinase domain of the epidermal growth factor receptor" American Society of Clinical Oncology 42nd Annual Meeting, Atlanta GE, USA, 2-6 June 2006. Proc ASCO 2006;24:18S (abstr 7020)

- Sirera R, Camps C, Llobat L, Berrocal A, Bremnes RM, Blasco A, Juarez A, Taron M, Sanchez JJ, Rosell R. Poster Discussion: "The quantification of the catalytic subunit of telomerase in lasma is a prognostic factor in advanced non-small cell lung cancer patients" American Society of Clinical Oncology 42nd Annual Meeting, Atlanta GE, USA, 2-6 June 2006. Proc ASCO 2006;24:18S (abstr 7052)

- Taron M, Alberola V, Lpez-Vivanco G, Camps C, De las Peñas R, Alonso G, Provencio M, Salvatierra A, Sanchez J, Rosell R. Poster Discussion: "Excision cross-complementing group 1 single nucleotide olymorphisms and survival in cisplatindocetaxel-treated stage IV non-small cell lung cancer patients: a Spanish Lung Cancer Group study" American Society of Clinical Oncology 42nd Annual Meeting, Atlanta GE, USA, 2-6 June 2006. Proc ASCO 2006;24:18S (abstr 7053)

- Rosell R, Alberola V, Camps C, Lopez-Vivanco G, Moran T, Etxaniz O, De las Peñas R, Gupta J, Taron M, Sanchez J. Poster Discussion: "Clinical outcome of gemcitabine/cisplatin- vs docetaxel/cisplatin-treated stage IV non-small cell lung cancer patients according to X-ray repair cross-complementing group 3 polymorphism and age" American Society of Clinical Oncology 42nd Annual Meeting, Atlanta GE, USA, 2-6 June 2006. Proc ASCO 2006;24:18S (abstr 7055)

- Isla D, Salazar F, Ramirez J, Sanchez Ronco M, Cobo M, Mones A, Sanchez J, Catot S, Taron M, Rosell R. Poster Discussion: "Mitotic checkpoint gene CHFR methylation in pretreatment serum DNA of docetaxel/cisplatin-treated stage IV non-small cell lung cancer patients" American Society of Clinical Oncology 42nd Annual Meeting, Atlanta GE, USA, 2-6 June 2006. Proc ASCO 2006;24:18S (abstr 7056)

- Schoffski P, Casali PG, Taron M, Van oosterom AT, Judson IR, Grosso F, Blay JY, Maki RG, Tercero JC, Jimeno JM, Rosell R. Poster Discussion: "DNA repair functionality modulats the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743)" American Society of Clinical Oncology 42nd Annual Meeting, Atlanta GE, USA, 2-6 June 2006. Proc ASCO 2006;24:18S (abstr 9522)

- Garrido Lopez P, Isla D, Gil B, Lopez-Brea M, Lianes P, Gonzalez Larriba J, Medina B, Sanchez Ronco M, Taron M, Rosell R. General Poster Session: "Efficacy and pharmacogenomic correlation of the combination of oxaliplatin and paclitaxel in first line advanced non-small cell lung cancer. Preliminary results of the Spansh Lung Cancer Group 0103 phase II trial." American Society of Clinical Oncology 42nd Annual

Meeting, Atlanta GE, USA, 2-6 June 2006. Proc ASCO 2006;24:18S (abstr 7022)

- Santarpia M, Altavilla G, Margeli M, Mesiti M, Cavaliari V, Cirauqui B, Reguart N, Barnadas A, Taron M, Rosell R. General Poster Session: "PIK3CA mutations in breast cancer: a potential predictive marker" American Society of Clinical Oncology 42nd Annual Meeting, Atlanta GE, USA, 2-6 June 2006. Proc ASCO 2006;24:18S (abstr 639)

- Rosell R. "DNA Methylation of BRCA1 and BRCA2 in serum and tumor of NSCLC patients" IV European Spring Oncology Conference (ESOC), Marbella, Spain, 16 June, 2006

- Rosell R. Chairperson: "Clinical Trials of EGFR-TKI" Molecular Targeted Therapy in Metastatic NSCLC, 2nd WJTOG International Symposium on Lung Cancer Clinical Trials, Nara, Japan, 6-8 July 2006.

- Rosell R. "Biomarkers & Clinical Trials" 2nd WJTOG International Symposium on Lung Cancer Clinical Trials, Nara, Japan, 6-8 July 2006

- Rosell R. "¿Qué hacer en caso de progresión de erlotinib en pacientes con mutaciones del gen EGFR?" Tarceva Erlotinib de la Mano del Experto, Barcelona, Spain, 13 July, 2006

- Rosell R. "A look at the future of lung cancer therapy" 7th European Perspectivas in Lung Cancer Conference, Athens, Greece, 8-9 September, 2006

- Rosell R. "Clinical trial methodology for molecular targeted therapy" CSCO-ASCO-ESMO Joint Symposium: Targeted Therapy in Oncology, 7th International Conference of the Asian Clinical Oncology Society (ACOS) & 9th Annual Meeting of Chinese Society of Clinical Oncology (CSCO), Beijing, China, 14-18 September, 2006
- Rosell R. "Molecular markers as predictive of tumor response and survival in lung cancer" Cours de Groupe d'Oncologie Throacique de Langue Française (GOLF), Limoges, France, 18-21 September 2006

- Rosell R. "Pharmacogenomics as a way to improve the efficacy of cytotoxic chemotherapy" 2nd IASLC International Workshop: Early Invasive Lung Cance, New Diagnostic Tools & Treatment Strategies, Turín, Italy, 24-26 September 2006

- Rosell R. Presidential Symposium (Awarded Certificate of Merit): "Customizing cisplatin based on quantitative excision repair cross-complementing 1 (ERCC1) mRNA expression: a phase III randomized trial in non-small-cell lung cancer" 31st European Society for Medical Oncology (ESMO) Congress, Istanbul, Turkey, 29 September – 3 October 2006
- *** Awarded Certificate of Merit***

- Camps C, Domine M, Alberola V, Alonso G, Arta A, Gonzalez Larriba JL, Gracia Gomez R, Baron-Duarte FJ, Pujol-Obis E, Rosell R. Oral Presentation: "Clinical outcome of gemcitabine/cisplatin vs docetaxel/cis vs doc/gem-treated stage IV non-small-cell lung cancer patients according to X-ray repair cross-complementing group 3 (XRCC3) polymorphism and age" 31st European Society for Medical Oncology (ESMO) Congress, Istanbul, Turkey, 29 September – 3 October 2006

- Massuti B, Reguart N, Lopez Vivanco G, Provencio M, Isla D, Camps C, Paz Ares L, Pradas A, Taron M, Rosell R. Oral Presentation: "First-line erlotinib in stage IV non-small-cell lung cancer patients with mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EFGR)" 31st European Society for Medical Oncology (ESMO) Congress, Istanbul, Turkey, 29 September – 3 October 2006

- Porta R, Terrasa J, Rolfo C, Gonzalez Larriba JL, Garcia Campelo R, Mesia C, Pallares C, Lianes P, Queralt C, Rosell R. Oral Presentation: "Deciding on second- or third-line erlotinib in stage IV non-small-cell lung cancer patients based on the presence of mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR)" 31st European Society for Medical Oncology (ESMO) Congress, Istanbul, Turkey, 29 September – 3 October 2006

- Sirera R, Camps C, Munoz-Navarro M, Blasco A, Safont MJ, Iranzo V, Berrocal A, Taron M, Rosell R, Alberola V. Poster Discussion: "Htert quantification in serum is a useful prognostic factor in advanced non-small cell lung cancer patients" 31st European Society for Medical Oncology (ESMO) Congress, Istanbul, Turkey, 29 September – 3 October 2006

- Isla D, Felip E, Garrido P, Viñolas N, Lianes P, Garcia-Campelo R, Sanchez JJ, Alberola V, Camps C, Rosell R. Poster Discussion: "Women with advanced non-small cell lung cancer participating in first-line Spanish Lung Cancer Group trials. Analysis of characteristics and treatment outcomes compared to men" 31st European Society for Medical Oncology (ESMO) Congress, Istanbul, Turkey, 29 September – 3 October

2006

- Salazar F, Cobo M, Ramlau R, Massuti B, Cardenal F, Provencio M, Viñolas N, Lopez Vivanco G, Muñoz MA, Rosell R. Poster: "Mitotic checkpoint gene CHFR methylation in pre-treatment serum DNA of docetaxel/cisplatin-treated stage IV non-small-cell lung cancer patients" 31st European Society for Medical Oncology (ESMO) Congress, Istanbul, Turkey, 29 September – 3 October 2006

- Provencio M, Izquierdo A, Viñolas N, Paz-Ares L, Feliu J, Constenia M, de las Heras B, Erustes M, Izquierdo MA, Rosell R. Poster: "Phase II clinical trial of Kahalalide F as a second line therapy in patients with advanced non-small cell lung cancer" 31st European Society for Medical Oncology (ESMO) Congress, Istanbul, Turkey, 29 September – 3 October 2006

- Gavila J, Camps C, Sirera R, Safont M, Blasco A, Caballero C, Muñoz-Navarro M, Taron M, Alberola V, Rosell R. Poster: "Correlation of nerbe growth factor serum level and clinical outcome in patients with advanced non-small cell lung cancer" 31st European Society for Medical Oncology (ESMO) Congress, Istanbul, Turkey, 29 September – 3 October 2006

- Sirera R, Camps C, Munoz-Navarro M, Gavila J, Blasco A, Safont MJ, Iranzo V, Taron M, Alberola V, Rosell R. Poster: "Analysis of the prognostic value of serum vascular endothelial growth factor and basic fibroblast growth factor in advanced non-small cell lung cancer" 31st European Society for Medical Oncology (ESMO) Congress, Istanbul, Turkey, 29 September – 3 October 2006

- Rosell R. "European early stage lung cancer clinical trial update" 3rd International Pan Pacific Lung Cancer Conference in conjunctin wih the 3rd China North and South Lung Cancer Summit, Shanghai, China, 12-15 October 2006

- Rosell R. "Update on pharmacogenomic treatment in lung cancer" 3rd International Pan Pacific Lung Cancer Conference in conjunctin wih the 3rd China North and South Lung Cancer Summit, Shanghai, China, 12-15 October 2006

- Rosell R. "Cáncer de pulmón en pacientes añosos: Buenas noticias en hallazgos moleculares" Congreso Internacional de Oncologia del Interior, Cordoba, Argentina, 2-4 November 2006

- Rosell R. Sesión plenaria: "Recomendaciones en el tratamiento de cáncer de pulmón" Congreso Internacional de Oncologia del Interior, Cordoba, Argentina, 2-4 November 2006

- Rosell R. "Erlotinib in EGFR mutation positive patients" 3rd IASLC/ASCO/ESMO International Conference on Targeted Therapies in Lung Cancer, Taormina, Sicily, Italy, 8-12 November 2006

- Rosell R. "Lesson from ERCC1 mRNA studies in advanced disease" 3rd IASLC/ASCO/ESMO International Conference on Targeted Therapies in Lung Cancer, Taormina, Sicily, Italy, 8-12 November 2006

- Rosell R. Special Lecture: "A uniform management of patients based on genetic abnormalities in lung cancer – easy to understand for patients and practical for oncologists" Plenary Session & 3rd Educational Symposium of the Spanish Lung Cancer Group, Madrid, Spain, 16-17 November 2006

- Rosell R. "Predictive medicine/pharmacogenomic approaches to advanced stage lung cancer" 8th Annual UCSF/UC Davis Thoracic Oncology Conference, San Francisco, California USA, 18 November 2006

- Rosell R. "Molecular understanding of lung cancer: A need for correct treatment" CNIO Symposium on Molecular Markers in Cancer Therapy: Present Use and Future Perspectives, Madrid, Spain, 27-29 November 2006

- Rosell R. "Preliminary pharmacogenomic results of the ANITA trial" Meeting Internazionale di Oncologia Toracica: Lo stato dell'arte alla fine del 2006, Bari, Italy, 30 November 2006

2005

- Rosell R. "The potential for cetuximab in NSCLC" 3rd Annual British Thoracic Oncology Group (BTOG) Meeting, Dublin, Ireland, January 26-29, 2005

- Rosell R. "Tratamiento medico del cáncer en el año 2005" VII Simposio de Revisiones en Cáncer, Madrid, Spain, February 9-11, 2005

- Rosell R. "Predictive assays for cancer translational research management" Gene Signatures Symposia '05, Madrid, Spain, March 9, 2005

- Rosell R. "Farmacogenómica, Presente y Future" Simposium Educacional del Grupo Español de Cáncer de Pulmón (GECP), Córdoba, Spain, March 11, 2005

- Rosell R. "Symposium: Retos en investigación clínica, cáncer de pulmón" VI Encuentros en Oncología, Segovia, Spain, March 18, 2005

- Rosell R. "Pre- vs. post-operative therapy: the Spanish experience" 3rd Annual Atlanta Lung Cancer Symposium, Atlanta USA, April 1-2, 2005

- Rosell R. "Pharmacogenomic Strategies" 3rd Annual Atlanta Lung Cancer Symposium, Atlanta USA, April 1-2, 2005

- Rosell R. "El tratamiento individualizado del cáncer del pulmón" II Salón Internacional de la Salud, Santiago de Compostela, Spain, April 13-15, 2005

- Rosell R. "Estado actual de la quimioterapia adyuvante en cáncer de pulmón. Mitos y realidades" VIII Reunión del Club de Cirujanos Torácicos, Sevilla, Spain, April 29 – May 1, 2005

- Rosell R. "EGFR mutations: a crucial biomarker in lung adenocarcinoma" Swiss Tarceva® Launch Symposium, Zurich, Switzerland, April 30, 2005

- Rosell R, Cobo M, Isla D, Massuti B, Montes A, Paz-Ares L, Munoz MA, Vinolas N, Vivasnco GL, Felip E. ERCC1 mRNA-based randomized phase III trial of docetaxel doublets with cisplatin or gemcitabine in stage IV non-small-cell lung cancer patients. American Society of Clinical Oncology 41st Annual Meeting, Orlando FL, USA, May 2005.
  *** Selected for "Best of ASCO" to be presented at Best of ASCO meetings across the USA and Japan.***

- Douillard JY, Rosell R, Delena M, Legroumellec A, Torres A, Carpagnano F. Oral Presentation: ANITA: Phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (stage I-III) non-small-cell lung cancer patients: Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. American Society of Clinical Oncology 41st Annual Meeting, Orlando FL, USA, May 2005. Proc ASCO 2005;23:16S (abstr 7013)

- Sandler A, Rosell R, Wada H. "Global views on adjuvant chemotherapy for non-small cell lung cancer" Clinical Problems in Oncology Case Study, American Society of Clinical Oncology 41st Annual Meeting, Orlando FL, USA, May 2005.

- Rosell R. "NSCLC – Recent Advances" Regional Medical Conference, Lilly Oncology: A decade of progress in oncology – Gezar®, Alimta® and beyond. Orlando, FL, USA, 13 May 2005

- Rosell R. "Desarrollo farmacogenómico de los antimetabolitos" Avances en el Diagnóstico y Tratamiento de los Tumores Torácicos, Sevilla, Spain, June 9-10, 2005

- Rosell R. "Applications of Genomics in NSCLC" Novel Treatmen Strategies for NSCLC, Sanofi Aventis Satellite Symposium, 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005

- Rosell R. The Dr. Dan Ihde Memorial Lecture: "Crossing the rubicon in NSCLC management" 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005

- Rosell R, de Lena M, Carpagnano F, Ramlau R, Gonzalez-Larriba J, Grodzki T, Le Groumellec A, Aubert D, Gasmi J, Douillard J. "ANITA: Phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (stage I-III) non-small cell lung cancer (NSCLC) patients: On behalf of Adjuvant Navelbine International Trial Association" 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 (Pr3)

- Mazieres J, He B, You L, Xu Z, Lee A, Reguart N, Rosell R. "Wnt inhibitory factor-1 (WIF-1) is silenced by promoter hypermethylation in human non-small cell lung cancer". 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 (O-003)

- Garrido P, Rosell R, Torres A, Gonzalez Larriba J, Provencio M, Isla D, Lago J, Astudillo J, Sanchez Ronco M, Taron M. "Docetaxel, cisplatin and gemcitabine as neoadjuvant treatment in stage IIIAN2 and T4N0-1 non-small cell lung cancer patients. Final results of SLCG phase II trial 9901". 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 (O-033)

- De las Peñas R, Camps C, Lopez-Vivanco G, Alonso G, Provencio M, Gonzalez-Larriba J, Artal A, Garcia Gomez R, Viñolas N, Rosell R. "Pharmacogenomic study of docetaxel and cisplatin in patients with non-small cell lung cancer stages IIIb (with malignant pleural effusions) and IV". 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 (O-105)

- Taron M, Santarpia C, Ichinose Y, Mok T, Massuti B, Queralt C, Sanchez J, Jahan T, Jablons D, Rosell R. "Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor and of the platelet-derived growh factor receptor α (PDGFRA) in gefitinib-treated non-small cell lung cancer patients". 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain, July 3-6, 2005 (O-195)

- Rosell R. "Tratamiento individualizado del cancer: importancia de los tests predictivos de respuesta." Jornada Científica del Colegio Oficial de Farmacéuticos de la Provincia de Alicante (COFA), Alicante, Spain, September 8, 2005

- Rosell R. "Pharmacogenomics and gemcitabine." 1st International Conference on Cancer by the National Cancer Institute of Veneto, Monastier, Italy, September 19-21, 2005

- Rosell R. "Report from the International Expert Panel on lung cancer in the elderly." 6th Meeting of the International Society of Geriatric Oncology, Geneva, Switzerland, October 1, 2005

- Rosell R. "Customized EGFR inhibitor therapy based on EGFR mutations in lung adenocarcinoma." 6th SASS International Conference: Molecular Targets for Cancer Therapy, Mallorca, Spain, October 13-15, 2005

- Rosell R. Invited Lecturer: "The key role of pharmacogenomics in customized chemotherapy and targeted therapies." Drug Development & Pharmacogenomics Academy Lecture, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia USA, October 18, 2005

- Rosell R. Invited Special Lecturer: "The Role of EGF Receptor in Lung Cancer." The 21st COE Program, Kurume University International COE Forum 2005, Fukuoka, Japan, November 11, 2005

- Rosell R. "Pharmacogenomics: Clinical Implications." Perspectives in Thoracic Oncology, organized by Lilly Italy, Torino, Italy, 15 November 2005

- Rosell R. "Pharmacogenomy: From concept to clinical practice."Practical Management of Non Small Cell Lung Cancer – European Perspectives, organized by Lilly France, Paris, France, November 17, 2005

- Rosell R. "Pharmacogenomy: Clinical Implications." From The Lecture To The Practice, organized by Lilly Spain, Madrid, Spain, November 21, 2005

- Rosell R. Co-chairperson. "Predictive Medicine."6th Congress on Lung Cancer, organized by the Spanish Lung Cancer Group, Barcelona, Spain, December 1-2, 2005

2004

- Rosell R. "Overview of Chemotherapy & C225 in NSCLC" 2nd Annual British Thoracic Oncology Group (BTOG) Meeting, Dublin, Ireland, January 21-24, 2004

- Rosell R. "Targeting Cytotoxic Chemotherapy" 2nd Annual British Thoracic Oncology Group (BTOG) Meeting, Dublin, Ireland, January 21-24, 2004

- Rosell, R. "Tratamiento Quimoterápico dr Primera Linea." 6th Simposio de Revisiones en Cáncer, Madrid, Spain, February 6, 2004

- Rosell, R. "Molecular Predictors for Choosing Chemotherapy" Targeted Therapies for the Treatment of Lung Cancer Investigatros' Meeting, San Diego, CA, USA, February 19-21, 2004

- Rosell, R. "Pharmacogenomics: Individualizing T reatment for NSCLC: The GILT Trial" 2nd Annual Atlanta Lung Cancer Symposium, Atlanta, USA, March 26-27, 2004.

- Rosell, R. "Pre- vs. Post-Surgery Adjuvant Therapy: The Spanish Experience" 2nd Annual Atlanta Lung Cancer Symposium, Atlanta, USA, March 26-27, 2004.

- Rosell, R. "Molecule-Targeted Therapies: Towards a Carcinoma-Free State" International Consensus Experts Panel on Treatment of Advanced NSCLC in the Elderly, Naples, Italy, April 19, 2004.

- Rosell, R. Keynote Address: "Current Perspectives in the Treatment of NSCLC" 1st WJTOG Inernational Symposium on Lung Cancer Clinical Trial, Nara-Ken, Japan, April 30-May 1, 2004.

- Rosell, R. "European Trials in Molecular Targeted Therapy" 1st WJTOG Inernational Symposium on Lung Cancer Clinical Trial, Nara-Ken, Japan, April 30-May 1, 2004.

- Rosell, R. Chairman / Organizer, First Messina Conference on Cancer Pharmacogenomics, Messina, Italy, May 14-15, 2004.

- Rosell, R. "Tailoring Cancer Therapy" First Messina Conference on Cancer Pharmacogenomics, Messina, Italy, May 14-15, 2004.

- Rosell, R. "Aportación actual de la genómica en el cáncer de pulmón inicial y futuras aplicaciones" Simposium del Grupo Español de Cáncer de Pulmón y del Grupo Gallego de Cáncer de Pulmon, Santiago de Compostela, Spain, May 21, 2004.

- Rosell, R. "Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients with epidermal growth factor receptor(EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)" American Society of Clinical Oncology 40th Annual Meeting, New Orleans LA USA, June 2004.

- Rosell, R. "Chemoresistance mechanisims in NSCLC" Royal Society of Medicine Conference on Lung Cancer, London, U.K., June 16, 2004.

- Rosell, R. "Choice of appropriate chemotherapy based on molecular predictors" 5th International Lung Cancer Congress, Kauai, Hawaii, USA, June 30-July 3, 2004.

- Rosell, R. "EGFR mutations and sensitivity" International Association for the Study of Lung Cancer, EGFR Summit Meeting, Baltimore, USA, July 9-10, 2004.

- Rosell, R. "EGFR mutation data and real-life experiences" 2nd IASLC/ASCO/ESMO International Conference on Molecular Targeted Therapies in Lung Cancer, Algarve, Portugal, September 1-5, 2004.

- Rosell, R. "Individualized therapy of non-small cell lung cancer" International Association for the Study of Lung Cancer (IASLC) 9th Central European Lung Cancer Conference, Gdansk, Poland, September 23-25, 2004.

- Rosell, R. "Pharmacogenomics: The model of lung cancer" 6th National Congress of Italian Association for Medical Oncology, Bologna, Italy, September 21-24, 2004.

- Rosell, R. "SNPs: Overview and translational research trials" Italian Spanish Cooperative Educational Course in Lung Cancer, Barcelona, Spain, September 3-October 2, 2004.

- Rosell, R. "Beyond the tantalizing present: The promising future of targeted therapies" Italian Spanish Cooperative Educational Course in Lung Cancer, Barcelona, Spain, September 3-October 2, 2004.

- Rosell, R. "Essentials of molecular biology & molecular predictors for choosing chemotherapy" Italian Spanish Cooperative Educational Course in Lung Cancer, Barcelona, Spain, September 3-October 2, 2004.

- Rosell, R. "Future of adjuvant treatment in NSCLC" Italian Spanish Cooperative Educational Course in Lung Cancer, Barcelona, Spain, September 3-October 2, 2004.

- Rosell, R. “Individual treatment for patients with lung cancer ased on the molecular profile” National Healthcare Group Annual Scientific Congress, Singapore, October 9-10, 2004.

- Rosell, R. “Non-small-cell lung cancer (NSCLC) tumors from gefitinib.responsive patients harbor EGFR kinase domain mutations” 29th Congress of the European Society for Medical Oncology (ESMO),Vienna, Austria, 29 October-2 November, 2004. *Annals of Oncology* 2004;15:iii166 (abstr 629O)

- Rosell, R. “Correlation between the pattern of DNA repair efficiency and the natural history of patients with advanced sarcoma treated with ET-743 (Yondelis)” 29th Congress of the European Society for Medical Oncology (ESMO),Vienna, Austria, 29 October-2 November, 2004. *Annals of Oncology* 2004;15:iii197 (abstr 745O)

- Rosell, R. Chair, Combined Therapy for Locally Advanced and Metastatic NSCLC Session, 10th Annual Scientific Symposium of the Hong Kong Cancer Institute, Hong Kong SAR, China, November 6-7, 2004.

- Rosell, R. “Tailoring chemotherapy and EGFR inhibitors” 10th Annual Scientific Symposium of the Hong Kong Cancer Institute, Hong Kong SAR, China, November 6-7, 2004.

- Rosell, R. “Tábaco y cancer: alteraciones moleculares” 5º Congreso de la Federación Española de Sociedades Oncológicas (FESEO), Valencia, Spain, November 17-19, 2004.

- Rosell, R. “Tecnología molecular y celular en diagnóstico e investigación en cáncer” Reunión de la Red Temática de Investigación Cooperativa de Centros de Cáncer (RTICCC) del Instituto de Salud Carlos III, Valencia, Spain, November 19, 2004.

- Rosell, R. “Can there be a molecular basis for the treatment of cancer?” European Institute of Healthcare Symposium on “Cancer – understand it, see it, target it, treat it”, Barcelona, Spain, November 20, 2004.

- Rosell, R. Chairman / Organizer, 2nd Educational Symposium of the Spanish Lung Cancer Group, Bilbao, Spain, November 25-26, 2004.

- Rosell, R. “Predicting metastases in stage I NSCLC” 2nd Educational Symposium of the Spanish Lung Cancer Group, Bilbao, Spain, November 25-26, 2004.

- Rosell, R. “Global evaluation of translational research in NSCLC” 2nd Educational Symposium of the Spanish Lung Cancer Group, Bilbao, Spain, November 25-26, 2004.

2003

- Rosell, R. "The role of biomarkers in therapy selection." New strategies in the treatment of advanced non-small-cell lung cancer. Berlin, Germany, January 11, 2003.

- Rosell R. “Towards a customized systemic therapy in NSCLC, the relevance of the DNA repair mechanism.” IV PharmaMar MoA Symposium, Madrid, January 24-25, 2003

- Rosell R. “Management of systemic disease in non-small-cell lung cancer.” Moffitt Comprehensive Lung Cancer Conference, Duck Key, FL, February 5-8, 2003

- Rosell, R. “Tratamiento quimioterápico de primera línea. ERCC1 & RRM1 mRNA expresión & Transcription-Coupled Repair Polymorphisms.” V Simposio de Revisiones en Cáncer. Hospital Clínico San Carlos, Madrid, February, 13, 2003

- Rosell, R. “Genetic assessment of chemotherapy response in NSCLC.” Lecture on Chemoresistance of Lung Cancer in the Swedish Lung Cancer Group. Stockholm, Sweden, March 28, 2003

- Rosell, R. “Genetic assessment of chemotherapy cesponse in NSCLC.” Lecture in the Cancer Centre Karolinska Stockholm, Sweden, March 28, 2003

- Rosell R. “Genetic testing for chemotherapy in NSCLC.” VI Conferenza Nazionale AIOM Genetic testing for chemotherapy in non-small-cell lung cancer. Alghero, Italy, March 30, 2003

- Rosell R. "Aportación de la biología molecular al diagnóstico y tratamiento." VI Reunión de Consenso en Tratamiento Oncológico: Cáncer de Pulmón. Cordoba, April 4, 2003

- Rosell R. "Predictive markers for patient selection for personalized chemotherapy." 20th Annual Meeting of the Japanese Association for Chest Surgery. Tokyo, Japan, May 8, 2003

- Rosell R. "Predictive markers for selecting or personalizing chemotherapy." Discussion, Tumor Biology/Human Genetics, American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003; Program p.58

- Rosell R. Chairman: Predictive Risk and Outcome in Solid Tumors. American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003; Program p. 96

- Rosell R. "ERCC1 and RRM1 expression predicts survival: A genetic analysis of a Spanish Lung Cancer Group trial of gemcitabine / cisplatin vs gem/cis/vinorelbine vs sequential doublets of gem/vrb and vrb/ifosfamide in stage IV non-small-cell lung cancer (NSCLC)." American Society of Clinical Oncology 39th Annual Meeting, Chicago IL USA, June 2003. Proc ASCO 2003;22:644 (abstr 2590)

- Rosell R. "Translational research in lung cancer." (Invited Speaker) ESMO Summer Educational Conference, Edinburgh, Scotland, UK. June 19-22, 2003.

- Rosell R. "The Spanish Lung Cancer Group." 4th International Lung Cancer Congress, Maui, Hawaii. June 26-28, 2003.

- Rosell R. "Tumor biology and genetics." Innovators in Lung Cancer meeting. Paris, France. July 23-25, 2003.

- Rosell R. ,"Pharmacogenomics: individualized therapy." (Invited Speaker) International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August, 2003. Lung Cancer IASLC 2003;41(S3) (abstr E-63)

- Rosell R. "Ribonucleotide reductase M1 (RRM1) mRNA expression and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus cisplatin." International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) (abstr O-43)

- Rosell R. "Randomized phase II clinical trial of cetuximab in combination with cisplatin an dvinorelbine or cisplatin and vinorelbine alone in patients with advanced epidermal growth factor receptor (EGFR)-positive non-small-cell lung cancer (NSCLC)." International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer, Vancouver, Canada, August 2003. Lung Cancer IASLC 2003;41(S2) (abstr O-245)

- Rosell R. “Randomized phase II clinical trial of cetuximab in combination with cisplatin (C) and vinorelbine (V) or CV alone in patients with advanced Epidermal Growth Factor Receptor (EGFR)-expressing non-small-cell lung cancer (NSCLC).” (Proferred Paper) European Cancer Conference, Copenhagen, Denmark, September 2003. European Journal of Cancer ECCO 12 2003;1(5) (abstr 55)

- Rosell R. “The Promise of Pharmacogenomics: Gemzar & Alimta.” Alimta Consultants Meeting, Edinburgh, Scotland UK, September 4-7, 2003

- Rosell R. “Una nueva esperanza en el tratamiento del cáncer.” Congreso de Oncología, Córdoba, Argentina, September 10-13, 2003

- Rosell R. "The Promise of Pharmacogenomics." Congreso de Oncología, Córdoba, Argentina, September 10-13, 2003

- Rosell R. "Screening in Luna Cancer." Congreso de Oncología, Córdoba, Argentina, September 10-13, 2003

- Rosell R. “Molecular Predictors of Chemotherapy Response.” Conference on Novel Agents in the Treatment of Lung Cancer, Cambridge, Massachusetts, USA, October 16-18, 2003

- Rosell R. "Translational Research in the Management of Lung Cancer Patients." Cretan Association for Biomedical Research, Heraklion, Crete, November 15, 2003

- Rosell R. Chairperson. "Predictive Markers for Selecting and Personalizing Chemothearpy." Spanish Lung Cancer Group: Fifth Congress on Lung Cancer, Barcelona, Spain, November 20-21, 2003

- Rosell R. "Neoadjuvant Therapy for Locally-Advanced Lung Cancer: Ten Years Later." Third International Workshop on Surgical Exploration of the Mediastinum and Systematic Nodal Dissection, Terrassa, Barcelona, Spain, November 26-28, 2003

- Rosell R. "Why Trials Testing Molecular Targeted Therapies Have Failed." 4th European Conference of Perspectives in Lung Cancer, Monte Carlo, Monaco, November 27-28, 2003

- Rosell R. "Molecular Factors and Chemo-Resistance/-Sensitivity in Advanced Stage NSCLC." Marseille's Workshop on Lung Cancer, Marseille, France, December 4, 2003